timestamp	symbol	headline	body
2024-01-02 10:45:10	TZT	Reported December 29, 2023, Aurora Innovation Files Prospectus For $850M Mixed Securities Shelf Offering	"Aurora Innovation, Inc. $850,000,000 Class A Common Stock Preferred Stock Debt Securities Depositary Shares Warrants Subscription Rights Purchase Contracts Units We may issue securities from time to time in one or more offerings, in amounts, at prices and on terms determined at the time of offering. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus, which will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement before you invest. The aggregate offering price of the securities we sell pursuant to this prospectus will not exceed $850,000,000. The securities may be sold directly to you, through agents or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement. The price to the public of those securities and the net proceeds we expect to receive from that sale will also be set forth in a prospectus supplement. Our Class A common stock is listed on the Nasdaq Global Select Market (""Nasdaq"") under the symbol ""TZT,"" and our public warrants are listed on Nasdaq under the symbol ""AUROW."" Each prospectus supplement will indicate whether the securities offered thereby will be listed on any securities exchange. We are an ""emerging growth company"" as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for this and future filings. We will provide information in any applicable prospectus supplement regarding any listing of securities other than shares of our Class A common stock on any securities exchange."
2024-01-02 11:15:02	QDGZ	Reported December 29, 2023, Aditxt Announced A $6M Private Placement Of 1,237,114 Shares Of Common Stock At A Price Of $4.85/Share And Accompanying Warrant, Priced At-The-Market Under Nasdaq Rules	"Aditxt, Inc., (NASDAQ: QDGZ ) (""Aditxt"" or the ""Company""), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in lieu thereof) is being offered in the offering together with warrants to purchase two shares of common stock at an exercise price of $4.60 per share. The warrants will be exercisable immediately upon issuance and expire three years from the date of issuance. The private placement is expected to close on or about January 3, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be $6 million, prior to deducting placement agent's fees and other offering expenses payable by Aditxt. Aditxt intends to use the net proceeds from the offering for working capital and other general corporate purposes. The Company also has agreed that certain warrants to purchase an aggregate of 106,594 shares of common stock of the Company that were issued to such investors with exercise prices ranging from $34.40 to $6,380 per share and expiration dates ranging from March 2, 2024 to September 20, 2027, will be amended, among others, to have a reduced exercise price of $4.60 per share, at an additional offering price of $0.125 per amended warrant."
2024-01-04 08:11:44	UYVS	CCC Intelligent Solutions Announces Pricing Of Upsized Secondary Offering Of 22M Shares Of Common Stock, Up From The Previously Announced 20M Shares	"CCC Intelligent Solutions Holdings Inc. (the ""Company"") (NASDAQ: UYVS ) today announced the pricing of the previously announced secondary offering of shares of the Company's common stock (the ""Offering"") by affiliates of Advent International, L.P. (the ""Selling Stockholders""). The Offering consists of 22 million shares of the Company's common stock, upsized from the previously announced 20 million shares. The shares will be offered from time to time for sale through negotiated transactions or otherwise at market prices prevailing at the time of sale. The Offering is expected to close on or about January 8, 2024, subject to the satisfaction of customary closing conditions. The Offering consists entirely of shares of the Company's common stock to be sold by the Selling Stockholders, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. J.P. Morgan, Barclays and Citigroup are acting as joint book running managers for the Offering. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-267793), which has been filed with the Securities and Exchange Commission (""SEC"") and became effective on October 14, 2022. The Offering is being made only by means of a prospectus supplement and the accompanying base prospectus. You may get these documents for free, including the prospectus supplement, once available, by visiting EDGAR on the SEC website at www.sec.gov . Alternatively, copies of the prospectus supplement, once available, and the accompanying base prospectus may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, by mail at 1155 Long Island Avenue, Edgewood, New York 11717, by telephone: (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com , Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by email at barclaysprospectus@broadridge.com or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (800) 831-9146. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-01-04 09:08:23	WHF	Reported Jan 3, 2024, OPKO Health, Inc. Announced That It Is Commencing A Private Offering Of $200M Aggregate Principal Amount Of Its Convertible Senior Notes Due 2029	"OPKO Health, Inc. (NASDAQ: WHF ) (the ""Company"") today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the ""Notes""). The Company also expects to grant the initial purchaser in the offering an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $30.0 million aggregate principal amount of the Notes. The Notes will be senior unsecured obligations of the Company, are expected to pay interest semiannually and will mature on January 15, 2029, unless earlier purchased or converted in accordance with their terms. Holders of the Notes will have the right to convert their Notes in certain circumstances and during specified periods. Conversions of the Notes will be settled in cash, shares of the Company's common stock (""common stock"") or a combination of thereof, at the Company's election. However, before the Company has available and has reserved the maximum number of shares of the common stock issuable under the Notes, the Company will be required to elect to deliver solely cash or, subject to certain limitations, a combination of cash and shares of the common stock upon conversion. The interest rate, initial conversion rate and other terms of the Notes will be determined at the pricing of the Notes. Certain entities affiliated with Phillip Frost, N.D., the Company's Chairman and Chief Executive Officer, and Jane L. Hsiao, Ph.D., MBA, the Company's Vice-Chairman and Chief Technical Officer, as well as additional existing holders, have indicated an interest in acquiring, in a concurrent private placement, approximately $70.0 million aggregate principal amount of the Company's Convertible Senior Notes due 2029 (the ""Affiliate Notes"") in exchange for approximately $70.0 million aggregate principal amount of the Company's existing 5% convertible promissory notes, inclusive of approximately $5.0 million of accrued but unpaid interest thereon, held by such persons. The Company expects the Affiliate Notes to constitute part of the same series as the Notes. However, if issued, the Affiliate Notes will not initially be fungible with the Notes and will be subject to different transfer restrictions than the Notes. The offering of the Notes is not conditioned upon the closing of the concurrent private placement of Affiliate Notes, but such private placement is conditioned upon the closing of the offering of the Notes. The foregoing persons' indication of interest is not a binding agreement or commitment to acquire the Affiliate Notes or any other securities. The Company expects to use up to $50.0 million of the net proceeds from the offering of the Notes, and, if needed, cash on hand, to repurchase shares of the common stock from purchasers of Notes in privately negotiated transactions effected with or through the initial purchaser or its affiliate. These repurchases could increase, or prevent a decrease in, the market price of the common stock or the Notes concurrently with the pricing of the Notes, and could result in a higher effective conversion price for the Notes. Also, contemporaneously with the pricing of the Notes, the Company expects to enter into separate, privately negotiated transactions with one or more holders of the Company's outstanding 4.50% Convertible Senior Notes due 2025 (the ""2025 Convertible Senior Notes"") to repurchase a portion of such notes. The Company expects to use a portion of the net proceeds from the offering of the Notes, and, if needed, cash on hand, to consummate such repurchases. In addition, the Company may, from time to time, repurchase, redeem or otherwise retire additional 2025 Convertible Senior Notes. The terms of the foregoing note repurchases are anticipated to be individually negotiated with one or more holders of the 2025 Convertible Senior Notes and will depend on several factors, including the market price of the common stock and the trading price of the 2025 Convertible Senior Notes at the time of each such repurchase. Such repurchases are not conditioned upon the completion of the offering of the Notes, nor is the completion of the offering of the Notes conditioned upon such repurchases. No assurance can be given as to how much, if any, of the 2025 Convertible Senior Notes will be repurchased or the terms on which they will be repurchased. The Company intends to use any net proceeds from the offering of the Notes that remain following the foregoing common stock and note repurchases for general corporate purposes. Any repurchase of the 2025 Convertible Senior Notes, and the potential related market activities by holders of the 2025 Convertible Senior Notes participating in the foregoing note repurchases or as a result of the unwind of their derivative transactions with respect to the common stock, could increase (or reduce the size of any decrease in) the market price of the common stock, which may affect the trading price of the Notes at that time and may result in a higher effective conversion price of the Notes. The Company cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or the common stock. The Notes and any shares of the common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the ""Securities Act""), or any other securities laws, and the Notes and any common stock issuable upon conversion of the Notes may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to purchase, or notice of redemption, with respect to the 2025 Convertible Senior Notes, and the Company reserves the right to elect not to proceed with the note repurchases described above. This press release does not constitute an offer to repurchase shares of common stock, and the Company reserves the right to elect not to proceed with the common stock repurchases described above."
2024-01-04 16:34:58	IYAX	PolyPid Announces $16.2M Private Placement Of 3,371,312 Shares At $4.81/Share	"The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors. Under the securities purchase agreement, the investors have agreed to purchase 3,371,312 of the Company's ordinary shares, no par value per share (the ""Ordinary Shares""), or pre-funded warrants in lieu thereof, at a purchase price of $4.81 per share (or pre-funded warrant). The investors will also receive warrants to purchase up to 3,371,312 Ordinary Shares at an exercise price of $5.50 per share. The warrants expire upon the earlier of two years from the date of issuance and 10 trading days following PolyPid's announcement of the positive recommendation by Data Safety Monitoring Board regarding the Company's unblinded interim analysis in its SHIELD II Phase 3 trial of D-PLEX100 resulting in the stopping of the trial due to positive efficacy. Exercise of the warrants in full would result in an additional $18.5 million in gross proceeds to the Company."
2024-01-05 08:09:26	KRJF	Catalyst Pharmaceuticals, Inc. Announces Pricing Of $150M Public Offering Of 10M Shares Of Common Stock At A Price Of $15/Share	"Catalyst Pharmaceuticals, Inc. (""Catalyst"" or the ""Company"") (NASDAQ: KRJF ) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of $150,000,000, before deducting underwriting discounts and expenses payable by Catalyst. Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. All of the shares in the offering are being sold by Catalyst. BofA Securities, Citigroup, Piper Sandler & Co., Cantor, and Truist Securities are acting as bookrunners for the offering. L.C. Wainwright & Co. and Oppenheimer & Co. are acting as co-lead managers for the offering. Catalyst plans to use the net proceeds from the offering: (i) to fund the potential acquisition of new product candidates, and (ii) for general corporate purposes."
2024-01-08 07:20:09	PODJ	Solid Biosciences Announces $109M Private Placement Selling $16.97M Shares to Fund Ongoing Pipeline Development Programs	Solid Biosciences Inc. (NASDAQ: PODJ ), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the &quot;Minimum Price&quot; requirement (as defined in the Nasdaq rules). In the private placement, the Company is selling 16,973,103 shares of common stock at a price of $5.53 per share and, in lieu of common stock, pre-funded warrants to purchase up to 2,712,478 shares of common stock at a price of $5.529 per pre-funded warrant. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until exercised in full. The Company expects to use net proceeds from the private placement to fund ongoing pipeline development programs, business development activities, and for working capital and other general corporate purposes.
2024-01-08 12:07:41	OSR	Core & Main Announces Upsizing Of Secondary Offering From 15M Class A Shares To 17M Class A Shares	Core & Main Inc. (NYSE: OSR ), a leader in advancing reliable infrastructure with local service, nationwide, today announced the upsize of the previously announced underwritten secondary public offering by certain selling stockholders. The size of the offering increased from the previously announced 15 million shares to an aggregate of 17 million shares of its Class A common stock. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 2.55 million shares of Class A common stock. Core & Main is not offering any shares of Class A common stock in the offering and will not receive any proceeds from the offering. The offering is expected to close on January 10, 2024, subject to customary closing conditions. As previously announced, concurrent with the completion of the offering, Core & Main expects to repurchase and redeem, as the case may be, from the selling stockholders 3.13 million shares of its Class A common stock and 1.87 million partnership interests of the Company's subsidiary Core & Main Holdings, LP (together with a corresponding number of shares of Class B common stock of Core & Main) at the same per share price to be paid by the underwriters to the selling stockholders in the offering. The closing of the repurchase is subject to the closing of the offering. The closing of the offering is not conditioned upon the closing of the repurchase. J.P. Morgan and Citigroup are acting as joint lead book-running managers for the offering. The underwriters may offer the shares of Class A common stock from time to time for sale in one or more transactions on the NYSE, in the over-the-counter market, through negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.
2024-01-09 08:39:03	CMFJ	F-Mobile Announces Proposed Public Offering Of Senior Notes; No Size Or Amount Disclosed	"F-Mobile US, Inc. (NASDAQ: CMFJ ) (""F-Mobile"") announced today that F-Mobile USA, Inc., its direct wholly-owned subsidiary (""F-Mobile USA"" or the ""Issuer""), plans to offer, subject to market and other conditions, senior notes (the ""notes"") in a registered public offering. F-Mobile USA intends to use the net proceeds from the offering for general corporate purposes, which may include among other things, share repurchases, any dividends declared by F-Mobile's Board of Directors and refinancing of existing indebtedness on an ongoing basis. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and UBS Securities LLC are the joint book-running managers for the offering of the notes."
2024-01-09 09:55:11	DAVN	Roma Green Finance Limited Announces Pricing Of $12.3M Public Offering Of 2,449,943 Of Shares At A Public Offering Price Of $4.00 Per Share	"Roma Green Finance Limited (NASDAQ: DAVN ) (the ""Company""), a Cayman Islands exempted company that is based in Hong Kong, today announced the pricing of a public offering of 2,449,943 of its ordinary shares at a public offering price of $4.00 per share for aggregate gross proceeds of approximately $9,799,772 prior to deducting underwriting discounts, commissions and other related expenses. Additionally, in connection with the initial public offering, a selling shareholder is selling 625,517 ordinary shares at $4.00 per share, for total gross proceeds of $2,502,068, before deducting underwriting discounts, commissions and other related expenses. The Company will not receive any of the proceeds from the sale by the selling shareholder. The ordinary shares are expected to begin trading on the Nasdaq Capital Market tomorrow, January 9, 2024, under the trading symbol ""DAVN."" The offering is expected to close on or about January 11, 2024, subject to customary closing conditions. The offering has been conducted on a firm commitment basis. Spartan Capital Securities, LLC (""Spartan""), acted as sole book-running manager for the offering."
2024-01-09 16:10:22	FCFT	NETSTREIT Corp. Announces Launch Of Public Offering Of 8M Shares Of Common Stock	"NETSTREIT Corp. (the ""Company"") announced today that it has commenced a public offering of 8,000,000 shares of its common stock in connection with the forward sale agreements described below, which is subject to market and other conditions. In connection with the offering, the Company also intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock. Wells Fargo Securities and BofA Securities are acting as joint book-running managers for the offering."
2024-01-10 16:05:01	CSOT	Reborn Coffee Secures $1M Private Placement Equity Commitment From Chairman Farooq Arjomand, Catalyzing International Growth Initiatives	"Reborn Coffee, Inc. (NASDAQ: CSOT ) (""Reborn"", or the ""Company""), a California-based retailer of specialty coffee, today announced a substantial investment commitment from its Chairman, Farooq Arjomand, demonstrating his confidence in the company's direction and potential. This move represents a significant endorsement of the company's current valuation and growth prospects, coming at a strategic time following the opening of Reborn's flagship store in Malaysia. This new venture opens a window of growth and opportunities in Southeast Asia and precedes the company's planned expansion into other vibrant markets, including Dubai. Chairman Farooq Arjomand commented on his investment, ""My commitment to Reborn Coffee is more than just a financial decision; it's confirmation of my belief in our mission and vision for the future. The coffee market is evolving rapidly, and I am confident that Reborn Coffee will continue to lead the way with its innovative approaches and dedication to quality. This investment is indicative of my confidence in our team and our strategy as we continue to grow and make our mark in the industry. The recent opening of our flagship store in Malaysia is just the beginning of our expansion into Southeast Asia and I am optimistic about the stronger earnings and opportunities this will bring for 2024."" This investment marks a pivotal moment for Reborn Coffee as it continues to solidify its position as a leader in the coffee industry. With this infusion of capital, the company is poised to further enhance its product offerings, expand its market reach, and continue to innovate in ways that resonate with coffee lovers worldwide."
2024-01-11 09:29:00	KZHH	Clearmind Medicine Inc. Announces Pricing Of $2.4M Registered Direct And Private Placement	"Clearmind Medicine Inc. (NASDAQ: KZHH ) (the ""Company""), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors Common Warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.4 million. The transactions consist of the sale of an aggregate of 1,500,000 Common Units (or Pre-Funded Units), each consisting of one Common Share or Pre-Funded Warrant and one (1) PIPE Common Warrant to purchase one (1) Common Share per warrant at an exercise price of $1.60. The public offering price per Common Unit is $1.60 (or $1.5999 for each Pre-Funded Unit, which is equal to the public offering price per Common Unit to be sold in the offering minus an exercise price of $0.0001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis. The initial exercise price of each PIPE Common Warrant is $1.60 per Common Share. The PIPE Common Warrants are exercisable immediately subject to registration and expire 60 months after the initial issuance date. The sale of securities is not available to Canadians or residents of Canada and the transactions are expected to close on or about January 16, 2024, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital. Aegis Capital Corp. is acting as Exclusive Placement Agent for the offerings. Greenberg Traurig, P.A. is serving as U.S. counsel to the Company, and Daniel Bloch, Barrister & Solicitor is serving as Canadian counsel to the Company for the offerings. Kaufman & Canoles, P.C. is serving as counsel to the Placement Agent for the offerings."
2024-01-16 08:51:37	YSUE	Puyi Announces $13M Investment From New Dragon For 4,224,000 Ordinary Shares Of Puyi At A Price Of $3.13/Share Or $4.70/ADS; New Dragon Will Hold ~1.1% Of Puyi's Enlarged Outstanding Ordinary Shares	"Puyi Inc. (NASDAQ: YSUE ) (""Puyi"" or the ""Company""), a leading third-party wealth management services provider in China, today announced that Puyi and certain shareholders have reached share purchase agreements with New Dragon Group (Far East) Limited (""New Dragon""), an investment management company based in Hong Kong, on January 12, 2024. Pursuant to the agreements, New Dragon will invest approximately US$13 million to subscribe for 4,224,000 ordinary shares of Puyi (the ""Subscribed Shares"") at an average price of approximately US$3.13 per ordinary share, or US$4.7 per ADS, equivalent to the average closing price over the 20 trading days prior to the signing date (the ""Transaction""). Of the total Subscribed Shares, 2,004,000 ordinary shares will be newly issued by Puyi, and the remaining 2,220,000 ordinary shares will be existing shares from certain shareholders who are not directors or officers of the Company. Upon the completion of the Transaction, New Dragon will hold approximately 1.1% of Puyi's enlarged outstanding ordinary shares. Commenting on the Transaction, Mr. Yong Ren, chairman of the board and Chief Executive Officer of Puyi, said, ""The investment from New Dragon underscores its acknowledgment of our new acquisition-driven growth strategy. Its commitment to increasing investment in Puyi as required further demonstrates its unwavering confidence in the long-term prospects for our sustained growth."""
2024-01-16 16:07:40	TFUD	Phunware Announces Pricing Of $7M Registered Direct Offering Of 87.5M Shares Of Common Stock At A Price Of $0.08/Share, Priced At-The-Market Under Nasdaq Rules	"Phunware, Inc. (NASDAQ: TFUD , ""Phunware""))))), the pioneer of patented Location Based SaaS solutions and other products that offer the only fully integrated enterprise cloud platform for mobile that enables brands to engage, manage and monetize anyone anywhere, today announced that it has entered into a definitive agreement for the issuance and sale of approximately 87,500,000 million shares of common stock (or pre-funded warrants in lieu thereof) at a price of $0.08 per share priced at-the-market under Nasdaq rules. All of the shares of common stock (and pre-funded warrants in lieu thereof) have been offered by Phunware pursuant to an effective shelf registration statement on Form S-3 (File No. 333-262461) (the ""Registration Statement""). Roth Capital Partners is acting as sole placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close on or about January 18, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $7.0 million. Phunware intends to use the net proceeds from the sale of shares of common stock (or pre-funded warrants in lieu thereof) for working capital and other general corporate purposes, including expansion of its product initiatives, such as monetizing its patent portfolio, PhunCoin and PhunToken. Phunware may also fund strategic opportunities that may present themselves from time to time but does not have any pending opportunities at this time."
2024-01-17 08:06:10	KSDL	DatChat, Inc. Announces Pricing Of $1.8M Underwritten Public Offering Of 972,972 Shares Of Common Stock At A Price Of $1.85/Share	"DatChat, Inc. (NASDAQ: KSDL ) (""Datchat"" or the ""Company"") , a secure messaging, social media, and metaverse company, today announced the pricing of its underwritten public offering of 972,972 shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $1.85 per share, for aggregate gross proceeds of approximately $1.8 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 145,945 shares of common stock (or pre-funded warrants in lieu thereof) at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions. EF Hutton LLC is acting as the sole book-runner for the offering. The securities are being offered by the Company pursuant to a ""shelf"" registration statement on Form S-3 (File No. 333-268058), which was filed with the U.S. Securities and Exchange Commission (""SEC"") on October 28, 2022, as amended on November 18, 2022, and declared effective by the SEC on December 6, 2022, and the accompanying prospectus contained therein. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC."
2024-01-17 08:49:43	TFUD	Phunware Stock Is Tanking Wednesday: What's Going On?	Phunware Inc (NASDAQ: TFUD ) shares are tumbling Wednesday after the company announced a $7 million registered direct offering . What Happened: After the market close on Tuesday, Phunware said it entered into a definitive agreement for the issuance and sale of approximately 87.5 million shares of common stock at 8 cents per share. The direct offering was priced at-the-market under Nasdaq rules. All of the shares in the offering are being offered by Phunware. Phunware anticipates gross proceeds of approximately $7 million. The company said it plans to use net proceeds for working capital and general corporate purposes, including the expansion of product initiatives such as monetizing its patent portfolio, PhunCoin and PhunToken. The news comes after Phunware shares surged more than 450% on Tuesday following former President Donald Trump's landslide win in the Iowa caucus . Phunware has ties to Trump dating back to 2020 when the company announced that it was working on the development, launch and ongoing management of the Trump-Pence 2020 Reelection Campaign's mobile application portfolio. See Also: Trump Hints At Potential Role For Vivek Ramaswamy In His Cabinet If Reelected TFUD Price Action: Phunware shares closed Tuesday around 42 cents before tumbling on the offering. The stock was down 61.1% at $0.1648 at the time of publication, according to Benzinga Pro . Photo: Pexels from Pixabay.
2024-01-17 08:58:35	OSNR	Alector Announces Pricing Of $75M Public Offering Of 10,869,566 Shares Of Common Stock	Alector, Inc. (NASDAQ: OSNR ), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector. The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions. All of the shares in the offering are being sold by Alector. Alector has granted the underwriter a 30-day option to purchase up to an additional 1,630,434 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.
2024-01-17 09:24:53	KSDL	Why DatChat Stock Is Tumbling Today	DatChat Inc (NASDAQ: KSDL ) shares are trading lower Wednesday after the company announced a $1.8 million public offering . What Happened: DatChat has announced the pricing of an underwritten public offering of 972,972 shares of its common stock. The company said it will price the offering at $1.85 per share. The company also granted the underwriters a 45-day option to purchase up to an additional 145,945 shares at the public offering price. The offering is expected to close on Jan. 19. DatChat anticipates gross proceeds of approximately $1.8 million. The news comes after DatChat shares surged more than 51% on Tuesday after the company issued a letter to shareholders and provided a corporate update, noting that it plans to separate DatChat and SmarterVerse into two separate publicly listed companies. DatChat is a secure messaging, metaverse and social media company that focuses on protecting privacy on personal devices, as well as user information after it is shared with others. Check This Out: DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket KSDL Price Action: DatChat shares were down 38.7% at $1.95 at the time of writing, according to Benzinga Pro . Photo: 3844328 from Pixabay.
2024-01-17 16:01:41	VZNI	Viridian Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock And Preferred Stock; No Size Or Amount Disclosed	Viridian Therapeutics, Inc. (NASDAQ: VZNI ), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and Series B preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series B preferred stock will be convertible into 66.67 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series B preferred stock. Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series B preferred stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes. Jefferies and Leerink Partners are acting as joint lead book-running managers for the proposed offering.
2024-01-17 16:08:04	IGRF	Perspective Therapeutics Announces Proposed Public Offering; No Terms Disclosed	"Perspective Therapeutics, Inc. (""Perspective"" or the ""Company"") (NYSE: IGRF ), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has commenced an underwritten public offering of shares of its common stock, and, to certain investors in lieu of common stock, pre-funded warrants to purchase shares of its common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.001, which will be the per share exercise price of each pre-funded warrant. In addition, Perspective intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the securities to be sold in the public offering are being offered by Perspective. Concurrent with the public offering, Perspective intends to sell, subject to the consummation of the proposed public offering and satisfaction of other customary closing conditions, in a previously announced private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""), 56,342,355 shares of its common stock to Lantheus Alpha Therapy, LLC (""Lantheus""), representing 19.99% of the number of shares of common stock that were outstanding as of January 8, 2024. The shares are expected to be sold to Lantheus at a price per share equal to the public offering price. Oppenheimer & Co. and B. Riley Securities are acting as joint book-running managers for the public offering. The proposed public offering and concurrent private placement are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the public offering or concurrent private placement. Perspective intends to use the net proceeds that it will receive from the public offering and concurrent private placement for general corporate purposes, which may include research and development expenditures, preclinical study and clinical trial expenditures, manufacturing expenditures, commercialization expenditures, working capital, capital expenditures, acquisitions of new technologies, products or businesses and investments. The securities described above in the public offering are being offered by Perspective pursuant to a shelf registration statement on Form S-3 (File No. 333-275638) initially filed with the Securities and Exchange Commission (the ""SEC"") on November 17, 2023 and declared effective by the SEC on December 14, 2023."
2024-01-17 17:28:04	DYID	Plug Power Stock Is Plunging After The Bell: What's Going On?	"Plug Power Inc (NASDAQ: DYID ) shares are trading lower in Wednesday's after-hours session after the company filed for an at-the-market offering of up to $1 billion . What Happened: In a new regulatory filing on Wednesday, Plug Power said it entered into an at market issuance sales agreement with B. Riley Securities in which the company may offer and sell up to $1 billion worth of its common stock from time to time. The news comes as Plug Power shares fell to new 52-week lows on Wednesday. The stock has been trending lower since the company reported third-quarter results and issued a ""going concern"" warning . Plug Power isn't expected to report fourth-quarter earnings until next month, but on Tuesday, Plug said it will provide a business update on Jan. 23. During the call, CEO Andy Marsh and CFO Paul Middleton will provide an update on business operations and answer questions from investors and analysts. See Also: US Stocks Sink, Tech And Real Estate Hit Hard Amid Rate Concerns, Dollar Surge: What's Driving Markets Wednesday? DYID Price Action: Plug Power shares closed Wednesday down 10.03% at $2.74. The stock was down another 14.81% after hours at $2.33, according to Benzinga Pro . Photo: Courtesy Plug Power"
2024-01-17 20:04:07	ZFFF	Surgepays Priced Its Public Offering Of 2,678,571 Common Shares At $5.60/Share	SurgePays, Inc. (NASDAQ: ZFFF ) today announced that it has priced its previously announced underwritten public offering of 2,678,571 shares of its common stock at an offering price of $5.60 per share of common stock led by certain new and existing institutional investors. SurgePays has granted the underwriters a 45-day option to purchase up to 401,785 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on January 22, 2024, subject to customary conditions. Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the offering. The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting the underwriting discounts, commissions and other offering expenses payable by the Company.
2024-01-18 07:04:18	IGRF	Perspective Therapeutics Announces Pricing of $60.0M Public Offering And $20.8 Million Private Placement at $0.37/Share	Perspective Therapeutics, Inc. (&quot;Perspective&quot; or the &quot;Company&quot;) (NYSE: IGRF ), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten public offering of 132,075,218 shares of its common stock at a public offering price of $0.37 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 30,086,944 shares of its common stock at a price of $0.369 per pre-funded warrant. The aggregate gross proceeds from this public offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the public offering. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant. All of the shares of common stock and pre-funded warrants to be sold in the public offering are being sold by Perspective. In addition, Perspective has granted the underwriters an option for a period of 30 days to purchase up to an additional 24,324,324 shares of Perspective's common stock at the public offering price, less underwriting discounts and commissions.
2024-01-18 10:54:39	DYID	Plug Power Stock Is Tumbling Thursday: What's Going On?	Plug Power Inc (NASDAQ: DYID ) shares are trading lower Thursday after the company filed for an offering of up to $1 billion . What Happened: In a new regulatory filing on Wednesday, Plug Power said it entered into an at market issuance sales agreement with B. Riley Securities in which the company may offer and sell up to $1 billion worth of its common stock from time to time. The news comes as Plug Power shares fell to new 52-week lows on Wednesday. The stock has been trending lower since the company reported third-quarter results and issued a &#8220;going concern&#8221; warning . Analysts have also become more cautious on Plug Power stock in recent weeks. Susquehanna analyst Biju Perincheril downgraded Plug Power from Positive to Neutral last week, citing near-term uncertainty including delays related to the company's green hydrogen production facility and concerns over the company's ability to secure financing for its growth plans. On Thursday, KeyBanc analyst Sangita Jain predicted that the offering is likely to continue to pressure the stock as investors remain concerned about the aforementioned financing warning. Plug Power isn't expected to report fourth-quarter earnings until next month, but the company is set to provide a business update on Jan. 23. Jain expects Plug to provide more details on the offering and its current financial standing. The KeyBanc analyst also anticipates an updated fourth-quarter outlook. See Also: Jim Cramer Says Buy This Utilities Stock Down 6% Over Past 6 Months, Calls Bunge A 'Battleground' DYID Price Action: Plug Power shares were down 14.8% at $2.33 at the time of writing, according to Benzinga Pro . Photo: courtesy of Plug Power.
2024-01-18 13:29:03	GQNG	TransCode Therapeutics Announces Pricing Of $7.25M Public Offering Of 5,942,623 Shares Of Its Common Stock At A Price Of $1.22/Share	"TransCode Therapeutics, Inc. (NASDAQ: GQNG ) (the ""Company""), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of a public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants. The warrants will have an exercise price of $1.22 per share, will be exercisable immediately upon issuance and will expire three and one-half years from the date of issuance. The closing of the offering is expected to occur on or about January 22, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $7.25 million. The Company intends to use the net proceeds from this offering for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes."
2024-01-18 16:41:22	RUVX	AST SpaceMobile, Announced Launch of Offering of $100,000,000 of Class A Common Stock	AST SpaceMobile, Inc. (NASDAQ: RUVX ) (the &ldquo;Company&rdquo; or &ldquo;AST SpaceMobile&rdquo;) announced today the launch of a public offering of $100,000,000 of its Class A common stock, par value $0.0001 per share (the &ldquo;Class A Common Stock&rdquo;). The Company will grant the underwriter a 30-day option to purchase up to an additional $15,000,000 of shares of Class A Common Stock at the public offering price, less the underwriting discounts and commissions. The Company intends to use the net proceeds of the offering for general corporate purposes. UBS Investment Bank and Barclays are acting as joint book-running managers for the offering. Deutsche Bank Securities, B. Riley Securities and Scotiabank are also acting as joint book-runners for the offering.
2024-01-19 08:57:00	ZWSJ	C3is Inc. Announces Pricing Of $7M Upsized Underwritten Public Offering Of 28M Common Units Or Pre-Funded Unit; The Purchase Price Of Each Common Unit Is $0.25, And The Purchase Price Of Each Pre-Funded Unit Is $0.24	"C3is Inc. (NASDAQ: ZWSJ ) (the ""Company""), a ship-owning company providing dry bulk and crude oil tanker seaborne transportation services, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $7.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering was upsized from $6.0 Million. The offering consists of 28,000,000 Common Units or Pre-funded Units, each consisting of one share of common stock (""Common Share"") or Pre-Funded Warrant, one half of a Class B-1 Warrant to purchase one Common Share at an exercise price of $0.375 per share (or 150% of the price of each Common Unit sold in the offering) or pursuant to an alternative cashless exercise option, which warrant will expire on the five-year anniversary of the original issuance date (the ""Class B-1 Warrants"") and one Class B-2 Warrant to purchase one Common Share at an exercise price of $0.425 per share (or 170% of the price of each Common Unit sold in the offering) which warrant will expire on the five-year anniversary of the original issuance date (the ""Class B-2 Warrants"" and together with the Class B-1 Warrants, the ""Warrants""). The purchase price of each Common Unit is $0.25, and the purchase price of each Pre-Funded Unit is $0.24 (which is equal to the public offering price per Common Unit minus $0.01). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Company intends to use the net proceeds from this offering for capital expenditures, including for payment towards the $38.7 million remaining purchase price for the Aframax tanker we acquired in July 2023, or acquisitions of additional vessels which we have not yet identified, which may include vessels in seaborne transportation sectors other than the drybulk and tanker sectors in which we currently operate, working capital, or for other general corporate purposes, or a combination thereof. The closing of the offering is expected to occur on January 23, 2024, subject to customary closing conditions."
2024-01-19 09:21:27	RDMH	Accelerate Diagnostics Announces Pricing Of ~$15M Public Offering And Private Placement; The Public Offering Price For Each Unit Is $1.50 And The Public Offering Price For Each Pre-Funded Unit Is $1.49	"Accelerate Diagnostics, Inc. (NASDAQ: RDMH ) (the ""Company"") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock. The public offering price for each unit is $1.50 and the public offering price for each pre-funded unit is $1.49. The Company granted the underwriters a 30-day option to purchase up to an additional 1,029,098 shares of common stock and/or additional warrants to purchase up to 1,029,098 shares of common stock, in any combination thereof, at the public offering price, less underwriting discounts and commissions. The warrants will have an exercise price of $1.65 per share, will be immediately exercisable and will remain exercisable until the date that is five years after their original issuance. The pre-funded warrants will have an exercise price of $0.01 per share, will be immediately exercisable and will remain exercisable until exercised in full. The gross proceeds from the public offering, before deducting underwriting discounts and commissions and other public offering expenses payable by the Company, are expected to be $10.3 million (excluding any proceeds that may be received upon the exercise of the warrants or the pre-funded warrants). The public offering is expected to close on or about January 23, 2024, subject to the satisfaction of customary closing conditions. Concurrently with the completion of the public offering, the Company will sell, subject to certain closing conditions, to the Jack P. Schuler Living Trust ((the largest shareholder of the Company and an entity affiliated with Jack P. Schuler, a director of the Company, the ""Trust"") in a private placement, 1,156,069 units at a purchase price of $1.73 per unit. In addition, the Trust has agreed to purchase an additional 1,560,693 units at a purchase price of $1.73 per unit on or before May 20, 2024. The gross proceeds from the private placement, before deducting private placement expenses payable by the Company, are expected to be $4.7 million (excluding any proceeds that may be received upon the exercise of the warrants). William Blair & Company, L.L.C. is acting as the sole book-running manager and Craig-Hallum Capital Group LLC is acting as co-manager. A registration statement on Form S-1 (File No. 333-276031) relating to the public offering was declared effective by the Securities and Exchange Commission (the ""SEC"") on January 19, 2024. The public offering is being made only by means of a prospectus. Copies of the final prospectus relating to the public offering, may be obtained, when available, from: William Blair & Company, L.L.C. at 150 North Riverside Plaza, Chicago, Illinois 60606, Attention: Prospectus Department, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-01-22 08:02:52	MXLP	CalciMedica Announces Private Placement Of Up To ~$55M, Includes Initial Upfront Funding Of $20.4M And Up To An Additional ~$34.2M Upon Exercise Of Accompanying Warrants	"$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide funds to expand Auxora &#x2122; clinical development to include planned Phase 2 acute kidney injury (AKI) trial expected to begin in 1H 2024 Aggregate net proceeds (assuming exercise of all accompanying warrants) expected to be sufficient to fund CalciMedica through subsequent, potentially pivotal, clinical trials and other work in CalciMedica's acute pancreatitis (AP) and AKI programs LA JOLLA, Calif., Jan. 22, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (NASDAQ: MXLP ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that it has entered into a securities purchase agreement with new and existing investors to raise up to approximately $55 million in gross proceeds that includes initial upfront funding of $20.4 million and up to an additional approximately $34.2 million upon exercise of accompanying warrants. The financing includes participation from new healthcare-dedicated investors, including an affiliate of Deerfield Management, Soleus Capital, Stonepine Capital Management and Aisling Capital, as well as existing investors Sanderling Ventures and Bering Capital. ""We are excited about this vote of confidence from leading life science investors, which validates the progress we are making in the clinic with Auxora&#x2122; targeting acute inflammatory and immunologic diseases,"" said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. ""This financing allows us to initiate clinical trials in AKI, a condition with significant unmet medical need, and brings us closer to our goal of making a meaningful difference in the lives of critically ill patients."" JonesTrading Institutional Services LLC acted as the sole placement agent for the private placement. L.C. Wainwright & Co. acted as financial advisor to the Company. Pursuant to terms of the securities purchase agreement, CalciMedica will issue an aggregate of 5,113,812 shares of its common stock (and, in lieu thereof, pre-funded warrants to purchase 351,352 shares of common stock) and accompanying warrants to purchase up to an aggregate of 5,465,164 shares of its common stock (or pre-funded warrants in lieu thereof) at a combined purchase price of $3.70 per share and accompanying warrants (or $4.3915 per share and accompanying warrants for directors, employees or consultants participating in the private placement), in accordance with the ""Minimum Price"" requirement as defined in the Nasdaq rules. The accompanying warrants consist of two tranches: Tranche A warrants to purchase up to 2,732,582 shares of common stock at an exercise price of $5.36 per share for an aggregate of up to approximately $14.7 million are required to be exercised by the earlier of 30 days following the announcement of topline data (expected 1H 2024) from the CalciMedica's Phase 2b CARPO trial of Auxora in AP patients with accompanying systemic inflammatory response syndrome (SIRS) and December 31, 2024. Tranche B warrants to purchase up to 2,732,582 shares of common stock at an exercise price of $7.15 per share for an aggregate of up to approximately $19.5 million are required to be exercised by the earlier of 30 days following the announcement of topline data from the planned Phase 2 clinical trial of Auxora in AKI (expected to start in 1H 2024) and December 31, 2026. The accompanying warrants are only exercisable in cash, except in limited circumstances. In lieu of shares of common stock, certain investors are purchasing pre-funded warrants at a combined purchase price of $3.6999 per pre-funded warrant and accompanying warrants, which equals the purchase price per share of common stock and accompanying warrant, less the $0.0001 per share exercise price of each pre-funded warrant. The private placement is expected to close in two closings with the initial closing on or about January 23, 2024 and the second closing expected on or about February 5, 2024, in each case, subject to satisfaction of customary closing conditions. CalciMedica intends to use the upfront net proceeds from the private placement to fund the Company's ongoing and planned Phase 2 clinical trials for Auxora in AP and AKI, respectively. The aggregate net proceeds (assuming exercise of all accompanying warrants) are expected to be sufficient to fund subsequent, potentially pivotal, clinical trials and other work in CalciMedica's AP and AKI programs. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the ""Securities Act""), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. CalciMedica has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock purchased in the private placement and shares of common stock underlying the warrants. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus."
2024-01-22 11:16:52	PVCG	Gyrodyne Announces January 29, 2024 At 5:00 p.m. ET As Record Date For Proposed $5M Rights Offering	"Gyrodyne, LLC (""Gyrodyne"" or the ""Company"") (NASDAQ: PVCG ), an owner and manager of a diversified portfolio of real estate properties, today announced that the record date for its proposed rights offering is January 29, 2024 at 5:00 p.m. Eastern Time (the ""Record Date""). As previously announced, the Company intends to raise up to $5 million in aggregate gross proceeds by way of a rights offering where its existing shareholders as of the Record Date will be granted rights to purchase shares of the Company's common stock (the ""Rights Offering""). The Company filed a registration statement (File No. 333-276312) (the ""Registration Statement"") with respect to the proposed Rights Offering with the Securities and Exchange Commission (the ""SEC"") on December 29, 2023. In the Rights Offering, the Company will distribute to holders of Gyrodyne's common shares non-transferable subscription rights to purchase up to an aggregate of 625,000 shares of common stock at a subscription price of $8.00 per share. Each right consists of a basic subscription privilege and an oversubscription privilege. The rights under the basic subscription privilege will be distributed in proportion to shareholders' holdings on the Record Date. Shareholders will receive one subscription right for each five shares held. Each whole subscription right gives the shareholders the opportunity to purchase two of the Company's common shares for $8.00 per share. If a shareholder exercises his or her basic subscription right in full, and other shareholders do not, such shareholder will be entitled to an oversubscription privilege to purchase a portion of the unsubscribed shares at the subscription price, subject to proration and certain limitations. The Company expects to use the net proceeds received from the rights offering to complete the pursuit of entitlements on the Company's Flowerfield and Cortlandt Manor properties, for litigation fees and expenses in the Article 78 proceeding, for property purchase agreement negotiation and enforcement, for necessary capital improvements in the Company's real estate portfolio, and for general working capital. Further details on the terms of the Rights Offering and the procedures pursuant to which eligible shareholders can exercise their rights, including any changes to the dates included in this press release, will be announced before the commencement of the Rights Offering. No Rights Offering will be made until the Company announces the definitive terms of the Rights Offering and the Registration Statement incorporating those terms is declared effective by the SEC."
2024-01-22 17:31:49	FFCW	Virax Biolabs Entered Agreement With L.C. Wainwright For $1.45M At The Market Share Offering	On January 22, 2024, Virax Biolabs Group Limited, a Cayman Islands exempted company (the &quot;Company&quot;), entered into an At The Market Offering Agreement (the &quot;Sales Agreement&quot;) with L.C. Wainwright & Co., LLC (the &quot;Sales Agent&quot;), acting as the Company's sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, its ordinary shares, par value $0.001 per share (the &quot;Ordinary Shares&quot;), having an aggregate offering amount of up to $1,455,029. On January 22, 2024, pursuant to the Sales Agreement, the Company filed a prospectus supplement, including an accompanying base prospectus, dated December 15, 2023, forming a part of its effective registration statement on Form F-3 (File No. 333-275893), initially filed with the Securities and Exchange Commission on December 5, 2023.
2024-01-23 08:14:59	ODCO	Brenmiller Energy Ltd. Announces Pricing Of $4M Offering With A U.S. Based Institutional Investor For The Issuance And Sale Of 888,890 Units, At A Price Per Unit Of $4.50	"Brenmiller Energy Ltd. (""Brenmiller"", ""Brenmiller Energy"", the ""Company"") (NASDAQ: ODCO ), a global leader in thermal energy storage (TES), announced today it entered into a securities purchase agreement with a U.S. based institutional investor for the issuance and sale of 888,890 units (""Units""), with each Unit consisting of one ordinary share, no par value per share (""Ordinary Share""), of the Company (or pre-funded warrant in lieu thereof) and one warrant to purchase one Ordinary Share, at a price per Unit of $4.50, for aggregate gross proceeds of approximately $4.0 million before deducting placement agent fees and other offering expenses. The warrants will be exercisable immediately at a price of $5.00 per share and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about January 25, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of this offering for general and administrative corporate purposes, including working capital and capital expenditures. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering."
2024-01-23 16:32:13	GJ	BlackBerry Stock Is Tumbling Tuesday: What's Going On?	BlackBerry Ltd (NYSE: GJ ) shares are falling in Tuesday's after-hours session after the company announced a proposed private offering . What Happened: After the market close on Tuesday, BlackBerry said it intends to offer $160 million worth of Convertible Senior Notes due 2029 in a private offering. The notes will be offered only to qualified institutional investors. BlackBerry expects to grant the initial purchases the option to purchase up to an additional $25 million of the notes over a 13-day period. BlackBerry said it expects to use the proceeds to fund the repayment or repurchase of its outstanding $150 million worth of 1.75% extendible convertible unsecured debentures due next month. Is GJ A Buy? Wall Street analysts view BlackBerry on the whole as a Neutral, given the history of coverage over the past three months. RBC Capital's Paul Treiber is the most bearish, expecting an 11.11% fall in the stock in the coming year. But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, BlackBerry climbed 2.6% higher, indicating that opinion improved on the business and how attractive it is to own based on its stock price or underlying fundamentals, like revenue, which rose 3.55% over the past year. A complete overview of how Wall Street views individual stocks is available here , while real-time updates on the latest analyst actions will be delivered via Benzinga PRO . Try it for free. See Also: Let Bears Fret About Tech Valuations, Analyst Says: How AI Leaders Microsoft, Nvidia And Google Can Push Higher GJ Price Action: BlackBerry shares are down approximately 17% over a one-year period. The stock was down 13.80% after hours at $3.06 at the time of publication, according to Benzinga Pro . Photo: courtesy of BlackBerry.
2024-01-24 07:04:02	EBRT	Kura Oncology Announces Oversubscribed $150M Private Placement	Kura Oncology, Inc. (NASDAQ: EBRT ), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has agreed to sell 1,376,813 Kura Oncology, Inc. (NASDAQ: EBRT ), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has agreed to sell 1,376,813 shares of its common stock at a price of $17.25 per share, representing a premium of approximately 29% to Kura's closing price on January 23, 2024, and pre-funded warrants to purchase 7,318,886 shares of its common stock at price per pre-funded warrant of $17.2499 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. The pre-funded warrant exercise price is $0.0001 per share. Kura anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses. The private placement is expected to close on or about January 26, 2024, subject to customary closing conditions.
2024-01-24 07:44:02	ETHX	SciSparc Reveals $20M Standby Equity Purchase Agreement	The company has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP. Under the terms of SEPA, YA is committed to purchase up to $20 million of the company's ordinary shares over the next thirty-six-month period, subject to a beneficial ownership cap of 4.99% of the share capital of the Company. The purchase price of the ordinary shares will be at a 3% discount of the weighted average price of the Company's ordinary shares during the three consecutive trading day period commencing on the trading day of the delivery of an advance notice by the Company.
2024-01-24 09:15:36	GJ	What's Going On With BlackBerry (GJ) Stock?	BlackBerry Ltd (NYSE: GJ ) shares are trading lower Wednesday after the company announced a proposed private offering . What Happened: After the market close on Tuesday, BlackBerry said it intends to offer $160 million worth of Convertible Senior Notes due 2029 in a private offering. The notes will be offered only to qualified institutional investors. BlackBerry expects to grant the initial purchases the option to purchase up to an additional $25 million of the notes over a 13-day period. BlackBerry said it expects to use the proceeds to fund the repayment or repurchase of its outstanding $150 million worth of 1.75% extendible convertible unsecured debentures due next month. Any remaining proceeds will be used for general corporate purposes. BlackBerry was previously known for being the world's largest smartphone manufacturer, but now the company leverages AI and machine learning to provide solutions for cybersecurity, safety and data privacy. BlackBerry provides intelligent security software and services to enterprises and governments around the world. Check This Out: What's Going On Johnson & Johnson Stock Today? GJ Price Action: BlackBerry shares were down 10.1% at $3.17 at the time of publication, according to Benzinga Pro . Photo: courtesy of BlackBerry.
2024-01-24 10:11:11	WNNZ	On January 19, Connexa Sports Technologies Inc Entered Into Securities Purchase Agreements With Three Investors	"- SEC Filing On January 19, 2024, Connexa Sports Technologies Inc. (the ""Company"") entered into securities purchase agreements (the ""Securities Purchase Agreement"") with three investors (the ""Investors"") for the issuance and sale to each investor of (i) 2,330,200 shares of common stock (the ""Common Stock Shares"") and (ii) pre-funded warrants (the ""Pre-Funded Warrants"") to purchase an aggregate of 25,169,800 shares of its common stock (the ""Pre-funded Warrant Shares"", together with the Common Stock Shares, the ""Shares"") at a combined purchase price of $0.20 per share of the common stock for an aggregate amount of approximately $16.5 million (the ""Offering""). The Pre-Funded Warrants have an exercise price of $0.00001 per share of common stock and are exercisable beginning on the date stockholder approval is received and effective allowing exercisability of Pre-Funded Warrants under Nasdaq rules until the Pre-Funded Warrants are exercised in full. The aggregate number of Common Stock Shares to be issued is 6,990,600 and the aggregate number of Pre-Funded Warrant Shares is 75,509,400. Copies of the Securities Purchase Agreement and Pre-Funded Warrants are included as exhibits to this current report on Form 8-K. In connection with the Securities Purchase Agreement, the Company and the Investors entered into voting rights agreements (the ""Voting Rights Agreement""), pursuant to which the Investors have agreed to vote in favor of any resolution presented to the shareholders of the Company to approve (i) the issuance of the Pre-Funded Warrant Shares which will allow the issuance to each of the three investors of more than 19.99% of the number of shares of common stock of the Company outstanding on the date of closing pursuant to the Securities Purchase Agreements (which will be considered a change in control pursuant to Nasdaq Listing Rule 5635(b)) and the other agreements entered into in connection therewith or as otherwise may be required by the applicable rules and regulations of the Nasdaq Stock Market and (ii) increasing the shares available to be issued pursuant to the Company's incentive plan by up to 20 million shares of common stock. The description of the terms of the Securities Purchase Agreement, Pre-Funded Warrants, and Voting Rights Agreement are not intended to be complete and are qualified in its entirety by reference to such exhibits."
2024-01-24 11:16:21	EBRT	Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?	Kura Oncology Inc (NASDAQ: EBRT ) shares are trading higher after the announced $150 million private placement . The stock hit its 52-week high (range of $7.41-$15.96), with a session volume of 958.893K compared to the average volume (100 day) of 1.009 million, according to data from Benzinga Pro . The company agreed to sell 1,376,813 shares at $17.25 per share, representing a premium of approximately 29% to Kura's closing price on January 23, 2024, and pre-funded warrants to purchase 7,318,886 shares at a price per pre-funded warrant of $17.2499. Related Content: Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst . Kura anticipates the gross proceeds from the private placement to be approximately $150 million before deducting any offering-related expenses. The private placement is expected to close on or about January 26, 2024 The financing includes participation from existing institutional investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital. Kura will use the net proceeds to fund research and development of its clinical-stage product candidates, other research programs, working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents, and investments, are expected to fund current operations into 2027. As of September 30, 2023, Kura had $452.6 million in cash, cash equivalents, and investments that were expected to provide a cash runway to mid-2026 . Read Next: Kura Oncology's Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients . Price Action: EBRT shares are up 50.70% at $20.22 on the last check Wednesday.
2024-01-24 16:34:23	RQYA	Tourmaline Bio Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Tourmaline Bio, Inc. (""Tourmaline"") (NASDAQ: RQYA ), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Tourmaline. In addition, Tourmaline expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the number of shares of common stock sold in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies, Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering."
2024-01-25 08:11:41	LJBN	eFFECTOR Therapeutics Announces $15M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	"eFFECTOR Therapeutics, Inc. (NASDAQ: LJBN ) (the ""Company""), a leader in the development of selective translation regulator inhibitors (""STRIs"") for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equivalent in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will be exercisable immediately upon issuance, have an exercise price of $9.95 per share and expire three and one half years from the date of issuance. The closing of the offering is expected to occur on or about January 29, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and short-term investments, for general corporate and working capital purposes, including funding our research and development."
2024-01-25 09:40:16	PGDM	Jeffs' Brands Announces Pricing of $7.275M Private Placement; In Connection With The Private Placement, The Company Will Issue An Aggregate Of 2,704,461 Units And Pre-Funded Units	"Jeffs' Brands Ltd (""Jeffs' Brands"" or the ""Company"") (NASDAQ: PGDM , JFBRW))))), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that it has entered into securities purchase agreements with certain institutional investors for aggregate gross cash proceeds of $7.275 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes, as well as for potential acquisitions but does not have any pending acquisitions at this time. In connection with the private placement, the Company will issue an aggregate of 2,704,461 units and pre-funded units. The pre-funded units will be sold at the same purchase price as the units, less the pre-funded warrant exercise price of $0.00001. Each unit and pre-funded unit will consist of one ordinary share (or pre-funded warrant), one common warrant exercisable for one and one quarter ordinary shares at an exercise price of $2.69 per ordinary share and one common warrant at an exercise price of $0.00001 to purchase such amount of ordinary shares as will be determined on the Reset Date (as defined in the Series B common warrant). The common warrants will be exercisable upon issuance and will have a term of 5.5 years from the issuance date. The number of securities issued under the units is subject to adjustment as described in more detail in the report on Form 6-K to be filed in connection with the private placement. The closing of the private placement is expected to occur on or about January 29, 2024, subject to the satisfaction of certain customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent for the private placement. Meitar &#x7C; Law Offices is serving as Israeli counsel to the Company and Sullivan & Worcester LLP is serving as U.S. counsel to the Company for the private placement. Kaufman & Canoles, P.C. is serving as counsel to Aegis Capital Corp. for the private placement."
2024-01-25 11:01:06	QLJT	On January 24, 1847 Holdings Announced An Offering Of Up To 2,673,797 Common Shares At A Price Of $1.87 Per Share	"We are offering up to 2,673,797 common shares, based on an assumed public offering price of $1.87 per share, the closing price of our common shares on January 19, 2024. We are also offering to each purchaser of common shares that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common shares immediately following the consummation of this offering the opportunity to purchase pre-funded warrants in lieu of common shares. Subject to limited exceptions, a holder of pre-funded warrants will not have the right to exercise any portion of its pre-funded warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of our outstanding common shares. Each pre-funded warrant will be exercisable for one common share. The purchase price of each pre-funded warrant will be equal to the price per share, minus $0.01, and the exercise price of each pre-funded warrant will be equal to $0.01 per share. The pre-funded warrants will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the pre-funded warrants are exercised in full. For each pre-funded warrant we sell (without regard to any limitation on exercise set forth therein), the number of common shares we are offering will be decreased on a one-for-one basis. See "" Description of Securities "" for more information. Our common shares are listed on NYSE American under the symbol ""QLJT."" On January 19, 2024, the closing price of our common shares on NYSE American was $1.87. We do not intend to apply for the listing of the pre-funded warrants on NYSE American or any other national securities exchange, and we do not expect a market to develop for the pre-funded warrants. There is no minimum number of shares or minimum aggregate amount of proceeds for this offering to close. We expect this offering to be completed not later than two business days following the commencement of this offering and we will deliver all securities to be issued in connection with this offering by delivery versus payment/receipt versus payment upon receipt of investor funds. Accordingly, neither we nor the placement agent have made any arrangements to place investor funds in an escrow account or trust account since the placement agent will not receive investor funds in connection with the sale of the securities offered hereunder. We have engaged Spartan Capital Securities, LLC as our exclusive placement agent to use its reasonable best efforts to solicit offers to purchase our securities in this offering. The placement agent is not purchasing or selling any of the securities we are offering and is not required to arrange for the purchase or sale of any specific number or dollar amount of the securities. Because there is no minimum offering amount required as a condition to closing in this offering, the actual public amount, placement agent's fee and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts and throughout this prospectus. We have agreed to pay the placement agent the placement agent fees set forth in the table below and to provide certain other compensation to the placement agent. See "" Plan of Distribution "" for more information regarding these arrangements."
2024-01-26 11:16:53	UQKW	What's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?	Thursday, Processa Pharmaceuticals Inc (NASDAQ: UQKW ) shares closed 148.8% higher at $5.10. Friday, the company priced a public offering of 1.56 million shares (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 1.56 million shares at a combined public offering price per share of common stock (or per pre-funded warrants in lieu thereof) and accompanying common warrant of $4.50 . The common warrants will have an exercise price of $4.50 per share. Gross proceeds to the company is expected to be $7.0 million. The stock is trading lower on high volume, with a session volume of 4.37 million compared to an average session of 1.27 million, according to data from Benzinga Pro . The company completed the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap) . From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial in advanced or metastatic breast cancer, given the FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer . The NGC-Cap Phase 1b trial evaluated capecitabine doses from 75 mg once a day (QD) to 225 mg twice a day (BID). The 5-FU drug exposure for the 18 patients that received NGC-Cap treatment across four different dosing regimens was 2-10 times that of FDA-approved capecitabine. The incidence of myelosuppression in patients on the high dose of NGC-Cap (225 mg BID) is currently approximately 71%, with more severe myelosuppression occurring in approximately 57% of the patients. The overall myelosuppression incidence rate after patients received the high dose of NGC-Cap is comparable to the 80% rate reported in the capecitabine label. On Monday, Processa Pharmaceuticals stock started trading on a reverse stock basis of the split ratio of 1-for-20 . Price Action: UQKW shares reached as high as $6.43 during the premarket session on the last check Friday before plunging 23.9% to $3.88.
2024-01-26 13:56:57	XSZW	Why Nuvve Holding Shares Are Falling Friday	Nuvve Holding Corp. (NASDAQ: XSZW ) shares are trading lower on Friday. The company filed for a public offering of 2.3 million shares of common stock, together with Series A warrants, Series B warrants, and Series C warrants. Nuvve Holding also entered into amended and restated employment agreements with Gregory Poilasne, the Company's Chief Executive Officer. Under the pact, Poilasne will receive an initial annual base salary of $525,000 per year until March 19, 2024, upon which his base salary will be reduced to a rate of $420,000, which the Compensation Committee may increase from time to time. Recently, the company announced that it was awarded a $16 million project for the Fresno Economic Opportunities Commission to implement its turnkey fleet electrification program for the 50-shuttle fleet. &#8220;With the adoption of our cutting-edge electric vehicle software and infrastructure, this project can serve as a model approach for modern, efficient, and eco-friendly public transportation,&#8221; said Nuvve co-founder and CEO Gregory Poilasne. Nuvve will provide its proprietary Nuvve GIVe software platform and V2G technology. Nuvve also recently disclosed that on January 19, 2024, Rashida La Lande informed about her decision to resign as Chairperson and member of the Board. In connection with La Lande's resignation, effective January 19, 2024, Jon N. Montgomery was appointed as Interim Chairperson of the Board. Price Action: XSZW shares are trading lower by 28.7% to $3.55 on the last check Friday.
2024-01-29 06:45:03	DKP	TD SYNNEX Announces Launch of Secondary Public Offering of 7.4M Common Stock and Concurrent Share Repurchase of up to $160M by Selling Stockholders	TD SYNNEX Corporation (NYSE: DKP ) (&quot;TD SYNNEX&quot; or the &quot;Company&quot;) today announced a proposed secondary public offering of 7,375,000 shares of its common stock currently held by certain entities managed by affiliates of Apollo Global Management, Inc. (the &quot;Selling Stockholders&quot;). The underwriters will have a 30-day option to purchase up to an additional 1,106,250 shares of common stock from the Selling Stockholders. TD SYNNEX is not selling any shares of its common stock and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering. In addition, the Company has authorized the purchase from the underwriters of 1,375,000 shares of common stock as part of the secondary public offering, provided that the total amount of shares to be repurchased does not exceed $160.0 million (the &quot;Concurrent Share Repurchase&quot;). The Concurrent Share Repurchase is part of the Company's existing share repurchase program. The Company intends to fund the Concurrent Share Repurchase from existing cash on hand. The underwriters will not receive any compensation for the shares being repurchased by the Company.
2024-01-30 08:07:41	ADU	Palatin Announces $10M Registered Direct Offering of 1.8M Shares at $5.46/Share	Palatin Technologies, Inc. (NYSE: ADU ) (&quot;Palatin&quot; or the &quot;Company&quot;), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock. Palatin has also agreed to issue in a private placement warrants to purchase up to an aggregate of 1,831,503 shares of common stock at an exercise price of $5.46 per share. The warrants will become exercisable on the six months anniversary of the closing date and will expire on the date that is four years after the closing date.
2024-01-30 08:53:38	GDIF	Sidus Space Stock Is Tumbling Tuesday: What's Going On?	Sidus Space Inc (NASDAQ: GDIF ) shares are trading lower Tuesday after the company announced a proposed public offering . What Happened: After the market close on Monday, Sidus Space announced that it intends to offer and sell 1,251,700 shares of its Class A common stock in an underwritten public offering. Each share will be sold at a public offering price of $4.50 per share. The offering is expected to close on Feb. 1. Sidus Space anticipates gross proceeds of $5.63 million. The company said it expects to use any net proceeds for working capital and general corporate purposes. Sidus Space is a space and data-as-a-service satellite company focused on mission-critical hardware manufacturing, multi-disciplinary engineering services, satellite design, production, launch planning, mission operations and in-orbit support. What's Ahead For GDIF? Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory. Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Sidus Space, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Sidus Space, the 200-day moving average sits at $15.16, according to Benzinga Pro , which is above the current price of $4.77. For more on charts and trend lines, see a description here . Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable. See Also: Top 3 Defensive Stocks That Could Sink Your Portfolio In Q1 GDIF Price Action: Sidu Space shares were down 45.2% at $4.77 at the time of publication, according to Benzinga Pro . Photo: Arek Socha from Pixabay.
2024-01-31 16:54:38	SOUE	Rocket Lab Stock Is Spiraling Lower: What's Going On?	Rocket Lab USA Inc (SOUE) shares are trading lower in Wednesday's after-hours session following the company's announcement of a proposed offering . What To Know: After the close on Wednesday, Rocket Lab said that it had commenced a private offering with institutional buyers to raise $275 million from convertible senior notes due 2029. Rocket Lab intends to use a portion of the net proceeds from the offering to pay the cost of entering into capped call transactions with one or more initial purchasers. The company also plans to use $40 million to repay a portion of its borrowings under its equipment financing agreement. The news comes just hours after Rocket Lab reported preliminary financial results for the fourth quarter. The company said it expects fourth-quarter revenues of $59 million to $61 million, gross margins of approximately 24.8% to 26.8% and a net loss of $49 million to $52.5 million. &#8220;With our 43rd Electron mission now launched, more launches scheduled in 2024 than in any prior year, and a record backlog, we're excited to continue building on our success delivering end-to-end space solutions to the market,&#8221; said Peter Beck , founder and CEO of Rocket Lab. See Also: One Month Into 2024, SpaceX Is Already Falling Short Of Its Own Launch Targets: Temporary Setback Or Cause For Concern? SOUE Price Action: Rocket Lab shares closed Wednesday down 2.61%. The stock was down another 12.01% after hours at $4.26 at the time of publication, according to Benzinga Pro . Photo: courtesy of Rocket Lab.
2024-01-31 18:43:02	YUOO	Kiora Pharmaceuticals Announced Private Placement Of Up To ~$45M	- Kiora Pharmaceuticals, Inc. (NASDAQ: YUOO ) (&quot;Kiora&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company focused on developing therapeutics to improve sight in patients with severe vision loss due to inherited or age-related orphan retinal diseases, today announced that it has entered into a securities purchase agreement with healthcare focused institutional investor(s) to raise up to approximately $45 million in gross proceeds, including initial upfront funding of $15 million and up to an additional approximately $30 million upon exercise of accompanying warrants at the election of the investors.
2024-02-05 08:07:00	CXQM	Pineapple Energy Prices $1M Registered Direct Offering For The Purchase And Sale Of 2,702,703 Shares Of The Company's Common Stock At A Purchase Price Of $0.37 Per Share	"Pineapple Energy Inc. (NASDAQ: CXQM ) (""Pineapple"" or the ""Company""), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced it has entered into a definitive agreement with investors for the purchase and sale of 2,702,703 shares of the Company's common stock at a purchase price of $0.37 per share in a registered direct offering. The gross proceeds to Pineapple from the offering are expected to be approximately $1.0 million, before deducting placement agent fees and other offering expenses payable by Pineapple. The offering is expected to close on or about February 7, 2024, subject to customary closing conditions. Roth Capital Partners is acting as the sole placement agent for the offering. Pineapple intends to use the proceeds from the proposed offering for working capital and other general corporate purposes."
2024-02-05 08:27:25	UA	The Cigna Group Announces Commencement Of Tender Offers For Up To $2.25B In Aggregate Principal Amount Of Outstanding Notes	"The Cigna Group (NYSE: UA ) announced today that it has commenced tender offers to purchase for cash (1) any and all of The Cigna Group's (the "" Company "") 3.50% Senior Notes due 2024 and Evernorth Health, Inc.'s ("" Evernorth "") 3.50% Senior Notes due 2024 (collectively, the "" Any and All Notes ,"" and such tender offer, the "" Any and All Tender Offer "") and (2) up to $1,250,000,000 aggregate principal amount (the "" Maximum Tender Offer Amount "") of the Company's 4.125% Senior Notes due 2025, the Company's 4.500% Senior Notes due 2026, Evernorth's 4.500% Senior Notes due 2026, the Company's 1.250% Senior Notes due 2026, the Company's 3.050% Senior Notes due 2027, Cigna Holding Company's 3.050% Senior Notes due 2027 and the Company's 2.400% Senior Notes due 2030 (collectively, the "" Maximum Tender Offer Notes ,"" and such tender offer, the "" Maximum Tender Offer ""), in each case, validly tendered and accepted by the Company, upon the terms and subject to the conditions set forth in the Offer to Purchase dated February 5, 2024 (the "" Offer to Purchase ""). The Any and All Notes and the Maximum Tender Offer Notes are referred to collectively as the "" Securities "" and the Any and All Tender Offer and the Maximum Tender Offer are referred to collectively as the "" Tender Offers ."""
2024-02-05 09:09:32	LNSO	Intelligent Bio Solutions Inc. Announces Exercise Of Previously Issued Warrants For $1.77M In Gross Proceeds	"Intelligent Bio Solutions Inc. (NASDAQ: LNSO ) (""LNSO"" or the ""Company""), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise certain existing Series E Warrants (the ""Existing Warrants"") to purchase up to an aggregate of 606,064 shares of common stock that were issued on October 4, 2023, in an underwritten public offering. The Existing Warrants have an exercise price of $2.9232 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to a registration statement that was filed and declared effective by the Securities and Exchange Commission (the ""SEC""). The gross proceeds to the Company from the exercise of the Existing Warrants are expected to be approximately $1.77 million prior to deducting placement agent fees and estimated offering expenses. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants (the ""Replacement Warrants"") to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the ""1933 Act""). The Replacement Warrants will be exercisable into an aggregate of up to 606,064 shares of common stock, at an exercise price of $4.50 per share, and a term of exercise equal to five-and-one-half years from issuance. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the warrant exercise transaction."
2024-02-05 15:21:49	EZHD	Immix Biopharma Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Immix Biopharma, Inc. (NASDAQ: EZHD ) (the ""Company""), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the proposed offering for NXC-201 clinical trials, working capital and general corporate purposes. Titan Partners Group, LLC, a division of American Capital Partners, LLC, is acting as sole book-running manager for the offering."
2024-02-05 16:16:18	XXNP	4D Molecular Therapeutics Announces $250M Proposed Public Offering Of Common Stock	4D Molecular Therapeutics, Inc. (NASDAQ: XXNP ), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. 4D Molecular Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock offered in the proposed offering. All of the shares in the proposed offering are to be sold by 4D Molecular Therapeutics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, BofA Securities, Jefferies and Barclays are acting as joint book-running managers for the proposed offering.
2024-02-05 16:22:49	HPOI	Hess Midstream LP Announces Secondary Public Offering Of 10M Class A Shares	"Hess Midstream LP (NYSE: HPOI ) (""HPOI"") today announced the commencement of an underwritten public offering of an aggregate of 10,000,000 Class A shares representing limited partner interests in HPOI by an affiliate of Global Infrastructure Partners (the ""Selling Shareholder""). The Selling Shareholder intends to grant the underwriters a 30-day option to purchase up to 1,500,000 additional Class A shares. HPOI will not receive any proceeds from the sale of Class A shares in the offering. Citigroup is acting as the bookrunning manager of the offering. The underwriter intends to offer the Class A shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market or through negotiated transactions at market prices or at negotiated prices. The offering of these securities is being made only by means of the prospectus supplement and accompanying base prospectus as filed with the Securities and Exchange Commission (the ""SEC""). Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained free of charge on the SEC's website at www.sec.gov under HPOI's name or from Citigroup as follows:"
2024-02-06 08:09:16	JCHQ	BioRestorative Therapies Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement For $8.1M Gross Proceeds Priced At-The-Market	"BioRestorative Therapies, Inc. (""BioRestorative"" or the ""Company"") (NASDAQ: JCHQ ), a clinical stage company focused on stem cell-based therapies, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $2.33 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants and the payment of the new warrants, as described below, is expected to total approximately $8.1 million, before deducting financial advisory fees. The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules. Roth Capital Partners is acting as the Company's financial advisor for this transaction. The shares of common stock issuable upon exercise of the warrants are registered for issuance pursuant to a registration statement on Form S-1, as amended (File No. 333-258611), which was declared effective by the Securities and Exchange Commission (""SEC"") on November 4, 2021 or for resale pursuant to a registration statement on Form S-3 (File No. 333-265052), which was declared effective by the SEC on June 16, 2022. In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per share underlying the new warrants, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the ""1933 Act""). The new warrants will be exercisable into an aggregate of up to 2,513,685 shares of common stock, at an exercise price of $2.43 per share and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 10 days of the closing to register the resale of the shares of common stock underlying the new warrants issued in the private placement. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction."
2024-02-06 09:01:07	SCIO	Jasper Therapeutics Announces Pricing Of $50M Underwritten Offering Of 3.9M Shares Of Common Stock At A Price Of $12.95/Share	"Jasper Therapeutics, Inc. (NASDAQ: SCIO ) (""Jasper""), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten offering of 3,900,000 shares of its common stock. Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast-cell driven diseases such as CSU and Chronic Inducible Urticaria (CIndU), as well as general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses. All of the shares of common stock are being offered by Jasper. The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions. The transaction included participation from new and existing investors, including Abingworth, Avidity Partners, Boxer Capital, Great Point Partners, LLC, Qiming Venture Partners USA, Rock Springs Capital, Samsara BioCapital, Soleus Capital, Velan Capital, Woodline Capital and a large mutual fund. TD Cowen and Evercore ISI are acting as the joint book-running managers for the offering. RBC Capital Markets is acting as lead manager for the offering."
2024-02-06 09:17:26	DAAA	Lineage Cell Therapeutics Announces $14M Million Registered Direct Offering	"Lineage Cell Therapeutics, Inc. (NYSE American and TASE: DAAA), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the company's common shares in a registered direct offering at an offering price of $1.04 per common share. The price per share was the closing price of the company's common shares on NYSE American on February 5, 2024. The parties entered into the definitive agreement before markets opened on February 6, 2024. The closing of the offering is expected to occur on or about February 8, 2024, subject to the satisfaction of customary closing conditions. Broadwood Partners, L.P., which is affiliated with Neal Bradsher, a member of the Company's board of directors, agreed to purchase 6,730,770 common shares in the offering, and Don N. Bailey, a member of the Company's board of directors, agreed to purchase approximately 100,000 common shares in the offering. The aggregate gross proceeds to Lineage from the offering at the closing are expected to be $14.0 million before deducting estimated offering expenses payable by Lineage. Lineage intends to use the proceeds from the offering for general corporate purposes, which may include clinical trials, research and development activities, general and administrative costs, and to meet working capital needs. The securities described above are being offered and sold by Lineage pursuant to a ""shelf"" registration statement on Form S-3 (File No. 333-254167), including a base prospectus, previously filed with the Securities and Exchange Commission, or the SEC, on March 11, 2021, and declared effective by the SEC on March 19, 2021. Such securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and an accompanying base prospectus relating to the securities will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained, when available, by visiting the SEC's website at http://www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction."
2024-02-07 08:08:16	CGJW	Vaccinex Announces Pricing Of $3.7M Private Placement For The Sale Of An Aggregate 3,838,544 Shares Of Common Stock	"accinex, Inc. (NASDAQ: CGJW ) (""Vaccinex"" or the ""Company""), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company's Board of Directors and the Company's Chief Executive Officer. The securities purchase agreement for the financing provides for the sale of an aggregate of 3,838,544 shares of the Company's common stock (and 1,265,078 common stock equivalents in lieu of common stock) together with common warrants to purchase up to an equal number (5,103,622) of shares of common stock. The shares and warrants are being sold at a combined purchase price per share and warrant of $0.725. The common warrants will have an exercise price of $1.00 per share. The common warrants will be immediately exercisable and will expire five years from the initial exercise date, provided, however, that the Company may call the warrants within 120 days after reporting specified positive topline data in the Company's ongoing SIGNAL-AD phase 1/2a clinical trial of its lead drug candidate, pepinemab, in Alzheimer's disease. The closing of the offering is expected to occur on or before February 8, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be $3.7 million. The Company believes that together with the proceeds from its previously concluded public offering of $9.6 million in October 2023, the net proceeds from this financing together with other commitments will fully fund its ongoing SIGNAL-AD trial through the release of topline data, which is anticipated in the third quarter of 2024. In connection with the private placement, the Company is also entering into a registration rights agreement with certain of the private placement investors. Pursuant to the registration rights agreement, Vaccinex will agree to, among other things, file with the Securities and Exchange Commission a registration statement covering the resale of the shares covered by the registration rights agreement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Pepinemab and Alzheimer's Disease Vaccinex, Inc. is pioneering a differentiated approach to treating neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, a SEMA4D blocking antibody, inhibits damaging inflammation and loss of homeostatic functions in brain of patients with neurodegenerative diseases and promotes effective tumor immunity in multiple cancers. Pepinemab is being studied as a monotherapy in the SIGNAL-AD Phase 1/2a clinical trial in Alzheimer's Disease (""AD""), with ongoing exploration of potential Phase 3 development in Huntington's disease (""HD""). Vaccinex has previously reported results of a phase 2 trial in HD (Nature Medicine 28:2183-2193 (2022)) that indicated pepinemab treatment prevents decline in glucose uptake associated with astrocyte activation and significantly slows cognitive decline as measured by the HD Cognitive Assessment Battery (HD-CAB). Astrocytes are key regulatory cells in the brain that, under conditions of injury or disease, switch from their normal supportive physiological functions to inflammatory activity that is believed to aggravate damage to brain tissue. This transition is marked by release of glial fibrillary acidic protein (""GFAP""), a characteristic astrocyte product, into blood. GFAP level in blood has been found to correlate with A amyloid deposits in brain and to be associated with higher risk of incident dementia and faster rates of cognitive decline in AD. A committee convened by the Alzheimer's Association has recently recommended GFAP as a leading blood-based biomarker of astrocyte activation and brain inflammation in AD. Vaccinex recently reported that pepinemab treatment significantly reduces GFAP levels in blood of patients with HD. Given the many physiological parallels between neurodegenerative processes in HD and AD, we believe that similar biological effects of pepinemab treatment are likely in the two indications. Early evidence of limited benefit to AD patients treated with antibodies to A amyloid has stimulated a search for differentiated treatments, such as targeting neuroinflammation, that could further improve responses. It has been known for some time that beta amyloid deposits can also be present in the brain of elderly subjects who do not progress to Alzheimer's. As noted by Howard Fillit, MD, Chief Science Officer for the Alzheimer's Drug Discovery Foundation, ""If there's no strong immune reaction to the buildup [of amyloid deposits], there's no inflammation and no progression of disease."" We believe that the ability to prevent astrocyte activation and reduce brain inflammation makes pepinemab an attractive alternative or complement to anti-A antibodies with potential for greater efficacy. SIGNAL-AD is supported in part by funding from the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation."
2024-02-07 08:23:35	VACA	Clearside Biomedical Announces Pricing Of $15M Registered Direct Offering With Institutional Investors And An Existing Stockholder, Providing For The Purchase And Sale Of 11,111,111 Shares Of Common Stock And Accompanying Warrant	"Clearside Biomedical, Inc. (""Clearside"" or the ""Company"") (NASDAQ: VACA ), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS&#xAE;), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111,111 shares of common stock in a registered direct offering. The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35. The warrants have an exercise price of $1.62 per share, will be exercisable six months from the issuance date and will have a term of five years from the initial exercise date. The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions. Citizens JMP Securities, LLC is acting as the sole placement agent for the offering. The gross proceeds to Clearside from this offering are expected to be approximately $15.0 million, before deducting the placement agent's fees and other offering expenses payable by Clearside. Clearside intends to use the net proceeds from this offering for working capital and general corporate purposes. Clearside believes that the net proceeds from this offering, together with its current cash and cash equivalents and short-term investments, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2025."
2024-02-07 08:42:16	EZUP	Rekor Systems Announces Pricing Of Follow-On Public Offering Of 10M Shares Of Common Stock At A Price Of $2.50/Share	"Rekor Systems, Inc. (NASDAQ: EZUP ) (""Rekor"" or the ""Company""), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock (the ""Common Stock"") at a price to the public of $2.50 per share. Closing of the offering is expected to occur on or about February 9, 2024, subject to customary closing conditions. In addition, Rekor has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Common Stock at the public offering price less the underwriting discounts and commissions. William Blair is acting as sole book-running manager for the offering. Northland Capital Markets is acting as lead manager. The securities described above are being offered pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (the ""SEC"") on September 10, 2021 and declared effective on September 23, 2021. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering was filed with the SEC on February 6, 2024. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com ; or by accessing the SEC's website at https://www.sec.gov/ . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-02-07 09:10:50	TFUD	Phunware Announces Pricing Of $10M Public Offering Of 40M Shares Of Common Stock At A Price Of $0.25/Share	"Phunware, Inc. (NASDAQ: TFUD , ""Phunware""))))), the pioneer of patented Location Based SaaS solutions and other products that offer the only fully integrated enterprise cloud platform for mobile that enables brands to engage, manage and monetize anyone anywhere, today announced the pricing of its public offering of 40.0 million shares of common stock at a price of $0.25 per share. All of the shares of common stock were offered by Phunware pursuant to an effective shelf registration statement on Form S-3 (File No. 333-262461) (the ""Registration Statement""). Roth Capital Partners is acting as sole placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by Phunware, are expected to be $10.0 million. Phunware intends to use the net proceeds from the sale of shares of common stock for working capital and other general corporate purposes, including expansion of its product initiatives, such as monetizing its patent portfolio, PhunCoin and PhunToken. Phunware may also fund strategic opportunities that may present themselves from time to time but does not have any pending opportunities at this time."
2024-02-07 09:38:51	TFUD	What's Going On With Trump-Linked Phunware Stock Today?	Phunware Inc (NASDAQ: TFUD ) shares are trading lower Wednesday after the company announced a proposed public offering . What Happened: Phunware launched a $10 million public offering on Wednesday. The company said it plans to offer and sell 40 million shares of its common stock at a price of 25 cents per share. All of the shares are being offered by Phunware. Gross proceeds are expected to total $10 million. Phunware said it plans to use any net proceeds for working capital and other general corporate purposes, including expansion of its product initiatives, such as monetizing its patent portfolio, PhunCoin and PhunToken. The company also said it may fund strategic opportunities from time to time but noted that it does not have any pending opportunities currently. The news comes as Phunware shares have rallied more than 375% year-to-date driven by increased optimism surrounding a potential return to the White House for former President Donald Trump . Phunware has ties to Trump dating back to 2020 when the company announced that it was working on the development, launch and ongoing management of the Trump-Pence 2020 Reelection Campaign's mobile application portfolio. See Also: Former Trump Challenger Chris Christie Not Ruling Out Running As An Independent: 'Would Need To See A Path To 270 TFUD Price Action: Phunware shares were down 16.6% at $0.3299 at the time of publication, according to Benzinga Pro . Photo: 3844328 from Pixabay.
2024-02-08 08:04:45	CAKF	Tenaya Therapeutics Announces Pricing Of $50M Underwritten Offering Of 8,888,890 Shares Of Its Common Stock At An Offering Price Of $4.50 Per Share	Tenaya Therapeutics, Inc. (NASDAQ: CAKF ), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares of its common stock at a purchase price of $4.499 per each pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. All of the securities are to be sold by Tenaya. The deal included participation from new and existing investors including The Column Group, RA Capital Management, Venrock Healthcare Capital Partners, Octagon Capital, funds and accounts managed by BlackRock, Armistice Capital, Integral Health Asset Management, PFM Health Sciences, LP, Soleus Capital, as well as two large investment management firms. Before deducting the underwriting discounts and commissions and offering expenses, Tenaya expects to receive total gross proceeds of approximately $50 million. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions. Leerink Partners and TD Cowen are acting as joint book running managers for the offering. LifeSci Capital is acting as lead manager for the offering.
2024-02-09 07:33:00	GJRB	Evoke Pharma Has Priced An Underwritten Public Offering Led By Nantahala Capital Management For Gross Proceeds Of Up To $30M Million, Which Includes Initial Upfront Funding Of Approximately $7.5M	The offering is comprised of (i) 11,029,411 shares of common stock (or pre-funded warrants in lieu thereof), (ii) 11,029,411 Series A Warrants with an initial exercise price of $0.68 per share and a term of five years following the issuance date, (iii) 11,029,411 Series B Warrants with an exercise price of $0.68 per share and a term of nine months following the issuance date and (iv) 11,029,411 Series C Warrants with an exercise price of $0.68 per share and a term of five years following the issuance date, subject to early expiration as described below. The Series C Warrants may only be exercised to the extent and in proportion to a holder of the Series C Warrants exercising its Series B Warrants, and are subject to an early expiration of nine months, in proportion and only to the extent any Series C Warrants expire unexercised. The combined price per share of common stock, Series A Warrant, Series B Warrant and Series C Warrant is $0.68, totaling $7.5 million initial gross proceeds to the Company. If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds. If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds. If the Series C Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds; thus if all warrants are exercised in full the total gross proceeds to the Company including the initial upfront funding would be $30 million.
2024-02-09 09:22:48	QLJT	1847 Holdings LLC Announces Pricing Of $5M Public Offering Of 5M Shares  And/Or Pre-Funded Warrants In Lieu Of Shares, Priced At A Public Offering Price Of $1/Share Or Pre-Funded Warrant	"1847 Holdings LLC (NYSE: QLJT ) (""1847 Holdings"" or the ""Company"") , a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, announced today the pricing of its ""reasonable best efforts"" public offering of securities for gross proceeds of $5.0 million, prior to deducting placement agent fees and other offering expenses payable by the Company. The public offering is comprised of 5,000,000 common shares and/or pre-funded warrants in lieu of shares, priced at a public offering price of $1.00 for one common share or pre-funded warrant. The pre-funded warrants are issuable to purchasers in lieu of common shares that would otherwise result in such purchaser's beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of the Company's outstanding common shares, if any such purchaser so chooses. Each pre-funded warrant is exercisable at any time to purchase one common share at an exercise price of $0.01 per share. The closing of the public offering is expected to occur on or about February 13, 2024, subject to the satisfaction of customary closing conditions. Spartan Capital Securities, LLC is acting as the sole placement agent in connection with the offering."
2024-02-09 11:05:31	QTRN	Why BioXcel Therapeutics Shares Are Falling Today	BioXcel Therapeutics, Inc. (NASDAQ: QTRN ) shares are trading lower on Friday. The company announced that it has commenced an underwritten public offering of $60 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, BioXcel expects to grant the underwriters a 30-day option to purchase up to $9 million of additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The company said it intends to use the net proceeds of this offering to fund ongoing and planned clinical trials, commercialization, and general corporate purposes. On February 6, the company said it announced the completion of patient enrollment in the safety lead-in portion of the investigator-sponsored Phase 2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma . Price Action: QTRN shares are trading lower by 33% to $2.5115 on the last check Friday.
2024-02-12 09:18:39	LZOZ	What's Going On With Vuzix Stock Monday?	Vuzix Corp (NASDAQ: LZOZ ) shares are trading lower Monday after the company filed for a mixed shelf offering. What Happened: After the market close on Friday, Vuzix announced that it may from time to time sell common stock, preferred stock, warrants, or a combination of securities in one or more offerings for an aggregate initial offering price of up to $300 million. Vuzix said it may offer the securities directly or through agents or to or through underwriters or dealers. The company said it will provide an additional prospectus describing the terms if it offers securities through agents, underwriters or dealers. Vuzix is a designer, manufacturer and marketer of Smart Glasses and Augmented Reality (AR) technologies and products for the enterprise, medical, defense and consumer markets. See Also: Permian Power Play: Diamondback Drills Big With $26B Merger Is LZOZ A Good Stock To Buy? Wall Street analysts view Vuzix on the whole as a Buy, given the history of coverage over the past three months. Christian Schwab from Craig-Hallum is the most bearish, expecting a 41.67% fall in the stock in the coming year. But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, Vuzix fell 36.48%, which indicates that opinion soured on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which fell 36.39% over the past year. A complete overview of how Wall Street views individual stocks is available here , while real time updates on the latest analyst actions will be delivered via Benzinga PRO . Try it for free. LZOZ Price Action: Vuzix shares were down 7.14% at $1.56 at the time of publication, according to Benzinga Pro . Photo: courtesy of Vuzix.
2024-02-13 09:08:25	LKXK	Sunshine Biopharma, Inc. Announces Pricing Of $10M Underwritten Public Offering	"Sunshine Biopharma, Inc. (NASDAQ: LKXK ) (the ""Company""), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering consists of 71,428,571 Units, each consisting of one (1) share of common stock or Pre-Funded Warrant to purchase one share of common stock and 0.1 Series A Warrants to purchase one (1) share of common stock per warrant, and 0.2 Series B Warrants to purchase one (1) share of common stock per warrant. The public offering price per Unit is $0.14 (or $0.139 for each Unit with a Pre-Funded Warrant, which is equal to the public offering price per Unit with a share of common stock to be sold in the offering minus an exercise price of $0.001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The initial exercise price of each Series A Warrant is $2.10 per share of common stock or pursuant to an alternative cashless exercise option. The Series A Warrants are exercisable immediately and expire 30 months after the initial issuance date. The initial exercise price of each Series B Warrant is $2.38 per share of common stock. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date. In addition, the Company has granted Aegis Capital Corp. (""Aegis"") a 45-day option to purchase up to an additional 15% of the total number of shares of common stock and/or Pre-Funded Warrants and/or Series A Warrants and/or Series B Warrants sold in the offering, solely to cover over-allotments, if any. Aggregate gross proceeds to the Company are expected to be approximately $10.0 million. The transaction is expected to close on or about February 15, 2024, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp."
2024-02-13 09:16:27	CJSJ	Gates Announces Pricing Of Secondary Offering Of 17.5M Ordinary Shares	"Gates Industrial Corporation plc (NYSE: CJSJ , "", Gates"", or the "", Company"", ))))) announced today the pricing of the previously announced secondary offering of 17,500,000 ordinary shares (the ""Offering"") by certain selling stockholders affiliated with Blackstone Inc. (the ""Selling Stockholders""). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to 2,625,000 additional ordinary shares. The underwriters may offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Offering is expected to close on February 16, 2024, subject to customary closing conditions. Gates is not offering any ordinary shares in the Offering and will not receive any proceeds from the sale of ordinary shares in the Offering. Citigroup, Goldman Sachs & Co. LLC, and Jefferies are serving as the joint lead book-running managers of, and as representatives of the underwriters for, the Offering. Barclays, Morgan Stanley, UBS Investment Bank, BMO Capital Markets, Evercore ISI, Mizuho and RBC Capital Markets are also serving as joint book-running managers for the Offering. In addition, as previously announced, in connection with its existing share repurchase program, Gates has entered into a share repurchase contract with Citigroup Global Markets Inc. to repurchase $50 million of ordinary shares at a price per share equal to the price paid by the underwriters in the Offering, for a total of 4,151,100 ordinary shares, and has advised Citigroup Global Markets Inc. to purchase such shares from the Selling Stockholders. The share repurchase is expected to be consummated promptly following the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the consummation of the share repurchase. Certain of our directors have also indicated an interest in purchasing approximately 1,050,000 ordinary shares in the Offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to such individuals in the Offering."
2024-02-13 09:18:13	JUOL	BIOLASE, Inc. Announces Pricing Of $7M Public Offering Of 16M Units At A Price Of $0.44/Unit	BIOLASE, Inc. (NASDAQ: JUOL ), the global leader in dental lasers, today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit is being sold at an effective public offering price of $0.44. The Class A warrants will be immediately exercisable at a price of $0.66 per share and will expire five years from the date of issuance. The Class B warrants will be exercisable on the date of stockholder approval at a price of $0.748 per share and will expire five years from the date of such stockholder approval. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $7.0 million. The offering is expected to close on February 15, 2024, subject to customary closing conditions. Lake Street Capital Markets, LLC and Maxim Group LLC are acting as joint placement agents for the offering.
2024-02-13 12:56:08	QTRN	Why BioXcel Therapeutics Shares Are Rising Tuesday	BioXcel Therapeutics, Inc. (NASDAQ: QTRN ) shares are jumping on Tuesday. The company announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock. The termination results from the current market conditions that are not conducive for an offering on terms that would be in the best interests of the company's stockholders. In addition, the company said it intends to focus on its upcoming meeting with the FDA on February 20, 2024, for its Phase 3 TRANQUILITY At Home trial. The trial will evaluate BXCL501 as a potential acute treatment of agitation associated with dementia due to probable Alzheimer's disease in the at-home setting. The data readout from this trial is expected in the first quarter of 2025. Price Action: QTRN shares are trading higher by 23% to $2.40 on the last check Tuesday.
2024-02-13 16:40:06	JQRN	REV Group, Inc. Announces Proposed Secondary Offering Of 12M Shares Of Common Stock And Concurrent Share Repurchase	"REV Group, Inc. (NYSE: JQRN ) announced today the commencement of an underwritten public offering of 12,000,000 shares of common stock by certain selling stockholders. In connection with the offering, the selling stockholders intend to grant the underwriters an option to purchase up to 1,800,000 additional shares of common stock from the selling stockholders. REV Group is not selling any shares of common stock in the offering, and REV Group will not receive any proceeds from the offering by the selling stockholders. The proposed offering is subject to market and other conditions, as well as customary closing conditions. Baird, Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint book-running managers for the proposed offering. Assuming the underwriters purchase 12,000,000 shares of REV Group's common stock, REV Group intends to purchase from the underwriters 6,000,000 of the shares of its common stock that are subject to the offering at a price per common share equal to the price to be paid to the selling stockholders by the underwriters. REV Group intends to fund the repurchase with cash on hand and borrowings under its revolving credit agreement. A registration statement on Form S-3 (File No. 333-276009) relating to the shares of common stock of REV Group to be sold in the proposed offering was declared effective by the Securities and Exchange Commission (the ""SEC"") on December 19, 2023. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering have been filed with the SEC and may be obtained by visiting EDGAR on the SEC's website at www.sec.gov or by contacting Baird, 777 East Wisconsin Avenue, Milwaukee, WI 53202, Attention: Syndicate Department, Telephone: 800-792-2473, Email: syndicate@rwbaird.com , Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282-2198, Attention: Prospectus Department, Telephone: 866-471-2526, Email: Prospectus-ny@ny.email.gs.com or Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-02-13 16:42:15	JLKY	Immunome Announces Proposed $200M Public Offering of Common Stock	"Immunome, Inc. (""Immunome"") (NASDAQ: JLKY ), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering."
2024-02-13 16:54:11	RDJG	Larimar Therapeutics Announces Proposed Underwritten Public Offering; No Size Or Amount Disclosed	"Larimar Therapeutics, Inc. (""Larimar"") (NASDAQ: RDJG ), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering. Leerink Partners, Citigroup and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering. Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp (CTI-1601) and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses."
2024-02-14 08:07:00	ZNTC	ToughBuilt Industries Announces Pricing Of $3.5M Public Offering Of 772,628 Shares Of Its Common Stock At A Price Of $4.53/Share	"ToughBuilt Industries, Inc. (""ToughBuilt"" or the ""Company"") (NASDAQ: ZNTC , TBLTW))))), today announced the pricing of a public offering of 772,628 shares of its common stock (or pre-funded warrants in lieu thereof), together with warrants to purchase up to 772,628 shares of its common stock at an offering price to the public of $4.53 per share (or pre-funded warrant) and associated warrant. The warrants will have an exercise price of $4.405 per share, be exercisable upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about February 16, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $3.5 million, before deducting the placement agent's fees and other offering expenses payable by ToughBuilt. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital."
2024-02-14 08:41:19	ABJ	CORRECTION: Ohmyhome Prices Upsized $4.8M Public Offering Of 3,555,555 Ordinary Shares At $1.35/ Share	"Ohmyhome Ltd. (NASDAQ: ABJ , ""Ohmyhome""))))), a one-stop-shop property technology platform providing end-to-end property solutions and services to buy, sell, rent, and renovate homes, as well as property management services for condominiums in Singapore, today announced the pricing of its upsized public offering of 3,555,555 ordinary shares at a public offering price of $1.35 per ordinary share. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.8 million. The offering is expected to close on February 16, 2024, subject to customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with this offering."
2024-02-14 09:02:23	TWSJ	Unusual Machines Announces Pricing Of $5M Initial Public Offering Of 1.25M Shares Of Common Stock At A Price Of $4/Share	"Unusual Machines, Inc. (""Unusual Machines"" or the ""Company""), an emerging leader in first-person view (FPV) drone technology, announced today the pricing of its initial public offering (the ""Offering"") of 1,250,000 shares of common stock at a public offering price of $4.00 per share. The shares are expected to begin trading on the NYSE American on February 14, 2024, under the ticker symbol ""TWSJ"". The Company expects to receive aggregate gross proceeds of $5.0 million from the Offering, before deducting underwriting discounts and other related expenses. The Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 common shares at the public offering price (the ""Over-allotment Option""), less underwriting discounts. The Offering is expected to close on or about February 16, 2024, subject to the satisfaction of customary closing conditions. Proceeds from the Offering will be used to pay the cash portion of the purchase price for the Fat Shark and Rotor Riot acquisitions, working capital, and general corporate purposes."
2024-02-14 16:36:50	ZFFZ	Prime Medicine Announces $125M Proposed Public Offering Of Common Stock	Prime Medicine, Inc. (NASDAQ: ZFFZ ), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, Jefferies, TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering. Chardan is acting as the lead manager for the proposed offering.
2024-02-14 18:55:01	ZGGA	Bakkt Shelf Registration Statement Declared Effective By The SEC; Registration Statement Allows Bakkt, So Long As It Is Effective, To Raise Up To An Aggregate Of $150M Of Capital In One Or More Offerings Over The Subsequent 3-Years	"Bakkt Holdings, Inc. (""Bakkt"") (NYSE: ZGGA ) announced that its ""universal shelf"" registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (the ""SEC"") on February 14, 2024. This registration statement allows Bakkt, so long as it is effective, to raise up to an aggregate of $150 million of capital in one or more offerings over the subsequent three years. If Bakkt decides to raise capital in a future offering using such registration statement, Bakkt will describe the specific details of that future offering in a prospectus supplement that is filed with the SEC. Bakkt believes the flexibility of a shelf registration on Form S-3 will provide the Company with significant benefits when raising capital in the future. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy the securities that are proposed to be registered on such registration statement, nor shall there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state. Any offer of securities will occur solely by means of the prospectus included in the registration statement and one or more prospectus supplements that would be issued at the time of the offering."
2024-02-15 08:04:00	XTRS	Vivos Therapeutics Announces Exercise Of Warrants For ~$4M Aggregate Gross Proceeds	"Vivos Therapeutics, Inc. (""Vivos"" or the ""Company"") (NASDAQ: XTRS ), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (EDZ)), today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Vivos common stock for gross proceeds to the Company of approximately $4.0 million. As part of this transaction, the investor agreed to exercise the existing warrant (which was originally issued in November 2023 and had an exercise price of $3.83 per share) at a revised exercise price of $4.02 per share. The resale of the shares of common stock issuable upon exercise of the warrant were registered pursuant to an effective registration statement on Form S-1 (No. 333-275726). In consideration for the immediate exercise of the existing warrant for cash, Vivos has agreed to issue to the investor two new unregistered warrants, each to purchase 735,296 shares of common stock (or an aggregate of 1,470,592 shares) at an exercise price of $5.05 per share. The new warrants will be exercisable immediately upon issuance. Such warrants are identical, except that one warrant has a term of five years and the second warrant has a term of eighteen months. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering."
2024-02-15 09:26:27	AICR	Tevogen Bio Entered Into A Securities Purchase Agreement With An Investor Pursuant To Which The Investor Agreed To Purchase Shares Of Series A Preferred Stock Of The Company For An Aggregate Purchase Price Of $8M	"On February 14, 2024, Tevogen Bio Holdings Inc. (the ""Company"") (NASDAQ: AICR ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified F cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million. ""We are excited to begin our journey as a public company with this additional investment,"" said Dr. Ryan Saadi, the Company's Chief Executive Officer and Chairperson. ""We believe Tevogen's patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen's mission to become the very first life science company offering commercially attractive and affordable personalized F cell therapies for large patient populations in virology, oncology, and neurology."" The shares of Series A Preferred Stock will be issued in the first quarter and will be convertible into a total of 2,000,000 shares of the Company's common stock at the election of the holder. The Series A Preferred Stock is subject to a call right providing the Company the right to call the stock if the volume weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the underlying common stock. The Series A Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year."
2024-02-16 09:30:20	WYVO	China Natural Resources, Inc. Announces Registered Direct Placement Of $3.27M Of 1,487,870 Common Shares And Private Placement Warrants At A Price Of $2.20/Unit	"CHINA NATURAL RESOURCES, INC. (NASDAQ: WYVO ) (the ""Company"") announced that it has entered into a securities purchase agreement with certain institutional investors for a registered direct placement of approximately $3.27 million of common shares, no par value, at a price of $2.20 per share. The Company will issue a total of 1,487,870 common shares to the institutional investors. In a concurrent private placement, the Company will also issue to the investors common share warrants (""Warrants"") initially exercisable for the purchase of up to 1,115,903 common shares at an exercise price of $3.00 per share, which Warrants will have a term of 42 months from the date of issuance. The net proceeds from this offering will be used for general working capital purposes. The completion of the offering is expected to occur on or about February 21, 2024, subject to the satisfaction of customary closing conditions. FT Global Capital, Inc. acted as the exclusive placement agent for the transaction."
2024-02-20 06:34:18	YFGA	Iovance Biotherapeutics Prices $211M Underwritten Offering of Common Stock to Support the Commercial Launch of AMTAGVI	Iovance Biotherapeutics, Inc. (NASDAQ: YFGA ) (&quot;Iovance&quot; or &quot;Company&quot;), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (&quot;TIL&quot;) therapies for patients with cancer, today announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $211 million. The offering is expected to close on or about February 22, 2024, subject to customary closing conditions. Iovance intends to use the proceeds from this offering to support the commercial launch of AMTAGVI&trade;, to fund ongoing clinical programs including its NSCLC registrational study, IOV-LUN-202, and its frontline advanced melanoma Phase 3 confirmatory trial, TILVANCE-301, to continue the development of its pipeline candidates, and for other general corporate purposes.
2024-02-20 09:14:04	CEHL	two And LatAm Logistic Properties S.A. Announces That It Has Entered Into A Subscription Agreement For A Private Placement Of 1.5M Ordinary Shares At A Price Of $10 Per Share	"- two (NYSE: CEHL ) (""CEHL"") today announced that it has entered into a subscription agreement for a private placement of 1.5 million ordinary shares at a price of $10.00 per share, which is expected to yield gross proceeds of $15 million, to be consummated in connection with the closing of its business combination with LatAm Logistic Properties S.A. (d/b/a LatAm Logistic Properties ) (""LLP""). In the business combination, each of LLP and CEHL will merge with newly-formed subsidiaries of Logistic Properties of the Americas, a newly-formed holding company (""Pubco""), and Pubco will be the publicly traded parent company of each of CEHL and LLP following the consummation of the business combination. ""As a leading industrial and logistics real estate company in Central and South America, LLP continues to demonstrate the platform value of vertically integrated development, ownership, and management of institutional quality, class A industrial real estate,"" said Thomas Hennessy, Chairman and CEO of CEHL. ""This investment affirms that institutional investors recognize this value and have strong conviction in LLP's management. As we approach the final stages of closing on this important transaction, this common equity investment will support the growth plan to drive value for our stakeholders."" ""We are excited about this strategic investment, which underscores the confidence in our business model and growth prospects,"" said Esteban Saldarriaga, CEO of LLP. ""This equity infusion will further strengthen our position as a leading player in our region's industrial and logistics real estate sector, enabling us to pursue our expansion plans, including Mexico, and positioning us to deliver high-quality assets for our current and prospective tenants."" On August 15, 2023, LLP and CEHL entered into a definitive business combination agreement that would result in LLP becoming a publicly traded company. As a result of the business combination, LLP and CEHL shareholders will exchange their shares for shares in Pubco, in accordance with the terms of the business combination agreement. Upon closing of the transaction, Pubco's ordinary shares are expected to be listed on the New York Stock Exchange (""NYSE"") under the new ticker symbol ""LPA."""
2024-02-21 06:05:58	YMRZ	Concurrent To Twill Acquisition Deal, Dariohealth Priced $22.4M Equity Financing	Dario priced a $22.4 million private placement of convertible preferred stock, priced at the market under Nasdaq rules, with participation from investors from both companies. Pursuant to the terms of private placement, Dario agreed to issue shares of newly designated convertible preferred stock (the &quot;Preferred Stock&quot;). Each share of Preferred Stock will be sold at $1,000 per share, with conversion prices of $2.02 and $2.14, raising gross proceeds of $22.4 million
2024-02-21 06:52:59	DZY	Piedmont Lithium Sells 1.2B Sayona Mining Shares for A$0.052/Share	Piedmont Lithium (&quot;Piedmont&quot; or the &quot;Company&quot;) (NASDAQ: DZY , ASX: DZY))))), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced the Piedmont Lithium (&quot;Piedmont&quot; or the &quot;Company&quot;) (NASDAQ: DZY , ASX: DZY))))), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced the sale of the shares it held in Sayona Mining (&quot;Sayona&quot;) (ASX: SYA). The Company has agreed to sell 1,152.2 million shares of Sayona for A$0.052 Australian Dollars (&quot;A$&quot;) per share through a secondary block sale via Canaccord Genuity. The sale price represents a premium to the 20-day volume weighted average price and will result in gross proceeds of approximately A$59.9 million, or US$39.4 million for Piedmont. Following the transaction and some smaller recent public market share sales, Piedmont will no longer hold any shares of Sayona. The sale of these shares has no impact on Piedmont's joint venture or offtake position with Sayona Quebec.
2024-02-21 12:01:19	IWJB	On Feb 20, 2024 Wetouch Technology Announced Pricing Of $10.8M Public Offering Of Common Stock; Co Began Trading On The Nasdaq Capital Market Today	"Wetouch Technology Inc. (NASDAQ: IWJB ) (""Wetouch"" or the ""Company""), a Nevada company, through its wholly-owned subsidiary, engaged in the research, development, manufacturing, sales and servicing of projected capacitive touchscreens, announced today the pricing of an underwritten public offering of 2,160,000 shares of common stock at a price to the public of $5.00 per share (the ""Offering""). The gross proceeds to the Company from this Offering are expected to be $10.8 million, prior to deducting offering expenses, commissions and underwriting discounts. In addition, the Company granted the underwriters a 45-day option to purchase up to 324,000 additional shares of common stock at the public offering price per share, less commissions and underwriting discounts. The Offering is expected to close on February 23, 2024, subject to the satisfaction of customary closing conditions. Proceeds from the Offering will be used for the construction of a new factory, facilities and office buildings, the purchase of two production lines in the new factory, research and development, the repayment of convertible promissory notes, and working capital and general corporate purposes. The Offering is being conducted on a firm commitment basis. WestPark Capital, Inc. (""WestPark""), Craft Capital Management LLC, and R.F. Lafferty & Co., Inc. are the underwriters for the Offering, with WestPark being the lead book running manager for the Offering. The Crone Law Group P.C. is acting as U.S. counsel to the Company and Bevilacqua PLLC is acting as U.S. counsel to the underwriters in connection with the Offering. The Company is also pleased to announce its common stock has been approved to list on The Nasdaq Capital Market (""Nasdaq"") under its current ""IWJB"" ticker symbol and is expected to begin trading on Nasdaq on February 21, 2024."
2024-02-21 16:04:28	DWH	Symbotic Announces Primary Of 5M Shares Of Class A Common Stock And Secondary Offering Of 5M Shares Of Class A Common Stock	"Symbotic Inc. (NASDAQ: DWH ), a leader in A.I.-enabled robotics technology for the supply chain, today announced that it has commenced an underwritten public offering (the ""Offering"") of its Class A common stock by the Company and certain trusts for the benefit of, and entities controlled by, Richard Cohen, the Company's founder, chairman and chief executive officer, or members of his family (the ""Selling Securityholders""). The Company is offering 5,000,000 shares of its Class A common stock and the Selling Securityholders are offering 5,000,000 shares of Class A common stock. Symbotic expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. Symbotic currently intends to use the net proceeds from the Offering for general corporate purposes. The Selling Securityholders will receive all the net proceeds from the sale of shares of Class A common stock sold by them in the Offering. Goldman Sachs & Co. LLC is acting as sole book-running manager of the Offering."
2024-02-21 16:38:45	LFY	Sunrun Announces Proposed Private Offering Of $475M Of Convertible Senior Notes	"Sunrun Inc. (NASDAQ: LFY ) (""Sunrun"") today announced that it intends to offer, subject to market conditions and other factors, $475 million aggregate principal amount of convertible senior notes due 2030 (the ""notes"") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Sunrun also intends to grant the initial purchasers of the notes the option to purchase up to an additional $75 million aggregate principal amount of the notes within a 13-day period beginning on, and including, the date on which the notes are first issued. The notes will be senior, unsecured obligations of Sunrun and will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2024. The notes will mature on March 1, 2030, unless earlier converted, redeemed or repurchased. The notes will be convertible into cash, shares of Sunrun's common stock or a combination of cash and shares of Sunrun's common stock, at Sunrun's election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering. Sunrun intends to use (i) a portion of the net proceeds from the offering to repurchase a portion of its 0% Convertible Senior Notes due 2026 (the ""2026 notes"") concurrently with the pricing of the offering in privately negotiated transactions effected with or through one of the initial purchasers of the notes or its affiliate, (ii) a portion of the net proceeds from the offering to pay the cost of the capped call transactions described below, and (iii) the remainder of the net proceeds from the offering to repay outstanding debt and for other general corporate purposes, which may include working capital, capital expenditures, and potential acquisitions and future transactions. However, it has not designated any specific uses and has no definitive agreements with respect to any material acquisition or strategic transaction. Holders of the 2026 notes that are repurchased in the concurrent repurchases described above may purchase shares of Sunrun's common stock in the open market to unwind any hedge positions they may have with respect to the 2026 notes. These activities may increase (or reduce the size of any decrease in) the trading price of Sunrun's common stock and, if conducted concurrently with the offering, may result in a higher initial conversion price for the notes Sunrun is offering."
2024-02-21 16:46:06	OAJE	NEXGEL Announces $975,000 Registered Direct Offering Led By Insiders	NEXGEL, Inc. (&quot;NEXGEL&quot; or the &quot;Company&quot;) (NASDAQ: OAJE ), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 462,090 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 231,040 shares of common stock for a combined offering purchase price of $2.11 per share of common stock in a registered direct offering priced. The warrants will have an exercise price of $4.00 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance. NEXGEL insiders, including members of the management team and Board of Directors, participated in the offering. Insiders are subject to a six-month lock-up period from the date of closing. The gross proceeds from the offering are approximately $975,000, before deducting offering expenses. Adam Levy, CEO of NEXGEL, commented, &quot;After capital expenditures and strategic acquisition investments made in 2023, management and the Board agreed to provide additional working capital to the Company along with existing and new investors. We believe this capital will allow us to comfortably continue to operate the business and strengthens our balance sheet as we approach significant growth opportunities in the remainder of this year.&quot; Alere Financial Partners, LLC, a division of Cova Capital Partners, LLC acted as the exclusive placement agent for the offering.
2024-02-21 17:11:11	ORMJ	Supermicro Announces Proposed Offering Of $1.5B Of Convertible Senior Notes Due 2029	"Super Micro Computer, Inc. (NASDAQ: ORMJ ) (""Supermicro"" or the ""Company""), a Total IT Solution Manufacturer for AI, Cloud, Storage, and 5G/Edge, today announced that it intends to offer, subject to market conditions and other factors, $1.5 billion aggregate principal amount of convertible senior notes due 2029 (the ""Convertible Notes""). The Convertible Notes are to be offered and sold to ""qualified institutional buyers"" pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $225.0 million aggregate principal amount of the Convertible Notes. The Convertible Notes will be senior, unsecured obligations of the Company and will accrue interest payable semi-annually in arrears. The Convertible Notes will mature on March 1, 2029, unless earlier redeemed, repurchased or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding September 1, 2028, the Convertible Notes will be convertible only upon the satisfaction of certain conditions and during certain periods, and on and after September 1, 2028, at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date, the Convertible Notes will be convertible regardless of these conditions. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock at the Company's election. The initial conversion rate, interest rate and other terms of the Convertible Notes will be determined at the time of pricing in negotiations with the initial purchasers of the Convertible Notes. In connection with the pricing of the Convertible Notes, the Company expects to enter into privately negotiated capped call transactions with one or more financial institutions which may include one or more of the initial purchasers or their affiliates (the ""option counterparties""). If the initial purchasers exercise their option to purchase additional Convertible Notes, the Company expects to enter into additional capped call transactions with the option counterparties. The capped call transactions are expected generally to reduce the potential dilution to the Company's common stock upon conversion of the Convertible Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of the Convertible Notes, as the case may be, with such reduction and/or offset subject to a cap. In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to the Company's common stock and/or purchase shares of the Company's common stock concurrently with or shortly after the pricing of the Convertible Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company's common stock or the Convertible Notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company's common stock and/or purchasing or selling the Company's common stock or other securities of the Company in secondary market transactions following the pricing of the Convertible Notes and prior to the maturity of the Convertible Notes (and are likely to do so during any observation period related to a conversion of the Convertible Notes or following any repurchase of the Convertible Notes by the Company to the extent the Company elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or a decrease in the market price of the Company's common stock or the Convertible Notes, which could affect noteholders' ability to convert the Convertible Notes, and, to the extent the activity occurs during any observation period related to a conversion of the Convertible Notes, it could affect the amount and value of the consideration that noteholders will receive upon conversion of the Convertible Notes. The Company expects to use a portion of net proceeds of the offering to fund the cost of entering into the capped call transactions. The Company intends to use the remainder of the net proceeds from the offering for general corporate purposes, including to fund working capital for growth and business expansion. If the initial purchasers exercise their option to purchase additional Convertible Notes, the Company intends to use a portion of the net proceeds from the sale of additional Convertible Notes to fund the cost of entering into additional capped call transactions. This press release is neither an offer to sell nor a solicitation of an offer to buy the Convertible Notes or the shares of the Company's common stock issuable upon conversion of the Convertible Notes, if any, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be made only by means of a private offering memorandum. The offer and sale of the Convertible Notes and the shares of the Company's common stock issuable upon conversion of the Convertible Notes, if any, have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements."
2024-02-21 17:39:28	FWC	Parsons Announces Offering Of $700M Of Convertible Senior Notes Due 2029	"Parsons Corporation (NYSE: FWC ) announced today that it intends to offer, subject to market and other conditions, $700.0 million aggregate principal amount of convertible senior notes due 2029 (the ""notes"") in a private placement. Parsons also expects to grant the initial purchasers in the offering an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $100.0 million aggregate principal amount of notes. The notes will be senior unsecured obligations of Parsons. The notes will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2024. The notes will mature on March 1, 2029, unless earlier repurchased, redeemed or converted. Prior to October 1, 2028, the notes will be convertible at the option of the holders only upon the occurrence of specified events, and thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the notes will be convertible at any time. Upon conversion, the notes will settle for cash and, if applicable, shares of Parsons' common stock. Parsons may redeem for cash all or any portion of the notes, at its option, on or after March 8, 2027 and before the 51st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Parsons' common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. Parsons intends to use a portion of the net proceeds from the sale of the notes to fund the cost of entering into the capped call transactions described below. Additionally, Parsons expects to use a portion of the net proceeds from the offering to repurchase a portion of its outstanding 0.25% Convertible Senior Notes due 2025 (the ""Existing Convertible Notes"") concurrently with and/or shortly after the pricing of the offering in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. Parsons intends to use the remainder of the net proceeds from the offering for general corporate purposes, including but not limited to, potential acquisitions and working capital. If the initial purchasers exercise their option to purchase additional notes, Parsons expects to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. Any remaining proceeds will be used for general corporate purposes, including but not limited to, potential acquisitions and working capital. Parsons expects that some or all of the holders of the Existing Convertible Notes that are repurchased in the concurrent repurchases described above may enter into or unwind various derivatives with respect to Parsons' common stock or purchase shares of Parsons' common stock in open market transactions to unwind hedge positions they may have with respect to their investment in the Existing Convertible Notes concurrently with and/or shortly after the pricing of the offering. These transactions may place upward pressure on the trading price of Parsons' common stock, causing the common stock to trade at higher prices than would be the case in the absence of these transactions, which could increase the initial conversion price of the notes. In connection with issuing the Existing Convertible Notes, Parsons entered into convertible note hedge transactions (the ""existing convertible note hedge transactions"") and warrant transactions (the ""existing warrant transactions,"" and, together with the existing convertible note hedge transactions, the ""existing call spread transactions"") with certain financial institutions (the ""existing option counterparties""). If Parsons repurchases any of its Existing Convertible Notes, then Parsons intends to enter into agreements with the existing option counterparties concurrently with or shortly after the pricing of this offering to terminate a portion of the existing convertible note hedge transactions in a notional amount corresponding to the principal amount of Existing Convertible Notes repurchased. In addition, Parsons intends to enter into agreements with the existing option counterparties concurrently with or shortly after the pricing of this offering to terminate a portion of the existing warrant transactions with respect to a number of shares equal to the notional shares underlying such Existing Convertible Notes repurchased. In connection with such terminations and the related unwinding of the existing hedge position of the existing option counterparties with respect to such transactions, Parsons expects such existing option counterparties and/or their respective affiliates may purchase or sell shares of Parsons' common stock in the open market and/or enter into or unwind various derivative transactions with respect to Parsons' common stock concurrently with or shortly after the pricing of the notes. This activity could affect the market price of Parsons' common stock and the initial conversion price of the notes. The repurchases of the Existing Convertible Notes and the unwind of the existing call spread transactions described above, and the potential related market activities by holders of the Existing Convertible Notes participating in the repurchases of the Existing Convertible Notes and the existing option counterparties, as applicable, could increase (or reduce the size of any decrease in) or decrease (or reduce the size of any increase in) the market price of Parsons' common stock, which may affect the trading price of the notes offered hereby at that time and the initial conversion price of the notes. In connection with the pricing of the notes, Parsons expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates and/or certain other financial institutions (the ""option counterparties""). The capped call transactions are expected to initially cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Parsons' common stock that will underlie the notes. If the initial purchasers exercise their option to purchase additional notes, Parsons expects to enter into additional capped call transactions with the option counterparties. The capped call transactions are expected generally to reduce the potential dilution to Parsons' common stock upon any conversion of the notes and/or at its election (subject to certain conditions) offset any potential cash payments Parsons is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If, however, the market price per share of Parsons' common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price per share exceeds the cap price of the capped call transactions. In connection with establishing their initial hedges of the capped call transactions, the option counterparties and/or their respective affiliates expect to enter into various derivative transactions with respect to Parsons' common stock and/or purchase shares of Parsons' common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price per share of Parsons' common stock or the notes at that time. In addition, the option counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Parsons' common stock and/or purchasing or selling Parsons' common stock or other securities of Parsons in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and (x) are likely to do so during any observation period related to a conversion of notes and (y) are likely to do so following any repurchase of notes by Parsons if Parsons elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or a decrease in the market price per share of Parsons' common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the number of shares of Parsons' common stock and/or value of the consideration that noteholders will receive upon conversion of the notes. The offering is being made to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). The offer and sale of the notes and any shares of Parsons' common stock issuable upon conversion of the notes have not been and are not expected to be registered under the Securities Act, or under any state securities laws, and, unless so registered, the notes and such shares may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction."
2024-02-22 08:06:57	QFEE	Motus GI Holdings Enters Into Definitive Agreement For The Exercise Of An Outstanding Series B Common Stock Purchase Warrant Held By An Institutional Investor To Purchase An Aggregate Of 2,933,334 Shares Of Common Stock For ~$2.7M	"Motus GI Holdings, Inc. (NASDAQ: QFEE , or ""Motus"" or ""the Company""))))), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company's common stock for gross proceeds to the Company of approximately $2.7 million. As part of this transaction, the investor agreed to exercise the existing Series B common stock purchase warrant (which was originally issued in December 2023 and had an exercise price of $1.50 per share) at a revised exercise price of $0.925 per share. The shares of common stock issuable upon exercise of the warrant were registered pursuant to an effective registration statement on Form S-1 (No. 333-275121). In consideration for the immediate exercise of the existing warrant for cash, the Company has agreed to issue to the investor two new unregistered warrants, each to purchase 2,200,000 and 2,200,001 shares of common stock (or an aggregate of 4,400,001 shares) at an exercise price of $0.74 per share, respectively. The new warrants will be exercisable immediately upon issuance. Such warrants are identical, except that the first 2,200,000 warrants have a term of five years from the date of issuance and the second 2,200,001 warrants have a term of eighteen months from the date of issuance. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering. The transaction is expected to close no later than February 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes."
2024-02-22 09:29:31	ORMJ	What's Going On With Super Micro Computer Stock Thursday?	Super Micro Computer Inc (NASDAQ: ORMJ ) shares are trading higher Thursday. The stock appears to be moving in sympathy with Nvidia , despite announcing an offering late Wednesday . CSEK Q4 Earnings: Nvidia reported fourth-quarter revenue of $22.1 billion, which beat the consensus estimate of $20.62 billion. The company reported quarterly earnings of $5.16 per share, which beat estimates of $4.64 per share. Nvidia guided for fiscal first-quarter revenue of approximately $24 billion, plus or minus 2%, versus estimates of $22.16 billion. &#8220;Accelerated computing and generative AI have hit the tipping point. Demand is surging worldwide across companies, industries, and nations,&#8221; said Jensen Huang , founder and CEO of Nvidia. On the conference call, the Nvidia CEO said he believes every software enterprise company that is deploying software will run on Nvidia AI enterprise software in the future. Check This Out: Jensen Huang Predicts Every Enterprise On The Planet Will Eventually Run On Nvidia's Operating System For AI' What Else: Super Micro shares have rallied more than 150% since the start of the year, largely driven by AI optimism. On Tuesday, Super Micro announced that it's expanding its portfolio of AI solutions to enable customers to leverage the power of AI in edge locations using Super Micro application-optimized servers with Nvidia GPUs. Late Wednesday, Super Micro announced a proposed offering of $1.5 billion of convertible senior notes due 2029. The company said it expects to use a portion of net proceeds to fund the cost of entering into capped call transactions, as well as for general corporate purposes including funding working capital for growth and business expansion. ORMJ Price Action: Super Micro shares were up 11.5% at $818.50 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-02-22 17:14:22	JDC	Royal Caribbean Group Announces Upsizing And Pricing Of $1.25B Offering Of Senior Unsecured Notes To Refinance Its Senior Notes Due 2027	"Royal Caribbean Cruises Ltd. (NYSE: JDC) (the ""Company"") today announced that it has priced its private offering of $1.25 billion aggregate principal amount of 6.25% senior unsecured notes due 2032 (the ""Notes""). The aggregate principal amount of Notes to be issued was increased to $1.25 billion. The Notes will mature on March 15, 2032. The Notes are expected to be issued on or around March 7, 2024, subject to customary closing conditions. The Company intends to use the proceeds from the sale of the Notes, together with cash on hand and/or borrowings under the Company's revolving credit facilities, to redeem all of the outstanding 11.625% Senior Notes due 2027 (including to pay fees and expenses in connection with such redemption)."
2024-02-22 17:15:17	HFJU	Colliers International Group Inc. Announces $300M Bought Deal Public Offering Of Equity	"Colliers International Group Inc. (NASDAQ: HFJU ) (""Colliers"" or the ""Company"") has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and J.P. Morgan, under which the underwriters have agreed to buy on a ""bought deal"" basis 2,479,500 subordinate voting shares (the ""Subordinate Voting Shares""), at a price of US$121.00 per Subordinate Voting Share for gross proceeds of approximately US$300 million (the ""Offering""). Colliers has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The Offering is expected to close on or about February 28, 2024. The net proceeds of the Offering will be used to repay balances outstanding on the Company's credit facility and are intended to create additional capacity to fund potential future acquisition opportunities and growth initiatives, and for general corporate purposes."
2024-02-23 08:03:12	YYEW	Venus Concept Announces $1.2M Registered Direct Offering Priced At $1.465/Share	Venus Concept entered into definitive agreements for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 817,748 shares of common stock at an exercise price of $1.34 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance.
2024-02-26 06:27:42	ECD	ECD Selling Shareholders to Offload 15.5M Shares Via Secondary Stock Offering	ECD Inc. (&quot;ECD&quot; or the &quot;Company&quot;) (NASDAQ: ECD ), a leading global alternative asset management firm, today announced that certain stockholders of the Company (the &quot;Selling Stockholders&quot;) intend to offer 15,526,915 shares of ECD's Class A common stock, par value $0.001 per share (the &quot;Common Stock&quot;), pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the &quot;SEC&quot;). The offering consists entirely of secondary shares to be sold by the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.
2024-02-26 08:38:22	OXWK	Owlet Announces $9M Private Placement	Pursuant to the terms of the definitive agreements and the closing of the private placement, Owlet will issue shares of Series B preferred stock that are convertible into approximately 1.2 million shares of common stock. Each purchaser will also receive a warrant to purchase 150% of the number of shares of common stock into which their Series B preferred stock is convertible. The warrants will have a per share exercise price of $7.7125 and will be exercisable by the holder at any time on or after the issuance date for a period of five years.
2024-02-26 16:06:31	PCNZ	Five9 Announces Proposed $600M Convertible Notes Offering	"Five9, Inc. (NASDAQ: PCNZ ), the Intelligent CX Platform provider, today announced its intention to offer, subject to market conditions and other factors, $600 million aggregate principal amount of convertible senior notes due 2029 (the ""notes"") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Act""). Five9 also expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $90 million aggregate principal amount of the notes. The notes will be senior, unsecured obligations of Five9, and interest will be payable semi-annually in arrears. The notes will be convertible into cash, shares of Five9's common stock (""common stock""), or a combination thereof, at Five9's election. The interest rate, initial conversion rate and other terms of the notes are to be determined upon pricing of the offering. The notes will also be redeemable at the option of Five9 after a specified date if certain conditions are met. Five9 expects to use a portion of the net proceeds of the offering of the notes to pay the cost of the capped call transactions described below and to repurchase a portion of its outstanding 0.500% convertible senior notes due 2025 (the ""2025 notes"") (such transactions, the ""2025 note repurchases""). The remainder of the net proceeds from the offering would be used for working capital and other general corporate purposes. The terms of any 2025 note repurchases will depend on factors, including the trading price of the 2025 notes at the time of such 2025 note repurchases. Five9 also expects that holders of the 2025 notes that sell their 2025 notes to Five9 may enter into or unwind various derivatives with respect to Five9's common stock and/or purchase or sell shares of Five9's common stock in the market to hedge their exposure in connection with these transactions. These activities could increase (or reduce the size of any decrease in) the market price of Five9's common stock or the notes. These activities could affect the market price of Five9's common stock concurrently with the pricing of the notes, and could also result in higher effective conversion prices for the notes. In connection with the pricing of the notes, Five9 expects to enter into capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions (the ""option counterparties""). The capped call transactions are expected generally to reduce potential dilution to Five9's common stock upon any conversion of the notes and/or offset any potential cash payments Five9 is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap based on the cap price. The cap price of the capped call transactions will be determined upon pricing of the notes. If the initial purchasers exercise their option to purchase additional notes, Five9 expects to enter into additional capped call transactions with the option counterparties. Five9 expects that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates will purchase shares of Five9's common stock and/or enter into various derivative transactions with respect to Five9's common stock concurrently with, or shortly after, the pricing of the notes. These activities could increase (or reduce the size of any decrease in) the market price of Five9's common stock or the notes at that time. In addition, Five9 expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to Five9's common stock and/or by purchasing or selling shares of Five9's common stock or other securities of Five9 in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so (x) during any observation period related to a conversion of notes and (y) following any repurchase of notes by Five9 if it elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). These activities could cause or avoid an increase or a decrease in the market price of Five9's common stock or the notes, which could affect the ability of noteholders to convert the notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of the notes, could affect the amount and value of the consideration that noteholders will receive upon conversion of the notes. In connection with the issuance of the 2025 notes, Five9 entered into capped call transactions (the ""existing capped call transactions"") with certain financial institutions (the ""existing option counterparties""). If Five9 repurchases any of the 2025 notes, it expects to enter into agreements with the existing option counterparties to terminate a portion of the existing capped call transactions in a notional amount corresponding to the amount of 2025 notes purchased. In connection with the termination of any of these transactions, Five9 expects the existing option counterparties or their respective affiliates to sell shares of Five9's common stock and/or unwind various derivatives to unwind their hedge in connection with those transactions. This activity could decrease (or reduce the size of any increase in) the market price of Five9's common stock at that time and it could decrease (or reduce the size of any increase in) the market value of the notes. In connection with the termination of the existing option transactions, Five9 will receive payments in amounts that depend in part on the market price of Five9's common stock over a valuation period following the pricing of the notes. The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Act. Neither the notes nor the shares of common stock issuable upon conversion of the notes, if any, have been, nor will be, registered under the Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful."
2024-02-26 16:12:29	IJBN	Progress Software Announces Proposed $350M Convertible Senior Notes Offering	"Progress Software Corporation (NASDAQ: IJBN ) (""Progress"") today announced that it intends to offer, subject to market and other conditions, $350.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the ""Notes""), to be sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Progress also expects to grant to the initial purchasers of the Notes an option to purchase up to an additional $52.5 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued, solely to cover overallotments. The Notes will be Progress' senior unsecured obligations. The Notes will mature on March 1, 2030, unless earlier converted, redeemed or repurchased. Progress will satisfy its conversion obligations by paying cash up to the aggregate principal amount of Notes to be converted and pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election, in respect of the remainder. The interest rate, the initial conversion rate and the other terms of the Notes will be determined upon pricing of the offering. Progress intends to use the net proceeds from the offering (i) to repay amounts outstanding under its term loan credit facility, (ii) to fund the cost of entering into the capped call transactions described below, (iii) to repurchase shares of its common stock in an amount up to $25 million, pursuant to its existing share repurchase program concurrently with the pricing of the offering in privately negotiated transactions effected through one or more of the initial purchasers or their affiliates and (iv) for general corporate purposes, which may include repayment of other indebtedness. In connection with the pricing of the Notes, Progress expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions (the ""option counterparties""). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of common stock initially underlying the Notes. If the initial purchasers exercise their option to purchase additional Notes, then Progress expects to enter into additional capped call transactions with the option counterparties. The capped call transactions are expected generally to reduce the potential dilution to Progress' common stock upon any conversion of the Notes and/or offset any potential cash payments Progress is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions and the premium payable will be determined at the time of pricing of the offering. In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to purchase shares of Progress' common stock and/or enter into various derivative transactions with respect to Progress' common stock concurrently with or shortly after the pricing of the Notes. This activity could increase (or reduce the size of any decrease in) the market price of Progress' common stock or the Notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Progress' common stock and/or purchasing or selling Progress' common stock or other securities issued by Progress in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and (x) are likely to do so during any observation period related to a conversion of the Notes, following any redemption of the Notes by Progress or following any repurchase of the Notes by Progress in connection with any fundamental change and (y) are likely to do so following any repurchase of the Notes by Progress other than in connection with any such redemption or any such fundamental change if Progress elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or a decrease in the market price of Progress' common stock or the Notes, which could affect a Noteholder's ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of the Notes, it could affect the number of shares of Progress' common stock and value of the consideration that a Noteholder will receive upon conversion of the Notes. In addition, if any such capped call transaction fails to become effective, whether or not the offering of the Notes is completed, the option counterparty party thereto may unwind its hedge positions with respect to Progress' common stock, which could adversely affect the value of Progress' common stock and, if the Notes have been issued, the value of the Notes. The Notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The Notes and any shares of Progress' common stock issuable upon conversion of the Notes have not been registered under the Securities Act, or any state securities law, and the Notes and any such shares may not be offered or sold in the United States or to any U.S. persons absent registration under, or pursuant to an exemption from, or in a transaction not subject to, the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy the Notes or any shares of Progress' common stock issuable upon conversion of the Notes, nor shall there be any offer, solicitation or sale of any Notes or any such shares of Progress' common stock issuable upon conversion of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful."
2024-02-26 16:44:19	IVHS	Eightco Announces Early Repayment Of Debt, Private Placement Priced At A Purchase Price Of $0.82 Per Share And Issued To Certain Investors Promissory Notes; Announces Certain Changes At The Parent Company Level	"Eightco Holdings Inc. (NASDAQ: IVHS ) (the ""Company"") today announced that it has, ahead of schedule, made its final repayment pursuant to the Prepayment and Redemption Agreement, dated as of October 23, 2023, by and between the Company and Hudson Bay Master Fund Ltd. (""Hudson Bay"") in remaining principal due under the Senior Secured Convertible Note (the ""Hudson Bay Note"") issued to Hudson Bay in March 2023. In addition to lowering debt levels, the repayment of the Hudson Bay Note now gives the Company the ability to attract efficient capital to grow its subsidiary, Forever 8 Fund, LLC (""Forever 8""). The Company has also conducted a private placement priced at a purchase price of $0.82 per under Nasdaq rules (the ""Private Placement"") and (ii) issued to certain investors promissory notes (the ""Notes""). The Company also announced the appointment and departures of certain officers, as well as the issuance of common stock to reduce and satisfy certain outstanding obligations as related to consultants, former and current employees and directors of the company. The Company continues to reduce ongoing costs at the parent company level so it can focus its resources on delivering growth via its main subsidiary Forever 8. The offer and sale of the shares of common stock offered in the Private Placement and the Notes described above are being offered in private placements under Section 4(a)(2) of the Securities Act of 1933, as amended (the ""Act""), and Regulation D promulgated thereunder and have not been registered under the Act, or applicable state securities laws. Accordingly, the shares of common stock issued in the Private Placement and the Notes may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction."
2024-02-26 16:55:16	DPZ	Coeur Announces $25M Private Placement Of 7,704,725 Flow-Through Shares To Advance Silvertip Exploration	"C$34 million of expected proceeds to fund accelerated exploration program Coeur Mining, Inc. (""Coeur"" or the ""Company"") (NYSE: DPZ ) today announced that it has arranged a private placement (the ""Offering"") of 7,704,725 flow-through common shares of the Company that will qualify as ""flow-through shares"" within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the ""flow-through shares"") for gross proceeds of approximately $25 million (C$34 million), resulting in a 27% premium. The offering will be subject to a four-month hold period. The proceeds of the Offering will be used exclusively for qualifying Canadian Exploration Expenditures (""CEE"") (as such term is defined in the Income Tax Act (Canada), in conducting an exploration and mineral resource evaluation program on the Silvertip Property in British Columbia and Yukon to determine the existence, location, extent, and quality of the silver, lead, and zinc on the Silvertip Property. The flow-through shares will be privately placed with investors in certain provinces in Canada pursuant to applicable exemptions from the prospectus requirements. The initial Offering is expected to close on or about March 8, 2024. The Offering will be subject to the satisfaction or waiver of customary closing conditions. The flow-through shares will only be offered and sold outside the United States pursuant to Regulation S under the Securities Act of 1933, as amended (the ""U.S. Securities Act""). The Offering has not been, and will not be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful."
2024-02-27 07:58:25	PCNZ	Why Software Company Five9 Shares Are Sliding Premarket Today	Five9, Inc. (NASDAQ: PCNZ ) shares are trading lower Tuesday morning. Yesterday, the company announced a proposed $600 million convertible notes offering . The aggregate principal amount of convertible senior notes is due 2029 in a private placement to qualified institutional buyers. Five9 also expects to grant the initial purchasers of the notes a 13-day option to buy up to an additional $90 million principal amount. The interest for senior, unsecured obligations notes will be payable semi-annually in arrears. Five9 anticipates using a portion of the net proceeds from the offering to pay the cost of the capped call transactions and to repurchase a portion of its outstanding 0.500% convertible senior notes due 2025. The company plans to use the remainder of the net proceeds for working capital and other general corporate purposes. Last week, the company reported fourth-quarter revenue of $239.1 million, beating the consensus of $238.00 million, and adjusted EPS of $0.61 exceeded the estimate of $0.49 . As of December 31, 2023, Five9 held cash and equivalents plus marketable investments of $730 million. The company expects FY24 revenue of $1.053 billion-$1.057 billion vs. $1.055 billion estimate . Price Action : PCNZ shares are down 5.35% at $59.99 premarket on the last check Tuesday.
2024-02-27 08:57:19	XPUY	NRx Pharmaceuticals, Inc. Announces Pricing Of $1.5M Underwritten Public Offering Of Common Stock At A Price Of $0.30/Share Together With Investor Commitment For Additional $1M	"NRx Pharmaceuticals, Inc. (NASDAQ: XPUY ), (""NRx Pharmaceuticals"" or the ""Company""), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.30 per share, for aggregate gross proceeds of approximately $1,500,000 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of common stock (or pre-funded warrants in lieu thereof) at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on February 28, 2024, subject to satisfaction of customary closing conditions. EF Hutton LLC is acting as the sole book-runner for the offering. In parallel, the company has received a commitment from an existing investor to invest $1,000,000 on the same terms, to be concluded separately. NRx Pharmaceuticals intends to use the net proceeds from the offering for working capital and general corporate purposes. The Company additionally plans to use the net proceeds from the offering to service current debt obligations, rather than conveying stock for that purpose. ""Investors have asked management to provide context for this transaction and other recent events,"" said Jonathan Javitt, the Company's Chairman. ""Over the past two weeks, management has announced financing transactions that in aggregate create $7.5 million in working capital while incurring approximately 10% dilution to current shareholders. On a mathematical basis, that is highly accretive to current shareholder value while avoiding transactions involving hedge funds and warrants that are common in today's biotechnology marketplace. Common stock transactions without warrant coverage are uncommon in today's market and we thank EF Hutton for bringing fundamental retail investors to our Company. The additional capital extends the Company's runway well past the current clinical trial readouts and creates a solid platform for the launch of HOPE Therapeutics. Moreover, the capital provides the company with resources to service its current debt obligations in cash rather than paying in stock which has in the past created selling pressure on the Company's securities. We look forward to sharing the upcoming data readouts with investors, developing the NRX-101 registration program with Alvogen, and focusing on the execution of our launch of HOPE Therapeutics. Given recent developments disclosed in yesterday's presentation, we anticipate that HOPE will generate its first revenue from sales by the end of Q2 2024."""
2024-02-28 08:02:04	BQDG	Crinetics Pharmaceuticals Announces Oversubscribed $350M Private Placement Of 8,333,334 Shares Of Common Stock At A Price Of $42/Share	"Crinetics Pharmaceuticals, Inc. (NASDAQ: BQDG ) (""Crinetics"" or the ""Company""), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses. The private placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions. The financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P., Driehaus Capital Management, EcoR1 Capital, First Light Asset Management, GordonMD&#xAE; Global Investments LP, Invus, Janus Henderson Investors, Paradigm BioCapital, Perceptive Advisors, Rock Springs Capital, as well as multiple leading mutual funds. Leerink Partners, Piper Sandler, Baird, Citizens JMP, L.C. Wainwright & Co., and LifeSci Capital are acting as placement agents to the Company in connection with the private placement. Crinetics intends to use the net proceeds from the private placement to fund research and development of its clinical-stage product candidates, other research programs, working capital and general corporate purposes."
2024-02-28 11:01:20	KVAW	FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder	Applied Therapeutics Inc (NASDAQ: KVAW ) shares are trading higher on Wednesday after the FDA accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for Classic Galactosemia . The NDA was granted Priority Review status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024. The FDA also noted that it plans to hold an advisory committee meeting to discuss the application. Govorestat was previously granted Pediatric Rare Disease designation and will qualify for a Priority Review Voucher (PRV) upon approval. If approved, govorestat would be the first medication indicated for the treatment of Galactosemia and would be Applied Therapeutics' first commercial product. The company has also submitted a Marketing Authorization Application (MAA) for govorestat for Classic Galactosemia to the European Medicines Agency (EMA), which was validated in December 2023 and is under review by the EMA's Committee for Medicinal Products for Human Use. The company expects a decision by the EMA in the fourth quarter of 2024. Galactosemia is a rare genetic metabolic disease resulting in an inability to metabolize the simple sugar galactose. When not metabolized properly, galactose is converted to the toxic metabolite, galactitol, which causes neurological complications, including deficiencies in speech, cognition, behavior, and motor skills, and also results in juvenile cataracts and ovarian insufficiency (in women). Concurrently, Applied Therapeutics announced a private placement of $100 million with a sale of 12.3 million shares and 2 million pre-funded warrants at $6.999 . The company will use the net proceeds to fund govorestat (AT-007) commercial activities, develop other pipeline candidates, and work capital for general corporate purposes. The capital raised in the Private Placement and current cash and potential milestones expected from its Advanz European licensing partnership are expected to fund the business into 2026. Earlier this month, Applied Therapeutics released interim 12-month results from the ongoing Phase 3 INSPIRE trial of once-daily oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency. The study achieved the primary and several key secondary endpoints . Price Action: KVAW shares are up 36.20% at $7.60 on the last check Wednesday.
2024-02-28 13:53:57	BSFZ	Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?	Wednesday, vTv Therapeutics Inc (NASDAQ: BSFZ ) shares are soaring on a robust session volume of 2.7 million, compared to the average volume of 31.92 K as per the data from Benzinga Pro . The company closed a private placement to healthcare-focused institutional investors, including a life sciences-focused institutional investor, Samsara BioCapital, and the JDRF T1D Fund, of 464,377 shares at $11.81 per share and pre-funded warrants for 3.85 million shares in lieu of vTv common stock in a private placement financing for total gross proceeds of $51 million . Further, in conjunction with the PIPE, vTv has reduced the size of its Board of Directors from nine to seven members, three of whose members will be designated by the new investors, and includes Srinivas Akkaraju, MD, PhD, Founder and Managing General Partner at Samsara. vTv will use the proceeds to fund the first Phase 3 study of its lead product candidate, cadisegliatin, which is expected to be initiated in mid-2024. vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small-molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for type 1 diabetes. Price Action: BSFZ shares are up 103.8% at $17.32 on the last check Wednesday. Photo: Darko Stojanovic from Pixabay
2024-02-28 15:51:40	VTJE	Ampio Pharmaceuticals Files FormRW To Terminate That Certain At The Marketing Offering Agreement, Dated September 18, 2023	"- SEC Filing On February 26, 2024, Ampio Pharmaceuticals, Inc. (the ""Company"") provided a notice to L.C. Wainwright & Co., LLC to terminate that certain At The Marketing Offering Agreement, dated September 18, 2023, by and between the Company and L.C. Wainwright & Co., LLC (the ""ATM Agreement""), establishing an at-the-market equity distribution program for the offer and sale from time to time shares of the Company's common stock, par value $0.0001. In accordance with the ATM Agreement, the termination will be effective March 6, 2024. In connection with the termination of the ATM Agreement, the Company filed on February 28, 2024 a post-effective amendment to its Registration Statement on Form S-3 (File No. 333-274558) to withdraw and remove from registration any and all Company securities that remain unsold or otherwise unissued under such Registration Statement, including shares of the Company's common stock that were covered by the at-the-market offering agreement prospectus filed as part of the Registration Statement."
2024-02-28 16:55:24	FGH	Pinnacle West Announces Proposed Public Offering Of $650M Of Common Stock In Connection With The Forward Sale Agreements	"Pinnacle West Capital Corp. (NYSE: FGH ) (""Pinnacle West"") announced today that it is commencing a registered public offering of $650 million of its common stock in connection with the forward sale agreements described below, subject to market and other conditions. Pinnacle West intends to grant the underwriters the option to purchase up to an additional $97.5 million of its common stock. If such option is exercised, Pinnacle West may, in its sole discretion, enter into additional forward sale agreements with the forward purchasers in respect of, in the aggregate, the number of additional shares of Pinnacle West's common stock that are subject to the exercise of such option, and Pinnacle West currently anticipates that, if such option is exercised, it will do so. Barclays, Citigroup, Mizuho and Wells Fargo Securities are acting as joint book-running managers for this offering. The underwriters may offer shares of Pinnacle West's common stock in transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices."
2024-02-28 17:07:26	FGR	APi Group Announces Launch Of Secondary Public Offering Of Up To An Aggregate Of 8,130,082 Shares Of Common Stock	"APi Group Corporation (NYSE: FGR ) (""APi"" or the ""Company"") announced today that certain funds affiliated with Blackstone Inc. (the ""Blackstone Selling Stockholders"") and Viking Global Investors LP (the ""Viking Selling Stockholders""), collectively, the ""Selling Stockholders"", have commenced an underwritten registered public offering of up to an aggregate of 8,130,082 shares of common stock of the Company that the Selling Stockholders received upon conversion of existing 5.5% Series B Perpetual Convertible Preferred Stock (the ""Series B Preferred Shares""). In connection with the offering, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to 1,219,510 additional shares of common stock held by the Selling Stockholders. APi is not selling any shares of common stock and will not receive any proceeds from the sale of the shares of common stock in the offering. UBS Investment Bank and Citigroup are acting as joint bookrunning managers for the offering and Blackstone Securities Partners L.P. is acting as co-manager."
2024-02-28 17:16:18	JYHT	"Portillo's Inc. Announces Offering Of 8M Class A Common Stock In ""Synthetic Secondary"" Transaction"	Portillo's Inc. (&quot;Portillo's&quot; or the &quot;Company&quot;) (NASDAQ: JYHT ), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced the launch of an underwritten public offering of 8,000,000 shares of Portillo's Class A common stock (&quot;Class A common stock&quot;). The underwriter has a 30-day option to purchase up to an additional 1,200,000 shares of its Class A common stock. The proposed offering is considered non-dilutive, as Portillo's expects to use the net proceeds to (a) purchase limited liability company units of PHD Group Holdings LLC held by certain existing holders (and cancel the associated shares of the Company's Class B common stock (the &quot;Class B common stock&quot;)) and (b) repurchase shares of Class A common stock from certain existing holders, each in a &quot;synthetic secondary&quot; transaction. As a result, Portillo's will not receive any proceeds from this offering. Upon close of the transaction, the Company's total common stock share count, comprised of shares of Class A and Class B common stock, will remain the same; however, the amount of shares of Class A common stock will increase by the same amount of the decrease in the number of shares of Class B common stock. After this offering, it is expected that approximately 61,554,064 shares of Class A common stock and 11,579,326 shares of Class B common stock will be outstanding (or, if the underwriters' over-allotment option is exercised in full, 62,438,104 shares of Class A common stock and 10,695,286 shares of Class B common stock). BofA Securities is acting as the sole underwriter of the offering.
2024-02-29 17:24:58	YEH	YEH Automotive Launches Public Offering To Offer And Sell Its Class A Ordinary Shares; No Terms Disclosed	The Company expects to grant the underwriter a 20-day option to purchase up to an additional 15% of the number of ordinary shares sold in the offering to cover over-allotments, if any. N&G Investment Management Limited has indicated an interest in purchasing ordinary shares in the offering at the public offering price. YEH intends to use the net proceeds from the offering primarily for working capital and general corporate purposes, including continued product development and commercialization.
2024-03-01 14:20:48	RYY	Group 1 Automotive Inc Files For Mixed Shelf Offering, Group 1 Realty, Inc., As Guarantor; Size Not Disclosed	"- SEC Filing We may offer and sell the following securities from time to time in one or more transactions, classes or series and in amounts, at prices and on terms to be determined by market conditions at the time of our offerings: (i) debt securities, which may be senior debt securities or subordinated debt securities; (ii) common stock, $0.01 par value; (iii) preferred stock, $0.01 par value; (iv) warrants to purchase any of the other securities that may be sold under this prospectus; (v) rights to purchase debt securities, common stock, preferred stock or other securities; (vi) depositary shares and (vii) units consisting of one or more classes of these securities. One or more of our subsidiaries, including Group 1 Realty, Inc., may fully and unconditionally guarantee, jointly and severally, any debt securities that we issue. We may offer and sell these securities to or through one or more underwriters, dealers and agents, or directly to purchasers, on a continuous or delayed basis. See ""Plan of Distribution."" This prospectus describes the general terms of these securities and the general manner in which we will offer the securities. The specific terms of any securities we offer will be included in a supplement to this prospectus. The prospectus supplement will also describe the specific manner in which we will offer the securities."
2024-03-04 07:03:36	FC	FC Materials Announces Proposed Offering of $500M Convertible Notes	FC Materials Corp. (NYSE: FC ) (&quot;FC Materials&quot; or the &quot;Company&quot;) today announced that it plans to offer, subject to market and other conditions, $500 million principal amount of its Convertible Senior Notes due 2030 (the &quot;notes&quot;) through a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). FC Materials expects to grant the initial purchasers an option to purchase, for settlement within a 13-day period beginning on, and including, the date FC Materials first issues the notes, up to an additional $75 million principal amount of notes.
2024-03-04 08:03:03	ODSN	First Wave BioPharma, Inc. To Raise ~$4M Of Gross Proceeds In Registered Direct Offering Of 525,625 Shares Of Common Stock At A Price Of $7.61 Per Share	"First Wave BioPharma, Inc., (NASDAQ: ODSN ), (""First Wave BioPharma"" or the ""Company""), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 525,625 shares of the Company's common stock (or common stock equivalents) at a price of $7.61 per share in a registered direct offering. In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 525,625 shares of common stock. The warrants have an exercise price of $7.48 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $4.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about March 6, 2024, subject to the satisfaction of customary closing conditions."
2024-03-04 08:37:53	NACQ	Nektar Therapeutics Announces $30M Private Placement Financing With TCGX; Nektar Is Selling 25M Shares Of Its Common Stock, In The Form Of A Pre-Funded Warrant, At A Price Of $1.20 Per Share	"Nektar Therapeutics (NASDAQ: NACQ ), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the ""PIPE"") for gross proceeds of $30 million, before deducting expenses. In the PIPE, Nektar is selling 25 million shares of its common stock, in the form of a pre-funded warrant, at a price of $1.20 per share, representing a premium of approximately 80% to Nektar's 30-day volume-weighted average price. The pre-funded warrant will have an exercise price of $0.0001 per share and will not expire. The PIPE is expected to close on or before March 6, 2024, subject to customary closing conditions. Nektar has agreed to submit a registration statement filing for the underlying Common Stock no later than 90 days after the closing. ""We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata,"" said Howard Robin, President and Chief Executive Officer of Nektar Therapeutics. ""We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."" Rezpegaldesleukin is a novel agonistic F regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional F reg cells and engaging multiple immunoregulatory pathways. The private placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506 of Regulation D of the Securities Act of 1933, as amended and in reliance on similar exemptions under applicable state laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-03-04 09:26:45	IWDV	Revance Announces Pricing Of $100M Public Offering Of 16M Shares Of Common Stock At A Price Of $6.25/Share	"Revance Therapeutics, Inc. (NASDAQ: IWDV ) (""Revance"" or the ""Company"") today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. The gross proceeds from the public offering are expected to be $100.0 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about March 6, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY&#xAE; and the RHA&#xAE; Collection of dermal fillers, support the launch of DAXXIFY&#xAE; into the therapeutics market, as well as for working capital, research and development and general corporate purposes. Barclays is acting as the sole book-running manager for the proposed offering."
2024-03-04 09:31:08	AL	Permian Resources Corporation Announces Pricing Of Secondary Public Offering Of 48.5M Shares Of Class A Common Stock, At A Price To The Public Of $15.76 Per Share	"Permian Resources Corporation (""Permian Resources"" or the ""Company"") (NYSE: AL ) today announced the pricing of an underwritten public offering of an aggregate 48,500,000 shares of its Class A Common Stock, par value $0.0001 per share (""Class A common stock""), at a price to the public of $15.76 per share, by certain affiliates of EnCap Investments L.P., NGP Energy Capital Management L.L.C., Pearl Energy Investments and Riverstone Investment Group LLC and certain members of the Company's management (the ""Selling Stockholders""). Permian Resources will not sell any shares of Class A common stock in the offering and will not receive any proceeds therefrom. Concurrently with the closing of the offering, the Company has agreed to purchase (the ""Concurrent OpCo Unit Purchase"") from certain of the Selling Stockholders an aggregate 2,000,000 common units representing limited liability company interests (""OpCo Units"") in Permian Resources Operating, LLC, a Delaware limited liability company and a subsidiary of Permian Resources (""OpCo""), at a price per OpCo Unit equal to the price per share at which the underwriter purchases shares of Class A common stock in the offering and to cancel a corresponding number of shares of the Company's Class C Common Stock, par value $0.0001 per share, held by such Selling Stockholders. The offering of Class A common stock is not conditioned upon the completion of the Concurrent OpCo Unit Purchase, but the Concurrent OpCo Unit Purchase is conditioned upon the completion of the offering. Goldman Sachs & Co. LLC is serving as the underwriter for the offering. The offering is expected to close on March 6, 2024, subject to customary closing conditions. The offering is being made pursuant to a registration statement previously filed by the Company with the U.S. Securities and Exchange Commission (the ""SEC"") which became automatically effective upon filing on November 8, 2023."
2024-03-04 09:46:14	IGRF	Perspective Therapeutics Announces $87.4M  Private Placement Of 92,009,981 Shares Of Its Common Stock At A Price Of $0.95 Per Share	"Perspective Therapeutics, Inc. (""Perspective"" or ""the Company"") (NYSE: IGRF ), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate gross proceeds of approximately $87.4 million, before deducting placement agent fees and other offering expenses. In the private placement, the Company is selling 92,009,981 shares of its common stock at a price of $0.95 per share, representing the closing price per share of the Company's common stock on the NYSE American as of March 1, 2024. The private placement is expected to close on March 6, 2024, subject to the satisfaction of customary closing conditions. Oppenheimer & Co. is acting as lead placement agent for the private placement. B. Riley Securities is acting as a placement agent, and JonesTrading Institutional Services LLC and LifeSci Capital are acting as co-placement agents for the private placement."
2024-03-04 15:14:01	XAOD	USA Compression Partners, LP Announces Pricing Of $1B Offering Of Senior Notes	"USA Compression Partners, LP (NYSE: XAOD ) (the ""Partnership"") today announced the pricing of a private placement to eligible purchasers by the Partnership and its wholly-owned subsidiary, USA Compression Finance Corp., of $1.0 billion in aggregate principal amount of 7.125% senior unsecured notes due 2029 at par. The offering is expected to close on March 18, 2024, subject to customary closing conditions. The Partnership estimates that it will receive net proceeds of approximately $984.4 million, after deducting the initial purchasers' discounts and estimated offering expenses. The net proceeds from the offering will be used to repay a portion of existing borrowings under its asset-based revolving credit facility, redeem all of the 6.875% senior notes due 2026, and for general partnership purposes."
2024-03-04 16:03:20	WNDE	MicroStrategy Announces Proposed Private Offering Of $600M Of Convertible Senior Notes Due 2030	"MicroStrategy&#xAE; Incorporated (NASDAQ: WNDE ) (""MicroStrategy"") today announced that it intends to offer, subject to market conditions and other factors, $600 million aggregate principal amount of convertible senior notes due 2030 (the ""notes"") in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). MicroStrategy also expects to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $90 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed. The notes will be unsecured, senior obligations of MicroStrategy and will bear interest payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2024. The notes will mature on March 15, 2030, unless earlier repurchased, redeemed or converted in accordance with their terms. Subject to certain conditions, on or after March 22, 2027, MicroStrategy may redeem for cash all or any portion of the notes. If MicroStrategy redeems fewer than all the outstanding notes, at least $90 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date. Holders of the notes will have the right to require MicroStrategy to repurchase for cash all or any portion of their notes on September 15, 2028. The notes will be convertible into cash, shares of MicroStrategy's class A common stock, or a combination of cash and shares of MicroStrategy's class A common stock, at MicroStrategy's election. Prior to September 15, 2029, the notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. The interest rate, conversion rate, conversion price and certain other terms of the notes will be determined at the time of pricing of the offering. MicroStrategy intends to use the net proceeds from the sale of the notes to acquire additional bitcoin and for general corporate purposes."
2024-03-04 16:14:23	IAEJ	Tandem Diabetes Care Announces Proposed $250M Private Placement Of Convertible Notes Due 2029	"Tandem Diabetes Care, Inc. (NASDAQ: IAEJ ), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the ""notes"") in a private placement (the ""offering"") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Tandem also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $37.5 million principal amount of notes. The notes will be general unsecured obligations of Tandem and will accrue interest payable semiannually in arrears. Upon conversion, Tandem will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering. Tandem expects to use the net proceeds from the offering, together with cash on hand, to pay the cost of the capped call transactions described below, to repurchase for cash certain of its 1.50% Convertible Senior Notes due 2025 (the ""2025 notes"") and to repurchase up to $30.0 million of its common stock in privately negotiated transactions, each as described below. If the initial purchasers exercise their option to purchase additional notes, Tandem expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions and the remainder for general corporate purposes, which may include additional repurchases of the 2025 notes from time to time following this offering, or the repayment at maturity, of the 2025 notes."
2024-03-04 16:18:42	ZCK	Kosmos Energy Ltd. Announces Offering Of $300M Of Convertible Senior Notes Due 2030	Kosmos Energy Ltd. (NYSE/LSE: ZCK) (&quot;Kosmos&quot; or the &quot;Company&quot;) announced today that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of its convertible senior notes due 2030 (the &quot;notes&quot;) in a private placement. The Company also expects to grant the initial purchasers an option to purchase up to an additional $45 million aggregate principal amount of notes, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued. The notes will be senior, unsecured obligations of the Company. The notes will rank pari passu with the Company's existing senior notes and the Company's revolving credit facility. The notes will be guaranteed (i) on a senior, unsecured basis by certain of the Company's existing subsidiaries that guarantee on a senior basis the Company's revolving credit facility and the Company's existing senior notes, and (ii) on a subordinated, unsecured basis by certain of the Company's existing subsidiaries that borrow under or guarantee the Company's commercial debt facility and guarantee on a subordinated basis the Company's revolving credit facility and the Company's existing senior notes. Upon conversions of the notes, the Company will satisfy its conversion obligation by paying cash up to the aggregate principal amount of the notes to be converted, and paying or delivering, as the case may be, cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the notes to be converted. The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering. The Company intends to use the net proceeds from the sale of the notes to (i) repay a portion of outstanding indebtedness under the Company's commercial debt facility; (ii) pay the cost of the capped call transactions described below; and (iii) pay fees and expenses related to the offering.
2024-03-04 16:50:53	UAC	Albemarle Stock Slides On $1.75B Offering: The Details	Albemarle Corp (NYSE: UAC ) shares are trading lower after the bell on Monday following a proposed offering from the lithium producer . What Happened: Albemarle has commenced an offering of $1.75 billion of depositary shares in an underwritten registered public offering. The company plans to grant the underwriters a 30-day option to purchase up to an additional $262.5 million of its depositary shares. Albemarle said it intends to use the net proceeds for general corporate purposes, which may include funding growth capital expenditures, such as the construction and expansion of lithium operations in Australia and China, and repaying the company's outstanding commercial paper. Albemarle reported fourth-quarter financial results in mid-February. The company said it had approximately $1.9 billion in liquidity, including $889.9 million in cash and cash equivalents as of Dec. 31. Check This Out: Why New York Community Bancorp Stock Is Tumbling UAC Price Action: Albemarle shares were down 9.38% after hours at $120.70 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-03-05 06:18:56	FC	FC Prices $650M 3.00% Convertible Notes Offering	FC Materials Corp. (NYSE: FC ) (&quot;FC Materials&quot; or the &quot;Company&quot;) today announced the pricing of an offering of $650 million principal amount of its 3.00% Convertible Senior Notes due 2030 (the &quot;notes&quot;) through a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). FC Materials has also granted the initial purchasers an option to purchase, for settlement within a 13-day period beginning on, and including, the date FC Materials first issues the notes, up to an additional $97.5 million principal amount of notes. The offering was upsized from the previously announced offering of $500 million principal amount. The offering is expected to close on March 7, 2024, subject to customary closing conditions.
2024-03-05 08:00:07	XMDV	Momentus Announces $4M Registered Direct Offering Of 4,624,280 Shares Of Common Stock At A Purchase Price Of $0.865 Per Share, Under Nasdaq Rules	"Momentus Inc. (NASDAQ: XMDV ) (""Momentus"" or the ""Company""), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced that it has entered into a securities purchase agreement with a single U.S. institutional investor for the purchase and sale of 4,624,280 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.865 per share and warrant pursuant to a registered direct offering priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $4.0 million, before deducting placement agent commissions and other estimated offering expenses. The Company further agreed to issue to the investors warrants to purchase up to an aggregate of 4,624,280 shares of common stock. The warrants will have an exercise price of $0.74, will be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about March 7, 2024, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering."
2024-03-05 08:02:01	KVIL	Quoin Pharmaceuticals Announces Pricing Of $6.5M Public Offering	"Quoin Pharmaceuticals Ltd. (NASDAQ: KVIL ) (the ""Company"" or ""Quoin""), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its ""reasonable best efforts"" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares and Series E warrants to purchase an aggregate of up to 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares at a combined purchase price of $1.60 per American Depositary Share and associated Series D warrant and Series E warrant for aggregate gross proceeds of approximately $6.5 million before deducting placement agent fees and other offering expenses. The Series D and Series E warrants will have an exercise price of $1.60 per share, will be exercisable immediately following the date of issuance and will expire in two years and five years, respectively, from their issuance. The closing of the offering is expected to occur on or about March 7, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering."
2024-03-05 08:22:45	WBFE	SoFi Technologies, Inc. Announces Proposed Convertible Senior Notes Offering Due 2029	"SoFi Technologies, Inc. (""SoFi"") (NASDAQ: WBFE ) today announced its intention to offer, subject to market and other conditions, $750 million aggregate principal amount of convertible senior notes due 2029 (the ""notes"") in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). SoFi also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $112.5 million aggregate principal amount of notes. The notes will be unsecured, unsubordinated obligations of SoFi, will accrue interest payable semi-annually in arrears and will mature on March 15, 2029, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances into cash and, if applicable, shares of SoFi's common stock. Upon conversion, SoFi will pay cash up to the aggregate principal amount of the notes to be converted, and pay or deliver cash, shares of its common stock or a combination of cash and shares of its common stock, at SoFi's election, in respect of the remainder, if any, of SoFi's conversion obligation in excess of the aggregate principal amount of the notes being converted. The notes will also be redeemable, in whole or in part, for cash at SoFi's option at any time, and from time to time, on or after March 15, 2027 and on or before the 30th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of SoFi's common stock exceeds 130% of the conversion price for a specified period of time and certain liquidity conditions have been satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. SoFi intends to use a portion of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. SoFi intends to use the remainder of the net proceeds from the offering, together with cash on hand (i) to pay fees, costs and expenses relating to this offering and related transactions, (ii) to redeem its 12.5% Series 1 Preferred Stock and (iii) for general corporate purposes, which may include repayment of higher cost indebtedness. If the initial purchasers exercise their option to purchase additional notes, then SoFi intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below."
2024-03-05 09:03:08	WBFE	SoFi Technologies Stock Is Sliding Tuesday: What's Going On?	SoFi Technologies Inc (NASDAQ: WBFE ) shares are trading lower Tuesday after the company announced a proposed convertible senior notes offering . What Happened: SoFi announced that it intends to offer $750 million worth of convertible senior notes due 2029 in a private offering to qualified institutional buyers. The company also plans to grant the initial purchasers a 13-day window to purchase up to an additional $112.5 million of the notes. SoFi said it intends to use a portion of the net proceeds from the offering to fund the cost of entering into capped call transactions. The company expects to use the remainder of the proceeds together with cash on hand to pay fees, costs and expenses related to this offering and to redeem its 12.5% Series 1 Preferred Stock, as well as for general corporate purposes, which may include repayment of higher cost indebtedness. See Also: Cathie Wood's Ark Invest Sells Nearly $31M Worth Of Coinbase Shares Amid Searing Bitcoin Rally  Loads Up On Mark Zuckerberg's Meta Platforms How To Buy WBFE Stock By now you're likely curious about how to participate in the market for SoFi &#8211; be it to purchase shares, or even attempt to bet against the company. Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. In the case of SoFi, which is trading at $7.78 as of publishing time, $100 would buy you 12.85 shares of stock. If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline. WBFE Price Action: SoFi shares were down 7.23% at $7.96 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-03-05 10:05:07	UAC	Why Albemarle Stock Is Tumbling Tuesday	Albemarle Corp (NYSE: UAC ) shares are trading lower Tuesday after the company announced a proposed public offering . What To Know: After the market close on Monday, Albemarle commenced an offering of $1.75 billion of depositary shares in an underwritten registered public offering. The company said it plans to grant the underwriters a 30-day option to purchase up to an additional $262.5 million of its depositary shares. Albemarle expects to use the net proceeds for general corporate purposes, which may include funding growth capital expenditures, such as the construction and expansion of lithium operations in Australia and China, and repaying the company's outstanding commercial paper. Albemarle reported fourth-quarter financial results a couple of weeks ago. The company said it had approximately $1.9 billion in liquidity, including $889.9 million in cash and cash equivalents as of Dec. 31. Don't Miss This: American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday How To Buy UAC Stock By now you're likely curious about how to participate in the market for Albemarle &#8211; be it to purchase shares, or even attempt to bet against the company. Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. In the case of Albemarle, which is trading at $119.10 as of publishing time, $100 would buy you 0.84 shares of stock. If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline. UAC Price Action: Albemarle shares were down 12.4% at $116.70 at the time of writing, according to Benzinga Pro . This illustration was generated using artificial intelligence via MidJourney.
2024-03-05 11:47:16	XMDV	Why Space Company Momentus Shares Are Taking Off Today	Shares of commercial space company Momentus Inc (NASDAQ: XMDV ) are soaring after it received a flight and payload integration services contract from NASA. Momentus is among the 15 companies that NASA has selected to provide flight and payload integration services to advance technologies and procedures for operating in space. The services provided by the companies will also include testing in high-altitude, reduced gravity, or other relevant environments. The indefinite-delivery/indefinite-quantity base contract awards are firm-fixed-price with a total combined value of $45 million and a performance period of five years. The services provided under the contract will be used by NASA and other government agencies. The platforms that will be used for testing include suborbital rockets, high-altitude balloons, orbital spacecraft and satellites, and suborbital rockets. &#8220;We are honored to be selected by NASA for this important opportunity to support the United States' efforts in space,&#8221; said John Rood, CEO of Momentus. In another development, Momentus entered into a securities purchase agreement with a single U.S. institutional investor for the purchase and sale of 4.62 million shares of common stock at a purchase price of $0.865 per share and warrant pursuant to a registered direct offering, resulting in total gross proceeds of approximately $4.0 million. Price Action : XMDV shares are trading higher by 5.13% at $0.82 on the last check Tuesday.
2024-03-05 16:05:06	HPJ	Cheniere Announces Pricing Of $1.5B Senior Notes Due 2034	"Cheniere Energy, Inc. (""Cheniere"") (NYSE: HPJ ) today announced that it has priced its previously announced offering of Senior Notes due 2034 (the ""Cheniere 2034 Notes""). The Cheniere 2034 Notes will bear interest at a rate of 5.650% per annum. The Cheniere 2034 Notes will be issued at 99.789% of par and will mature on April 15, 2034. The closing of the offering is expected to occur on March 19, 2024. Cheniere intends to use the proceeds from the offering to retire all or a portion of the approximately $1.5 billion outstanding aggregate principal amount of Cheniere Corpus Christi Holdings, LLC's senior secured notes due 2025 (the ""CCH 2025 Notes""). This press release does not constitute an offer to purchase or a solicitation of an offer to sell the CCH 2025 Notes or a notice of redemption under the indenture governing the CCH 2025 Notes. The Cheniere 2034 Notes will rank pari passu in right of payment with existing senior notes at Cheniere, including the senior notes due 2028. The offer of the Cheniere 2034 Notes has not been registered under the Securities Act of 1933, as amended (the ""Securities Act"") and the Cheniere 2034 Notes may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction."
2024-03-05 16:18:54	BACA	NAPCO Security Technologies Announces Secondary Public Offering Of Shares Of Common Stock By Selling Stockholder; No Size Or Amount Disclosed	"NAPCO Security Technologies, Inc. (NASDAQ: BACA ) (the ""Company""), one of the leading manufacturers and designers of high-tech electronic security devices, wireless recurring communication services for intrusion and fire alarm systems as well as a leading provider of school safety solutions, announced today that its Chairman of the Board and President and Chief Executive Officer, Richard L. Soloway (the ""Selling Stockholder""), intends to offer and sell shares of common stock beneficially owned by the Selling Stockholder in an underwritten secondary public offering. The Selling Stockholder expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. NAPCO is not issuing or selling any shares of common stock in the offering and therefore will not receive any of the proceeds from the sale of the outstanding shares of common stock by the Selling Stockholder, and the offering will not result in dilution to existing stockholders. Needham & Company and TD Cowen are acting as joint book-runners for the offering, and D.A. Davidson & Co. is acting as the lead manager for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering."
2024-03-05 16:30:45	CYGY	Apogee Therapeutics Announces Commencement Of $350M Proposed Underwritten Public Offering	Apogee Therapeutics, Inc. (NASDAQ: CYGY ), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced that it has commenced an underwritten public offering of approximately $350.0 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Apogee. Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen, and Stifel are acting as joint book-running managers for the proposed offering.
2024-03-06 06:03:18	UAC	Albemarle Corp Announces $2.0B Upsized Offering of Depositary Shares, up from Prior $1.75B	Albemarle Corporation (NYSE: UAC ) (&quot;Albemarle&quot; or the &quot;Company&quot;), a global leader in providing essential elements for mobility, energy, connectivity, and health, announced that it has priced its previously announced offering (the &quot;Offering&quot;) of 40,000,000 depositary shares (&quot;Depositary Shares&quot;), each representing a 1/20th interest in a share of Series A Mandatory Convertible Preferred Stock of the Company (&quot;Preferred Stock&quot;), at a public offering price of $50 per share, in an underwritten registered public offering. In addition, Albemarle granted the underwriters in the Offering a 30-day option to purchase up to an additional 6,000,000 Depositary Shares, at the public offering price per share, less an underwriting discount. This reflects an upsizing of the previously announced offering of $1.75 billion of Depositary Shares to $2.0 billion of Depositary Shares and the previously announced option to purchase up to an additional $262.5 million to $300.0 million granted to the underwriters. The Offering is expected to close on or about March 8, 2024, subject to the satisfaction of customary closing conditions.
2024-03-06 08:38:59	WNDE	What's Going On With MicroStrategy Stock Today?	MicroStrategy Inc (NASDAQ: WNDE ) shares are trading higher. The company on Wednesday announced the pricing of its convertible senior notes offering . What Happened: MicroStrategy said it will offer $700 million aggregate principal amount of 0.625% convertible senior notes due 2030 in a private offering to qualified institutional buyers. The company plans to grant the initial purchasers a 13-day window to buy an additional $100 million worth of the notes. MicroStrategy said at the beginning of the week that it expected to offer $600 million worth of its convertible senior notes, so the offering has been upsized by $100 million. MicroStrategy anticipates approximately $684.3 million in net proceeds from the offering. The company expects to use the proceeds to buy more bitcoin, as well as for general corporate purposes. The offering is expected to close on March 8. The offering comes as MicroStrategy shares have surged more than 106% over the last month alongside rising bitcoin prices. MicroStrategy shares hit their highest levels since March 2000 this week. MicroStrategy is a business intelligence, mobile software and cloud-based services company, focused on accumulating bitcoin. Last week, the company said it bought an additional 3,000 Bitcoin in February. MicroStrategy held 193,000 Bitcoin as of Feb. 25. Read Next: Bitcoin To Reach $355K? Veteran Trader Tone Vays Predicts 'Surprise' Upward Swing WNDE Price Action: MicroStrategy shares were up 5.52% at $1,107.77 at the time of publication, according to Benzinga Pro . Photo: Eivind Pedersen from Pixabay.
2024-03-06 09:16:15	WBFE	What's Going On With SoFi Technologies Stock?	SoFi Technologies Inc (NASDQ:WBFE) shares are in the spotlight Wednesday after the company priced its convertible senior notes offering. The stock fell more than 15% on Tuesday after the offering was first announced . What To Know: SoFi shares closed Tuesday down 15.3% at $7.27 after the company announced a proposed convertible senior notes offering . After the market close on Tuesday, SoFi priced its private offering of 1.25% convertible senior notes due 2029 in an aggregate principal amount of $750 million. The notes will be sold in a private offering to people reasonably believed to be qualified institutional buyers. The company also plans to grant the initial purchasers a 13-day window to purchase up to an additional $112.5 million of the notes. SoFi anticipates net proceeds from the offering of approximately $735 million. SoFi said it intends to use approximately $78.8 million of the net proceeds to fund the cost of entering into capped call transactions. The company expects to use the remainder of the proceeds together with cash on hand to pay fees, costs and expenses related to this offering, to redeem its 12.5% Series 1 Preferred Stock and for general corporate purposes, which may include repayment of higher cost indebtedness. The issuance and sale of the notes is expected to settle on or about March 8. See Also: Private Employment Grows By 140,000 In February, Misses Forecasts: 'It Doesn't Tip The Scales' For The Fed, Economist Says Is WBFE A Good Stock To Buy? Wall Street analysts view SoFi on the whole as a Neutral, given the history of coverage over the past three months. Dan Dolev from Mizuho in SoFi is the most bearish, expecting a 20% fall in the stock in the coming year. But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, SoFi fell 6.42%, which indicates that opinion soured on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 34.01% over the past year. A complete overview of how Wall Street views individual stocks is available here , while real time updates on the latest analyst actions will be delivered via Benzinga PRO . Try it for free. WBFE Price Action: SoFi shares were bouncing back Wednesday, up 2.06% at $7.42 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-03-06 09:46:57	DUJN	bioAffinity Technologies Announces Pricing Of $2.5M Registered Direct Offering And Concurrent Private Placement	bioAffinity Technologies, Inc. (NASDAQ: DUJN ) today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering) at a combined purchase price of $1.5625 per common share. The common warrants issued pursuant to the concurrent private placement will have an exercise price of $ 1.64 per share, are initially exercisable on the date that shareholder approval of the exercise of the warrants is obtained and will expire five years from the date of such approval. The closing of the offering is expected to occur on or about March 8, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $2,500,000, excluding any proceeds that may be received upon the exercise of the warrants and before deducting placement agent fees and other offering expenses payable by the Company. WallachBeth Capital is acting as sole placement agent for the Offering.
2024-03-06 13:03:53	LSD	Why Photocopy Giant Xerox Shares Are Down Today	Xerox Holdings Corporation (NASDAQ: LSD ) shares are trading lower today. Yesterday, Xerox announced its intention to offer, $300 million of convertible senior notes in a private placement to qualified institutional buyers. The company expects to grant the initial purchasers of the Notes a 13-day option to purchase up to $45 million of additional notes. The company also announced an increase in the maximum tender cap for 5.000% senior notes due 2025. The company raised the maximum principal amount of its $750 million principal amount outstanding to $362 million from $94 million for 5.000% Senior Notes due 2025, which can be repurchased under its previously announced cash tender offer for the 2025 Notes. The terms of the previously announced cash tender offer by Xerox for its 3.800% senior notes due 2024 remain unchanged. Xerox expects to use the net proceeds to fund the cost of the capped call transactions and for general corporate purposes. Last month, Xerox reported a fourth-quarter sales decline of 9.1% Y/Y to $1.77 billion, missing the $1.79 billion estimate and adjusted EPS of $0.43, which fell short of the $0.52 expected . The company witnessed equipment sales drop 17.3%, post-sale revenue down 5.8%, and guided FY24 revenue below consensus . Price Action : LSD shares are down 9.21% at $17.06 on the last check Wednesday.
2024-03-06 14:14:42	NZZW	In Connection With The Equity Capital Raise Transaction, NZZW Will Sell And Issue Shares Of Common Stock At A Price Per Share Of $2.00 And A Series Of Convertible Preferred Stock With A Conversion Price Of $2.00, For An Aggregate Investment Amount Of $1.05B	Transaction Details In connection with the equity capital raise transaction, NZZW will sell and issue, in the aggregate, to the Investors shares of common stock of the Company at a price per share of $2.00 and a series of convertible preferred stock with a conversion price of $2.00, for an aggregate investment amount of $1.05 billion. In addition, investors will receive 60% warrant coverage to purchase non-voting, common-equivalent stock with an exercise price of $2.50 per share, a 25% premium to the price paid on common stock. Holders of the preferred stock will not have voting rights and will be entitled to quarterly non-cumulative cash dividends, as and if declared by the Board. Each share of preferred stock is convertible into common stock on a 1 preferred share  1,000 common shares basis. Series B preferred stock will automatically convert upon certain transfers permitted by federal banking regulations and stockholder approval of a charter amendment to increase the Company's authorized common stock, while Series C preferred stock will automatically convert upon the achievement of certain trigger events related to receipt of antitrust clearance under the Hart Scott Rodino Act and the charter amendment. The Company will provide customary shelf and piggyback registration rights to each of the Investors. Additionally, Liberty will also have the ability to request an underwritten shelf take-down and block trade rights.
2024-03-06 16:30:42	QBCI	REGENXBIO Announces Proposed $125M Public Offering Of Common Stock	REGENXBIO Inc. (NASDAQ: QBCI ) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENXBIO intends to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of common shares sold in connection with the offering. Morgan Stanley, Goldman Sachs & Co. LLC, Barclays and Stifel are acting as joint book-running managers of the offering
2024-03-06 16:38:24	VQG	VQG Announces Launch Of Secondary Public Offering Of 55M Common Stock And 15M Concurrent Share Repurchase, The Share Repurchase Is Part Of The Co's Existing $350M Share Repurchase Program	VQG Inc. (NYSE: VQG ) (&quot;VQG&quot; or the &quot;Company&quot;) today announced the commencement of a proposed secondary public offering of 55,000,000 shares of the Company's common stock held by certain entities managed by affiliates of Apollo Global Management, Inc. (the &quot;Selling Stockholders&quot;). The underwriters will have a 30-day option to purchase up to an additional 8,250,000 shares of common stock from the Selling Stockholders. The Company is not selling any shares and will not receive any proceeds from the proposed offering. In addition, VQG has authorized the concurrent purchase from the underwriters of 15,000,000 shares of common stock as part of the secondary public offering (the &quot;Share Repurchase&quot;) subject to the completion of the offering. The Share Repurchase is part of the Company's existing $350 million share repurchase program. The underwriters will not receive any underwriting fees for the shares being repurchased by the Company. Morgan Stanley, Barclays, Apollo Global Securities and RBC Capital Markets are acting as book-running managers for the proposed offering.
2024-03-06 16:43:13	XRAH	Crescent Energy Company Announces Secondary Public Offering Of 12M Shares Of Common Stock And Intention To Repurchase 2M OpCo Units	Crescent Energy Company (&quot;Crescent&quot; or the &quot;Company&quot;) (NYSE: XRAH ) today announced the commencement of an underwritten public offering of 12,000,000 shares of its Class A common stock, par value $0.0001 per share (&quot;common stock&quot;). The common stock is being offered by Independence Energy Aggregator L.P. (the &quot;Selling Stockholder&quot;), the direct owner of the shares being offered and the entity through which certain unaffiliated limited partners and affiliated entities hold their interests in the Company and its subsidiary Crescent Energy OpCo LLC. The Company will not sell any shares of its common stock in the offering and will not receive any proceeds therefrom. The Selling Stockholder expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. Wells Fargo Securities, LLC, Evercore Group L.L.C. and Raymond James & Associates, Inc. are serving as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Concurrently with the closing of the offering, the Company intends to purchase from the Selling Stockholder an aggregate of 2,000,000 units of Crescent Energy OpCo LLC (&quot;OpCo Units&quot;) at a price per share equal to the price per share at which the underwriters purchase shares of common stock in the offering and cancel a corresponding number of shares of the Company's Class B common stock, par value $0.0001 per share (&quot;Class B common stock&quot;) (the &quot;OpCo Unit Purchase&quot;). If the underwriters exercise their option to purchase additional shares from the Selling Stockholder in the offering, the Company intends to purchase a number of additional OpCo Units from the Selling Stockholders and to cancel a corresponding number of shares of Class B common stock held by Selling Stockholder in equal proportion to the number of additional shares of common stock sold pursuant to the underwriters' option. The offering of common stock is not conditioned upon the completion of the OpCo Unit Purchase, but the OpCo Unit Purchase is conditioned upon the completion of the offering
2024-03-06 16:48:39	VQG	VQG Stock Is Tumbling After Hours: What's Happening?	VQG Inc (NYSE: VQG ) shares are trading lower after the bell on Wednesday after the company announced a secondary public offering and share repurchase . What Happened: Security provider VQG has commenced a proposed secondary public offering of 55 million shares of its common stock held by certain entities managed by affiliates of Apollo Global Management. The underwriters will have a 30-day option to purchase up to an additional 8.25 million shares. VQG is not selling any shares and will not receive any proceeds from the offering. The company said it will be concurrently buying 15 million shares from the underwriters as part of the secondary offering. The share repurchase will be part of the company's existing $350 million buyback authorization. See Also: Victoria's Secret Stock Is Spiraling Lower: What's Going On? Is VQG A Good Stock To Buy? Wall Street analysts view VQG on the whole as a Buy, given the history of coverage over the past three months. George Tong from Goldman Sachs in VQG is the most optimistic, expecting a 10.67% rise in the stock in the coming year. But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, VQG rose 19.52%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which fell 25.71% over the past year. A complete overview of how Wall Street views individual stocks is available here , while real time updates on the latest analyst actions will be delivered via Benzinga PRO . Try it for free. VQG Price Action: VQG shares were down 9.57% after hours at $6.76 following the announcement, according to Benzinga Pro . Photo: 3844328 from Pixabay.
2024-03-06 16:58:58	RLVE	Avid Bioservices Announces Proposed $160M Private Placement Of Convertible Notes Due 2029	"Avid Bioservices, Inc. (NASDAQ: RLVE ), a dedicated biologics contract development and manufacturing organization (RLVE), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the ""2029 Notes"") in a private placement (the ""Offering"") to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the ""Securities Act""). The company expects to price the Offering before open of market on March 7, 2024. The 2029 Notes will represent senior unsecured obligations of the company and will accrue interest payable semiannually in arrears. Upon conversion, the company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the Offering. The company expects to use the net proceeds from the Offering (i) to repurchase for cash a portion of its 1.250% Exchangeable Senior Notes due 2026 (the ""2026 Notes"") in privately negotiated transactions from certain noteholders and (ii) to the extent there are 2026 Notes outstanding after such repurchase, to repay in full any remaining outstanding 2026 Notes by depositing the required payoff amount with the trustee under the indenture of the 2026 Notes. In connection with the repurchase or repayment of the 2026 Notes, the company expects to unwind its capped call transactions with respect to the 2026 Notes with the applicable counterparties. In connection with any such termination, the company expects the counterparties to such capped call transactions and/or their respective affiliates will unwind various derivatives with respect to the company's common stock and/or sell shares of the company's common stock concurrently with such termination. This activity could decrease the market price of the company's common stock at that time."
2024-03-07 07:17:01	TXGV	Mind Medicine (MindMed) Priced Underwritten Offering of $175M Common Shares and Concurrent Private Placement at $6/Share	Mind Medicine (MindMed) Inc . (NASDAQ: TXGV ) (Cboe Canada: MMED) (the &quot;Company&quot; or &quot;MindMed&quot;), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share. All of the common shares are being sold by MindMed. Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.
2024-03-07 12:10:41	EUH	Akso Health Group Offering 37.1M ADS Shares, Representing Three Ordinary Shares, Directly To Institutional Investors At Price Per ADS Of $1.33	"- SEC Filing AKSO HEALTH GROUP 37,100,000 American Depositary Shares Representing 111,300,000 Ordinary Shares We are offering 37,100,000 of our American depositary shares, or ADSs, each representing three ordinary shares, par value $0.0001 per share, directly to certain institutional investors pursuant to that certain Securities Purchase Agreement, dated March 5, 2024, at a price per ADS of $1.33. In a concurrent private placement, we are also selling to the investors warrants to purchase an aggregate of up to 222,600,000 of our ordinary shares. The warrants are exercisable immediately as of the date of issuance at an exercise price of $0.4933 per ordinary share, or $1.48 per ADS and expire five years from the date of issuance. The warrants and the ordinary shares issuable upon the exercise of the warrants are not being registered under the Securities Act of 1933, as amended, or the Securities Act, pursuant to the registration statement of which this prospectus supplement and the accompanying prospectus. The warrants and the ordinary shares issuable upon the exercise of the warrants are being offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D. The aggregate market value of our outstanding ordinary held by non-affiliates, or public float, was approximately $276.52 million, which was calculated based on Ordinary Shares outstanding held by non-affiliates and a price per ADS of $2.60, which was the last reported price on the Nasdaq Capital Market of our ADS on February 2, 2024. Our ADSs are currently traded on the Nasdaq Capital Market, or Nasdaq, under the symbol ""EUH."" On March 5, 2024, the closing sale price of our ADSs was $1.23 per ADS. We expect that delivery of the ADSs being offered pursuant to this prospectus supplement and the accompanying prospectus will be made on or about March 7, 2024."
2024-03-07 16:39:03	AJK	Delek Logistics Partners, LP Announces $120M Proposed Public Offering Of Common Units	Delek Logistics Partners, LP (NYSE: AJK ) (&quot;Delek Logistics&quot;) announced today that it has commenced an underwritten public offering of $120,000,000 of common units representing limited partner interests in Delek Logistics pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;). A preliminary prospectus supplement relating to the offering will also be filed with the SEC. Delek Logistics intends to grant the underwriters a 30-day option to purchase up to an additional $13,500,000 of common units. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Delek Logistics intends to use the net proceeds from the offering (including any net proceeds from the underwriters' exercise of their option to purchase additional common units) to repay outstanding borrowings under its revolving credit agreement. Delek US Holdings, Inc. (&quot;Delek Holdings&quot;), the sponsor of Delek Logistics and owner of its general partner, has indicated an interest in purchasing up to $30,000,000 of the common units offered in the offering at the price offered to the public. Because this indication is not a binding agreement or commitment to purchase, Delek Holdings may elect not to purchase any units in the offering, or the underwriters may elect not to sell any units in the offering to Delek Holdings. In the event that Delek Holdings confirms its interest, Delek Logistics will request that the underwriters consider selling to Delek Holdings such amount of the common units offered in the offering.
2024-03-07 16:50:11	KSCD	KSCD Properties Announces Pricing Of Public Offering Of $1.05B Of Senior Unsecured Notes	"KSCD Properties Inc. (NYSE: KSCD ) (""KSCD Properties"" or the ""Company"") announced today that its subsidiary, KSCD Properties L.P. (the ""Issuer""), has priced a public offering of $1.05 billion in aggregate principal amount of senior unsecured notes (the ""Notes"") consisting of: $550 million aggregate principal amount of 5.750% senior unsecured notes due 2034 (the ""2034 Notes""). The 2034 Notes will be issued at 99.186% of par value and will mature on April 1, 2034. $500 million aggregate principal amount of 6.125% senior unsecured notes due 2054 (the ""2054 Notes""). The 2054 Notes will be issued at 98.192% of par value and will mature on April 1, 2054. Interest on the 2034 Notes and the 2054 Notes is payable in cash in arrears on April 1 and October 1 of each year, beginning on October 1, 2024. The offering is expected to close on March 18, 2024, subject to the satisfaction of customary closing conditions. The Issuer intends to use the net proceeds from the offering to repay its outstanding (i) $1,024.2 million in aggregate principal amount of the 5.625% senior exchange notes due 2024 and (ii) $25.8 million in aggregate principal amount of the 5.625% senior notes due 2024."
2024-03-11 08:32:56	KDTZ	Aprea Therapeutics Announces Private Placement Financing Of Up To $34M	"Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in total gross proceeds DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: KDTZ ) (""Aprea"", or the ""Company""), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain Company insiders to raise up to $34.0 million in gross proceeds, including initial upfront funding of $16.0 million and up to an additional $18.0 million upon cash exercise of accompanying warrants at the election of the investors. The financing is being led by Sphera Healthcare and includes participation from new and existing healthcare-focused investors, including Nantahala Capital, DAFNA Capital Management, Exome Asset Management and Stonepine Capital Management, among others, as well as certain Company insiders. ""This meaningful financing led by high quality healthcare institutions will support Aprea in our goal to be a leader in the field of Synthetic Lethality (SL) and TWU Damage and Response (DDR),"" said Dr. Oren Gilad, President and CEO of Aprea. ""It will provide the capital to fund our Phase 1 ACESOT-1051 clinical trial evaluating a highly potent, oral WEE1 inhibitor for Cyclin E over-expressing cancers including breast and ovarian cancers as well as continuation of patient enrollment in the dose expansion portion of the Phase 1/2a clinical trial (AR-276-01) evaluating ATR inhibitor, ATRN-119, in patients with advanced solid tumors having mutations in defined DDR-related genes."" Maxim Group LLC is acting as the sole placement agent for the private placement. Pursuant to terms of the securities purchase agreement, Aprea will issue an aggregate of 2,194,788 shares of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to an aggregate of 2,194,788 shares of its common stock at a combined purchase price of $7.29 per share and accompanying warrants, in accordance with the ""Minimum Price"" requirement as defined in the Nasdaq rules. The accompanying warrants will consist of two tranches: Tranche A warrants to purchase up to 1,097,394 shares of common stock at an exercise price of $7.29 per share for an aggregate of up to $8.0 million and will expire at the earlier of (i) 30 days following the announcement of the recommended Phase 2 dose for the Company's ATR inhibitor program for ATRN-119 and the daily VWAP of the Company's common stock equaling or exceeding $14.58 per share for 30 consecutive trading days following the announcement and (ii) three years from the date of issuance. Tranche B warrants to purchase up to 1,097,394 shares of common stock at an exercise price of $9.1125 per share for an aggregate of up to $10.0 million and will expire at the earlier of (i) 30 days following the announcement of the recommended Phase 2 dose for the Company's WEE1 inhibitor program for APR-1051 and the daily VWAP of the Company's common stock equaling or exceeding $18.225 per share for 30 consecutive trading days following the announcement and (ii) five years from the date of issuance. In lieu of shares of common stock, certain investors are purchasing pre-funded warrants at a combined purchase price of $7.289 per pre-funded warrant and accompanying warrants, which equals the purchase price per share of common stock and accompanying warrant, less the $0.001 per share exercise price of each pre-funded warrant. The private placement is expected to close on or about March 13, 2024 subject to satisfaction of customary closing conditions. Aprea intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund clinical development of APR-1051, the Company's WEE1 inhibitor product candidate which recently received IND clearance. The aggregate net proceeds (assuming the cash exercise of all accompanying warrants) are expected to be sufficient to fund the Company into 2026. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the ""Securities Act""), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock purchased in the private placement and shares of common stock underlying the warrants. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus."
2024-03-11 16:02:33	JGOK	Essential Properties Realty Trust, Inc. Announces Public Offering Of Common Stock; No Size Or Amount Disclosed	"Essential Properties Realty Trust, Inc. (NYSE: JGOK , the ""Company""))))) announced today that it has commenced an underwritten public offering of 8,000,000 shares of its common stock on a forward basis in connection with the forward sale agreements described below. BofA Securities, Wells Fargo Securities, Truist Securities and Mizuho are acting as the joint book-running managers for the offering. In connection with the offering, the Company expects to enter into forward sale agreements with BofA Securities, Wells Fargo Securities, Truist Securities and Mizuho (or affiliates thereof) (the ""forward purchasers""), with respect to 8,000,000 shares of the Company's common stock. The underwriters have been granted a 30-day option, exercisable in whole or in part from time to time, to purchase up to an additional 1,200,000 shares of the Company's common stock. If the option to purchase additional shares of the Company's common stock is exercised, the Company expects to enter into one or more additional forward sale agreements with the forward purchasers in respect of the number of shares of the Company's common stock that are subject to exercise of the option to purchase additional shares."
2024-03-12 08:08:42	ZKBT	Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?	Tuesday, Regulus Therapeutics Inc (NASDAQ: ZKBT ) released topline results from the second cohort of patients in its Phase 1b multiple-ascending dose (MAD) study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) . The study evaluates RGLS8429 treatment across three different weight-based dose levels, including measuring changes in urinary polycystins 1 and 2 (PC1 and PC2), height-adjusted total kidney volume (htTKV), cyst architecture, and overall kidney function . PC1 and PC2 are the protein products of the PKD1 and PKD2 genes and have been shown to correlate with disease severity inversely. RGLS8429 was well tolerated, with no safety findings of concern. Clear evidence of a mechanistic dose response at a 2mg/kg dose level based on urinary PC1 and PC2 polycystin levels was observed. Urinary measurements of PC1 and PC2 demonstrated greater biological activity of RGLS8429 at 2mg/kg compared to 1mg/kg and placebo, which was most evident after three months of dosing. Exploratory results of imaging-based biomarkers were encouraging, with three patients with the highest increases in PC1 and PC2 having reductions in htTKV >4%, with corresponding reductions in total kidney cyst volume (TKCV). The third cohort is being dosed at 3mg/kg of RGLS8429 or placebo every other week for three months. Data readout is anticipated in mid-2024. The company recently added a fourth cohort for an open-label fixed dose of 300mg of RGLS8429 dosed every other week for three months. Screening is expected to start in the second quarter of 2024. Concurrently, Regulus Therapeutics announced an oversubscribed $100 million equity private placement . Under the securities purchase agreement, the investors have agreed to purchase shares at $1.60 per share. Certain investors have also agreed to purchase, in lieu of common shares, shares of newly designated, non-voting Class A-6 convertible preferred stock at a purchase price of $160.00 per share. Price Action: ZKBT shares are up 52% at $2.11 during the premarket session on the last check Tuesday. Photo: Darko Stojanovic from Pixabay
2024-03-12 08:14:15	HPOI	Hess Midstream LP Announces Signing Of Accretive $100M Sponsor Unit Repurchase	Hess Midstream LP (NYSE: HPOI ) (&quot;Hess Midstream&quot;), today announced the execution of a definitive agreement providing for the repurchase of approximately $100 million of Class B units by its subsidiary, Hess Midstream Operations LP, from affiliates of Hess Corporation and Global Infrastructure Partners, Hess Midstream's sponsors (the &quot;Sponsors&quot;). The terms of the proposed unit repurchase transaction were unanimously approved by the Board of Directors of Hess Midstream's general partner, based on the unanimous approval and recommendation of its conflicts committee composed solely of independent directors. &quot;We continue to execute unit repurchase transactions as part of our unique and differentiated financial strategy, which prioritizes shareholder returns and a strong balance sheet,&quot; said Jonathan Stein, Chief Financial Officer of Hess Midstream. &quot;Since the beginning of 2021 through this current transaction, we will have returned $1.65 billion to shareholders through ongoing unit repurchases from our Sponsors that have reduced the total unit count by over 20%. Following this unit repurchase, which is expected to provide immediate accretion to our shareholders, we expect to continue to have more than $1.25 billion of financial flexibility through 2026 that can be used to support potential incremental unit repurchases.&quot; Pursuant to the terms of the repurchase agreement, the repurchased units will be cancelled upon the closing of the unit repurchase transaction, which is expected to result in increased distributable cash flow per Class A share providing capacity for incremental distribution growth above Hess Midstream's annual distribution target of at least 5% through 2026, consistent with Hess Midstream's return of capital framework. Unit Repurchase Summary Hess Midstream Operations LP, Hess Midstream's consolidated subsidiary, agreed to repurchase 2,816,901 Class B units of Hess Midstream Operations LP, equal to approximately 1.2% of the consolidated company, held by the Sponsors for an aggregate purchase price of approximately $100 million. The purchase price per Class B unit is $35.50, the closing price of the Class A shares on March 11, 2024. After completing the unit repurchase transaction, ownership of Hess Midstream on a consolidated basis will be approximately 35.4% for the public, 26.8% for Global Infrastructure Partners and 37.8% for Hess Corporation. The unit repurchase is anticipated to close on March 14, 2024. Hess Midstream expects to fund the unit repurchase through borrowings under its existing revolving credit facility.
2024-03-12 08:21:00	SZYK	Li-Cycle Announces It Has Entered Into An Agreement To Issue A Senior Secured Convertible Note In An Aggregate Principal Amount Of $75M To An Affiliate Of Glencore Plc	Builds upon existing long-term partnership and further demonstrates Glencore's endorsement of Li-Cycle's Spoke & Hub model, patented recycling technology, and development plans for the Rochester Hub, as part of Glencore's ambition to bring more circularity to the battery materials space Agreement amends existing Glencore convertible note to provide for extended maturity, market-based re-pricing and granting of security interest in two future tranches Li-Cycle Holdings Corp. (NYSE: SZYK ) (&quot;Li-Cycle&quot; or the &quot;Company&quot;), a leading global lithium-ion battery resource recovery company, is pleased to announce that it has entered into an agreement (the &quot;Note Purchase Agreement&quot;) to issue a senior secured convertible note in an aggregate principal amount of $75 million (the &quot;Note&quot;) to an affiliate of Glencore plc (LON: GLEN) (&quot;Glencore&quot;), a leading producer, recycler, and marketer of nickel and cobalt for the production of lithium-ion batteries. Ajay Kochhar, Li-Cycle co-founder and CEO, commented: &quot;We are pleased to secure an additional $75 million investment from Glencore, following Glencore's June 2022 investment, to improve our liquidity position while we continue our ongoing comprehensive review process. This financing enhances Li-Cycle and Glencore's existing long-term, strategic partnership and represents an interim step in our funding strategy to support Li-Cycle's future plans. We also continue to work closely with the U.S. Department of Energy on the conditional commitment for a loan of up to $375 million.&quot; Tim Johnston, Li-Cycle co-founder and Executive Chairman, commented: &quot;As part of our previously announced comprehensive review, Li-Cycle is continuing to review our global recycling network. We are also reviewing our go-forward strategy for the paused Rochester Hub, including analyzing potential end-product mix options and construction strategy. We believe the demand for critical battery materials continues to accelerate and Li-Cycle continues to work to position itself as a future leader in the production of critical battery materials through our sustainable, safe, and patented recycling technology.&quot; Kunal Sinha, Global Head of Recycling for Glencore, and Non-Executive Director of Li-Cycle's Board of Directors, commented: &quot;Glencore is committed to bringing scalable and sustainable circularity into the supply chain of battery materials. Our original investment in Li-Cycle, alongside key commercial agreements, formed part of this strategy. Today, we are pleased to further support Li-Cycle through this additional $75 million investment so both Li-Cycle and Glencore can continue to build the battery circularity platform of choice for our customers.&quot; Following the announcement by the Company in October 2023 in respect of the Rochester Hub, the Company formed a Special Committee (the &quot;SC&quot;) composed solely of independent and disinterested members of the Board (and which excluded Glencore's Board representative). The SC engaged Moelis & Company LLC, a leading global investment bank (&quot;Moelis&quot;), as its financial advisor and placement agent. The SC, with the assistance of Moelis, conducted a robust process to review and evaluate potential financial and strategic alternatives available to the Company. After a careful review and assessment of the alternatives identified by the SC through this process, the Company entered into the agreement with Glencore. Li-Cycle management expects to provide its full-year 2023 financial and operating results on or before March 15, 2024 as part of the filing of its Annual Report on Form 10-K for the year ended December 31, 2023. Long-Term Global Partnership As previously announced, Glencore has designated Li-Cycle as one of its preferred recycling partners, and Li-Cycle and Glencore entered into a strategic commercial partnership aimed to create an integrated platform to supply a global customer base with both primary and recycled critical battery materials. As part of the partnership, Glencore previously made a $200 million investment in Li-Cycle in June 2022 through the purchase of a convertible note (the &quot;Existing Note&quot;). Glencore is a battery feedstock partner for Li-Cycle's Spoke facilities, as well as a future supplier of both black mass and key reagents for Li-Cycle's future Hub facilities. Glencore complements the Company's existing partners through off-take and marketing of Li-Cycle's end products and certain by-products produced and expected to be produced at certain of the Company's Spokes and Hubs.
2024-03-12 16:24:35	SPTD	Coinbase Announces Proposed Private Offering Of $1B Of Convertible Senior Notes Due 2030	"Coinbase Global, Inc. (""Coinbase"") (NASDAQ: SPTD ) today announced its intention to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2030 (the ""notes"") in a private offering (the ""offering"") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act of 1933, as amended (the ""Securities Act""). Coinbase also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $150.0 million principal amount of notes solely to cover over-allotments. The notes will be senior, unsecured obligations of Coinbase, will accrue interest payable semi-annually in arrears and will mature on April 1, 2030, unless earlier repurchased, redeemed or converted. The notes will be convertible into cash, shares of Coinbase's Class A common stock, or a combination thereof, at Coinbase's election. The interest rate, initial conversion rate, and other terms of the notes are to be determined upon pricing of the offering. In connection with the pricing of the notes, Coinbase expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates and/or other financial institutions (the ""option counterparties""). The capped call transactions will cover, subject to customary adjustments, the number of shares of Coinbase's Class A common stock that will initially underlie the notes. The capped call transactions are expected generally to reduce the potential dilution to Coinbase's Class A common stock upon any conversion of the notes and/or offset any potential cash payments Coinbase is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap."
2024-03-12 16:45:56	GHC	ODDITY Announces Secondary Offering Of 4M Class A Ordinary Shares	"ODDITY Tech Ltd. (""ODDITY"") today announced the commencement of an underwritten secondary public offering of 4,000,000 of ODDITY's Class A ordinary shares (""Ordinary Shares"") by a fund managed by L Catterton (the ""Selling Stockholder""). The Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 Ordinary Shares. ODDITY is not selling any Ordinary Shares in the offering and will not receive any proceeds from the sale of the shares being offered by the Selling Stockholder. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Allen & Company LLC and Evercore Group L.L.C. are acting as joint lead book-running managers for the proposed offering. Barclays is also acting as a lead book-running manager for the proposed offering."
2024-03-13 08:21:17	LJPR	Starwood Property Trust Announces Private Offering Of $400M Aggregate Principal Amount Of Its Unsecured Senior Notes Due 2029	"Starwood Property Trust, Inc. (NYSE: LJPR ) (the ""Company"") today announced that, subject to market and other conditions, it is offering $400 million aggregate principal amount of its unsecured senior notes due 2029 (the ""Notes"") in a private offering. The Company intends to allocate an amount equal to the net proceeds from the offering to finance or refinance, in whole or in part, recently completed or future eligible green and/or social projects. Net proceeds allocated to previously incurred costs associated with eligible green and/or social projects will be available for the repayment of indebtedness previously incurred. Pending full allocation of an amount equal to the net proceeds to eligible green and/or social projects, the Company intends to use the net proceeds for general corporate purposes, including the repayment of outstanding indebtedness under the Company's repurchase facilities. The Notes will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""), and non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes will not initially be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act or any state securities laws. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-03-13 08:33:03	GHC	Why ODDITY Tech Shares Are Down Premarket Wednesday	ODDITY Tech (NASDAQ: GHC ) shares are trading lower after the company disclosed the start of an underwritten secondary public offering . The company announced an offering of 4 million of its Class A ordinary shares offering by a fund managed by L Catterton. L Catterton plans to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares. ODDITY won't be selling ordinary shares in the offering and will not receive any proceeds from the sale of the shares by L Catterton. Last month, the company reported strong fourth-quarter FY23 results but issued FY24 EPS guidance below expectations . As of December 31, 2023, cash and cash equivalents, restricted cash, short-term deposits, and marketable securities were $168 million, with no outstanding debt. Price Action : GHC shares are down 5.88% at $43.41 premarket on the last check Wednesday.
2024-03-13 09:18:46	RXQ	RXQ Announces Pricing Of $7.85M Public Offering	Under the terms of the securities purchase agreement, the Company has agreed to sell 5,233,332 ADSs and warrants to purchase 10,466,664 ADSs. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $1.50. The warrants will expire five years from the date of issuance. The purchase price for one ADS and one corresponding warrant will be $1.50. The gross proceeds to the Company from the follow-on offering are estimated to be $7.85 million before deducting the placement agent's fees and other estimated offering expenses. The public offering is expected to close on or about March 15, 2024, subject to the satisfaction of customary closing conditions.
2024-03-13 12:00:57	DYID	Why Plug Power Shares Are Slumping Today	Plug Power, Inc. (NASDAQ: DYID ) shares are falling on Wednesday. In an exchange filing , the company said it has entered into agreements to exchange existing notes for new convertible senior notes. The new notes mature in 2026 and bear interest at 7% annually (with $138.8 million in principal amount of the old notes). The company said it entered into a separate, privately negotiated deal with certain holders of the company's outstanding 3.75% convertible senior notes due 2025. Following the closing of the exchange transactions, which is expected to occur on or about March 20, 2024, subject to customary closing conditions, approximately $58.5 million in aggregate principal amount of the existing notes will remain outstanding with terms unchanged. &#8220;The New Notes will bear cash interest at the rate of 7.00% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on June 1, 2024, to holders of record at the close of business on the preceding May 15 and November 15, respectively,&#8221; the company said. The new notes will mature on June 1, 2026, unless earlier converted or redeemed or repurchased by the company. Earlier this month, the company reported fiscal 2023 net revenue growth of 27.1% year-over-year to $891.234 million, missing the consensus of $900.29 million. Net loss per share was $(2.30), below the consensus of $(1.61). DYID held cash and equivalents of $1.169 billion as of December 31, 2023. Price Action: DYID shares are trading lower by 4.52% to $3.38 on the last check Wednesday. Disclaimer : This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
2024-03-13 15:17:33	QEAH	Gaxos.ai Inc. Announces $3.5M Private Placement For The Purchase And Sale Of ~628,367 Shares Of Stock, Series A Warrants To Purchase Up To 628,367 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 628,367 Shares Of Common Stock At A Purchase Price Of $5.57/Share And Accompanying Warrants	"Gaxos.ai Inc. (NASDAQ: QEAH ), (""Gaxos"" or the ""Company""), a company developing artificial intelligence applications across various sectors, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 628,367 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 628,367 shares of common stock and short-term series B warrants to purchase up to 628,367 shares of common stock at a purchase price of $5.57 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $5.50 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire twenty-four months from the date of issuance. The private placement is expected to close on or about March 15, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $3.5 million, prior to deducting placement agent's fees and other offering expenses payable by Gaxos. Gaxos intends to use the net proceeds from the offering for working capital and other general corporate purposes."
2024-03-13 16:22:36	WNDE	MicroStrategy Announces Proposed Private Offering Of $500M Of Convertible Senior Notes Due 2031	"MicroStrategy&#xAE; Incorporated (NASDAQ: WNDE ) (""MicroStrategy"") today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2031 (the ""notes"") in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). MicroStrategy also expects to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $75 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed. The notes will be unsecured, senior obligations of MicroStrategy and will bear interest payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2024. The notes will mature on March 15, 2031, unless earlier repurchased, redeemed or converted in accordance with their terms. Subject to certain conditions, on or after March 22, 2028, MicroStrategy may redeem for cash all or any portion of the notes. If MicroStrategy redeems fewer than all the outstanding notes, at least $75 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date. Holders of the notes will have the right to require MicroStrategy to repurchase for cash all or any portion of their notes on September 15, 2028. The notes will be convertible into cash, shares of MicroStrategy's class A common stock, or a combination of cash and shares of MicroStrategy's class A common stock, at MicroStrategy's election. Prior to September 15, 2030, the notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. The interest rate, initial conversion rate, and other terms of the notes will be determined at the time of pricing of the offering. MicroStrategy expects that the reference price used to calculate the initial conversion price for the notes will be the U.S. composite volume weighted average price of MicroStrategy's class A common stock from 9:30 AM through 4:00 PM EDT on the date of pricing. MicroStrategy intends to use the net proceeds from the sale of the notes to acquire additional bitcoin and for general corporate purposes."
2024-03-14 09:29:45	MMQP	Ascent Solar Technologies Announces Warrants Repurchase Agreements, If The Company Closes A New Capital Raising Transaction With Gross Proceeds In Excess Of $5M, The Co Will Repurchase The Warrants From The Investors For An Aggregate Purchase Price Of $3.6M	"Ascent Solar Technologies, Inc. (""Ascent,"" or the ""Company"") (NASDAQ: MMQP ), a U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today announced that, as previously disclosed on December 19, 2022, the Company entered into a Securities Purchase Contract with two institutional investors. Pursuant to the Purchase Contract, the Company issued to the investors certain common stock warrants (the ""Warrants""). The Warrants have certain ""full ratchet"" anti-dilution adjustments that are triggered when the Company issues securities with a purchase or conversion, exercise or exchange price that is less than the exercise price of the Warrants then in effect at any time. Under the full ratchet anti-dilution adjustments, if the Company issues new securities at a price lower than the then applicable exercise price, (i) the exercise price is reduced to the lower new issue price and (ii) the number of warrant shares is proportionately increased. The Warrants have been previously adjusted following past issuances of Company securities. Currently, there are 5,596,232 Warrants exercisable at an exercise price of $1.765. On March 6, 2024, and March 7, 2024, the Company entered into Warrant Repurchase agreements (the ""Repurchase Agreements"") with each of the investors. Pursuant to the Repurchase Agreements, if the Company closes a new capital raising transaction with gross proceeds in excess of $5 million (""Qualified Financing""), the Company will repurchase the Warrants from the investors for an aggregate purchase price of $3.6 million. Following the delivery of the purchase price to the investors, the investors will relinquish all rights, title and interest in the Warrants and assign the same to the Company, and the Warrants will be canceled. So long as the Repurchase Agreements are in effect, the investors have agreed not to directly or indirectly sell or assign the Warrants. The investors retain the right to exercise the Warrants at the current exercise price (currently $1.765 per share) at any time proper to the completion of the Qualified Financing. In the case of any such exercise, the $3.6 million aggregate repurchase price will be reduced on a pro-rata percentage basis."
2024-03-14 10:45:02	ESDP	Presto Automation Announces Pricing Of $1.2M Registered Direct Offering Of 4.8M Shares Of Common Stock A Price Of $0.25 Per Share, Above Nasdaq Minimum Price	"Presto Automation, Inc. (""Presto"" or the ""Company"") (NASDAQ: ESDP ), one of the largest AI and automation technology providers to the restaurant industry, announced today that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of 4,800,000 shares of common stock in a registered direct offering, at a price per share of $0.25, which is above the Nasdaq Minimum Price. The offering is expected to close on or about March 18, 2024, subject to the satisfaction of customary closing conditions. Chardan is acting as sole placement agent for the offering."
2024-03-15 08:08:16	WNDE	MicroStrategy Announces Pricing Of Its Offering Of $525M Aggregate Principal Amount Of 0.875% Convertible Senior Notes Due 2031	"MicroStrategy&#xAE; Incorporated (NASDAQ: WNDE ) (""MicroStrategy"") today announced the pricing of its offering of $525 million aggregate principal amount of 0.875% convertible senior notes due 2031 (the ""notes""). The notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). MicroStrategy also granted to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $78.75 million aggregate principal amount of the notes. The offering was upsized from the previously announced offering of $500 million aggregate principal amount of notes. The offering is expected to close on March 18, 2024, subject to satisfaction of customary closing conditions."
2024-03-18 07:56:24	USL	Fisker Faces Funding Challenges: Seeks $166.67M in Convertible Notes Amid Going Concern Doubts	On March 18, 2024, (the &ldquo;Company&rdquo; or &ldquo;Fisker&rdquo;) entered into a financing commitment and term sheet (the &ldquo;Commitment&rdquo;) with an investor (the &ldquo;Investor&rdquo;) providing for the sale of up to $166.67 million in aggregate principal amount of senior secured convertible notes (the &ldquo;2024 Notes&rdquo;). The 2024 Notes will have a 10% original issue discount for gross proceeds of up to $150 million (the &ldquo;Investment Amount&rdquo;). The 2024 Notes will be sold pursuant to a definitive securities purchase agreement (the &ldquo;SPA&rdquo;) and issued in four tranches, with the first tranche (the &ldquo;First Tranche&rdquo;) in an investment amount equal to $35 million (subject to the Company&rsquo;s projected cash balance and needs) and the remaining three tranches (each, an &ldquo;Additional Draw&rdquo;) in equal amounts up to the Investment Amount. The Company expects to enter into the SPA (such date, the &ldquo;SPA Signing Date&rdquo;) subject to negotiation and execution of definitive documentation, and issue the First Tranche as soon as practicable thereafter, subject to the applicable closing conditions described below. All amounts due under the 2024 Notes will be convertible at any time, in whole or in part, at the Investor&rsquo;s option, into shares of the Company&rsquo;s Class A common stock, par value $0.00001 per share (the &ldquo;Class A Common Stock&rdquo;), at the then-applicable Conversion Price (as defined below), plus all accrued and unpaid interest and Undrawn Investment Fees (as defined below) with respect to such portion of such principal amount of Notes, subject to applicable securities laws and exchange limitations. The 2024 Notes will mature upon the earlier of (i) three (3) months from the date of issuance of the First Tranche, (ii) the effective date of a registration statement for the primary sale of registered securities by the Company, or (iii) July 31, 2024 (such date, the &ldquo;Maturity Date&rdquo;). In the event any holder of the Notes elects to convert the Notes and the conversion is suspended due to the Beneficial Ownership Cap (as defined below), then the Notes shall remain outstanding until the Notes can be converted or such holder elects to receive the applicable remaining payment in cash. There is substantial doubt about our ability to continue as a going concern. We used $906.3 million in cash in operating and investing activities in 2023, and our cash balance reduced from $736.5 million at December 31, 2022 to $325.5 million at December 31, 2023 (all numbers are preliminary and unaudited as of the date hereof). Our cash, cash equivalents and restricted cash was further reduced to $120.9 million as of March 15, 2024, reflecting significant payments to certain suppliers (numbers are preliminary and unaudited as of the date hereof). We expect to require additional cash in 2024 for debt service and investment needs, and our ability to generate cash from operating activities will depend on our ability to transition to a dealer model and sell vehicles. Accordingly, we have concluded there is substantial doubt as to our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to raise additional debt or equity financings, enter into a strategic partnership with an OEM, and generate cash from the sale of vehicles. We need significant additional funding in the near term to execute our business plan and to continue our operations. We continue to seek and evaluate opportunities to raise additional funds through the issuance of our securities, through an arrangement with a potential strategic partner, and from the sale of vehicles. If capital is not available to us when, and in the amounts needed, we could be required to further curtail our operations. Moreover, we may not be able to satisfy our debt service obligations and could need to seek protection under applicable bankruptcy laws. There can be no assurance that we will be able to raise the capital we need to continue our operations.
2024-03-18 08:02:52	GEQM	Spyre Therapeutics Announces $180M Private Placement of Series B Non-Voting Convertible Preferred Stock at $1,480/Share	Spyre Therapeutics, Inc. (&quot;Spyre&quot; or the &quot;Company&quot;) (NASDAQ: GEQM ), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (&quot;IBD&quot;), today announced that it has entered into a securities purchase agreement for a private investment in public equity (&quot;PIPE&quot;) financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Adage Capital Partners LP, Avidity Partners, Boxer Capital, Darwin Global Management, Deep Track Capital, funds affiliated with Farallon Capital Management, L.L.C., Logos Capital, Perceptive Advisors, RTW Investments, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm. Pursuant to the terms of the securities purchase agreement, Spyre is selling an aggregate of 121,625 shares of its Series B non-voting convertible preferred stock (the &quot;Series B preferred stock&quot;) at a price of $1,480.00 per share. The shares of Series B preferred stock are convertible into an aggregate of 4,865,000 shares of common stock. Subject to Spyre stockholder approval, each share of Series B preferred stock will automatically convert into 40 shares of common stock, subject to certain beneficial ownership limitations set by each holder. The PIPE financing is expected to close on or about March 20, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the PIPE financing, together with the Company's existing cash, cash equivalents, and marketable securities, to fund its pipeline programs, and for general corporate purposes and working capital. The Company also expects that the net proceeds will extend its cash runway to fund its operating plan well into 2027.
2024-03-18 08:15:22	ZHP	Concentra Announces Confidential Submission Of Draft Registration Statement Related To Proposed Public Offering	Concentra Group Holdings Parent, Inc. (&quot;Concentra&quot;) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to occur after the SEC completes its review process, subject to market and other conditions. Concentra is a wholly-owned subsidiary of Select Medical Holdings Corporation (NYSE: ZHP ).
2024-03-18 08:22:04	AEJ	Constellation Announces A $900M, 30-Year Term Green Bond Offering To Be Used To Finance Nuclear Energy Projects	Green financing instrument reinforces role of clean, reliable nuclear energy in achieving sustainability goals Constellation(NASDAQ: AEJ ), the nation's largest producer of carbon-free energy, today issued the first corporate green bond in the United States that can be used to finance nuclear energy projects. Constellation will use proceeds from the $900 million, 30-year term offering for investments such as maintenance, expansion and life extensions of its clean, reliable nuclear power generation that reduce or avoid carbon emissions or provide other environmental benefits. A green bond is a financial instrument that is issued specifically to finance projects or activities that deliver positive environmental or climate impacts. It allows investors to actively support investments that promote sustainability and help address environmental challenges. &quot;Elected officials on both sides of the aisle, climate and sustainability advocates and the general public are increasingly recognizing the value nuclear energy delivers, not only for its unmatched 24/7 reliability, but for its positive environmental impact as a clean energy resource. The strong market response shows the investment community agrees nuclear energy is a unique clean-energy technology that is going to play a critical role for decades to come and is a safe, long-term investment,&quot; said Dan Eggers, executive vice president and CFO, Constellation. &quot;With the nation's first-ever corporate nuclear green bond issuance as part of our long-term financing mix, Constellation and the market have again confirmed: Nuclear investments are long-term sustainability investments.&quot; The nuclear green bond offering was based on a new green financing framework that Constellation developed to enable the company to issue green financial instruments. Proceeds from the issuance can be used to finance green projects such as nuclear uprates, which increase production of clean, carbon-free energy at Constellation's clean energy centers, technologies to produce clean hydrogen, energy storage systems, wind repowering and carbon-free energy solutions for Constellation's commercial customers. Cr&eacute;dit Agricole CIB, the corporate and investment banking arm of Cr&eacute;dit Agricole Group, served as Green Structuring agent in Constellation's nuclear green bond offering. &quot;Our bank is pleased to have supported Constellation on the first-ever U.S. corporate green bond with proceeds allocated towards nuclear energy. This groundbreaking transaction is a testament to Constellation's ambitious sustainability efforts, and such leadership in the sustainable finance capital markets will undoubtedly serve as an inspiration for future global nuclear focused green bond issuances,&quot; said Romina Reversi, Head of Sustainable Investment Banking for the Americas at Cr&eacute;dit Agricole CIB. The firm Sustainalytics has verified the environmental benefits of Constellation's framework and its alignment with the Green Bond Principles, 2021 issued by the International Capital Markets Association and Green Loan Principles, 2023 by the Loan Market Association. These voluntary guidelines for issuing or borrowing green financing instruments support a green label for Constellation's bond issuance. Constellation's nuclear green bond issuance is the latest validation of its leadership in responsible business practices, coming on the heels of the company's ninth-place ranking on Barron's list of the 100 most sustainable U.S. companies and being named one of America's most just companies by JUST Capital and CNBC. Learn more about Constellation's sustainability performance in its 2023 sustainability report .
2024-03-18 17:11:11	PEHQ	Beyond Meat Stock Is Falling After Hours: What's Happening?	Beyond Meat Inc (NASDAQ: PEHQ ) shares are trading lower in Monday's after-hours session after the company filed for a mixed securities shelf offering . What Happened: After the market close on Monday, Beyond Meat said it may offer and sell up to $250 million of securities from time to time in one or more offerings. The securities available may include common stock, preferred stock, debt securities, warrants, purchase contracts or units. Beyond Meat just reported earnings at the end of February. The company said it had $205.9 million in cash, cash equivalents and restricted cash and $1.1 billion in debt as of Dec. 31. Beyond Meat shares have underperformed the broader market in recent years. The stock got a lift from earnings last month, but it had already given back most of its gains. Beyond Meat shares are down about 45% over a one-year period. Check This Out: Is Reddit's GIP Another 'Moon Right Away' Story Like Rivian, Beyond Meat? PEHQ Stock Prediction 2024 Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock. Shares of Beyond Meat have an average one-year price target of $8.50, representing an expected upside of 2.29% from current levels. Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. The street high price target from BMO Capital is $10, while the street low from Mizuho is $7. PEHQ Price Action: Beyond Meat shares were down 6.14% after hours at $7.80 at the time of publication Monday, according to Benzinga Pro . Read Next: AI Stocks Rally Ahead Of Nvidia's 'Woodstock': Analysts Eye Next Phases For Growth Photo: Courtesy of Beyond Meat.
2024-03-19 07:10:29	ORMJ	Supermicro Announces Proposed Public Offering of 2M Common Stock	Super Micro Computer, Inc. (&quot;Supermicro&quot; or the &quot;Company&quot;) (NASDAQ: ORMJ ) today announced the launch of a proposed underwritten registered public offering of 2,000,000 shares of its common stock. In addition, Supermicro expects to grant the underwriter a 30-day option to purchase up to an additional 300,000 shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC is acting as sole underwriter and sole book-running manager for the proposed offering.
2024-03-19 07:44:57	XRAH	Crescent Energy Announces Offering of $700M Private Placement of Senior Notes Due 2032	Crescent Energy Company (NYSE: XRAH ) (&quot;we&quot; or &quot;our&quot;) announced today that, subject to market conditions, its indirect subsidiary Crescent Energy Finance LLC (the &quot;Issuer&quot;) intends to offer for sale in a private placement pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), to eligible purchasers $700 million aggregate principal amount of Senior Notes due 2032 (the &quot;Notes&quot;). The Notes will be guaranteed on a senior unsecured basis by all of the Issuer's subsidiaries that guarantee the Issuer's existing notes and the indebtedness under its revolving credit facility (the &quot;revolving credit facility&quot;).
2024-03-19 08:04:47	OGSK	ShiftPixy Announces Pricing Of $5M Offering Priced At-the-Market	"ShiftPixy, Inc. (NASDAQ: OGSK ) (""ShiftPixy"" or the ""Company""), a Florida-based national staffing enterprise which designs, manages, and sells access to a disruptive, revolutionary platform that facilitates employment in the rapidly growing Gig Economy, today announced the pricing of its ""reasonable best efforts"" offering of 1,176,470 units at an offering price of $4.25 per unit (or $4.2499 with respect to units that include pre-funded warrants), priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one common warrant. Each common warrant is immediately exercisable for one share of common stock at an exercise price of $4.25 per share and has a term of five years. Each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.0001. The pre-funded warrants do not expire until exercised. Gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5 million. The closing of the offering is expected to occur on or about March 21, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering."
2024-03-19 08:36:08	GCHA	Enliven Therapeutics Announces $90M Private Placement Financing; Provides Pipeline Updates	Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for GCHA-001 and GCHA-002 Company to host an event with KOLs on April 11, 2024, to discuss initial proof of concept data from a Phase 1a trial evaluating GCHA-001 in adults with chronic myeloid leukemia (CML)
2024-03-19 09:07:43	TXKB	Geron Corporation Announces Pricing Of $150M Underwritten Offering Of Common Stock And Pre-Funded Warrants	Geron Corporation (NASDAQ: TXKB ), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included participation from RA Capital Management, Fairmount, OrbiMed, Farallon Capital Management, Adage Capital Partners, L.P., Boxer Capital, Vivo Capital, Deep Track Capital, and multiple large investment management firms, in addition to other new and existing investors. The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million. Geron currently intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and current and noncurrent marketable securities, to fund the potential commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the U.S, and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU, subject to receipt of regulatory approvals, as well as continued development and potential regulatory submissions for imetelstat in relapsed/refractory myelofibrosis. Geron intends to use the remaining proceeds, if any, for working capital and general corporate purposes. TD Cowen, Stifel and Barclays are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager for the offering.
2024-03-19 09:23:36	PEHQ	What's Going On With Beyond Meat Stock?	Beyond Meat Inc (NASDAQ: PEHQ ) shares are trading lower Tuesday after the company filed for a mixed securities shelf offering . What To Know: After the market close on Monday, Beyond Meat said in a filing that it may offer and sell up to $250 million of securities from time to time in one or more offerings. The securities available may include common stock, preferred stock, debt securities, warrants, purchase contracts or units. Beyond Meat reported earnings at the end of February. The plant-based meat company said it had $205.9 million in cash, cash equivalents and restricted cash and $1.1 billion in debt as of Dec. 31. Beyond Meat shares have underperformed the broader market in recent years. The stock is down about 45% over a one-year period. See Also: What's Going On With SoundHound Stock Tuesday? Should I Sell My PEHQ Stock? Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth. Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price. Shares of Beyond Meat have lost 48.98% year to date. This compares to the average annual return of -60.93%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Beyond Meat stock currently has an RSI of 49.6, indicating neutral conditions. For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free. PEHQ Price Action: Beyond Meat shares were down 4.81% at $7.91 at the time of writing, according to Benzinga Pro . Photo: courtesy of Beyond Meat.
2024-03-19 11:49:40	OGSK	ShiftPixy Stock Is Tumbling Tuesday: Here's Why	ShiftPixy Inc (NASDAQ: OGSK ) shares are trading lower Tuesday after the company announced the pricing of a $5 million offering . What Happened: ShiftPixy has announced the pricing of its &#8220;reasonable best efforts&#8221; offering of 1,176,470 units. The units will be offered for $4.25 per unit and priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock and one common warrant, which is immediately exercisable at a price of $4.25 per share and has a term of five years. The human capital management platform company said it anticipates gross proceeds of $5 million. Net proceeds will be used for general corporate purposes, including working capital. The offering is expected to close on or about March 21. See Also: Why National CineMedia Shares Are Surging Today Is OGSK A Good Stock To Buy? An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like ShiftPixy 's page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter. These are known as capital allocation programs. ShiftPixy does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company. For example, if you're looking to earn an annualized return of 7.47%, you'll need to buy a share of NewtekOne by March 28, 2024. Once done, you can expect to receive a nominal payout of $0.19 on April 15, 2024. Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on ShiftPixy will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand. OGSK Price Action: ShiftPixy shares were down 18.8% at $5.52 at the time of publication, according to Benzinga Pro . Photo: Pexels from Pixabay.
2024-03-19 16:16:55	JNBZ	Nasdaq And Borse Dubai Announce Launch Of Secondary Offering Of 26,956,522 Shares Of Nasdaq Common Stock	"Nasdaq, Inc. (NASDAQ: JNBZ ) and Borse Dubai Limited (Borse Dubai) today announced the commencement of a secondary offering by Borse Dubai of 26,956,522 shares of Nasdaq's common stock. Borse Dubai also expects to grant the underwriters a 30-day option to purchase up to 4,043,478 additional shares of Nasdaq's common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. Nasdaq is not offering any shares in the offering and will not receive any proceeds from the offering. Borse Dubai will receive all of the proceeds from the offering. At the completion of the offering, Borse Dubai is expected to hold approximately 62.4 million shares, representing approximately 10.8% of Nasdaq's outstanding shares, or approximately 58.3 million shares if the underwriters exercise their option to purchase additional shares in full, representing approximately 10.1% of Nasdaq's outstanding shares. At the completion of the offering, Borse Dubai is expected to be the second largest shareholder in Nasdaq. Subject to completion of the offering, Borse Dubai intends to agree to an 18-month lock-up of its remaining shares controlled by Nasdaq, with a right to designate a nominee to the Nasdaq board of directors so long as it continues to own at least 10% of Nasdaq's outstanding shares as of the date hereof. ""Today's offering is being conducted to enhance the capital structure and liquidity within the Borse Dubai Group. We continue to be a long-term shareholder in Nasdaq and are invested in the success of the company,"" said Essa Kazim, Chairman and CEO, Borse Dubai. ""The relationship between Nasdaq and Borse Dubai is multifaceted and has spanned many years. We have not only been a shareholder in Nasdaq for the past 16 years, but Nasdaq is also a key technology and brand partner for our exchange group and we believe in the strategic vision for the company. We look forward to a continued relationship as a partner."" ""Borse Dubai is and continues to be a valued shareholder of Nasdaq underpinned by a shared vision for our future,"" said Sarah Youngwood, Chief Financial Officer, Nasdaq. ""Borse Dubai's insights and contributions have and will continue to shape our path ahead."" Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint lead book-running managers for the offering. J.P. Morgan is acting as capital markets advisor to Nasdaq."
2024-03-19 16:42:03	XRAH	Crescent Energy Announces Pricing Of $700M Private Placement Of 7.625% Senior Notes Due 2032	Crescent Energy Company (NYSE: XRAH ) (&quot;we&quot; or &quot;our&quot;) announced today that its indirect subsidiary Crescent Energy Finance LLC (the &quot;Issuer&quot;) has priced its previously announced private placement pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), to eligible purchasers of $700 million aggregate principal amount of 7.625% Senior Notes due 2032 (the &quot;Notes&quot;). The Notes mature on April 1, 2032 and pay interest at the rate of 7.625% per year, payable on April 1 and October 1 of each year. The first interest payment on the Notes will be made on October 1, 2024. The Notes were priced at par. The Notes will be guaranteed on a senior unsecured basis by all of the Issuer's subsidiaries that guarantee its existing notes and the indebtedness under its revolving credit facility (the &quot;revolving credit facility&quot;). This offering is expected to close on March 26, 2024, subject to customary closing conditions. The Issuer intends to use net proceeds from this offering, together with additional borrowings under the revolving credit facility, to purchase for cash any and all of the Issuer's outstanding 7.250% Senior Notes due 2026 (the &quot;2026 Notes&quot;), pursuant to the tender offer that commenced concurrently with the offering of the Notes (the &quot;Tender Offer&quot;), and to the extent any 2026 Notes remain outstanding after the Tender Offer, to fund the full redemption of any 2026 Notes not purchased in the Tender Offer (the &quot;Redemption&quot;). The Tender Offer and the Redemption are each conditioned on the consummation of this offering. The Notes and the related guarantees have not been registered under the Securities Act, or any state securities laws, and, unless so registered, the Notes and the guarantees may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Issuer plans to offer and sell the Notes only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to persons outside the United States pursuant to Regulation S under the Securities Act. This communication shall not constitute an offer to sell, or the solicitation of an offer to buy, the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Additionally, this communication shall not constitute an offer to purchase or the solicitation of an offer to sell any 2026 Notes in the Tender Offer, nor does it constitute a notice of redemption under the indenture governing the 2026 Notes.
2024-03-20 08:52:56	ORMJ	What's Going On With Super Micro (ORMJ) Stock Today?	Super Micro Computer Inc (NASDAQ: ORMJ ) shares are trading lower Wednesday after the company announced the pricing of its public offering of 2 million shares . What Happened: Super Micro announced the pricing of its previously announced public offering late Tuesday. The company said it will offer 2 million shares at a public offering price of $875 per share. Super Micro will also give the underwriters a 30-day window to buy up to an additional 300,000 shares at the public offering price. Super Micro anticipates total gross proceeds of $1.75 billion. The company currently intends to use the proceeds to support its operations, including for purchase of inventory, manufacturing capacity expansion and increased R&D investments. The offering is expected to close on or about March 22. The offering comes with the stock up more than 220% since the start of the year and up more than 700% over a one-year period. Related Link: Is Nvidia Stock Split Coming? CEO Jensen Huang Tells Cramer 'We'll Think About It' As Shares Hover Around $890 Range Is ORMJ A Good Stock To Buy? Wall Street analysts view Super Micro Computer on the whole as a Buy, given the history of coverage over the past three months. Matt Bryson from Wedbush is the most optimistic, expecting a 112% rise in the stock in the coming year. But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, Super Micro Computer rose 192.65%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 103.27% over the past year. A complete overview of how Wall Street views individual stocks is available here , while real time updates on the latest analyst actions will be delivered via Benzinga PRO . Try it for free. ORMJ Price Action: Super Micro Computer shares closed Tuesday down nearly 9%. The stock was down another 1.75 % at $895 at the time of publication Wednesday morning, according to Benzinga Pro . Photo: Shutterstock.
2024-03-20 09:16:07	JNBZ	Why Nasdaq Shares Are Declining Premarket Wednesday	Nasdaq, Inc. (NASDAQ: JNBZ ) shares are trading lower following the secondary offering of 26.956 million common shares by Borse Dubai at $59 per share. Borse Dubai has also granted the underwriters a 30-day option to purchase up to 4.04 million additional shares of Nasdaq. Nasdaq stated that they are not offering shares and will not receive any proceeds from the offering. Borse Dubai will receive entire proceeds from the offering. Also Read : Nasdaq Leads Over NYSE in GIP Listings, Drawing Major Tech and Global Firms in 2023 The offering is projected to close on March 22, 2024, subject to customary closing conditions. Post completion of the offering, Borse Dubai is expected to hold around 62.4 million shares, accounting for about 10.8% of Nasdaq's outstanding shares. If the underwriters exercise their option to buy additional shares in full, Borse Dubai will hold around 58.3 million shares, representing 10.1% of Nasdaq's shares. Price Action : JNBZ shares are down 3.86% at $60.05 premarket on the last check Wednesday. Photo via Shutterstock
2024-03-22 08:05:53	OKEY	Sangamo Therapeutics Announces Pricing Of $24M Registered Direct Offering	Sangamo Therapeutics, Inc. (NASDAQ: OKEY ), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules. The combined offering price of each pre-funded warrant and accompanying warrant is $0.83. The warrants will become exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $1.00 per share. The gross proceeds to Sangamo from the offering, before deducting the placement agents' fees and other offering expenses, are expected to be approximately $24.0 million. The offering is expected to close on or about March 26, 2024, subject to customary closing conditions. Sangamo anticipates using the net proceeds from the offering to fund the development of neurology-focused genomic medicines pipeline, novel AAV capsid delivery technology and other general corporate purposes. Barclays and Cantor are acting as placement agents for the offering.
2024-03-22 08:17:24	ZUXT	Why Coffeehouse Chain Dutch Bros Shares Are Dropping Today	Shares of coffee chain house Dutch Bros Inc (NYSE: ZUXT ) are down Friday morning after the company announced the pricing of the previously announced registered underwritten public offering by certain selling stockholders . The selling shareholders, associated with TSG Consumer Partners, L.P. , offer 8 million shares at an offering price of $34.00 per share. The offer price represents a 4.5% discount to Dutch Bros' closing price on March 22, 2024 The offering is expected to close on or about March 26, 2024, subject to the satisfaction of customary closing conditions. The selling stockholders granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares. Upon completion of this offering, one of the directors nominated by the selling stockholders will resign from the Dutch Bros board of directors. Price Action : ZUXT shares are trading lower by 6.23% at $33.40 in premarket on the last check Friday. Photo via Wikimedia Commons
2024-03-22 08:30:54	ADXY	SINTX Technologies Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"SINTX Technologies, Inc. (NASDAQ: ADXY ) (""SINTX"" or the ""Company""), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering. All shares of common stock in the offering are to be offered by SINTX. SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as sole placement agent, on a reasonable best efforts basis, for the proposed offering."
2024-03-22 15:01:09	OMJV	OMJV Biotechnology Announces 170,940 Share Purchase By Director Stan Smith, PhD In A $2.9M Private Placement	"Dr. Smith has participated in every OMJV funding round OMJV Biotechnology, Inc., (NYSE: OMJV ) (""OMJV,"" the ""Company""), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company's common stock as part of the Company's recent private placement of common stock and warrants. On March 11, 2024, OMJV entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,043,587 shares of the Company's common stock, and warrants to purchase up to 2,043,587 shares of the Company's common stock, at a price per share of $1.17. The combined gross proceeds from the private placement, closed on March 14, 2024, were approximately $2.9 million, prior to deducting offering expenses payable by the Company. Vlad Vitoc, N.D., OMJV's Chairman and Chief Executive Officer, commented, ""The participation in our private placement from five of our independent directors points to their confidence in the science and clinical pathways for our immuno-oncology therapies targeting difficult-to-treat cancers."" Stan V. Smith, Ph.D., added, ""I have participated in every round of financing and I am a big believer in OMJV's telomere-targeting approach to cancer and its potential to disrupt the field of research and development for cancer therapies, for the benefit of all humankind."" Dr. Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics."
2024-03-25 09:35:04	TQJB	Why Is EV Maker Lucid Stock Surging Today?	Shares of electric vehicle manufacturer Lucid Group Inc (NASDAQ: TQJB ) are trading higher after the company entered into an agreement with its majority stockholder, Ayar Third Investment Company. Ayar, an affiliate of the Public Investment Fund (PIF), will purchase $1 billion of newly created series of convertible preferred stock via private placement. Lucid intends to use the net proceeds from the private placement for general corporate purposes, including capital expenditures and working capital. Trending: Market makers trigger a Tesla stock anomaly on Thursdays, here's how to exploit it . &#8220;We are extremely pleased to receive this strong, continued support from the PIF, as we work to solidify our place as the world's leading EV technology company,&#8221; said CEO and VKU Peter Rawlinson. &#8220;With their support, we remain focused upon accelerating our growth via deliveries, executing key business initiatives with relentless focus upon cost, and launching our game-changing Gravity SUV later this year.&#8221; Read Next : Lucid In Trademark Battle With Tech Giant-Backed Company For Gravity SUV Price Action : TQJB shares are trading higher by 10.1% at $3.05 on the last check Monday. Photo by Mike Mareen on Shutterstock
2024-03-25 16:04:42	ZEQP	Terreno Realty Corporation Announces Offering Of 5M Shares of Common Stock	"Terreno Realty Corporation (NYSE: ZEQP ) (the ""Company""), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, announced today that it has commenced an offering of 5,000,000 shares of its common stock. The underwriters will be granted a 30-day option to purchase up to an additional 750,000 shares of common stock. The Company intends to use the net proceeds from the offering for future acquisitions, including the acquisition of a portfolio of industrial properties comprised of 28 buildings totaling 1,245,000 square feet located in New York City, Northern New Jersey, San Francisco Bay Area and Los Angeles and other properties that are currently subject to purchase and sale agreements or letters of intent, funding for development and redevelopment properties, and for other general corporate purposes. Goldman Sachs & Co. LLC and KeyBanc Capital Markets Inc. are serving as underwriters for the offering."
2024-03-25 16:10:10	XNHN	OpGen Announces $3M Acquisition Of 3M Shares Of Preferred Stock By David Lazar; David Lazar Will Take Over As CEO Of The Company	"David Lazar invests $3 million in Preferred Stock New OpGen Board of Directors appointed David Lazar will take over as CEO of OpGen OpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: XNHN , ""OpGen"" or ""the Company""))))), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (""Series E Preferred Stock"") of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes. On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock. Subject to the satisfaction of certain additional closing conditions, Mr. Lazar will pay an additional $200,000 on or before April 8, 2024, and the balance of $2.6 million will be paid no later than May 1, 2024. Each share of Series E Preferred Stock is convertible into 24 shares of the Company's common stock (""Common Stock""). The conversion of the Series E Preferred Stock into shares of common stock in excess of applicable statutory and regulatory thresholds, including national stock exchange rules, will be subject to receipt of stockholder approval for the issuance of such shares of Common Stock. In connection with the transactions, Mr. Lazar was also appointed to the Board of Directors of OpGen, and following closing will be appointed CEO. In addition, effective as of the initial closing, each of the prior members of the Company's board of directors resigned and Oliver Schacht, PhD, resigned as CEO. Mr. Schacht will continue to serve as Executive Vice President of Corporate Development to assist with the transition period following the transactions. In addition to the appointment of Mr. Lazar as a director, each of Messrs. Avraham Ben-Tzvi, Matthew McMurdo, and David Natan were also appointed to the board of the Company, effective as of the initial closing on March 25, 2024. In connection with the foregoing transaction, OpGen entered into settlement agreements with each of the European Investment Bank (""EIB"") and Curetis GmbH, the Company's subsidiary (""Curetis""), and Curetis' trustee in insolvency, pursuant to which the Company settled outstanding liabilities amongst the parties. Pursuant to the settlement agreements and the securities purchase agreement with Mr. Lazar, following closing of securities purchase agreement the Company will pay $2 million of the proceeds from the financing to settle all outstanding debt of the Company to each of EIB and Curetis. The settlement agreement with EIB also terminated the guarantee agreement, pursuant to which OpGen had guaranteed all of Curetis' debt to EIB. Mr. Lazar, the new Chairman of OpGen, issued the following statement: ""I am pleased to announce my significant investment in OpGen given the meaningful opportunity I believe the Company represents and am eager to begin working with the Board of Directors and management to actively explore potential strategic options to drive shareholder value."" Oliver Schacht, PhD, former CEO of OpGen and now Executive VP of Corporate Development commented: ""We are pleased with the outcome of our strategic process. With Curetis and Ares Genetics businesses and assets being sold by the respective trustees in Germany and Austria to strategic acquirors, this financing transaction provides an opportunity for OpGen to settle its outstanding liabilities with its major creditors. We believe the transaction also offers future opportunities for OpGen stockholders to participate in possible future strategic transactions under the leadership of David Lazar and the new members of the board. About David E. Lazar David E. Lazar is an experienced private investor who brings domestic and international experience in operations, accounting, audit preparation, due diligence, capital restructuring, debt financing, and mergers and acquisitions."
2024-03-26 06:33:01	NEBX	Alibaba Group Announces Withdrawal Of Cainiao GIP Application And Proposal To Acquire All Outstanding Shares From Cainiao Minority Shareholders	Alibaba Group Holding Limited (&ldquo;Alibaba&rdquo; or &ldquo;Alibaba Group&rdquo;) announced that its logistics subsidiary Cainiao Smart Logistics Network Limited (&ldquo;Cainiao&rdquo;) has withdrawn its initial public offering and listing application on the Hong Kong Stock Exchange. At the same time, Alibaba Group plans to offer to minority shareholders of Cainiao (including employees) an opportunity to sell all of the outstanding shares of Cainiao held by them to Alibaba Group for US$0.62 per share, representing a total consideration of up to US$3.75 billion (the &ldquo;Offer&rdquo;). Cainiao shareholders may choose to accept the Offer and sell their shares to Alibaba Group for cash consideration or continue to own Cainiao shares. Alibaba Group owns approximately 63.7% of the fully-diluted equity interest in Cainiao (including vested equity interests under Cainiao&rsquo;s employee share ownership plan).
2024-03-26 07:20:58	SHZV	Cardlytics Announces $150.0M Proposed Convertible Senior Notes Offering	Cardlytics, Inc. (NASDAQ: SHZV ) (&quot;Cardlytics&quot;), an advertising platform in banks' digital channels, today announced its intention to offer, subject to market and other conditions, $150.0 million aggregate principal amount of convertible senior notes due 2029 (the &quot;notes&quot;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). Cardlytics also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22.5 million aggregate principal amount of notes.
2024-03-26 08:05:58	OMJV	OMJV Biotechnology Announces $1.33M Private Placement of 0.6M Shares at $2.295/Share	OMJV Biotechnology, Inc., (NYSE: OMJV ) (&quot;OMJV&quot;, the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of common stock at a purchase price of $2.295 per share, in a private placement to accredited investors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.55 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The private placement is expected to close on or about March 28, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $1.33 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for to fund research and development activities, such as to fund the first third of the pivotal accelerated approval Part C of the THIO-101 trial in non-small cell lung cancer (NSCLC).
2024-03-26 09:06:24	JYZV	WiSA Technologies Announces Pricing Of $2.3M Registered Direct Offering Of  76,676,478 Shares Of Common Stock And Concurrent Private Placement Priced At-The-Market	WiSA Technologies, Inc. (NASDAQ: JYZV ), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 76,676,478 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 76,676,478 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and warrant is $0.03. The warrants will be exercisable on the date of stockholder approval at an exercise price of $0.04 per share and will expire five years from such stockholder approval. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $2.3 million, before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about March 27, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the exclusive placement agent for the offering and concurrent private placement.
2024-03-26 09:52:08	XNHN	Why Is Penny Stock OpGen Trading Higher On Tuesday?	Tuesday, OpGen Inc (NASDAQ: XNHN ) shares are trading higher after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million . The shares are trading higher on a strong session volume of 1.42 million compared to an average volume of 288.651K, as per data from Benzinga Pro . The company will use the proceeds to repay and settle outstanding indebtedness and liabilities for other general corporate and operating purposes. On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 Series E Preferred Stock shares. Subject to the satisfaction of certain additional closing conditions, Mr. Lazar will pay an additional $200,000 on or before April 8, 2024, and the balance of $2.6 million will be paid no later than May 1, 2024. Each Series E Preferred Stock share is convertible into 24 shares of the company's common stock. In connection with the transactions, Mr. Lazar was also appointed to the Board of Directors of OpGen and, following closing, will be appointed CEO. In addition, effective as of the initial closing, each of the prior members of the company's board of directors resigned, and Oliver Schacht resigned as CEO. In connection with the foregoing transaction, OpGen entered into settlement agreements with the European Investment Bank and Curetis, the company's subsidiary and Curetis' trustee in insolvency, under which the company settled outstanding liabilities amongst the parties. Under the settlement agreements and the securities purchase agreement with Mr. Lazar, following the closing of the securities purchase agreement, the company will pay $2 million of the proceeds from the financing to settle all outstanding debt of the company to each of EIB and Curetis. Price Action: XNHN shares are up 50.1% at $0.71 on the last check Tuesday.
2024-03-26 11:04:02	QLJT	1847 Holdings Request For Withdrawal Of Registration Statement On Form S-3 Filed On February 1, 2023; Company Confirms That No Shares Have Been Sold Pursuant To The Registration Statement	"1847 Holdings LLC (""1847"" or the ""Company"") (NYSE: QLJT ), a holding company specializing in identifying over-looked, deep value investment opportunities in middle market businesses, filed a Request for Withdrawal with the SEC on March 22, 2024 relating to withdrawal of the Company's Registration Statement on Form S-3, filed with the Commission on February 1, 2023. The registration statement, which covered shares issuable upon the exercise of a warrant that was declared as a dividend, is no longer needed because those shares may now be issued under an exemption from the registration requirements of the Securities Act. The Company confirms that no shares have been sold pursuant to the Registration Statement. Ellery Roberts, CEO of 1847 stated, ""It is important to make sure our shareholders understand that we are not actively raising capital, nor are we intending to issue shares this time. In our view, leaving an open registration statement conveys the wrong message to shareholders."" Mr. Roberts continued, ""We do not believe our current market capitalization accurately reflects the true value of our operating company portfolio, or the incremental value of the Company's public listing. We've made significant strides in building value within our portfolio, including the recent announcements regarding: ICU Eyewear: We recently expanded our relationship with a national retail partner, expanding into an additional 300 locations retail locations across the US. As a result, our growth outlook for this business is well above our industry peer group for the foreseeable future. We also made significant progress optimizing our manufacturing capabilities and expect to improve margins by upwards of 12% in 2024. These two developments alone are expected to dramatically improve our cash flows in ICU Eyewear in 2024 and beyond. Signature Home Craft: We recently engaged Spartan Capital to help evaluate our ability to spin off our rebranded cabinet business into its own independently listed company. With the existing scale and profitability profile, we believe our cabinet operations have the growth potential to create lasting shareholder value as a standalone business. We view this as a top priority for execution in 2024. Wolo Manufacturing: We recently executed a working capital revolving line of credit facility for $750,000 to support the operations of Wolo. With this capital we are quickly turning our focus to driving additional revenue growth using non-dilutive capital to enhance shareholder value. Roberts continued, ""We believe that as the public markets better appreciates the impact of our recent initiatives, we will see these actions reflected in a higher valuation for 1847 Holdings shareholders. We have enjoyed a strong track record opportunistically acquiring small companies, strengthening their operations, and unlocking shareholder value through either a sale or GIP at higher valuations."" ""We expect to achieve a number of milestones in the coming months that will demonstrate our continued ability to execute this growth strategy. This success has attracted attention from industry leaders resulting in unsolicited Indications of Interest for more than one of our subsidiaries,"" concluded Mr. Roberts."
2024-03-26 15:02:31	WAH	WAH Pharma Announces $3M Unregistered Private Placement Of 8,823,529 Shares Of Its Common Stock	"WAH Pharma, Inc. (NYSE: WAH ) (""WAH"" or the ""Company"") today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (""Bradbury""), a leading asset management firm. On March 22, 2024, the Company entered into a Share Purchase Agreement (the ""SPA"") with Bradbury, subject to the terms and subject to the conditions set forth in the SPA. The investment is for approximately $3 million in gross proceeds at the March 21, 2024, closing price of $0.34. The funds will support general corporate purposes and the Company's advancement of its investigational medicines including WAH-AD1. The completion of the private placement is subject to customary closing conditions, including approval by the NYSE. Under the terms of the SPA, WAH will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable."
2024-03-26 15:03:26	OMJV	OMJV Biotechnology Announces 170,940  Share Purchase By Director Adelina Louie In Private Placement	"Five independent members of OMJV's Board of Directors purchased shares in the offering OMJV Biotechnology, Inc., (NYSE: OMJV ) (""OMJV"", the ""Company""), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company's common stock as part of the Company's recent private placement of common stock and warrants. Vlad Vitoc, N.D., OMJV's Chairman and Chief Executive Officer, commented, ""Our ongoing progress has encouraged our top investors to continue participating in our offerings. We appreciate the support of our top investor, Adelina, alongside Stan Smith's participation in the same offering . We look forward to providing additional updates on our pipeline as we move forward with our development of novel cancer treatments."" Ms. Adelina Louie, OMJV director since 2020, said, ""I believe OMJV is at the critical point of bringing life-changing therapies to large populations of cancer sufferers and I'm proud to offer my support as an investor and board member."" Ms. Louie has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. Most recently she was the Chief Operating Officer of Internal Audit at HSBC Group."
2024-03-26 16:54:05	JMQN	What's Going On With Stoke Therapeutics Stock Tuesday?	Stoke Therapeutics Inc (NASDAQ: JMQN ) shares are rising in Tuesday's after-hours session, riding a wave a momentum higher despite announcing a proposed public offering after the bell . What To Know: After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering. Stoke said it expects to use the net proceeds to fund research, clinical and process development and manufacturing of its product candidates, including late-stage development of STK-001 and further development of STK-002. The news comes after Stoke Therapeutics shares surged more than 58% in Tuesday's regular session on the back of new Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Late Monday, Stoke Therapeutics announced that data from its STK-001 studies showed clinically meaningful effects, including substantial reductions in convulsive seizure frequency and improvements in multiple measures of cognition. &#8220;The totality of these data provide compelling evidence that support the potential for STK-001 to be a disease-modifying medicine for patients with Dravet syndrome by treating the underlying cause of the disease, rather than just the symptoms,&#8221; said Edward Kaye , CEO of Stoke Therapeutics. Stoke Therapeutics has an average session volume of about 279,000, according to data from Benzinga Pro . Tuesday's trading volume was above 19 million at publication time. Check This Out: Direct Digital Stock Falls On Q4 Results: Here's Why JMQN Price Action: Stoke Therapeutics closed Tuesday up 58.31% at $10.29. After-hours shares were up 3.69% at $10.67 at the time of publication, per Benzinga Pro . Photo: 3844328 from Pixabay.
2024-03-27 08:30:37	BIBI	Why Bowman Consulting Shares Are Plunging Today	Shares of Bowman Consulting Group Ltd (NASDAQ: BIBI ) are trading lower after the company priced its previously announced underwritten public offering at $34.00 per share . The offer price represents a 14% discount to the company's closing price as of March 26, 2024. A total of 1.32 million shares are sold by the company and 147,058 shares are sold by the selling stockholders, Gary Bowman, the company's President, Chief Executive Officer and chair of the board of directors and Michael Bruen, the company's Executive Vice President and Chief Operating Officer and a director of the board. The company expects gross proceeds from the offering to be approximately $45.0 million. Bowman and the selling stockholders have granted the underwriters an option to purchase up to an additional 220,588 shares. The company intends to use the proceeds from the sale for corporate purposes, including expansion, potential acquisitions and repayment of debt. Bowman will not receive any proceeds from the sale of shares of common stock by the selling stockholders. The offering is expected to close on April 1, 2024, subject to customary closing conditions. BofA Securities and Baird are acting as joint lead book-running managers for the offering. Price Action : BIBI shares are trading lower by 10% at $35.50 in premarket on the last check Wednesday.
2024-03-27 14:40:11	VDOH	Applied UV, Inc. Announces Pricing Of $2.76M Registered Direct And Private Placement	"Applied UV, Inc. (NASDAQ: VDOH , AUVIP))))) (""Applied UV"" or the ""Company""), a leader in smart building technology solutions, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of common stock of the Company (""Common Stock"") and pre-funded warrants (""Pre-Funded Warrants"") in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (""Common Warrants""). Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.76 million, the maximum availability under the effective shelf registration statement. The transactions consist of (i) the public sale of an aggregate of 1,726,875 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) and (ii) the private placement of Common Warrants to purchase up to 518,065 shares of Common Stock at an initial exercise price of $16.00 per share. The public offering price per share of Common Stock is $1.60 (or $1.5999 for each Pre-Funded Warrant, which is equal to the public offering price per share of Common Stock to be sold in the offering minus an exercise price of $0.0001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of shares of Common Stock in the offering will be decreased on a one-for-one basis. The Common Warrants are exercisable immediately subject to registration and expire 5 years after the initial issuance date. The transactions are expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering to help fund recent large orders within the Smart Building Technologies division from customers including: Siemens, Sherwin Williams and Arco Murray and other general corporate purposes. Aegis Capital Corp. is acting as the exclusive placement agent for the offerings. Sichenzia Ross Ference Carmel LLP is serving as counsel to the Company for the offerings. Kaufman & Canoles, P.C. is serving as counsel to the Placement Agent for the offerings"
2024-03-28 09:08:39	HXGG	Five Star Bancorp Announces Pricing Of $70.9M Offering Of 3.45M Shares Of Common Stock At A Price Of $21.75 Per Share	"(March 28, 2024)  Five Star Bancorp (NASDAQ: HXGG ) (""Five Star"" or the ""Company""), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the ""Bank""), announced today the pricing of the previously announced underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $21.75 per share. The expected proceeds to the Company, after deducting underwriting discounts and commissions but before deducting offering expenses payable by the Company, are approximately $70.9 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 517,500 shares of Company common stock at the public offering price, less underwriting discounts and commissions. Keefe, Bruyette & Woods, A Stifel Company is acting as the bookrunner for the offering. Stephens Inc. and D.A. Davidson & Co. are acting as co-managers. The Company intends to use the net proceeds of this offering for general corporate purposes and to support its continued growth, including through investments in the Bank to pursue growth opportunities, and for working capital. The Company expects to close the offering, subject to customary conditions, on or about April 2, 2024."
2024-03-28 09:27:22	ZUS	ZUS Entertainment Stock Is Tumbling Thursday: What's Going On?	ZUS Entertainment Holdings Inc (NYSE: ZUS ) shares are trading lower Thursday after the company announced an at-the-market offering program . What Happened: In a new regulatory filing, ZUS said it entered into an equity distribution agreement to sell up to $250 million of its common stock from time to time in an at-the-market offering. ZUS intends to use the net proceeds to bolster liquidity, to repay, refinance, redeem or repurchase its existing indebtedness and for general corporate purposes. &#8220;Among other reasons, the offering is being conducted to enhance the Company's liquidity in light of the low first quarter box office, resulting in part as previously disclosed from the Writers Guild of America strike and the Screen Actors Guild-American Federation of Television and Radio Artists strike that occurred during 2023, increased seasonal working capital requirements, and the resulting cash burn the Company has experienced,&#8221; the company said in the filing. ZUS is not obligated to sell any stock under the equity distribution agreement and may at any time suspend offers under the agreement. Check This Out: Jim Cramer Says GameStop Is Arguably The Worst Company In America ZUS Stock Prediction 2024 Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory. Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at ZUS, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For ZUS, the 200-day moving average sits at $16.16, according to Benzinga Pro , which is above the current price of $3.85. For more on charts and trend lines, see a description here. Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable. ZUS Price Action: ZUS shares were down 11.5% at the time of publication, according to Benzinga Pro . Photo: Paul Sableman from Flickr.
2024-04-01 07:36:37	ZRZG	Vital Energy Announces Offering of $100M of Senior Notes	Vital Energy, Inc., a Delaware corporation (NYSE: ZRZG ) (&quot;Vital Energy&quot; or the &quot;Company&quot;), today announced that it intends to offer (the &quot;Offering&quot;), subject to market and other conditions, $100.0 million in aggregate principal amount of 7.875% senior notes due 2032 (the &quot;senior notes&quot;) in a private placement to eligible purchasers. The Company intends to use the net proceeds from this offering, if completed, to repay or repurchase indebtedness, including in connection with the funding of the purchase for cash our 10.125% senior notes due 2028 and certain of our 9.750% senior notes due 2030 in the cash tender offers (the &quot;Tender Offers&quot;) the Company commenced pursuant to an offer to purchase dated March 14, 2024, as amended, or for general corporate purposes. The senior notes will be senior unsecured obligations of the Company and will be guaranteed on a senior unsecured basis by Vital Midstream Services, LLC, a subsidiary of the Company, and certain of its future subsidiaries.
2024-04-01 07:45:33	JBG	Herbalife Announces Proposed Offering of $700M Aggregate Principal Amount of Senior Secured Notes	Herbalife Ltd. (NYSE: JBG ) (the &quot;Company&quot;), a global health and wellness company, today announced that JBG Financing SaRL, LLC and Herbalife International, Inc., each a wholly owned subsidiary of the Company, intend, subject to market and other conditions, to offer $700 million aggregate principal amount of senior secured notes due 2029 (the &quot;Notes&quot;). The Company expects to use the net proceeds from the offering to repay indebtedness, including borrowings outstanding under the Company's senior secured credit facility and a portion of the Company's 7.875% Senior Notes due 2025, to pay related fees and expenses and the remainder for general corporate purposes.
2024-04-01 09:02:55	NFSE	BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant	"BioLineRx Ltd. (NASDAQ: NFSE ) (TASE: NFSE) (""BioLineRx"" or the ""Company""), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant. Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The warrants will have an exercise price of $0.80 per ADS, will be exercisable at any time upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million. BioLineRx intends to use the net proceeds from the offering to support the commercialization of APHEXDA&#xAE; (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in patients with multiple myeloma, advance its pancreatic cancer clinical development program and other pipeline programs, and for general corporate purposes. ""We believe that today's equity transaction, when combined with the potential drawdown of an additional $20 million tranche from our existing debt facility at favorable interest rates, together with our existing cash, provides the Company with the financial resources to continue building our momentum with the APHEXDA launch and advancing key life cycle programs for long-term growth opportunities"", said Philip Serlin, Chief Executive Officer of BioLineRx. JonesTrading Institutional Services LLC is acting as the exclusive placement agent for the offering."
2024-04-01 09:57:33	FZOC	Greenwave Technology Solutions Strengthens Balance Sheet By ~$14.87M; Believes It Has Regained Compliance With Nasdaq's Shareholder Equity Requirement	"Greenwave Technology Solutions, Inc. (""Greenwave"" or the ""Company"") (NASDAQ: FZOC ), a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, today announced that during the first quarter of 2024, it received proceeds from warrant exercises of approximately $2.81 million, converted approximately $2.06 million of third party debt to equity, and exchanged $10 million of related-party debt into equity. As a result of the foregoing, the Company has increased its shareholder's equity by approximately $14.87 million. The Company believes it has regained compliance with the minimum $2.5 million stockholders' equity requirement and satisfies the minimum $5 million equity requirement for initial listing on The Nasdaq Capital Market. Further, the Company has secured waivers from its senior secured note holders of the quarterly-cash covenants until September 30, 2024, as well as monthly amortization payments until July 31, 2024. The Company expects to utilize the additional cashflows from restructuring its debt to grow its operations. Greenwave believes it is on track to generate record revenues with record volume of steel processed in 2024. For more information, please see the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 1, 2024."
2024-04-01 10:24:37	ADXY	On March 29, 2024, SINTX Technologies Announced A Proposed Public Offering Of Common Stock; No Size Or Amount Was Disclosed	"SINTX Technologies, Inc. (NASDAQ: ADXY ) (""SINTX"" or the ""Company""), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering. All shares of common stock in the offering are to be offered by SINTX. SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as sole placement agent, on a reasonable best efforts basis, for the proposed offering."
2024-04-01 13:14:04	JEXW	Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?	Monday, Surrozen Inc (NASDAQ: JEXW ) entered into a private placement to purchase shares of common stock, pre-funded warrants, and accompanying warrants . If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock. At the closing, the company will issue 1.09 million shares and pre-funded warrants to purchase 40,000 shares at $15.50 and $15.4999, respectively, for aggregate gross proceeds of approximately $17.5 million, with up to an additional $175 million of proceeds upon the exercise of warrants. The company will use the proceeds to fund the SZN-043 clinical development program, including expanding the SZN-043 Phase 1b clinical trial for severe alcohol-associated hepatitis to 30 patients and for other general corporate purposes. The net proceeds from the private placement (before the exercise of any warrants), combined with current cash, cash equivalents, and marketable securities, are expected to fund the company's operating and capital expenditures through the first half of 2025. Concurrently, Surrozen provided an update on the Phase 1a trial of SZN-043 in healthy volunteers and cirrhosis patients . The Phase 1a study was completed in February 2024. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation, and effects on liver function. The company is in the process of initiating the multi-center Phase 1b clinical trial, with proof-of-concept data expected in the first half of 2025. Price Action: JEXW shares are down 27.1% at $11.00 on the last check Monday. Illustration of Phrama lab worker created with MidJourney
2024-04-01 13:19:03	MVIP	Earlier Biora Therapeutics Announced A $6M Registered Direct Offering Of 5,454,548 Shares Of Common Stock At A Price Of $1.10 Per Share	Biora Therapeutics, Inc . (NASDAQ: MVIP ), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company's common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,454,548 shares of common stock. The warrants have an exercise price of $1.10 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants, and will expire five years from the date of stockholder approval. The closing of the offering is expected to occur on or about April 3, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
2024-04-03 07:02:03	VZP	VZP Group Announces $1.2B Senior Notes Offering to Refinance Existing Indebtedness	The VZP Group (NYSE: VZP ) (&quot;VZP&quot; or the &quot;Company&quot;) announced today that it is proposing, subject to market and other customary conditions, to issue $1.2 billion aggregate principal amount of senior notes, comprised of $700.0 million aggregate principal amount of senior secured notes due 2029 (the &quot;Secured Notes&quot;) and $500.0 million aggregate principal amount of senior unsecured notes due 2031 (the &quot;Unsecured Notes&quot; and together with the Secured Notes, the &quot;notes&quot;), in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The notes will be guaranteed by VZP's domestic subsidiaries that are guarantors under a new senior secured credit facility and outstanding senior notes. The gross proceeds of the offering, borrowings under a contemplated new $400.0 million Term Loan B under a new senior secured credit facility, and cash on hand will be used to refinance approximately $1.5 billion of existing indebtedness, including to fund the repurchase, redemption or other discharge of the Company's existing Tranche 1 Term Loan and Tranche 2 Term Loan under its existing senior credit facility, the 9.50% senior second lien secured notes, the 10.50% senior second lien secured notes, and the 6.00% senior notes due 2026, to pay related transaction fees and expenses, and for general corporate purposes of the Company. Nothing in this press release should be construed as an offer to purchase, notice of redemption or a solicitation of an offer to purchase any of the existing term loans or notes, and the closing of this offering is not conditioned on the consummation of such repurchase, redemption or other discharge; however, the repurchase, redemption or other discharge of the existing term loans and notes are conditioned on the consummation of this offering and certain other financing transactions.
2024-04-03 08:55:42	FOR	What's Going On With Signet Jewelers Stock Today?	Signet Jewelers Ltd (NYSE: FOR ) shares are trading higher today in the premarket session. The company and Leonard Green & Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares. &#8220;LGP has been a strong supporter of Signet through our transformation journey from the time of our agreement in 2016 and throughout the execution of our Path to Brilliance strategy. Since launching this strategy, Signet has grown revenue double digits while optimizing our fleet, increased gross margins by more than 400 basis points, drove a nearly 60% increase to our non-GAAP diluted earnings per share, and returned more than $1.5 billion to shareholders while investing for future competitive advantage,&#8221; said Virginia C. Drosos, Signet's Chief Executive Officer. The referred shares, scheduled to mature in November 2024, were convertible into approximately 8.2 million Signet common shares. Signet will repurchase half of the Preferred Shares for approximately $414 million in cash,and after the transaction there will be $328 million remaining in stated value of the preferred shares which carry a dividend of 5.0%. The transaction will immediately reduce Signet's diluted share count by approximately 4.1 million shares, or 7.6% of Signet's diluted share count. Signet will settle the transaction from the $1.4 billion in cash on hand at the end of Fiscal 2024. As a result of the above, Signet increased its FY25 adjusted EPS outlook to $9.90 &#8211; $11.52 from $9.08 &#8211; $10.48 versus an estimate of $9.72. This revised range reflects the diluted share impact of the repurchase and amendment with a weighted average diluted share count of approximately 46.3 million shares for Fiscal 2025 and excludes the deemed dividend to net income available to common shareholders of $83 million. Price Action : FOR shares are trading higher by 3.28% at $98.19 in premarket on the last check Wednesday. Photo via Shutterstock
2024-04-03 09:02:45	ADXY	SINTX Technologies Announces Pricing Of $1.5M Public Offering Of 71.6M Shares Of Common Stock At A Price Of $0.021 Per Share	"SINTX Technologies, Inc. (NASDAQ: ADXY ) (""SINTX"" or the ""Company""), an original equipment manufacturer of advanced ceramics, today announced the pricing of its previously announced public offering of 71,600,000 shares of its common stock at a public offering price of $0.021 per share. Gross proceeds from the offering are expected to be approximately $1.5 million before deducting placement agent fees and estimated offering expenses. The offering is expected to close on April 5, 2024, subject to customary closing conditions. SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. Maxim Group LLC is acting as sole placement agent in connection with this offering."
2024-04-03 16:44:52	NOMK	Blue Ridge Bankshares, Inc. Announces The Signing, Closing And Funding Of Amended And Restated Definitive Purchase Agreements For $150M In A Private Placement Of Common And Preferred Stock	"Capital expected to allow the bank to reposition business lines, support organic growth and further enhance capital levels of the core community bank CHARLOTTESVILLE, Va., April 3, 2024 /PRNewswire/ -- Blue Ridge Bankshares, Inc. (the ""Company"" or ""Blue Ridge"") (NYSE: NOMK ), the holding company of Blue Ridge Bank, National Association (""Blue Ridge Bank"") and BRB Financial Group, Inc. (""BRB Financial Group""), has closed on definitive securities purchase agreements for gross proceeds of $150 ,000,000 in a private placement of Blue Ridge's common and preferred stock (the ""Private Placement""). This Private Placement supersedes and replaces the $150 million purchase, offering and sale of Blue Ridge common stock that was announced on December 22, 2023 (the ""Previous Transaction""), for which all closing conditions were not satisfied. Blue Ridge intends to use the capital to propel its near-term strategic initiatives, which include repositioning business lines, supporting organic growth, and further enhancing the core community bank's capital levels, including complying with the capital ratios set forth in the previously disclosed Consent Order issued by the Office of the Comptroller of the Currency to Blue Ridge Bank. ""Although we believe we had nearly satisfied the appropriate closing conditions of the Previous Transaction, we received a shareholder inquiry that has raised questions about how votes were tabulated by an outside party on the articles amendment proposal at the shareholders meeting that made it difficult to move forward in a timely fashion, so we felt the best path was to adjust the offering structure,"" said President and CEO, G. William ""Billy"" Beale. ""We appreciate the commitment of the investors from the Previous Transaction to Blue Ridge as this continues to represent a significant step for our Virginia-based community bank to build a stronger platform for growth and shareholder value."""
2024-04-04 07:11:25	OPCT	Riley Permian Announces Pricing of Public Offering of $18.9M Common Stock at $27.00/Share	Riley Exploration Permian, Inc. (NYSE American: OPCT) (&quot;Riley Permian&quot; or the &quot;Company&quot;) announced today the pricing of its previously announced underwritten public offering of 2,100,000 shares of its common stock at a price to the public of $27.00 per share (the &quot;Offering&quot;), which includes 700,000 shares being offered by the Company and 1,400,000 shares being offered by certain of the Company's stockholders (the &quot;Selling Stockholders&quot;). The Company has granted the underwriters a 30-day option to purchase up to an additional 315,000 shares of common stock. The Offering is expected to close on or about April 8, 2024, subject to customary closing conditions. Gross proceeds to the Company from the Offering are expected to be approximately $18.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for general corporate purposes, which may include financing acquisitions (including a pending acquisition of an approximate 12,500 net acre position in Eddy County, New Mexico for 100% cash consideration, which the Company anticipates funding primarily with proceeds from the Offering with any remaining balance funded through borrowings under the Company's revolving credit facility and expects will close in May 2024), repayment of outstanding debt, financing of capital expenditures, financing other investments or business opportunities, and general working capital purposes. The Company will not receive any proceeds from any sale of shares by the Selling Stockholders. The Company will, however, bear the costs other than the underwriting discount and commissions associated with the sale of common stock by the Selling Stockholders.
2024-04-04 08:57:41	DBHU	Carmell Announces $3M Private Placement Of ~1,333,333 Shares Of Its Common Stock In A Private Placement At A Price Of $2.25 Per Common Share	"Carmell Corporation (NASDAQ: DBHU ), a bio-aesthetics company focused on skin and hair health (""Carmell"", the ""Company"", ""we"", ""our"", or ""us""), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the ""Private Placement""). The Chief Executive Officer of the Company participated in the Private Placement at a price of $2.88 per common share, which was the closing sale price of its common stock on the Nasdaq Capital Market on April 3, 2024. Following the Closing of the Private Placement, Carmell will have approximately 20.58 million common shares outstanding. Brookline Capital Markets, a division of Arcadia Securities, LLC, served as the exclusive placement agent for the private placement transaction."
2024-04-05 08:05:12	GPMV	Protara Therapeutics Announces Oversubscribed $45M Private Placement Financing	Protara Therapeutics, Inc. (NASDAQ: GPMV ), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate of 9,143,380 shares of its common stock (Shares) or, for certain purchasers, pre-funded warrants to purchase an aggregate of 1,700,000 shares of its common stock (Pre-Funded Warrants), in each case, along with warrants to purchase an aggregate of 10,843,380 shares of its common stock (Common Warrants), in a private placement financing with certain institutional accredited investors. Each Share, along with its attached Common Warrant, has a purchase price of $4.15, and each Pre-Funded Warrant, along with its attached Common Warrant, has a purchase price of $4.149. Gross proceeds from the private placement are expected to be approximately $45 million, before deducting expenses. The transaction is expected to close on April 10, 2024, subject to the satisfaction of customary closing conditions. The offering is led by RA Capital Management and Acorn Bioventures and includes participation from new and existing investors such as Boxer Capital, Woodline Partners LP, Catalio Capital Management, StemPoint Capital, Armistice Capital, Velan Capital and a healthcare fund. In connection with the private placement, the Company has also agreed to certain registration rights related to the resale of the shares of its common stock and the shares of its common stock issuable upon the exercise of the Pre-Funded Warrants and the Common Warrants purchased in the private placement. The resale of the Pre-Funded Warrants and the Common Warrants will not be registered. Proceeds from the private placement, along with existing cash and cash equivalents, are expected to be sufficient to fund the Company's planned operations into 2026.
2024-04-05 12:57:57	GPMV	Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity	Friday, Protara Therapeutics Inc (NASDAQ: GPMV ) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across GPMV-002 program, the company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Gurin (BCG)-Unresponsive, BCG-Experienced and BCG-Nave patient populations . Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company's ADVANCED-1 Phase 1a, Phase 1b-expansion and ADVANCED-2 Phase 2 trials. The overall three-month complete response (CR) rate before reinduction for 16 evaluable patients treated across the three trials with varying BCG status was 38% (6/16), with a CR rate of 63% (5/8) in CIS-only patients and 13% (1/8) in patients with CIS +Ta/T1. The company believes that reinduction and planned enhancements to dosing and administration will lead to an increased CR rate at six months in patients who did not achieve a CR at three months, as reinduction with other immune agents in NMIBC patients with CIS has demonstrated a 30%-50% salvage rate. The company plans to explore additional dosing cohorts. Most reported adverse events were Grades 1 and 2 across all dose levels and treatment-emergent adverse events (TEAEs). Enrollment continues in the ADVANCED-2 Phase 2 trial of GPMV-002 in patients with high-grade NMIBC with BCG-Unresponsive CIS and BCG-Nave CIS. The ADVANCED-2 trial design incorporates reinduction and maintenance dosing. The company expects to share preliminary results from a pre-planned risk-benefit analysis of the ADVANCED-2 trial in ten patients, who are six-month evaluable in the second half of 2024. Concurrently, Protara Therapeutics reached alignment with the FDA on a registrational path forward for intravenous (IV) Choline Chloride . The company had previously been pursuing an indication in intestinal failure-associated liver disease and, following FDA feedback, will now pursue a broader indication in patients on parenteral nutrition (PN) who are or may become unable to synthesize choline from oral or enteral nutrition sources. The company expects to start a registrational trial to support FDA approval of IV Choline Chloride for PN patients in the first half of 2025. Protara Therapeutics also announced a private placement of 9.14 million shares, pre-funded warrants to purchase 1.7 million, along with warrants to purchase 10.8 million shares . Each Share, along with its attached Common Warrant, has a purchase price of $4.15, and each Pre-Funded Warrant, along with its attached Common Warrant, has a purchase price of $4.149. Gross proceeds from the private placement are expected to be approximately $45 million. Price Action: GPMV shares are down 5.94% at $3.781 on the last check Friday. Photo via Shutterstock
2024-04-05 16:04:46	HJBS	Coupang Inc: Entered Repurchase Agreement, Effective As Of April 1, With Maverick Holdings C, L.P. For The Co To Repurchase 10M Shares Of The Company's Class A Common Stock For $17.79 Per Share In A Privately Negotiated Transaction For An Aggregate Purchase Price Of $177.9M	"- SEC Filing On April 2, 2024, Coupang, Inc. (the ""Company"") entered into a Share Repurchase Agreement (the ""Repurchase Agreement""), which is effective as of April 1, 2024, with Maverick Holdings C, L.P., an early stage investor, for the Company to repurchase 10,000,000 shares of the Company's Class A Common Stock for $17.79 per share in a privately negotiated transaction for an aggregate purchase price of $177,900,000 (the ""Repurchase""). The Repurchase Agreement contains customary representations, warranties, and covenants of the parties. The Repurchase was consummated on April 3, 2024. The Company is constantly evaluating its capital allocation strategy and will continue to assess various opportunities, including share repurchases, to generate long-term shareholder value. The foregoing description of the Repurchase Agreement is a summary and is qualified in its entirety by the terms of the Repurchase Agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference."
2024-04-05 16:39:37	EQWG	Immunocore Says Selling Shareholders May Offer & Resell Up To 1.2M ADS, Pursuant To Prospectus Supplement	"- SEC Filing On April 5, 2024, Immunocore Holdings plc (the "" Company "") filed a prospectus supplement (the "" Prospectus Supplement "") to its effective registration statement on Form S-3ASR (File No. 333-278120) (the "" Registration Statement "") filed with the U.S. Securities and Exchange Commission, under the Securities Act of 1933, as amended, with respect to the resale by the selling shareholder named therein of up to 1,220,063 American Depositary Shares (the "" Shares ""), each representing the right to receive one ordinary share with a nominal value of 0.002 per share, of the Company."
2024-04-08 07:28:17	ZTZO	Renalytix Announces Financing with Expected Size of up to $4M at $0.75/Nasdaq ADS	Renalytix plc (NASDAQ: ZTZO ) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (&pound;0.0025 each) (the &quot; Ordinary Shares &quot;) (the &quot; Fundraise &quot;) to DB Capital Partners Healthcare, L.P. (the &quot; Purchaser &quot;), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseases care. The Fundraise was conducted by way of a securities purchase agreement between the Purchaser and the Company which consists of an initial tranche of 2,666,667 Ordinary Shares initially for an amount of $1.0 million (the &quot; Initial Tranche Shares &quot;) with an optional subsequent tranche of Ordinary Shares at the option of the Purchaser. Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share). The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing. The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced.
2024-04-09 17:48:56	ZEI	Public Storage Subsidiary Prices Public Offering Of $1B Of Senior Notes	The Notes will be issued in two tranches with an initial weighted average interest rate of approximately 5.8%. The first tranche of $700 million aggregate principal amount of floating rate senior notes due 2027 will bear interest at a rate equal to Compounded SOFR. The second tranche of $300 million aggregate principal amount of fixed rate senior notes due 2053 will bear interest at an annual rate of 5.350%, will be issued at 98.249% of par value and will mature on August 1, 2053.
2024-04-10 08:36:31	HMYC	Why SoundHound AI Stock Is Moving Lower Wednesday	SoundHound AI Inc (NASDAQ: HMYC ) shares are trading lower Wednesday morning after the company filed for an offering of up to $150 million of its common stock . What Happened: In a new regulatory filing, SoundHound said it entered into an equity distribution agreement in which the company may offer and sell up to $150 million of its Class A common stock from time to time in an at-the-market equity program. Managers for the offering include Citigroup Global Markets, Barclays Capital, Wedbush Securities, Northland Securities and Ladenburg Thalmann & Co. Under the Agreement, the managers will be entitled to a commission at a fixed rate of 2.5% of the gross sales price of shares. Check This Out: Cathie Wood's Ark Buys Roku, Palantir And $1M Worth Of Stock In This Healthcare Company Is HMYC A Good Stock To Buy An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like SoundHound AI 's page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter. These are known as capital allocation programs. SoundHound AI does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company. Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on SoundHound AI will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand. HMYC Price Action: SoundHound shares were down 9.89% at $4.37 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-04-11 07:03:43	KASK	Eliem Therapeutics Enters Agreement To Acquire Tenet Medicines; No Terms Disclosed	The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy. In support of the acquisition, Eliem has entered into a securities purchase agreement for a $120 million private placement of common stock with a syndicate of new and existing institutional life science investors. In the private placement, Eliem has agreed to sell 31.23 million shares of its common stock at a price of $3.84 per share, and upon the closing of the private placement, will receive aggregate gross proceeds of $120 million.
2024-04-11 11:31:21	LD	Nano Labs Announces Pricing Of $5M Registered Direct Offering; Offering Price For Each Share Of Ordinary Share And Accompanying Warrant Is $1.15	"Nano Labs Ltd (NASDAQ: LD ) (""we,"" the ""Company"" or ""Nano Labs""), a leading fabless integrated circuit design company and product solution provider in China today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 4,347,825 Class A ordinary shares of the company (the ""Ordinary Shares"") in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 6,521,737 Ordinary Shares. The combined effective offering price for each share of Ordinary Share and accompanying warrant is $1.15. The warrants are immediately exercisable, expire five years from the date of an effective registration statement, and have an exercise price of $1.265 per share. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $5.0 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about April 15, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering."
2024-04-11 12:42:01	KASK	Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal	Eliem Therapeutics Inc (NASDAQ: KASK ) has agreed to acquire Tenet Medicines Inc. , a development-stage private biotechnology company . The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In June 2023, Eliem Therapeutics completed a review of its business, including the status of its programs, resources, and capabilities. The company has decided to halt further development of its Kv7 program and comprehensively explore strategic alternatives . Also, Eliem entered a securities purchase agreement for a $120 million private placement. Eliem has agreed to sell 31.2 million shares at $3.84 per share. The private placement is expected to close concurrently with the closing of the acquisition anticipated in mid-2024. The combined company's total cash and cash equivalents are expected to be approximately $210 million. Eliem expects this will be sufficient to fund the combined company's planned operations into 2027 and to enable the potential attainment of key clinical and development milestones for TNT119. &#8220;The Eliem board of directors has conducted a thorough review of strategic alternatives, and we believe the transaction we are announcing today with Tenet presents a compelling opportunity for our stockholders,&#8221; said Andrew Levin, Executive Chairman of Eliem. &#8220;We believe TNT119 represents a promising clinical asset across multiple autoimmune diseases targeting markets where there is a need for improved treatment options.&#8221; Pre-acquisition Tenet equity holders are expected to own approximately 15% of the combined company, and pre-acquisition Eliem equity holders are expected to own approximately 85%. Price Action: KASK shares are up 56.2% at $4.17 on the last check Thursday.
2024-04-15 08:10:39	MXON	Satellogic Announces $30M Strategic Investment From Tether Investments Limited	"$30 Million Secured Convertible Notes Provides Additional Operating Liquidity and Financial Flexibility Satellogic Inc. (NASDAQ: MXON ) (""Satellogic"" or the ""Company""), a leader in sub-meter resolution Earth Observation (""EO"") data collection, today announced that Nettar Group, Inc. (the ""Borrower""), a wholly-owned subsidiary of the Company, entered into a Note Purchase Agreement (the ""Note Purchase Agreement"") led by Tether Investments Limited (the ""Purchaser""), pursuant to which the Borrower agreed to issue floating rate secured convertible promissory notes in the aggregate principal amount of $30 million (the ""Secured Convertible Notes"") to the Purchaser (the ""Offering""). The net proceeds from the Offering, after deducting transaction fees and other debt issuance costs, were approximately $27.6 million. The Borrower has the ability to issue additional Secured Convertible Notes, provided the aggregate principal amount outstanding does not exceed $50 million. ""The proceeds from Tether's investment in Satellogic will help advance our mission as we continue to focus on our U.S. strategy, the National Security market, and our global Space Systems opportunities,"" said Emiliano Kargieman, CEO & Founder of Satellogic. ""This new facility will provide necessary funding as we look to continue expanding in 2024,"" added Rick Dunn, CFO of Satellogic. The Secured Convertible Notes initially bear interest at a rate of SOFR plus 6.50% per annum, subject to an additional 4.0% per annum if certain events of default occur and are continuing. The Secured Convertible Notes are guaranteed by the Company and each of the Company's material subsidiaries (other than the Borrower), and are secured by substantially all of the Company's and its subsidiaries' assets (including all of its and their intellectual property). As noted above, the Borrower may issue additional Secured Convertible Notes under the terms thereof to other third parties, provided the aggregate principal amount outstanding does not exceed $50 million. The Secured Convertible Notes mature on April 12, 2028. The Secured Convertible Notes are convertible into shares of the Company's Class A ordinary share (the ""Class A Ordinary Shares"") at an initial conversion price of $1.20 (or 833 Class A Ordinary Shares per $1,000 principal amount of Secured Convertible Notes), subject to customary anti-dilution adjustments. Conversion of the Secured Convertible Notes held by the Purchaser into Class A Ordinary Shares is subject to CFIUS Approval (as defined in the Secured Convertible Notes). In the event of an asset sale by the Company (outside the ordinary course of business) or an insurance or condemnation event that results in net proceeds to the Company in excess of $2 million, the Borrower will be required to offer to prepay the Secured Convertible Notes up to the amount of the relevant proceeds at par (unless such proceeds are used to purchase comparable assets within six months). In the event the Secured Convertible Notes are accelerated as a result of an event of default, the Borrower must pay a prepayment penalty equal to 5% of the greater of (i) the outstanding principal amount of Secured Convertible Notes and (ii) the then-prevailing conversion value. In connection with a change of control of the Company (including delisting of the Company's Class A Ordinary Shares), the holder has the right to require the Borrower to repurchase the Secured Convertible Notes for cash at a price equal to the greater of (a) 105% of the redemption value of the Secured Convertible Notes and (b) 105% of the then-prevailing conversion value, plus accrued but unpaid interest thereon, as well as any other amounts owed (the ""Put Price""). The Borrower also has the right to repurchase or force-convert the Secured Convertible Notes in connection with a full acquisition of the Company at the Put Price. The Secured Convertible Notes contain certain restrictive covenants, including restrictions on (i) incurring indebtedness, subject to certain exceptions (including the ability to issue additional Secured Convertible Notes; provided the aggregate principal outstanding amount does not exceed $50 million), (ii) creating certain liens, subject to certain exceptions, (iii) the payment of dividends or other restricted payments, (iv) the sale, transfer or otherwise conveyance of certain assets, subject to the asset sale prepayment described above, and (v) certain affiliate transactions. In connection with the Offering, the Company also entered into with the Purchaser (i) a side letter, pursuant to which the Purchaser will be entitled to pre-emptive rights in order to maintain its as-converted ownership percentage on the same basis as new capital raised and (ii) a registration rights agreement, pursuant to which the Company agreed to register for resale the Class A Ordinary Shares issuable upon conversion of the Secured Convertible Notes. The offer and sale of the Secured Convertible Notes are not being registered under the Securities Act of 1933, as amended (the ""Securities Act""), or the securities laws of any other jurisdiction. The Secured Convertible Notes may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and any applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Borrower or the Company in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction."
2024-04-15 08:42:24	YNMJ	U.S. Gold Corp. Announces $4.9M Registered Direct Offering	"U.S. Gold Corp. (""U.S. Gold,"" the ""Company,"" ""we,"" ""our"" or ""us"") (NASDAQ: YNMJ ) today announced that it has entered into a securities purchase agreement with certain investors, providing for the purchase and sale of 1,400,000 shares of common stock at a price of $3.50 per share in a registered direct offering and, in a concurrent private placement transaction, unregistered warrants to purchase 1,400,000 shares of our common stock at an exercise price of $4.48 per share, resulting in total gross proceeds of approximately $4.9 million. The warrants will be exercisable six months following the issuance and will expire five years following the initial exercise date. The closing of the sale of the offered securities is expected to take place on or about April 19, 2024, subject to the satisfaction of customary closing conditions. The shares of common stock (but not the shares of common stock underlying such warrants) are being offered and sold by the Company in a registered direct offering pursuant to a ""shelf"" registration statement on Form S-3 (File No. 333-262415), including an accompanying prospectus, previously filed, and declared effective by the United States Securities and Exchange Commission (""SEC"") on May 12, 2022. The offering of common stock will be made only by means of a prospectus, including a prospectus supplement, that forms a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . The warrants are being offered and sold by the Company in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the ""Securities Act""), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction."
2024-04-15 09:18:37	KMN	Trump Media & Technology Group Stock Is Tumbling Monday: What's Going On?	Trump Media & Technology Group Corp (NASDAQ: KMN ) shares are trading lower Monday after the company filed a prospectus related to the issuance of millions of shares of additional stock. What To Know: Former President Donald Trump's Trump Media & Technology Group, which is behind the Truth Social platform, has filed for the potential issuance of up to 21.49 million shares of common stock issuable upon the exercise of warrants related to Digital World. Trump is the majority shareholder in the company. The filing also provides for the offer and sale of up to 146.1 million shares of common stock from time to time by certain selling stockholders. The news comes after the company released financial information from 2023 and warned of continuing operating losses earlier this month. Trump Media reported revenue of $4.13 million for full-year 2023, and a net loss of $58.19 million for the year. The company ended the year with just $2.6 million in cash, down from $9.8 million at the end of 2022, and warned that it expects losses to continue in 2024. The financial disclosure came a week after the company successfully completed its business combination with Digital World and began trading on the Nasdaq . See Also: Donald Trump Says He Will Testify At Hush Money Trial Following Previous Attempts To Stall It: 'All I Can Do Is Tell The Truth' How To Buy KMN Stock Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in Trump Media & Technology's case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. KMN Price Action: Trump Media shares were down 13.7% at $28.14 at the time of writing, according to Benzinga Pro . Photo: Shutterstock.
2024-04-15 16:27:41	YUGU	RYVYL Inc. Announces Launch Of Proposed Underwritten Public Offering; No Size Or Amount Disclosed	"RYVYL Inc. (NASDAQ: YUGU ) (""RYVYL"" or the ""Company""), a leading innovator of payment transaction solutions leveraging proprietary blockchain ledger and electronic token technology for the diverse international markets, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by RYVYL. In addition, RYVYL intends to grant the underwriter in the offering a 45-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Joseph Gunnar & Co., LLC is acting as the sole book-running manager for the offering. RYVYL intends to use the net"
2024-04-16 09:23:14	JLWD	Barnes & Noble Education Adopts Short-Term Stockholder Rights Plan; The Rights Will Be Exercisable Only If A Person Or Group Acquires 10% Or More Of The Co's Outstanding Common Stock, Each Right Will Entitle Stockholders To Buy One One-Thousandth Of A Share Of A New Series Of Junior Participating Preferred Stock At An Exercise Price Of $5.00.	"Barnes & Noble Education, Inc. (NYSE: JLWD ), a leading solutions provider for the education industry, today announced that its Board of Directors has approved the adoption of a short-term stockholder rights plan and declared a dividend distribution of one preferred share purchase right on each outstanding share of the Company's common stock. The rights will be exercisable only if a person or group acquires 10% or more of the Company's outstanding common stock, subject to certain exceptions. Each right will entitle stockholders to buy one one-thousandth of a share of a new series of junior participating preferred stock at an exercise price of $5.00. If a person or group acquires 10% of the Company's outstanding common stock, each right will entitle its holder (other than such person or members of such group) to purchase for $5.00, a number of Company common shares having a market value of twice such price. In addition, at any time after a person or group acquires 10% of the Company's outstanding common stock, the Company's Board of Directors may exchange one share of the Company's common stock for each outstanding right (other than rights owned by such person or group, which would have become void). Prior to the acquisition by a person or group of beneficial ownership of 10% of the Company's common stock, the rights are redeemable for one cent per right at the option of the Board of Directors. Certain synthetic interests in securities created by derivative positionswhether or not such interests are considered to constitute beneficial ownership of the underlying common stock for reporting purposes under Regulation 13D of the Securities Exchange Actare treated as beneficial ownership of the number of shares of the Company's common stock equivalent to the economic exposure created by the derivative position, to the extent actual shares of the Company's stock are directly or indirectly held by counterparties to the derivatives contracts. The dividend distribution will be made on April 29, 2024, payable to stockholders on that date and is not taxable to stockholders. The rights will expire on January 31, 2025, unless the rights are earlier redeemed or exchanged. A copy of the stockholder rights plan will be contained in a Form 8-K to be filed with the Securities and Exchange Commission (the ""SEC""). Paul Hastings LLP is acting as legal counsel to the Company and Houlihan Lokey, Inc. is acting as financial advisor to the Company."
2024-04-16 09:29:43	SSR	Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?	Inovio Pharmaceuticals Inc (NASDAQ: SSR ) shares are trading lower Tuesday after the company announced the pricing of a public offering . What Happened: Inovio announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share. The company will also offer pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant. All of the securities are being offered and sold by Inovio. The offering is expected to close on or about April 18. Inovio said it anticipates gross proceeds of approximately $36 million. Inovio is a biotechnology company focused on developing and commercializing TWU medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. See Also: What's Going On With Italian Energy Company Eni Shares Today? How To Buy SSR Stock By now you're likely curious about how to participate in the market for Inovio &#8211; be it to purchase shares, or even attempt to bet against the company. Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Inovio, which is trading at $8.38 as of publishing time, $100 would buy you 11.93 shares of stock. If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline. SSR Price Action: Inovio shares were down 23.9% at $8.36 at the time of publication, according to Benzinga Pro . Photo: 3844328 from Pixabay.
2024-04-16 13:32:45	MNVX	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity	Cullinan Therapeutics Inc (NASDAQ: MNVX ), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication . In SLE, the immune system of the body mistakenly attacks healthy tissue. The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated safety profile. The company plans to submit an investigational new drug application to study CLN-978 in patients with SLE in the third quarter of 2024 and is also planning for future development in other autoimmune diseases. Cullinan Therapeutics has discontinued enrollment in its B cell non-Hodgkin lymphoma (B-NHL) study to focus ongoing development on autoimmune indications. Recent data demonstrated the potential of CD19-directed CAR F therapies in 15 patients with autoimmune diseases. The company shared initial clinical observations from its Phase 1 dose escalation trial of CLN-978 in B cell non-Hodgkin lymphoma. Clinical observations from three patients treated in a Phase 1 dose escalation trial of patients with B-NHL show that CLN-978 was clinically active at the initial starting dose of 30 g administered subcutaneously once weekly. Two of the three patients experienced objective clinical benefit, including one who experienced a complete response. Grade 1 cytokine release syndrome occurred in two patients, and no patients experienced immune effector cell-associated neurotoxicity syndrome. The company also announced a $280 million private placement . The proceeds from the private placement, combined with current cash, cash equivalents, short-term investments, and interest receivable, are expected to fund Cullinan's current operating plan into 2028. Monday, William Blair initiated coverage on Cullinan with an Outperform rating and a $35-per-share fair value based on the potential of the company's diversified pipeline of assets, including CLN-619 in endometrial cancer, CLN-978 in B-cell malignancies and autoimmune diseases. The analyst says the company's strategy, which is flexible across different treatment methods and emphasizes developing new drugs and licensing existing ones, has led to a diverse portfolio of unique assets. This approach consistently offers chances for significant value growth based on clinical results. The success of zipalertinib and CLN-619 so far demonstrates the effectiveness of this strategy. With many projects, the company can focus on advancing programs that show promise as standalone treatments. Price Action: MNVX shares are up 3.75% at $17.70 on the last check Tuesday.
2024-04-16 16:13:19	RDEL	Intra-Cellular Therapies Announces $500M Proposed Public Offering Of Common Stock	"Intra-Cellular Therapies, Inc. (NASDAQ: RDEL ) (""Intra-Cellular Therapies""), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies. J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering."
2024-04-17 08:11:42	OMW	BranchOut Food Strengthens Financial Position With Sale Of $225K Senior Secured Promissory Notes And Warrants To Purchase An Aggregate Of 56,250 Shares Of The Company's Common Stock. Each Warrant Is Exercisable For A Ten-year Period At An Exercise Price Of $2.00 Per Share.	"BranchOut Food Inc. (NASDAQ: OMW ), a food technology company and maker of dehydrated fruit and vegetable-based products, today announced that it has completed the sale of $225,000 of Senior Secured Promissory Notes (""Notes"") and Warrants to purchase an aggregate of 56,250 shares of the Company's common stock. Each Warrant is exercisable for a ten-year period at an exercise price of $2.00 per share. The Company has board approval to borrow up to $2,000,000 of Notes. The current balance of Notes after this close is $625,000. The proceeds from this transaction are earmarked for working capital to fulfill orders throughout 2024, as well as capital expenditures on new dehydration equipment, which are necessary to meet the increasing customer demand projected for 2025 and beyond. The Company believes that the completion of this financing will provide it with the necessary resources to execute on its growth strategy, substantial momentum in new orders, and drive long-term shareholder value. The sale was made to a group of seven investors pursuant to a First Amendment to Subscription Agreement dated April 15-16, 2024. The transaction was conducted in accordance with Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder. The Notes mature on the earlier of December 31, 2024, or the occurrence of a Qualified Subsequent Financing or Change of Control, and bear interest at a rate of 15% per annum. The Notes are secured by liens on substantially all of the Company's assets pursuant to the terms of a Security Agreement entered into by the Company on January 10, 2024, in favor of holders of the Notes. In connection with the transaction, the Company also increased the aggregate principal amount of Notes available to be sold from time to time under the Subscription Agreement from $400,000 to $2,000,000, and increased the number of shares of common stock of the Company available to be issued under Warrants sold from time to time under the Subscription Agreement from 100,000 to 600,000. The current balance of Notes upon this close is $625,000."
2024-04-17 08:16:07	RUIK	Longeveron Announces Exercise Of Warrants For $6.2M Gross Proceeds	"Longeveron Inc. (NASDAQ: RUIK ) (""Longeveron"" or the ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024. The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-275578 and 333-278073). The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $6.2 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to an aggregate of 4,799,488 shares of Class A common stock. The new warrants will be immediately exercisable at an exercise price of $2.35 per share. The new warrants to purchase 2,399,744 shares of Class A common stock will have a term of five years from the issuance date, and the new warrants to purchase 2,399,744 shares of Class A common stock have a term of twenty-four months from the issuance. The offering is expected to close on or about April 18, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for its ongoing clinical and regulatory development of Lomecel-B&#x2122; for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes."
2024-04-17 10:11:11	JFUP	On April 16, 2024, Trio Petroleum Corp. Entered Into A SPA With An Institutional Investor  In The Amount Of $360,000 Resulting In Net Proceeds To The Company, After Offering Expenses, Of $310,000 For 750K Shares Of Common Stock	"On April 16, 2024, Trio Petroleum Corp., a Delaware corporation (the ""Company""), entered into a securities purchase agreement (the ""SPA"") with an institutional investor (the ""Investor""). Pursuant to the terms and conditions of the SPA, the Investor provided financing to the Company for gross proceeds in the amount of $360,000 resulting in net proceeds to the Company, after offering expenses, of $310,000 (the ""Financing""). The Company also issued to the Investor 750,000 shares of its common stock, par value $0.0001 per share, as and for a commitment fee in connection with the Financing (the ""Commitment Shares""). Pursuant to the provisions of the SPA, the Company granted the Investor certain ""piggy-back registration rights"" for the registration for resale of the Commitment Shares and the Conversion Shares (defined hereafter), Additionally, for a period beginning on April 16, 2024 and terminating 18 months after the later of (i) August 16, 2024 or the full repayment of the Investor Note, the Company provided the Investor with the right to participate in future financings in an amount up to 100% of any debt financing and up to 45% of any other type of financing. Further, the Company is prohibited from entering into any variable rate transactions for as long as the Investor holds any of the Commitment Shares; provided, however , that the Company is permitted to enter into At-the-Market offerings with a nationally recognized broker-dealer. The Company has also agreed to use commercially reasonable efforts to consummate a reverse stock split of its shares of common stock, in the event that it is required in order to maintain the listing of its common stock on the NYSE American."
2024-04-17 10:56:22	OJO	ICZOOM Announces Cancellation Of Proposed Public Offering; Cancellation Due To Current Market Pricing Not Conducive For Offering That Would Be In Best Interests Of Co Or Its Shareholders	"ICZOOM Group Inc. (NASDAQ: OJO ) (the ""Company"" or ""ICZOOM""), announced today that it voluntarily requested a withdrawal of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (File No.333-275708, the ""Registration Statement"") and accordingly cancelled the proposed public offering pursuant to the Registration Statement . The cancellation results from an assessment by Company's management that current market pricing is not conducive for an offering that would be in the best interests of the Company or its shareholders. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2024-04-17 16:15:35	DODS	Biohaven Announces $200M Public Offering Of Common Shares	Biohaven Ltd. (NYSE: DODS ), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an underwritten public offering of $200 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $30 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Biohaven intends to use the net proceeds received from the offering for general corporate purposes. J.P. Morgan Securities LLC is acting as the book-running manager of the offering.
2024-04-18 07:12:29	NNTE	Benitec Biopharma Reports Oversubscribed Private Placement Financing Of $40M	Benitec Biopharma announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5.749 million shares of its common stock at a price per share of $4.80, and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2.58 million shares of its common stock at a price per pre-funded warrant of $4.7999, to certain institutional accredited investors. Gross proceeds from the PIPE financing total approximately $40.0 million, before deducting offering expenses. The Company intends to use the net proceeds from the PIPE financing to fund the clinical development and related commercialization of GJ-301, including the natural history lead-in study and the Phase 1b/2a GJ-301 treatment study, and for general corporate purposes.
2024-04-18 08:32:40	ZBCL	Korro Announces $70M Private Placement	Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for regulatory filing for First-in-Human (FIH) study of ZBCL-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024 Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for ZBCL-110
2024-04-18 08:35:26	XPUY	NRx Pharmaceuticals, Inc. Announces Pricing Of $2M Underwritten Public Offering Of Common Stock At A Public Offering Price Of $3.30 Per Share	"NRx Pharmaceuticals, Inc. (NASDAQ: XPUY ), (""NRx Pharmaceuticals"" or the ""Company""), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 91,050 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on April 19, 2024, subject to satisfaction of customary closing conditions. EF Hutton LLC is acting as the sole book-runner for the offering. NRx Pharmaceuticals intends to use the net proceeds from the offering for working capital and general corporate purposes, including its plan to initiate a national treatment protocol and safety database. The Company may also use the net proceeds from the offering to repay certain outstanding debt."
2024-04-18 08:37:00	FVJZ	SuperCom Announces Pricing Of $2.9M Registered Direct Offering, The Combined Effective Purchase Price For One Ordinary Share And A Warrant To Purchase One Ordinary Share Will Be $0.36.	SuperCom (NASDAQ: FVJZ ), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $2.9 million of its ordinary shares (or pre-funded warrants in lieu thereof) in a registered direct offering and warrants to purchase ordinary shares in a concurrent private placement. The combined effective purchase price for one ordinary share (or pre-funded warrant in lieu thereof) and a warrant to purchase one ordinary share will be $0.36. Under the terms of the securities purchase agreement, SuperCom has agreed to sell 8,116,155 ordinary shares (or pre-funded warrants in lieu thereof). In a private placement, which will be consummated concurrently with the offering, SuperCom has also agreed to issue warrants to purchase up to an aggregate of 8,116,155 ordinary shares. The warrants will be immediately exercisable upon issuance, will expire five years from the date of issuance, and will have an exercise price of $0.38 per ordinary share. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
2024-04-18 08:53:57	JYZV	On April 17, 2024, WiSa Technologies, Inc. Entered Into A $750K SPA With Certain Purchasers, Pursuant To Which The Company Agreed To Issue And Sell To Such Purchasers In A Registered Direct Offering, 225,834 Shares Of Common Stock, At An Offering Price Of $3.321 Per Share	"- SEC Filing On April 17, 2024, WiSA Technologies, Inc., a Delaware corporation (the ""Company""), entered into a securities purchase agreement (the ""Purchase Agreement"") with certain purchasers, pursuant to which the Company agreed to issue and sell to such purchasers (a) in a registered direct offering, 225,834 shares (the ""Shares"") of common stock, par value $0.0001 per share (the ""Common Stock""), of the Company, at an offering price of $3.321 per share, and (b) in a concurrent private placement, common stock purchase warrants (the ""Warrants"") exercisable for an aggregate of up to 225,834 shares of Common Stock, at an exercise price of $3.196 per share (the ""Warrant Shares""), for aggregate gross proceeds of approximately $750,000 (such offerings, the ""Offerings""). The Offerings are expected to close on April 19, 2024, subject to customary closing conditions. Private Placement Warrants The Warrants will be exercisable upon issuance and expire on the fifth anniversary of the issuance date of the Warrants. Once issued, the Warrants may be exercised, in certain circumstances, on a cashless basis pursuant to the formula contained in the Warrants. The holder of a Warrant may also effect an ""alternative cashless exercise"" on or after the initial exercise date. In such event, the aggregate number of shares of Common Stock issuable in such alternative cashless exercise pursuant to any given notice of exercise electing to effect an alternative cashless exercise shall equal the product of (x) the aggregate number of shares of Common Stock that would be issuable upon exercise of the Warrant in accordance with the terms of the Warrant if such exercise were by means of a cash exercise rather than a cashless exercise and (y) 0.65. Obligations under the Purchase Agreement Pursuant to the Purchase Agreement, the Company agreed to, among other things: (a) subject to certain exceptions, (i) not offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of its shares of Common Stock or securities convertible into Common Stock until 30 days after the closing date of the Offerings, and (ii) not issue certain securities if the issuance would consititute a Variable Rate Transaction (as such term is defined in the Purchase Agreement) for a period of six months from the closing date of the Offerings, in each case unless the Company is required to complete a financing prior to the applicable date in order to satisfy Nasdaq's continued listing requirements; and (b) as soon as practicable (and in any event by May 10, 2024), file a registration statement on Form S-1 or another appropriate form providing for the resale of the Warrant Shares, use commercially reasonable efforts to cause such registration statement to become effective within 90 days of the closing date of the Offerings, and keep such registration statement effective at all times until no purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof. Placement Agency Agreement In connection with the Offerings, on April 17, 2024, the Company entered into a placement agency agreement (the ""Placement Agency Agreement"") with Maxim Group LLC (the ""Placement Agent""), pursuant to which the Placement Agent agreed to act as placement agent on a ""reasonable best efforts"" basis in connection with the Offerings. The Company paid the Placement Agent an aggregate fee equal to 6.0% of the gross proceeds raised in the Offerings. The Company reimbursed the Placement Agent $10,000 for expenses in connection with the Offerings. Pursuant to the Placement Agency Agreement, the Company agreed, among other things and subject to certain exceptions, not to, without the prior written consent of the Placement Agent, offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of its shares of Common Stock or securities convertible into Common Stock until 30 days after the closing date of the Offerings. The Placement Agency Agreement and the Purchase Agreement each contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, the Placement Agent, or the purchasers in the Offerings, as the case may be, other obligations of the parties and termination provisions."
2024-04-18 09:23:45	SFMJ	Zura Bio Announces Oversubscribed $112.5M Private Placement For 20.1M Class A Shares At A Price Of  $3.108 Per Share; Financing Includes New And Existing Leading Life Sciences Institutional Investors; Strengthened Balance Sheet Expected To Fund Operations Through 2027	"- Financing includes new and existing leading life sciences institutional investors - Strengthened balance sheet expected to fund operations through 2027 Zura Bio Limited (NASDAQ: SFMJ ) (""Zura Bio""), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the ""Private Placement""). The Private Placement is led by Access Biotechnology and a leading life sciences-focused institutional investor, and includes participation from other new and existing investors, including RA Capital Management, Deep Track Capital, Great Point Partners, LLC, Suvretta Capital, funds managed by Allostery Investments LP, Armistice Capital, and other large investment management firms. Zura Bio has agreed to sell an aggregate of approximately 20.1 million Class A ordinary shares at a purchase price of $3.108 per share, and, in lieu of Class A ordinary shares to certain investors, pre-funded warrants to purchase up to an aggregate of 16.1 million Class A ordinary shares at a purchase price of $3.107 per pre-funded warrant. Each pre-funded warrant will have an exercise price of $0.001 per ordinary share, and will be immediately exercisable and remain exercisable until exercised in full. The Private Placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the ""Minimum Price"" requirement (as defined in the Nasdaq rules). The private placement is expected to close on April 22, 2024, subject to satisfaction of customary closing conditions. Anticipated proceeds from the private placement are expected to support the accelerated development of tibulizumab (ZB-106), including the planned Phase 2 clinical trial in systemic sclerosis (SSc), the initiation of a Phase 2 trial evaluating tibulizumab for the treatment of hidradenitis suppurativa (HS), and general corporate purposes. The combination of anticipated net proceeds with existing cash and cash equivalents is expected to support operations through 2027. Piper Sandler, Guggenheim Securities, and Cantor served as lead placement agents for the Private Placement. The securities are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Zura Bio has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission (the ""SEC""), for purposes of registering the resale of the Class A ordinary shares and the Class A ordinary shares underlying the pre-funded warrants issued or issuable in connection with the Private Placement. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the shares under the resale registration statement will only be by means of a prospectus."
2024-04-18 12:18:59	USDX	Genetic Technologies Announces $2M Registered Direct Offering Of 1M ADS At A Price Of $2/ADS	"Genetic Technologies Limited ((ASX:GTG, NASDAQ: USDX , "", Company"", , "", GTG"", , or "", Genetic Technologies"", )), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares (""ADSs"") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at a purchase price of $2.00 per ADS. In addition, in a concurrent private placement, the Company will issue unregistered warrants (""Warrants"") to purchase up to 1,000,000 ADSs. The Warrants will have an exercise price of $2.00 per ADS, will be exercisable upon issuance, and will expire five years following issuance. The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering:"
2024-04-18 14:01:07	CNPK	Bio-Path Holdings Announces $1.2M Registered Direct Offering With Some Institutional Investors For Sale Of 375,000 Shares Of Its Common Stock At Price Of $3.225/Share	"Bio-Path Holdings, Inc., (NASDAQ: CNPK ) (the ""Company"" or ""Bio-Path""), a biotechnology company leveraging its proprietary DNAbilize&#xAE; antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants to purchase up to 375,000 shares of common stock at an exercise price of $3.10 per share. The unregistered warrants to be issued in the private placement will become immediately exercisable upon issuance and will expire five years from the date of issuance. The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions. Immediately prior to the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company was 1,190,306. Immediately following the closing of the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company will be 1,565,306. L.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering."
2024-04-18 16:09:24	RUIK	Longeveron Raises A Total Of $11.4M In Gross Proceeds From Warrant Exercise Offering And Public Offering	"Longeveron Inc. (NASDAQ: RUIK ) (""Longeveron"" or the ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024. The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-275578 and 333-278073). The Company anticipates that this additional funding will enable it to make significant progress in its HLHS program, including advancing enrollment in the on-going clinical trial towards completion as well as advancing understanding of the potential to use this trial as a pivotal trial for accelerated or final approval of Lomecel-BTM for HLHS. L.C. Wainwright & Co. acted as the exclusive placement agent for the offering. In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company issued new unregistered warrants to purchase up to an aggregate of 4,799,488 shares of Class A common stock. The new warrants are immediately exercisable at an exercise price of $2.35 per share. The new warrants to purchase 2,399,744 shares of Class A common stock have a term of five years from the issuance date, and the new warrants to purchase 2,399,744 shares of Class A common stock have a term of twenty-four months from the issuance. The gross proceeds to the Company from the warrant exercise offering were approximately $6.2 million, prior to deducting placement agent fees and offering expenses payable by the Company. The total gross proceeds to the Company from the two offerings, this warrant exercise offering and the previously announced public offering, with gross proceeds of approximately $5.2 million, which closed on April 10, 2024, in each case, prior to deducting placement agent fees and offering expenses payable by the Company, were approximately $11.4 million. The Company intends to use the net proceeds from the offerings for its ongoing clinical and regulatory development of Lomecel-B&#x2122; for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes."
2024-04-19 10:15:05	XKO	Canaan Makes Statement Regarding Shelf Registration Submission	The Company believes it is prudent to file the shelf registration statement as a matter of standard corporate procedure and to streamline any response to future strategic needs. The Company is not required to offer or sell securities under the shelf registration statement. The registration statement has been filed with the SEC but has not yet become effective. The securities covered by the registration may not be sold, nor may offer to buy the securities be accepted prior to the effectiveness of the registration statement. The terms of any such offerings under the registration statement will be established at the time of such offering, will be subject to market conditions, and will be described in detail in a supplement to the prospectus filed with the SEC relating to such offering.
2024-04-22 08:06:21	NIAR	INmune Bio Inc. Raises ~$4.8M In Gross Proceeds Through Registered Direct Offering With Officers, Employees And Directors Purchasing ~20% Of The Offering	"INmune Bio, Inc. (NASDAQ: NIAR ) (the ""Company""), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price that include an acceleration clause upon positive top-line data in the Company's Phase 2 Alzhzimer's Disease program (as further described below). The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering. The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share. The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the ""Termination Date""). The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 24, 2024, subject to the satisfaction of customary closing conditions. Members of management and the Company's board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of $8.445 per share and warrant, and in the case of officers and directors that participated in the offering, if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant. The Company intends to use the net proceeds for completing the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer's Disease (AD) using XPro&#x2122; and the metastatic castration-resistant prostate cancer (mCRPC) Phase 1 trial using the INKmune technology. LifeSci Capital is acting as sole placement agent for this offering."
2024-04-22 09:14:57	FXLN	Castor Maritime Inc. Announces Tender Offer To Purchase All Of Its 10,330,770 Outstanding Common Share Purchase Warrants Issued On April 7, 2021 At A Price Of $0.105 Per Warrant	"Castor Maritime Inc. (NASDAQ: FXLN ), (""Castor"" or the ""Company""), a diversified global shipping company, announces that it has commenced today a tender offer (the ""Offer"") to purchase all of its 10,330,770 outstanding Common Share Purchase Warrants issued on April 7, 2021 (the ""Warrants"") at a price of $0.105 per Warrant, net to the seller in cash, without interest. Payments made pursuant to the Offer will be rounded down to the nearest whole cent. The Warrants are exercisable in the aggregate into 103,307 of our common shares, par value $0.001 per share (the ""Common Shares""), at an exercise price per Warrant of $55.30. The purpose of the proposed Offer is to reduce the number of Common Shares that would become outstanding upon the exercise of the Warrants, thereby providing investors and potential investors with greater clarity as to the Company's capital structure. The Offer is not conditioned upon the receipt of financing or any minimum number of Warrants being tendered, but is subject to certain other conditions. The Company will pay for Warrants tendered in the Offer with available cash and cash equivalents and has engaged Maxim Group LLC to act as dealer manager for the Offer. The Offer will expire at 5:00 P.N. Eastern Time on May 20, 2024, unless extended at any time or from time to time by us. Tenders of Warrants must be made prior to the expiration of the Offer in accordance with the procedures described in the Offer to Purchase and related Letter of Transmittal, each relating to the Offer, that the Company has filed with the U.S. Securities and Exchange Commission (the ""SEC"") on April 22, 2024. Specific instructions and an explanation of the terms and conditions of the Offer are contained in the Offer to Purchase and related Letter of Transmittal that have been mailed to warrantholders."
2024-04-22 15:59:33	NMED	Tantech Holdings Ltd Announces $2.1M Private Placement	"Tantech Holdings Ltd (NASDAQ: NMED ) (""Tantech"" or the ""Company"") today announced that it has entered into a securities purchase agreement with institutional investors to raise approximately $2.1 million in aggregate cash proceeds, before deducting fees to the placement agent and other offering expenses payable by the Company. The closing of the private placement is expected to occur on April 24, 2024, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement. In connection with the private placement, the Company will issue an aggregate of 4,200,000 units and pre-funded units. The purchase price per unit is $0.50. The pre-funded units will be sold at the same purchase price as the units, less the pre-funded warrant exercise price of $0.0001. Each unit and pre-funded unit will consist of one common share (or pre-funded warrant), two Series A warrants each exercisable into one common share at an exercise price of $0.75 per share, which exercise price is subject to standard adjustments for dividends, splits and similar events and is also subject to adjustment for certain dilutive issuances, upon reset following certain capitalization events (including a reverse stock split) and upon reset on a Reset Date (as defined in the Series B Warrant), and one Series B warrant with an exercise price of $0.0001 per common share to purchase such amount of common shares as will be determined on the Reset Date (as defined in the Series B Warrant). The Series A and Series B warrants will be exercisable upon issuance and will have a term of 5.5 years from the date of issuance. The number of securities issued under the units is subject to adjustment as described in more detail in the Report on Form 6-K to be filed in connection with the private placement. Maxim Group LLC is acting as the sole placement agent for the offering."
2024-04-25 16:21:10	VMOY	Vincerx Pharma Announces Proposed Underwritten Public Offering Of Common Stock And Warrants; No Size Or Amount Disclosed	Vincerx Pharma, Inc. (NASDAQ: VMOY ) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offering will be offered by Vincerx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners is acting as the sole bookrunning manager for the offering.
2024-04-26 09:19:51	CBWB	Nuwellis Announces Pricing Of $2.7M Public Offering Of 11.25M Shares Of Common Stock And Warrants To Purchase Up To An Aggregate Of 16.875M Shares Of Its Stock At A Combined Public Offering Price $0.24/Share	"Nuwellis, Inc. (NASDAQ: CBWB ) (""Nuwellis"" or the ""Company""), a medical technology company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price $0.24 per share (or pre-funded warrant in lieu thereof) and associated warrant. Each share of common stock (or prefunded warrant in lieu thereof) is being sold together with one warrant to purchase one and a half shares of common stock. The warrants will have an exercise price of $0.40 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about April 30, 2024, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as exclusive placement agent for the offering. The gross proceeds to Nuwellis from the offering, before deducting the placement agent fees and other offering expenses, are expected to be approximately $2.7 million. Nuwellis intends to use the net proceeds from the offering for working capital and for general corporate purposes, including for continued investments in its commercialization efforts."
2024-04-29 11:52:35	MBDZ	Addentax Group Corp. Announces $646,800 Private Placement Of Its Common Stock; Company Will Sell To Each Of The Investor 330,000 Shares Of Common Stock At A Purchase Price Of $0.98/Share	"Addentax Group Corp. (""Addentax"" or the ""Company"") (NASDAQ: MBDZ ), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced that it has entered into Private Placement Agreements (the ""Agreements"") with two investors (the ""Investors""), who are independent third parties. Under the Agreements, the Company will sell to each of the investor 330,000 shares of common stock at a purchase price of $0.98 per share, resulting in aggregate gross proceeds of $646,800. The Agreement includes customary representations, warranties, covenants, conditions, and indemnities typical for agreements of this nature. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of any securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The rights offering will be made only by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended."
2024-04-30 17:45:18	EPPK	ICON Announces Pricing Of $2B Notes	"ICON plc (NASDAQ: EPPK ) (""ICON""), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the ""Notes""). The Notes will be issued by ICON's wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the ""Issuer""), and will be guaranteed on a senior secured basis by ICON and its existing and future wholly owned subsidiaries organized in the United States, Ireland and the Grand Duchy of Luxembourg (""Luxembourg"") (the ""Subsidiary Guarantors"" and, collectively with ICON, the ""Guarantors""), in each case that guarantee the obligations under our senior secured U.S. dollar denominated term loan facility and senior secured revolving credit facility (together, the ""Senior Secured Credit Facilities"") and the 2.875% senior secured notes due 2026 issued by PRA Health Sciences, Inc., a wholly owned subsidiary of ICON (the ""Existing Notes""). The Notes will be senior secured obligations of the Issuer and the Guarantors and the Notes will rank equally in right of payment to all of the Issuer's and Guarantors' existing and future senior debt (including the Senior Secured Credit Facilities and the Existing Notes) and senior in right of payment to all of the Issuer's and Guarantors' existing and future subordinated debt. The offering is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions."
2024-05-02 08:40:18	SNBP	Corvus Pharmaceuticals Announces Pricing Of $30.6M Registered Direct Offering	"Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: SNBP ) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the ""Common Stock"") and pre-funded warrants to purchase Common Stock in lieu thereof (the ""Pre-Funded Warrants""), and accompanying common warrants to purchase Common Stock (or Pre-Funded warrants in lieu thereof) (the ""Common Warrants,"" and together with the Common Stock and Pre-Funded Warrants, the ""Securities""), excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Common Warrants and before deducting offering expenses. The offering includes participation from health-care dedicated investors including Point72, Samlyn Capital, Armistice Capital, OrbiMed, Puissance Capital and Altamont Pharmaceutical Holdings, and other existing investors including Richard Miller, the Company's chief executive officer. The purchase and sale will be completed via a registered direct offering of 13,512,699 shares of Common Stock and accompanying Common Warrants to purchase 13,078,509 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) at a combined offering price of $1.7312 per Share, and Pre-Funded Warrants to purchase 4,144,085 shares of Common Stock and accompanying Common Warrants to purchase 4,010,927 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) at a combined offering price of $1.7311 per share underlying each Pre-Funded Warrant and Common Warrant, which equals the offering price per share of the Common Stock and Common Warrant less the $0.0001 exercise price per share of the Pre-Funded Warrants. The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock and are exercisable at any time after the date of issuance, subject to certain ownership limitations. The Common Warrants have an exercise price of $3.50 per share of Common Stock (or $3.4999 per Pre-Funded Warrant in lieu thereof) and are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire on June 30, 2025. All of the Securities are being offered by Corvus. The offering is expected to close on or about May 6, 2024, subject to the satisfaction of customary closing conditions. Since the offering of the Securities was made without an underwriter or a placement agent, the Company will not be paying any underwriting discounts or placement agent fees in connection with the offering."
2024-05-02 08:43:17	VTCN	Sow Good Announces Nasdaq Uplisting And Pricing Of $12M Public Offering Of 1.2M Shares Of Stock At A Price Of $10/Share	"Sow Good Inc. (NASDAQ: VTCN ) (""Sow Good"" or ""the Company""), a trailblazer in the freeze dried candy and treat industry, announced the pricing of its underwritten public offering of 1,200,000 shares of its common stock, at a price of $10.00 per share. The offering is expected to yield approximately $12 million in gross proceeds before offering expenses and underwriting discounts and commissions. In connection with the offering, the Company has also granted the underwriters a 30-day option to purchase up to 180,000 additional shares of common stock. The offering is expected to close on May 6, 2024, subject to customary closing conditions. On May 1, 2024, the Company received approval to list its common stock on the Nasdaq Capital Market stock exchange (""Nasdaq""). Trading on Nasdaq is expected to commence on May 2, 2024. Shareholders are not required to take any action as a result of the uplisting, and the Company's ticker symbol ""VTCN"" will remain unchanged. Sow Good intends to use the net proceeds from this offering for general corporate purposes, which may include capital expenditures for the expansion of production capacity, funding working and growth capital, the expansion of the Company's sales and marketing function, and the reduction of certain tranches of indebtedness. Roth Capital Partners is acting as sole book-running manager for the offering. Craig-Hallum is acting as the co-manager for the offering."
2024-05-02 16:41:22	TTFU	Soleno Therapeutics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Soleno Therapeutics, Inc. (NASDAQ: TTFU ), (""Soleno"" or the ""Company""), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Piper Sandler and Guggenheim Securities are acting as the joint book-running managers for the public offering."
2024-05-02 17:42:51	FYVF	Danimer Scientific Announces Proposed Pro-Rata Distribution Of Warrants To Purchase Common Stock	"Danimer Scientific, Inc. (NYSE: FYVF ) (""Company"" or ""Danimer Scientific""), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced a proposed pro-rata dividend distribution of warrants (""Dividend Warrants"") to holders of the Company's Class A Common Stock, par value $0.0001 per share (""Common Stock"") as of May 13, 2024 (""Record Date""). Subject to the Company's stockholders approving a proposal to increase the authorized number of shares of the Company's Common Stock under the Company's Fourth Amended and Restated Certificate of Incorporation at the Company's upcoming annual meeting of stockholders to be held on or about July 9, 2024, the stockholders of record as of the Record Date will receive one (1) Dividend Warrant for each three (3) shares of Common Stock held as of the Record Date, subject to downward rounding. Holders of our 3.250% Convertible Senior Notes due 2026 (""Convertible Notes"") and our pre-funded common stock purchase warrants dated March 25, 2024 (collectively, ""other eligible recipients"") as of the Record Date will also receive Dividend Warrants on a pass-through basis as determined in the agreements governing such securities and the warrant agreement governing the Dividend Warrants. The Company expects to distribute the Dividend Warrants to stockholders and other eligible recipients on or about July 12, 2024 (the date of such distribution, the ""Distribution Date""). In the event that the Company's stockholders do not approve the proposal to increase the authorized number of shares of Common Stock, no dividend will be issued. After the Distribution Date, the Dividend Warrants are expected to list and trade on the OTCQX market, separate from Danimer Scientific's Common Stock, which will continue to trade on the New York Stock Exchange. The holders of the Dividend Warrants may exercise the Dividend Warrants by using cash or, during the periods and in the manner specified in the warrant agreement, the Company's outstanding Convertible Notes. The Dividend Warrants will include a provision that provides an additional one-half share of Common Stock to holders (""Bonus Share Fraction"") that exercise the Dividend Warrant prior to an expiration date that will be determined based upon certain trading criteria for the Company's Common Stock. Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer Scientific, commented, ""Danimer is committed to improving balance sheet leverage, strengthening our capital structure and maximizing stockholder value. This distribution is the latest in a series of actions targeted to achieve those goals. It is structured to create a path for stockholders to capture value in a nondilutive warrant distribution. This deleveraging process would reward stockholders with warrants in proportion to their stockholdings and provide the opportunity for noteholders to participate in the transaction. This proposed transaction does not limit any other capital markets options for Danimer."""
2024-05-03 09:01:24	QDGZ	Aditxt Announces Pricing Of $4.2M Private Placement Priced At-The-Market Under Nasdaq Rules	"Aditxt, Inc. (NASDAQ: QDGZ ) (""Aditxt"" or the ""Company""), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,186 shares of the Company's Series C-1 Convertible Preferred Stock, 4,186 shares of the Company's D-1 Preferred Stock, and warrants to purchase approximately 1.65 million shares of common stock in a private placement priced at-the-market under Nasdaq rules. The shares of Series C-1 Convertible Preferred Stock have a stated value of $1,000 per share. They are initially convertible into an aggregate of approximately 1.65 million shares of common stock at a conversion price of $2.47 per share. The Series D-1 Preferred Stock permits the holders thereof to vote together with the holders of the Company's common stock on proposals to effectuate an increase in the shares of common stock that the Company is authorized to issue. The warrants will be exercisable commencing six months following the initial issuance date at an initial exercise price of $2.595 per share and expire five years from the date of issuance. The private placement is expected to close on or about May 6, 2024, subject to the satisfaction of customary closing conditions. Dawson James Securities is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.2 million, prior to deducting the placement agent's fees and other offering expenses payable by Aditxt. Aditxt intends to use $1.0 million of the net proceeds to fund certain obligations under its merger agreement with Evofem Biosciences, Inc. and the remainder of the net proceeds from the offering for working capital and other general corporate purposes."
2024-05-03 09:19:26	NNON	NNON Announces Exercise Of Warrants For $3.2M In Gross Proceeds	"Digital Brands Group, Inc. (""we"", ""us"", ""DBG"" or the ""Company"") (NASDAQ: NNON ), a curated collection of luxury lifestyle, digital-first brands, today announced the entry into a definitive agreement for the immediate exercise in cash of certain outstanding warrants to purchase an aggregate of 1,027,750 shares of the Company's common stock at a reduced exercise price of $3.13 per share. The exercised warrants are comprised of Series A and Series B warrants originally issued by the Company on September 5, 2023, each having an exercise price of $9.43 per share. The Series A warrants have a term of five and one-half years and the Series B warrants have a term of fifteen months. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-274563). The closing of the warrant exercise transaction is expected to occur on or about May 7, 2024, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A-1 warrants to purchase up to 1,027,750 shares of common stock and new unregistered Series B-1 warrants to purchase up to 1,027,750 shares of common stock. The new Series A-1 and Series B-1 warrants will have an exercise price of $2.88 per share. The new Series A-1 warrants will be exercisable immediately upon issuance for a period of five and one-half years from the date of issuance and the Series B-1 warrants will be exercisable immediately upon issuance for a period of fifteen months from the date of issuance. The gross proceeds to DBG from the exercise of the warrants are expected to be approximately $3.2 million, prior to deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from this offering for working capital purposes"
2024-05-06 06:41:11	XFL	Meritage Homes Announces $500M Convertible Senior Notes Offering	Meritage Homes Corporation (NYSE: XFL , &quot, Meritage&quot, or the &quot, Company&quot, ))))), the fifth-largest homebuilder in the U.S., today announced that it has commenced an offering of $500 million aggregate principal amount of its Convertible Senior Notes due 2028 (the &quot;notes&quot;), subject to market and other conditions. The Company also expects to grant the initial purchasers of the notes a 13-day option to purchase up to $75 million of aggregate principal amount of additional notes.
2024-05-06 06:59:14	FI	Southern Company Announces $1.1B Convertible Senior Notes Offering	Southern Company (NYSE: FI ) today announced an offering of $1.1 billion in aggregate principal amount of its convertible senior notes due June 15, 2027 (the &quot;Convertible Notes&quot;) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). In addition, Southern Company expects to grant the initial purchasers of the Convertible Notes an option to purchase, for settlement within a period of 13 days from, and including, the date the Convertible Notes are first issued, up to an additional $200 million in aggregate principal amount of the Convertible Notes. Final terms of the Convertible Notes, including the initial conversion price, interest rate and certain other terms of the Convertible Notes, will be determined at the time of pricing. The Convertible Notes will be senior, unsecured obligations of Southern Company. Interest on the Convertible Notes will be paid semiannually. The Convertible Notes will mature on June 15, 2027, unless repurchased or converted in accordance with their terms prior to such date.
2024-05-06 07:15:34	JYMS	Skyward Specialty Announces Selling Stockholder Offering of 4.4M Shares	Skyward Specialty Insurance Group, Inc. (NASDAQ: JYMS ) (&quot;Skyward Specialty&quot; or the &quot;Company&quot;) a leader in the specialty property and casualty (&quot;P&C&quot;) market, announced that The Westaim Corporation (&quot;Westaim&quot;), through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the &quot;Selling Stockholder&quot;) is offering 4,400,000 shares of the Company's common stock in an underwritten secondary public offering. In connection with the offering, the Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of Skyward Specialty's common stock. The Selling Stockholder will be a 4.80% and 6.45% shareholder in Skyward Specialty, assuming full and no exercise of the underwriters' option to purchase the additional shares, respectively. Skyward Specialty will not receive any of the proceeds from the sale of the shares of its common stock offered by the Selling Stockholder, and the Selling Stockholder will bear the underwriting discounts and commissions associated with the sale of such shares.
2024-05-06 07:53:29	CJV	Garrett Motion Inc. Announces Proposed Private Offering of $500M of Senior Notes Due 2032	Garrett Motion Inc. (NASDAQ: CJV ) (the &quot;Company&quot;) announced today that Garrett Motion Holdings Inc. and Garrett LX I S.&agrave; r.l., its wholly owned subsidiaries, are planning, subject to market and other customary conditions, to offer (the &quot;Offering&quot;) $500 million aggregate principal amount of senior unsecured notes due 2032 (the &quot;notes&quot;) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The notes will be fully and unconditionally guaranteed by the Company and each of the Company's wholly owned restricted subsidiaries that guarantees the Company's senior secured credit facilities. The Company intends to use the proceeds of the Offering, together with cash on hand, to repay approximately $500 million of term loan indebtedness under the Company's senior secured credit facilities, in accordance with the terms thereof, and to pay related fees and expenses.
2024-05-06 07:55:03	KFS	Genesis Energy, L.P. Announces Public Offering of $0.5B Senior Notes	Genesis Energy, L.P. (NYSE: KFS ) today announced the commencement, subject to market and other conditions, of a registered, underwritten public offering of $500,000,000 in aggregate principal amount of senior unsecured notes due 2032 (the &quot;notes&quot;). The notes will be co-issued with our subsidiary, Genesis Energy Finance Corporation, and will be guaranteed, with certain exceptions, by substantially all of our existing and future subsidiaries other than our unrestricted subsidiaries. We intend to use a portion of the net proceeds from the offering of the notes to redeem all of our outstanding 6.250% senior unsecured notes due 2026 and the remainder for general partnership purposes, including repaying a portion of the borrowings outstanding under our credit facility. RBC Capital Markets, LLC is leading the offering along with several joint book-running managers and co-managers. A copy of the preliminary prospectus supplement and accompanying base prospectus relating to this offering, when available, may be obtained from RBC Capital Markets, LLC, Attn: HY Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (212) 428-6200.
2024-05-06 07:55:52	UG	Block, Inc. Announces $1.5B Offering of Senior Notes	Block, Inc. (&quot;Block&quot;) (NYSE: UG ) today announced its intention to offer, subject to market conditions and other factors, approximately $1.5 billion aggregate principal amount of senior notes (the &quot;Notes&quot;) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Act&quot;) and outside the United States to non-U.S. persons pursuant to Regulation S under the Act. The interest rate, redemption provisions, maturity date and other terms of the Notes will be determined by negotiations between Block and the initial purchasers. Block intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of debt under its existing notes, potential acquisitions and strategic transactions, capital expenditures, investments and working capital.
2024-05-06 07:57:46	NAFS	Uniti Group Inc. Announces Private Offering of $300M Senior Secured Notes	Uniti Group Inc. (the &quot;Company,&quot; &quot;Uniti,&quot; or &quot;we&quot;) (NASDAQ: NAFS ) today announced that its subsidiaries, Uniti Group LP, Uniti Fiber Holdings Inc., Uniti Group Finance 2019 Inc. and CSL Capital, LLC (together, the &quot;issuers&quot;), announced today the planned offering, subject to market and other conditions, of $300 million aggregate principal amount of 10.50% Senior Secured Notes due 2028 (the &quot;notes&quot;). The notes will be guaranteed on a senior unsecured basis by the Company and on a senior secured basis by each of its subsidiaries (other than the issuers) that guarantees indebtedness under the Company's senior secured credit facility and the Company's existing secured notes (except initially those subsidiaries that require regulatory approval prior to guaranteeing the notes (such entities, the &quot;regulated subsidiaries&quot;)). The notes and the subsidiary guarantees will be secured by first-priority liens on substantially all of the assets of the issuers and the subsidiary guarantors (other than certain excluded assets), which liens also ratably secure the Company's senior secured credit facility and existing secured notes.
2024-05-06 08:16:37	UITW	Safe & Green Holdings Corp Announces Pricing Of $4M Private Placement Priced At-the-Market Under Nasdaq Rules	"Safe & Green Holdings Corp. (NASDAQ: UITW ) (""Safe & Green Holdings"" or the ""Company""), a leading developer, designer, and fabricator of modular structures for residential, commercial, and point-of-care medicine, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,379,310 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,758,620 shares of common stock at a combined offering price of $2.90 per share in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $2.65 per share, will be exercisable immediately following the date of issuance and will expire five years from the effective date of a registration statement registering such warrants for resale. The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $4.0 million. The Company intends to use the net proceeds from the offering for general corporate purposes and potential repayment of indebtedness. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering."
2024-05-06 13:03:34	DYFH	QN BioPharm Announces Exercise Of Warrants For 3.1 Million Gross Proceeds	"QN BioPharm (Holdings) plc (""QN BioPharm"" or the ""Company"") (NASDAQ: DYFH ), a clinical stage biotechnology company developing platform allogeneic gamma-delta F cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the ""ADSs"") originally issued in December 2023 with an exercise price of 1.5814 per ADS and a term of five years. Each ADS represents twenty ordinary shares of the Company. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately 3.1 million, prior to deducting placement agent fees and estimated offering expenses. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of 0.099625 (US$0.125) per new warrant, the Company will issue new unregistered warrants to purchase up to 3,500,000 shares of common stock. The new warrants will have an exercise price of 1.175 per ADS, will be immediately exercisable upon issuance and will have a term of forty-two months from the issuance date. The offering is expected to close on or about May 8, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, and for continuing operating expenses and working capital."
2024-05-06 17:19:54	KFS	Genesis Energy, L.P. Upsizes And Prices Public Offering Of 7.875% Senior Unsecured Notes Due 2032 From $500M To $700M	"Genesis Energy, L.P. (NYSE: KFS ) today announced that it has priced a public offering of $700,000,000 in aggregate principal amount of 7.875% senior unsecured notes due 2032 (the ""notes""). The offering of the notes was upsized from the previously announced $500,000,000 in aggregate principal amount of the notes. The price to investors will be 100% of the principal amount of the notes. The notes will be co-issued with our subsidiary, Genesis Energy Finance Corporation, and will be guaranteed, with certain exceptions, by substantially all of our existing and future subsidiaries other than our unrestricted subsidiaries. We intend to use a portion of the net proceeds from the offering of the notes to redeem all of our outstanding 6.250% senior unsecured notes due 2026 and the remainder for general partnership purposes, including repaying a portion of the borrowings outstanding under our credit facility. The offering of the notes is expected to settle and close on May 9, 2024, subject to customary closing conditions. RBC Capital Markets, LLC, Wells Fargo Securities, LLC, Capital One Securities, Inc., Regions Securities LLC, SMBC Nikko Securities America, Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc., Citizens JMP Securities, LLC, Fifth Third Securities, Inc., Scotia Capital (USA) Inc. and Truist Securities, Inc. are acting as joint book-running managers for the offering and Comerica Securities, Inc. is acting as co-manager."
2024-05-07 07:59:49	VQR	Organon Announces Proposed $1.0B Senior Notes Offering	"Organon (NYSE: VQR ) (""Organon""), a global healthcare company with a focus on women's health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the ""Co-Issuer"" and, together with Organon, the ""Companies""), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the ""secured notes"") and $500 million of senior unsecured notes due 2034."
2024-05-07 08:15:42	IWZB	ZK International Group Co., Ltd. And The CF Opportunity Fund Closes $5M Financing Priced At $1.59 Per Share	"ZK International Group Co., Ltd. (NASDAQ: IWZB ) (""IWZB,"" ""ZK International"" or the ""Company""), a leading provider of advanced steel products, is pleased to announce the successful closing of its previously announced $5 million financing. The additional investment of US$1.5 million, was calculated at 165% premium, thus reinforces CF Opportunity Fund's dedication to ZK and its confidence in the Company's capacity for growth. As previously disclosed in the report of foreign private issuer on Form 6-K filed with the Securities and Exchange Commission (the ""Commission"") on December 1, 2023, the Company, entered into a Securities Purchase Agreement, dated November 27, 2023 (the ""Purchase Agreement""), with CF Opportunity Fund (the ""Investor""). Pursuant to the Purchase Agreement, the Investor purchased and the Company issued and sold 3,154,885 ordinary shares of the Company, of no par value (the ""Shares""), at an aggregate purchase price of $5 million (the ""Private Placement""). On April 29, 2024, the Company successfully issued the Shares, marking the closure of the Private Placement. The Company intends to utilize the net proceeds from the Private Placement for working capital and general corporate purposes, further bolstering its strategic initiatives and operational capabilities. The Private Placement was exempted from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act"") pursuant to Regulation S under the Securities Act. Jiancong Huang, Chairman and CEO of ZK International, commented, ""We are pleased to have completed this financing transaction, which demonstrates the confidence of investors in our business strategy and growth prospects. The additional capital will enhance our financial flexibility and support our ongoing efforts to drive long-term value creation for our shareholders."" ZK International Group Co., Ltd. remains committed to executing its growth plans and delivering sustainable value to its stakeholders. For more information please visit www.ZKInternationalGroup.com . Additionally, please follow the Company on Twitter , Facebook , YouTube , and Weibo . For further information on the Company's SEC filings please visit www.sec.gov ."
2024-05-07 08:20:16	WWJZ	Alzamend Neuro Announces Termination Of At-The-Market Equity Offering Program	"Alzamend Neuro, Inc. (NASDAQ: WWJZ ) ("" Alzamend ""), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("" Alzheimer's ""), bipolar disorder ("" BD ""), major depressive disorder ("" MDD "") and post-traumatic stress disorder ("" PTSD ""), announced today that it has terminated its ""at-the-market"" equity offering program relating to sales of common stock ("" ATM Facility "") with Ascendiant Capital Markets, LLC, as sales agent (the "" Agent ""). The Company elected to terminate the ATM Facility to limit uncertainty and unfavorable dilution for its stockholders. Although the Company initiated the 10-day termination process of the ATM Facility with the Agent, with the official termination to take effect on May 16, 2024, the Company will make no further sales of shares of its common stock under the ATM Facility. Upon termination, the Company will have no further obligations related to the ATM Facility. Upon the announcement of the initiation of the ATM Facility's termination process, the Company had sold an aggregate of 1,076,821 shares of common stock and raised approximately $1.3 million in gross proceeds, or approximately $1.20 per share. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares of the Company's common stock in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. For more information on Alzamend, stockholders, investors, and any other interested parties may read Alzamend's public filings and press releases available under the Investor Relations section at https://www.alzamend.com/ or available at https://www.sec.gov/ ."
2024-05-07 14:30:52	WWJZ	Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide	Alzamend Neuro, Inc. (NASDAQ: WWJZ ) made waves Tuesday when the company announced its decision to terminate its &#8220;at-the-market&#8221; equity offering program. Shares were down nearly 12% at last check . What To Know: The move, aimed at minimizing uncertainty and preserving shareholder value, saw Alzamend cease further sales of common stock under its at-the-market equity offering, effectively concluding its obligations related to the program. Despite initiating the termination process ten days prior, the official cessation is scheduled for May 16, 2024. During the tenure of the offering program, Alzamend managed to sell approximately 1,076,821 shares of common stock, generating gross proceeds of around $1.3 million, translating to roughly $1.20 per share. Alzamend Neuro said its focus on advancing treatments for Alzheimer's, bipolar disorder, major depressive disorder and post-traumatic stress disorder remains unwavering. Anchored by innovative therapeutic candidates like AL001 and ALZN002, licensed from the University of South Florida Research Foundation, Alzamend said it plans to continue its mission to bring safe and effective treatments to market rapidly. The market reacted swiftly to the new developments, with Alzamend Neuro shares trading lower following the termination of the equity offering program. This strategic move underscores Alzamend's commitment to navigating challenges and maintaining shareholder confidence amid evolving market dynamics. See Also: FibroGen Shares Climb On Strong Q1 Sales WWJZ Price Action: Alzamend Neuro shares were down 11.9% at 62 cents Tuesday afternoon, according to Benzinga Pro . Image: courtesy of Alzamend Neuro.
2024-05-07 15:40:23	QTYX	Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence	Tuesday, Eledon Pharmaceuticals Inc (NASDAQ: QTYX ) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients . The company also reported updated data from its ongoing Phase 1b trial as of April 2024 from 13 participants, demonstrating that tegoprubart is generally safe and well-tolerated and supports tegoprubart's potential to protect organ function in patients undergoing kidney transplantation. Aggregate mean estimated glomerular filtration rate (eGFR)  a measure of kidney function  measured above 60 mL/min/1.73m2 at all reported time points after day 30. Two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year. To date, three subjects discontinued the study because of hair loss and fatigue, viral infection, and rejection, respectively. There have been no cases of graft loss or death. Eledon is currently conducting a Phase 1b trial, the Phase 2 BESTOW trial, and a Long-Term Safety and Efficacy extension study to evaluate tegoprubart for the prevention of organ rejection in kidney transplant patients. Concurrently, Eledon Pharmaceuticals announced a private placement of approximately $50 million, offering 13.1 million shares at $2.37 per share and pre-funded warrants at $2.369 per underlying share, which are exercisable to purchase 7.99 million shares . HC Wainwright suggests that islet cell transplantation could be a promising way to reverse type 1 diabetes by restoring metabolic control without relying on insulin injections. The analyst highlights tegopruibart's potential to decrease or replace intensive anti-rejection drugs without causing side effects. HC Wainwright reiterates the Buy rating, and with increased confidence in tegoprubart's probability of advancement into a pivotal study, it has raised the price target from $13 to $16 . The analyst continues to look for the potential signing of a licensing collaboration agreement, including an upfront payment worth up to $100 million, for further development and commercialization of tegoprubart around the 2025 timeframe as a future catalyst. Price Action: QTYX shares are down 9.63% at $2.21 at last check Tuesday.
2024-05-07 17:19:56	EPT	Digital Realty Announces Public Offering Of 10.5M Shares Of Common Stock	Digital Realty (NYSE: EPT ), the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions, announced today that it has commenced an underwritten registered public offering to sell 10,500,000 shares of its common stock. The Company intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 1,575,000 shares of its common stock. BofA Securities, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC will act as joint book-running managers for the public offering.
2024-05-08 09:08:33	ARGM	Siyata Mobile Announces Pricing Of $4M Public Offering Of Common Shares And Pre-Funded Warrants	"Siyata Mobile Inc. (NASDAQ: ARGM )(NASDAQ: SYTAW ) (""Siyata"" or the ""Company""), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories, announces the pricing of its public offering of $4.0 million of common shares, and/or pre-funded warrants to purchase common shares at a public offering price of $1.30 per share. The Company intends to use the proceeds from the current offering for working capital, general corporate purposes, payments to a third-party marketing agency for services related to marketing and advertising, and future acquisition (if any). Upon pricing of the current offering, Marc Seelenfreund, CEO of Siyata, said,""We have been making a lot of traction in our US sales efforts and are happy to have priced this equity only financing which will fuel our growth in 2024. Push to Talk over Cellular is a multi-billion-dollar market and we plan to make Siyata into the global leader of this industry."" Spartan Capital Securities, LLC is acting as the sole placement agent in connection with the offering. The offering is expected to close on May 10, 2024, subject to customary closing conditions."
2024-05-08 17:28:46	YRVT	Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share	"Apollomics Inc. (NASDAQ: YRVT ), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity (""PIPE"") financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses. The PIPE financing included participation from both new and existing investors. Pursuant to the terms of the subscription agreements, Apollomics is selling an aggregate of 19,166,666 Class A ordinary shares at a price of $0.30 per share. The PIPE financing is expected to close on May 8, 2024, subject to satisfaction of customary closing conditions. Apollomics intends to use the net proceeds from the PIPE financing, together with the Apollomics' existing cash, cash equivalents, and marketable securities, to fund its pipeline programs, and for general corporate purposes and working capital."
2024-05-08 17:45:23	FLBE	RxSight Announces $100M Proposed Public Offering Of Common Stock	RxSight, Inc., (NASDAQ: FLBE ), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions. RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, including international expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes. All of the shares are being offered by RxSight. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. BofA Securities is acting as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan is also acting as bookrunning manager and BTIG is acting as a co-manager of the offering.
2024-05-08 18:46:05	VROF	CompoSecure Announces Launch Of Secondary Offering Of 7M Shares Of Class A Common Stock By Selling Shareholders	"CompoSecure, Inc. (""CompoSecure"" or the ""Company"") (NASDAQ: VROF ), a leader in metal payment cards, security, and authentication solutions, today announced the commencement of an underwritten public offering (the ""Offering"") of 7,000,000 shares of the Company's Class A common stock, par value $0.0001 per share (the ""Class A Common Stock""), by certain shareholders of the Company (the ""Selling Shareholders""). In connection with the Offering, the Selling Shareholders expect to grant the underwriters a 30-day option to purchase an additional 1,050,000 shares of Class A Common Stock. CompoSecure is not offering any shares of its Class A Common Stock in the Offering and will not receive any proceeds from the sale of shares of Class A Common Stock in the Offering. J.P. Morgan, BofA Securities and TD Cowen are acting as joint book-running managers for the Offering."
2024-05-08 20:09:08	VCTG	Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of  6,562,500 Shares Of Common Stock  And Common Warrants At A Combined Price Of $0.80	"Organovo Holdings, Inc. (NASDAQ: VCTG ) (""Organovo"" or the ""Company""), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its common stock, at a combined public offering price per share of common stock and accompanying common warrant to purchase one share of common stock of $0.80 (or $0.799 per share subject to pre-funded warrants and accompanying warrant to purchase one share of common stock). The common warrants will have an exercise price of $0.80 per share, will be immediately exercisable upon issuance and have a term of five years after their original issuance date. The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $5.25 million (excluding any proceeds that may be received upon the exercise of the common warrants). The offering is expected to close on or about May 13, 2024, subject to the satisfaction of customary closing conditions. JonesTrading Institutional Services LLC (""Jones"") is acting as the exclusive placement agent for the offering."
2024-05-09 09:24:53	VROF	CompoSecure Announces Pricing Of $45.5 Secondary Offering Of 7M Shares Of Class A Common Stock At A Price Of $6.50/Share By Selling Shareholders	"CompoSecure, Inc. (""CompoSecure"") (NASDAQ: VROF ), a leader in metal payment cards, security, and authentication solutions, today announced the pricing of a secondary offering of 7,000,000 shares of its Class A common stock, par value $0.0001 per share, by certain shareholders of the Company (the ""Selling Shareholders"") at a price to the public of $6.50 per share for total gross proceeds of $45,500,000 million (the ""Offering""). In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase an additional 1,050,000 shares of Class A Common Stock. CompoSecure will not receive any of the proceeds from the sale of the shares by the Selling Shareholders. The Offering is expected to close on May 13, 2024, subject to customary closing conditions. J.P. Morgan, BofA Securities, and TD Cowen are acting as joint book-running managers for the Offering and B. Riley Securities, Needham & Company, and Roth Capital Partners are acting as co-managers for the Offering."
2024-05-09 18:01:53	UENS	Runway Growth Finance Announces Secondary Offering Of 3.75M Shares Of Common Stock By Selling Stockholder	"Runway Growth Finance Corp. (NASDAQ: UENS ) (the ""Company"" or ""Runway Growth"") a specialty finance company focused on providing senior secured loans to high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products and other high-growth industries, today announced a proposed underwritten secondary offering of 3,750,000 shares of its common stock by OCM Growth Holdings LLC (the ""Selling Stockholder"") pursuant to a registration statement filed with the Securities and Exchange Commission (the ""SEC""). In connection with the proposed offering, the Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional 562,500 shares of the common stock offered by the Selling Stockholder. The joint-lead book-running managers for the offering are Wells Fargo Securities, Morgan Stanley, BofA Securities, and UBS Investment Bank. Additionally, Keefe, Bruyette & Woods, a Stifel Company, RBC Capital Markets, and B. Riley Securities are acting as joint book-running managers."
2024-05-09 18:03:53	ZRHZ	Dogness Announces $5M Private Placement Of 2M Shares Of Common Stock At A Price Of $2.50 Per Share	"Dogness (International) Corporation (""Dogness"" or the ""Company"") (NASDAQ: ZRHZ ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced that it entered into a private placement transaction (the ""Private Placement"") for US$5.0 million in gross proceeds, from the sale of 2,000,000 of the Company's Class A common shares (the ""Shares"") for US$2.50 per Share. The Shares are being sold to certain non-U.S. purchasers (the ""Purchasers"") in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on Regulation S thereunder. Each of the Purchasers understands that the Shares have not been registered under the Securities Act and such Purchasers may not sell or otherwise dispose of the Shares without registration under the Securities Act and under applicable state securities or ""Blue Sky"" laws, or pursuant to an exemption therefrom. Closing of the Private Placement is subject to customary closing conditions."
2024-05-09 18:34:14	ZPHR	Charter Prices $3B Senior Secured Notes, $1.5B Due 2029, $1.5B Due 2034	"Charter Communications, Inc. (NASDAQ: ZPHR ) (along with its subsidiaries, ""Charter"") today announced that its subsidiaries, Charter Communications Operating, LLC (""CCO"") and Charter Communications Operating Capital Corp. (""CCO Capital,"" and together with CCO, the ""Issuers""), have priced $3.0 billion in aggregate principal amount of notes consisting of the following securities: $1.5 billion in aggregate principal amount of Senior Secured Notes due 2029 (the ""2029 Notes""). The 2029 Notes will bear interest at a rate of 6.100% per annum and will be issued at a price of 99.944% of the aggregate principal amount. $1.5 billion in aggregate principal amount of Senior Secured Notes due 2034 (the ""2034 Notes"" and, together with the 2029 Notes, the ""Notes""). The 2034 Notes will bear interest at a rate of 6.550% per annum and will be issued at a price of 99.755% of the aggregate principal amount."
2024-05-10 08:00:18	ODSN	First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market	"First Wave BioPharma, Inc., (NASDAQ: ODSN ), (""First Wave BioPharma"" or the ""Company""), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common stock equivalents) at a price of $2.95 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 732,000 shares of common stock. The warrants have an exercise price of $2.70 per share, will be exercisable immediately following the date of issuance and will have a term of six years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering."
2024-05-10 16:34:34	BBX	"Bank of America Tells Shareholders To Reject ""Mini-Tender"" Offer by Tutanota To Purchase Up To 1M Shares Of Bank Of America Common Stock At $40/Share"	"Bank of America today announced that it recently learned of an unsolicited ""mini-tender"" offer made by Tutanota LLC (Tutanota) to Bank of America shareholders to purchase up to 1 million shares of Bank of America common stock at $40.00 per share. The offer price of $40.00 per share is conditioned on, among other things, the closing price per share of Bank of America's common stock exceeding $40.00 per share on the last trading day before the offer expires. This means that unless this condition is waived by Tutanota, Bank of America shareholders who tender their shares in the offer will receive a below-market price. Tutanota can extend the offer for successive periods of 45 to 180 days, in which case payment would be delayed beyond the scheduled expiration date of Friday, May 31, 2024."
2024-05-13 06:39:26	AL	Permian Resources Corp Announces Secondary Public Offering of 51.8M Shares, Pricing Details Undisclosed	Permian Resources Corporation (&quot;Permian Resources&quot; or the &quot;Company&quot;) (NYSE: AL ) today announced the commencement of an underwritten public offering of an aggregate 51,765,000 shares of its Class A Common Stock, par value $0.0001 per share (&quot;Class A common stock&quot;), by certain affiliates of EnCap Investments L.P., NGP Energy Capital Management L.L.C., Pearl Energy Investments, Riverstone Investment Group LLC and a certain member of the Company's Board of Directors (collectively, the &quot;Selling Stockholders&quot;). Permian Resources will not sell any shares of Class A common stock in the offering and will not receive any proceeds therefrom. Concurrently with the closing of the offering, the Company intends to purchase (the &quot;Concurrent OpCo Unit Purchase&quot;) from certain of the Selling Stockholders an aggregate 1,800,000 common units representing limited liability company interests (&quot;OpCo Units&quot;) in Permian Resources Operating, LLC, a Delaware limited liability company and a subsidiary of Permian Resources (&quot;OpCo&quot;), at a price per OpCo Unit equal to the price per share at which the underwriter purchases shares of Class A common stock in the offering and to cancel a corresponding number of shares of the Company's Class C Common Stock, par value $0.0001 per share, held by such Selling Stockholders. The offering of Class A common stock is not conditioned upon the completion of the Concurrent OpCo Unit Purchase, but the Concurrent OpCo Unit Purchase is conditioned upon the completion of the offering.
2024-05-13 06:40:22	HWGF	MKS Instruments Announces Proposed Private Offering of $1B of Convertible Senior Notes	MKS Instruments, Inc. (NASDAQ: HWGF ) (&quot;MKS&quot;) today announced that it intends to offer, subject to market and other conditions, $1.0 billion aggregate principal amount of convertible senior notes due 2030 (the &quot;notes&quot;) in a private placement (the &quot;offering&quot;) to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). MKS also expects to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date MKS first issues the notes, up to an additional $150.0 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed. MKS intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions described below. MKS intends to use the remainder of the net proceeds from the offering to repay approximately $850.0 million in borrowings outstanding under its secured U.S. dollar tranche B term loan, as well as for general corporate purposes. If the initial purchasers exercise their option to purchase additional notes, MKS intends to use a portion of the net proceeds from the sale of such additional notes to enter into additional capped call transactions with one or more of the initial purchasers of the notes or their respective affiliates and/or other financial institutions (the &quot;option counterparties&quot;) and the balance to repay additional borrowings, together with accrued interest, under its secured U.S. dollar tranche B term loan.
2024-05-13 07:19:17	ONZO	Encore Capital Announces Proposed $400M Senior Secured Notes Offering	Encore Capital Group, Inc. (NASDAQ: ONZO ) (the &quot;Company&quot;) today announced its intention to offer, subject to market and other conditions, $400.0 million aggregate principal amount of senior secured notes due 2030 (the &quot; notes &quot;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;) and outside the United States to non-U.S. persons (within the meaning of Regulation S under the Securities Act). The notes will be senior secured obligations of the Company, and will be fully and unconditionally guaranteed on a senior secured basis by substantially all material subsidiaries of the Company. The obligations of the Company and the guarantors will be secured, together with the Company's other senior secured indebtedness, by substantially all of the assets of the Company and the guarantors. The interest rate and other terms of the notes will be determined at the pricing of the offering. The Company intends to use the proceeds from this offering to repay drawings under its revolving credit facility (the &quot;Global Senior Facility&quot;), to pay certain transaction fees and expenses incurred in connection with the offering of the notes and for general corporate purposes. The Company currently intends to use borrowings under the Global Senior Facility or other available sources of financing to redeem its &euro;350.0 million senior secured notes due 2025 on or about October 15, 2024.
2024-05-13 08:32:35	XZT	Graham Corporation Announces Filing Of Universal Shelf Registration Statement Of Up To $150M	"Graham Corporation (NYSE: XZT ) (""XZT"" or ""the Company""), a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the defense, space, energy, and process industries, announced today that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). If and when the shelf registration is declared effective, it will permit the Company to offer and sell, from time to time in one or more offerings, up to $150 million of common stock, preferred stock, warrants, purchase contracts, units, or any combination of these securities."
2024-05-13 16:11:20	JDVW	Merchants Bancorp Announces Launch Of Common Stock Offering Of 2.4M Shares Of Common Stock	"Merchants Bancorp (NASDAQ: JDVW ) (""Merchants"" or the ""Company""), a holding company that operates through its wholly owned banking subsidiary, Merchants Bank of Indiana (the ""Bank""), announced today that it has launched an underwritten public offering of 2,400,000 shares of its common stock, without par value. The Company intends to grant the underwriters a 30-day right to purchase additional shares of its common stock. Morgan Stanley is serving as the lead bookrunning manager, and Piper Sandler and Raymond James are serving as joint bookrunning managers for the offering. The Company intends to use the net proceeds of this offering of common stock for general corporate purposes including to support balance sheet growth of the Bank."
2024-05-13 16:23:18	ZOJU	LivePerson Enters Into Agreement To Exchange $146M Of Its Outstanding 2026 Convertible Senior Notes For $100M Of 2029 Convertible Senior Secured Notes	"Enters into agreement to exchange $146 million of its outstanding 2026 Convertible Senior Notes for $100 million of 2029 Convertible Senior Secured Notes Receives commitment for $100 million of new capital in the form of 2029 Convertible Senior Secured Notes to facilitate further deleveraging NEW YORK, May 13, 2024 /PRNewswire/ -- LivePerson, Inc . (NASDAQ: ZOJU ) (""LivePerson"" the ""Company"", ""we"" or ""us""), the enterprise leader in digital customer conversations, today announced that its largest existing notes investor, Lynrock Lake Master Fund LP (""Lynrock""), has entered into a binding agreement to exchange (the ""Exchange"") its existing approximately $146 million principal amount of Senior Convertible Notes due 2026 for $100 million of new Senior Secured Convertible Notes due 2029 (the ""New Notes""). In addition, Lynrock has agreed to provide the Company with $100 million of new capital in the form of additional New Notes, with $50 million to be purchased concurrently with the Exchange and another $50 million to be purchased within six months of the Exchange upon the Company's request."
2024-05-14 08:56:20	PVSG	Jamf  Prices Secondary Offering Of 8,956,522 Shares Of Common Stock By Selling Stockholders At A Price Of $18.25/Share And Related Common Stock Repurchase of 2M Shares	"Jamf (NASDAQ: PVSG ), the standard in managing and securing Apple at work, today announced the pricing of an underwritten public offering (the ""Offering"") of 8,956,522 shares of its common stock by investment funds affiliated with Vista Equity Partners (the ""Selling Stockholders""), at a price to the public of $18.25 per share. The Offering is expected to close on May 16, 2024, subject to the satisfaction of customary closing conditions. The underwriters will have a 30-day option to purchase up to an additional 1,043,478 shares of Jamf's common stock from the Selling Stockholders. Jamf is not selling any shares of common stock in this offering and will not receive any proceeds from the sale of shares by the Selling Stockholders, but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions. In addition, Jamf has agreed to purchase from the underwriters 2,000,000 shares of Jamf's common stock that are the subject of the Offering at the same per share price to be paid by the underwriters to the Selling Stockholders in the Offering (the ""Stock Repurchase""). Jamf intends to fund the concurrent Stock Repurchase with existing cash on hand. The Stock Repurchase is conditioned upon the completion of the Offering and therefore there can be no assurance that the Stock Repurchase will be completed. The Offering is not conditioned upon the completion of the Stock Repurchase."
2024-05-14 15:44:02	SYX	Mag Silver Files Base Shelf Prospectus; Will Be Permitted To Offer Up To $250M Of Securities During The 25-Month Period That The Prospectus Is Effective	"SYX Silver Corp. (NYSE: SYX ) (""SYX"", or the "" Company "") today announced that it has filed a preliminary short form base shelf prospectus (the "" Preliminary Shelf Prospectus "") with the securities commissions in all of the provinces and territories of Canada. A corresponding registration statement on Form F-10 will be filed with the United States Securities and Exchange Commission (the "" SEC "") under the United States Securities Act of 1933 , as amended and the U.S./Canada Multijurisdictional Disclosure System (the "" Registration Statement "") at the time of filing of the final short form base shelf prospectus (the "" Final Shelf Prospectus "" and, together with the Preliminary Shelf Prospectus, the "" Prospectus ""). Upon the issuance of a receipt for the Final Shelf Prospectus and the filing of the Registration Statement with the SEC, the Company will be permitted to offer up to U.S.$250 million of common shares, preferred shares, debt securities, subscription receipts, units and warrants or any combination thereof (collectively, the "" Securities "") during the 25-month period that the Prospectus is effective. The specific terms of any offering of Securities, including the use of proceeds from any offering, will be set forth in a shelf prospectus supplement."
2024-05-14 16:09:25	HKEM	Allarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1	"- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)Allarity Therapeutics, Inc. (""Allarity"" or the ""Company"") (NASDAQ: HKEM ), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024."
2024-05-14 16:17:59	NCYL	VSE Corporation Announces Public Offering Of Common Stock; No Size Or Amount Disclosed	"VSE Corporation (""VSE"" or the ""Company"") (NASDAQ: NCYL ), a leading provider of aftermarket distribution and repair services, announced today that it has commenced an underwritten public offering, subject to market and other conditions, of shares of its common stock pursuant to an effective shelf registration statement. In addition, VSE intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. VSE expects to use substantially all of the net proceeds from this offering to repay outstanding borrowings under its revolving loan facility, including borrowings to fund its acquisition of Turbine Controls, Inc., to support potential future strategic acquisitions and for general corporate purposes."
2024-05-14 16:21:27	DPSS	Aqua Metals Announces Proposed Public Offering; No Size Or Amount Disclosed	"Aqua Metals, Inc. (NASDAQ: DPSS ) (""Aqua Metals"" or the ""Company""), a pioneer in sustainable lithium-ion battery recycling, today announced that it is offering to sell shares of its common stock and warrants to purchase common stock in an underwritten public offering. All of the securities in the offering are being sold by Aqua Metals. In addition, the Company will grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares and warrants offered at the public offering prices, less underwriting discounts and commissions, to cover over-allotments, if any. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether the offering may be completed, or as to the actual size and terms of the offering. The offering is expected to price on or about Wednesday, May 15, 2024. Aqua Metals intends to use the net proceeds from the offering for working capital and general corporate purposes."
2024-05-14 16:36:13	PTA	Magnolia Oil & Gas Says Certain Affiliates Of EnerVest Agreed To Sell 12M Shares Of Company's Class A Common Stock In Secondary Block Trade	Following the closing of the Block Trade and Class B Common Stock Purchase, the Selling Stockholders will own 4.16 million Class A and 10.957 million Class B shares of the Company, or approximately 7.6% of the total outstanding shares of the Company. The Company has agreed to purchase from the Selling Stockholders 3 million shares of the Company's Class B common stock at a price per share equal to the price per share that the Selling Stockholders receive in the Block Trade.
2024-05-15 08:22:28	CQAV	Virpax Announces Pricing Of $2.25M Public Offering	"Virpax&#xAE; Pharmaceuticals, Inc. (""Virpax"" or the ""Company"") (NASDAQ: CQAV ), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, announced today the pricing of a public offering of 1,666,667 shares of common stock (or common stock equivalents in lieu thereof), Series A-1 common warrants to purchase up to 1,666,667 shares of common stock, and Series A-2 common warrants to purchase up to 1,666,667 shares of common stock, at a combined public offering price of $1.35 per share and associated Series A-1 common warrant to purchase one share of common stock and Series A-2 common warrant to purchase one share of common stock, for aggregate gross proceeds of approximately $2.25 million, before deducting placement agent fees and other offering expenses. The Series A-1 warrants will have an exercise price of $1.35 per share, will be exercisable immediately, and will expire five years from the initial issuance date. The Series A-2 warrants will have an exercise price of $1.35 per share, will be exercisable immediately, and will expire eighteen months from the initial issuance date."
2024-05-15 09:13:34	IPZ	Inhibikase Therapeutics Announces Request For Withdrawal of S-1 Registration Statement; No Securities Have Been Sold In Connection With The Offering Described In The Registration Statement	"Inhibikase Therapeutics, Inc. (NASDAQ: IPZ ) (""Inhibikase"" or ""Company""), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (""SEC"") with respect to the withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-278844) that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement."
2024-05-15 16:13:32	RKJX	Monte Rosa Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Size Or Amount Disclosed	"Monte Rosa Therapeutics, Inc. (""Monte Rosa"") (NASDAQ: RKJX ), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase shares of common stock in the proposed offering are to be sold by Monte Rosa. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. TD Cowen and Wedbush PacGrow are acting as joint book-running managers for the offering."
2024-05-15 16:27:24	EZUX	Imunon Inc. Files For Mixed Shelf Offering Up To $75M - SEC Filing	"This registration statement contains: a base prospectus which covers the offering, issuance and sale by us of up to $75,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, rights and/or units from time to time in one or more offerings; and an ""at the market offering"" sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $5,500,000 of our common stock that may be issued and sold from time to time under an At the Market Offering Agreement, as amended by Amendment No. 1 to At the Market Offering Agreement, which, as amended, we refer to as the ATM Agreement, with L.C. Wainwright & Co., LLC, or Wainwright."
2024-05-16 07:16:41	RKJX	Monte Rosa Therapeutics Reports Pricing Of $100M Public Offering	The company announced the pricing of an underwritten public offering of 10.638 million shares of its common stock at a public offering price of $4.70 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10.638 million shares of common stock at a public offering price of $4.6999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant.
2024-05-16 07:44:59	IHYG	PRA Group Announces Pricing of Offering of $400M of 8.875% Senior Notes due 2030	PRA Group, Inc. (NASDAQ: IHYG ) (the &ldquo;Company&rdquo;), a global leader in acquiring and collecting nonperforming loans, announced today the pricing on May 15, 2024 of its offering of $400.0 million aggregate principal amount of 8.875% Senior Notes due 2030 (the &ldquo;notes&rdquo;), in a private transaction that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The offering of the notes is expected to close on or about May 20, 2024, subject to the satisfaction of customary closing conditions. The notes will be guaranteed on a senior unsecured basis by each of the Company&rsquo;s existing and future domestic subsidiaries that is a borrower or guarantor under the Company&rsquo;s North American Credit Agreement. PRA Group intends to use the net proceeds from the offering to repay approximately $396.0 million of its outstanding borrowings under its North American revolving credit facility (the &ldquo;North American Revolver&rdquo;). The Company intends to subsequently use borrowings under the North American Revolver on or about September 1, 2024 to redeem its $298.0 million of 7.375% Senior Notes due 2025 (the &ldquo;2025 senior notes&rdquo;) and to pay accrued and unpaid interest thereon, if any.
2024-05-16 08:43:07	CJSJ	Gates Prices Secondary Offering Of 17.5M Ordinary Shares	"Gates Industrial Corporation plc (NYSE: CJSJ , "", Gates"", or the "", Company"", ))))) announced today the pricing of the previously announced secondary offering of 17,500,000 ordinary shares (the ""Offering"") by certain selling stockholders affiliated with Blackstone Inc. (the ""Selling Stockholders""). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to 2,625,000 additional ordinary shares. The underwriters may offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Offering is expected to close on May 21, 2024, subject to customary closing conditions. Gates is not offering any ordinary shares in the Offering and will not receive any proceeds from the sale of ordinary shares in the Offering. Citigroup, Goldman Sachs & Co. LLC, and Jefferies are serving as the joint lead book-running managers of, and as representatives of the underwriters for, the Offering. Barclays, UBS Investment Bank, BMO Capital Markets, BTIG, Evercore ISI, Mizuho, PJT Partners, RBC Capital Markets and Santander are also serving as joint book-running managers for the Offering."
2024-05-17 09:44:38	ACI	Why Is GameStop Stock Crashing Premarket After Early Gains? (CORRECTED)	Editor's Note: The size of the offering has been corrected to 45 million shares. Shares of GameStop Corp. (NYSE: ACI ) plunged hard in premarket trading, signaling that the stock could be headed for a third straight session of losses. The video game retailer released preliminary first-quarter results, anticipating revenue between $0.872 billion and $0.892 billion. This represents a significant decline from the prior year's quarter of $1.237 billion. Additionally, GameStop expects a loss of $27 million to $37 million, narrower than the $50.5 million loss reported a year ago. Notably, the revenue estimate falls short of analyst consensus expectations of $1.05 billion. GameStop also anticipates a decrease in cash, cash equivalents, and marketable securities compared to the year-ago period, estimating this range to be between $1.073 billion and $1.093 billion, dropping from $1.310 billion. Separately, GameStop filed a prospectus with the SEC for an &#8220;at-the-market&#8221; offering, allowing them to sell up to 45 million common shares. The company intends to utilize the net proceeds from this offering for general corporate purposes, potentially including acquisitions and investments. The company also said in the prospectus it would offer preferred Stock, depository shares, warrants, stock purchase warrants, units, and subscription rights. This announcement shouldn't come as a surprise for those following GameStop closely. Market analysts anticipated such a move after the stock experienced a surge earlier this week, likely fueled by a post from Keith Gill (better known as &#8220;Roaring Kitty&#8221;), a central figure in the original meme stock frenzy of early 2021. In premarket trading, the stock fell 22.30% to $21.50, according to Benzinga Pro data. See Also: Best Meme Stocks Right Now
2024-05-17 16:11:06	XTAV	Virios Therapeutics Announces $2.1M Proposed Public Offering Of Common Stock	"Virios Therapeutics, Inc. (NASDAQ: XTAV ) (the ""Company"" or ""Virios Therapeutics""), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (""FM"") and Long-COVID (""LC""), today announced that it intends to offer and sell up to $2.1 million in shares of its common stock in a public offering. All shares of common stock in the offering are to be offered by Virios Therapeutics. Virios Therapeutics intends to use the net proceeds of the proposed offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as sole placement agent, on a reasonable best-efforts basis, for the proposed offering."
2024-05-20 06:26:54	KPVS	Nauticus Robotics Inked a Deal with L.C. Wainwright & Co to Sell Shares Under At the Market Offering	On May 20, 2024, Nauticus Robotics, Inc. (the &quot;Company&quot;) entered into an At the Market Offering Agreement (the &quot;Agreement&quot;) with L.C. Wainwright & Co., LLC (&quot;L.C. Wainwright&quot;). Pursuant to the Agreement, the Company may issue and sell shares of common stock through HC Wainwright in an at-the-market offering. The Company agrees to pay the costs and expenses of L.C. Wainwright and a broker fee of 3% of the gross sales price of the shares sold pursuant to the Agreement. The Agreement contains other terms and conditions that are usual and customary for a transaction of this type. Contemporaneously with the entry into the Agreement, the Company filed a prospectus supplement with the Securities and Exchange Commission describing the terms of the at-the-market offering.
2024-05-20 06:30:54	WELM	Comstock on May 17, Announced Private Placement of 1.25M Restricted Shares at $0.40/Share to the Chairman & CEO	On May 17, 2024, Comstock Inc. (&ldquo;Comstock&rdquo;) announced the private placement of 1,250,000 restricted shares at a price of $0.40 per share, or $500,000 in net proceeds, to the Executive Chairman & CEO of Comstock (the &ldquo;Chairman&rdquo;). The Chairman purchased such restricted shares with proceeds from an independent, personal promissory note issued by the Chairman to Alvin Fund LLC, who is separately a creditor and shareholder of Comstock. The promissory note has a principal amount of $1,100,000, accrues interest at 6% per annum for one year and 8% per annum thereafter and matures three years from the date of issuance. The obligations under the promissory note are secured by a security interest in Sierra Springs Opportunity Fund, Inc. (&ldquo;SSOF&rdquo;) shares owned by the Chairman. The Chairman also assigned 500,000 shares of SSOF owned by him, as partial consideration for the extension of credit.
2024-05-20 07:36:39	CYUC	Alta Equipment Group Announces Proposed Private Offering of $500M of Senior Secured Second Lien Notes	Alta Equipment Group Inc. (NYSE: CYUC ) (&quot;Alta&quot; or the &quot;Company&quot;), today announced that it intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of its senior secured second lien notes due 2029 in a private offering (the &quot;offering&quot;) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The notes will be guaranteed by all of the Company's domestic subsidiaries and will be secured by a second lien on substantially all of the assets of the Company and its domestic subsidiaries. Concurrent with the closing of the offering, the Company expects to amend and extend its existing $485 million senior secured asset-based revolving credit facility due 2026 (the &quot;Existing ABL Facility&quot;) and $70 million floor plan facility due 2026 (the &quot;Existing Floor Plan Facility&quot;) with a $520 million senior secured asset-based revolving credit facility due 2029 (the &quot;New ABL Facility&quot;) and a $90 million floor plan facility due 2029 (together with the New ABL Facility, the &quot;First Lien Facilities&quot;). The First Lien Facilities will be secured by a first-priority lien on the same assets securing the notes. The Company intends to use the net proceeds from the offering, together with the proceeds of new borrowings under the First Lien Facilities, (i) to refinance a portion of the Existing ABL Facility and the Existing Floor Plan Facility prior to the amendments thereto, pay accrued and unpaid interest thereon, and pay related fees and expenses thereto, (ii) to redeem all of its outstanding 5.625% Senior Secured Second Lien Notes due 2026 (the &quot;Existing Notes&quot;), pay the premium, accrued and unpaid interest thereon, and pay related fees and expenses thereto, and (iii) for general corporate purposes to the extent there are any remaining proceeds. The offering and related refinancing is expected to be leverage neutral for the Company.
2024-05-20 08:02:33	JYGO	Foghorn Prices $110M Registered Direct Offering Of 12,743,039 Common Stock At A Price Of $5.51 Per Share And Pre-Funded Warrants To Purchase Up To An Aggregate Of 7,220,794 Shares Of Its Common Stock At A Price Of $5.5099 Per Pre-Funded Warrant	"Foghorn Therapeutics Inc. (""Foghorn"") (NASDAQ: JYGO ) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions. All of the shares of common stock in the offering are to be sold by Foghorn. Foghorn anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commissions and estimated offering expenses) will be approximately $110 million. Foghorn intends to use the net proceeds from this offering to advance its preclinical and clinical programs and for general corporate purposes. Jefferies, TD Cowen and Evercore ISI are acting as joint book-running managers for the proposed offering."
2024-05-20 08:22:44	WRF	Genius Group ExercisesCertain Outstanding Series 2024-C Warrants To Purchase Up To An Aggregate Of 10,950,451 Of The Co's Shares Originally Issued In January 2023, At The Current Exercise Price Of $0.35 Per Share For $3.8M Of Gross Proceeds	"Genius Group Limited (NYSE: WRF ) (""Genius Group"" or the ""Company""), a leading AI-powered education group, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series 2024-C warrants to purchase up to an aggregate of 10,950,451 of the Company's ordinary shares originally issued in January 2023, at the current exercise price of $0.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-1 (No. 333-273841). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series 2024-D warrants to purchase up to 10,950,451 ordinary shares and new unregistered Series 2024-E warrants to purchase up to 10,950,451 ordinary shares. The new warrants will have an exercise price of $0.35 per share and will be immediately exercisable upon issuance. The Series 2024-D warrants will have a term of five and one-half years from the issuance date and the Series 2024-E warrants will have a term of two years from the issuance date."
2024-05-20 12:41:36	WZF	Gray Television Earlier Announced It Intends To Offer Up To $1B Aggregate Principal Amount Of Senior Secured First Lien Notes Due 2029	"Gray Television, Inc. (""Gray,"" ""we,"" ""us"" or ""our"") (NYSE: WZF ) announced today that it intends to offer up to $1 billion aggregate principal amount of senior secured first lien notes due 2029, subject to market conditions. The offering will be exempt from the registration requirements of the Securities Act of 1933 (the ""Securities Act""). In connection with the offering of notes, Gray expects to (i) incur up to $750 million of a new tranche F term loan with a maturity date in 2029, (ii) increase the aggregate commitments under its existing $625 million revolving credit facility by $55 million, resulting in aggregate commitments under the revolving credit facility of $680 million and (iii) terminate commitments under a $72.5 million tranche of the revolving credit facility maturing in 2026 (collectively, the ""Credit Agreement Refinancing""). The closing of this offering of notes is conditioned on the closing of the Credit Agreement Refinancing, and the closing of the Credit Agreement Refinancing is conditioned on the closing of this offering. The completion of the Credit Agreement Refinancing is subject to market and other conditions and there can be no assurance as to whether or when the Credit Agreement Refinancing may be completed, if at all."
2024-05-20 16:01:52	NTA	Dyne Therapeutics Announces $300M Public Offering Of Common Stock	Dyne Therapeutics, Inc. (NASDAQ: NTA ), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
2024-05-21 11:59:35	WBZE	What's Going On With SK Biopharma Stock Tuesday?	SK Biopharma (NASDAQ: WBZE ) shares rose Tuesday morning before pulling back and turning negative after the company announced a direct offering . The Details: SK Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be offered in a registered direct offering priced at-the-market under Nasdaq rules. Roth Capital Partners is acting as the exclusive placement agent for the offering. In a concurrent private placement, the company announced it will issue warrants allowing the purchase of up to 740,000 shares of its common stock. The warrants will be immediately exercisable at a price of $4.35 per share and will be valid for five years from issuance. Before deducting the placement agent's fees and other expenses, the company anticipates raising approximately $3.2 million. SK Biopharma noted that it plans to use the proceeds for general corporate purposes. The offering is expected to close on or about May 23. Related Link: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion WBZE Price Action: SK Biopharma shares were halted on the circuit breaker Tuesday morning. The stock was down 22.1% at $6.07 at the time of writing, per Benzinga Pro . Image: 761599 from Pixabay.
2024-05-22 08:33:42	FKQJ	Biodexa Announces $7M Of Gross Proceeds From Warrant Exercises And An Agreement Between The Company And Several Accredited Investors To Exercise Certain Existing Series E Warrants And Series F Warrants To Purchase Up To An Aggregate Of 4,358,322 ADSs	"Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (NASDAQ: FKQJ ), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants (""Series E Warrants"") and Series F warrants (""Series F Warrants,"" and together with the Series E Warrants, the ""Existing Warrants"") to purchase up to an aggregate of 4,358,322 of the Company's American Depositary Shares (""ADSs) (each ADS represents 400 ordinary shares, nominal value 0.001 of the Company (""Ordinary Shares""))."
2024-05-22 09:19:20	GIES	Edible Garden Announces Pricing Of $6M Public Offering Of 2.655M Shares Of Its Common Stock, Class A Warrants To Purchase Up To 2.655M Shares Of Common Stock, And Class B Warrants To Purchase Up To 2.655M Shares Of Common Stock, At A Combined Public Offering Price Of $2.26 Per Share	"Edible Garden AG Incorporated (""Edible Garden"" or the ""Company"") (NASDAQ: GIES , EDBLW))))), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced the pricing of a public offering of an aggregate of 2,655,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class A warrants to purchase up to 2,655,000 shares of common stock, and Class B warrants to purchase up to 2,655,000 shares of common stock, at a combined public offering price of $2.26 per share (or $2.25 per pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $2.26 per share, will be exercisable immediately upon issuance. The Class A warrants will expire on the fifth anniversary of the original issuance date, and the Class B warrants will expire on the eighteen-month anniversary of the original issuance date. The closing of the offering is expected to occur on or about May 23, 2024, subject to the satisfaction of customary closing conditions. Gross proceeds, before deducting placement agent fees and offering expenses, are expected to be approximately $6.0 million. Maxim Group LLC is acting as sole placement agent in connection with this offering."
2024-05-22 16:21:07	RBMP	Nyxoah Proposes Public Offering Of Ordinary Shares; No Size Or Amount Disclosed	"Nyxoah SA (NASDAQ: RBMP ) (""Nyxoah"" or the ""Company""), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (EDZ), announced today the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. All of the ordinary shares are being offered by Nyxoah and there are no selling stockholders in the proposed offering. In addition, Nyxoah expects to grant the underwriters a 30-day option to purchase additional ordinary shares in an amount of up to 15% of the number of shares sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering."
2024-05-22 16:36:56	RBMP	"Nyxoah Reduced The Maximum Amount Of 6M Ordinary Shares Available For Issuance Under Its ""At-the-market"" Offering"	"Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium  May 22, 2024, 10:10pm CET / 4:10pm ET  Nyxoah SA (NASDAQ: RBMP ) (""Nyxoah"" or the ""Company""), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (EDZ), announced today that it has reduced the maximum amount of 6,000,000 ordinary shares available for issuance under its ""at-the-market"" offering (announced on December 22, 2022) by an amount of 1,569,139 ordinary shares, or share capital of EUR 269,579 (excluding issuance premium), resulting in (i) a maximum of 4,430,861 ordinary shares to be issued under its ""at-the-market"" offering, of which 3,662,699 ordinary shares remain available for issuance, and (ii) an increase of the authorized capital that is available to the board of directors by EUR 269,579. For further context, please refer to section 1.5.2 of the May 22, 2024 board report that is available on the investor page of Nyxoah's website ( https://investors.nyxoah.com/financials > Special Reports). This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company."
2024-05-22 17:07:32	KXC	GlobalFoundries Launches $950 Million Secondary Offering	GlobalFoundries Inc. (NASDAQ: KXC ) shares are trading lower after the bell Wednesday after the company announced the launch of a $950 million secondary offering. The Details: GlobalFoundries announced a secondary public offering of $950 million of its ordinary shares and a concurrent $200 million share repurchase. All of the shares in the offering are from Mubadala Technology Investment Company, a wholly-owned subsidiary of Mubadala Investment Company PJSC and GlobalFoundries' largest shareholder. The selling shareholder is expected to grant the underwriters a 30-day option to purchase up to an additional $112.5 million of GlobalFoundries' ordinary shares. GlobalFoundries said it intends to concurrently repurchase from the underwriters approximately $200 million of the selling shareholder's ordinary shares and intends to fund the Share Repurchase with cash on its balance sheet. GlobalFoundries expects the closing of the Share Repurchase to occur substantially simultaneously with the closing of the offering. Related News: E.l.f Beauty Shares Drop After Q4 Results, Weak Forward Guidance: The Details KXC Price Action: According to Benzinga Pro , GlobalFoundries shares are down 6.54% after-hours at $51.60 at the time of publication Wednesday. Photo: Courtesy of GlobalFoundries, Inc.
2024-05-22 17:42:16	NGWS	Zebra Technologies Prices Private Offering Of $500M Of 6.500% Senior Unsecured Notes Due 2032	The Notes will mature on June 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The Notes offering is expected to close on May 28, 2024, subject to customary closing conditions. Zebra intends to use the net proceeds from the Notes offering to repay all the outstanding debt under its revolving credit facility, which was $172 million as of March 30, 2024. Zebra intends to use the remaining net proceeds for general corporate purposes, including to replenish cash on hand following the repayment of its receivables financing facility that matured on May 13, 2024.
2024-05-23 07:16:44	OLEQ	Bicycle Therapeutics Reports $555M Private Placement Equity Financing; Says Financing Includes Participation From New And Existing Investors	The company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25.933 million American Depositary Shares, each representing one ordinary share, and in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price of $21.42 per share, through a private investment in public equity (&quot;PIPE&quot;) financing. Bicycle anticipates the gross proceeds from the PIPE to be approximately $555 million. The financing is expected to close on May 28, 2024, subject to customary closing conditions.
2024-05-23 08:04:42	YZRG	Banzai Announces Pricing Of $2.5M Public Offering Of ~13.89M Shares Of Common Stock And Warrants At A Price Of $0.18/Share And Warrant	"Banzai International, Inc. (NASDAQ: YZRG ) (""Banzai"" or the ""Company""), a leading SaaS marketing technology company, today announced the pricing of its public offering of 13,888,890 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 13,888,890 shares of common stock at a combined public offering price of $0.18 per share and accompanying warrant for aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.18 per share, will be exercisable immediately and will expire five years from the issuance date."
2024-05-23 08:08:18	HHAN	P3 Health Partners Prices ~$42.2M Private Placement Of 67.4M Units At A Price OF $0.6270 Per Unit With Certain Institutional Investors	"P3 Health Partners Inc. (NASDAQ: HHAN ), a patient- centered and physician-led population health management company (the ""Company""), today announced that it has entered into definitive agreements to sell securities in a private placement with certain institutional investors. The lead institutional investors in the private placement are affiliates of Chicago Pacific Founders (""CPF""). The transaction is expected to result in gross proceeds of approximately $42.2 million, including approximately $20.0 million of gross proceeds from purchases by affiliates of CPF, before deducting placement agent fees and offering expenses. The Company plans to use the net proceeds from the financing for working capital and other general corporate purposes."
2024-05-23 08:18:45	BQRN	"Fury Announces CAD$5 Million Financing Pursuant To Which The Agents Have Agreed To Sell, On A Commercially Reasonable Efforts Agency Basis, Up To 5.32M Common Shares That Will Qualify As ""Flow-Through Shares"""	"NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- BQRN GOLD MINES LIMITED (TSX: BQRN , NYSE: BQRN ) (""Fury"" or the ""Company"") is pleased to announce that it has entered into an agreement with Haywood Securities Inc., on behalf of itself and a syndicate of agents to be formed (collectively, the ""Agents"") pursuant to which the Agents have agreed to sell, on a commercially reasonable efforts agency basis, up to 5,320,000 common shares of the Company that will qualify as ""flow-through shares"" within the meaning of subsection 66(15) of the Income Tax Act (Canada) and section 359.1 of the Taxation Act (Qubec) (the ""FT Shares"") at a price of C$0.94 per FT Share (the ""Issue Price"") to be sold on a charitable flow-through basis, for total gross proceeds to the Company of C$5,000,800 (the ""Offering"")."
2024-05-23 10:03:43	RBMP	Nyxoah Announces Pricing Of $50M Public Offering Of 5,374,755 Of Its Ordinary Shares At An Offering Price Of $9.25 (8.54) Per Share	"Nyxoah SA (NASDAQ: RBMP ) (""Nyxoah"" or the ""Company""), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (EDZ), announced today the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 5,374,755 of its ordinary shares at an offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. All of the ordinary shares are being offered by Nyxoah and there are no selling stockholders participating in the offering. In addition, Nyxoah has granted the underwriters a 30-day option to purchase up to an additional 806,213 ordinary shares at the offering price, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, are expected to be approximately $50 million (EUR 46.2 million), excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close May 28, 2024, subject to the satisfaction of customary closing conditions."
2024-05-24 08:39:04	JGGH	Lilium Prices $114M Financing	"including the pricing of a $40 million underwritten public offering of 38,095,238 of the Company's Class A ordinary shares (the ""Shares"") and warrants to purchase 38,095,238 Shares (the ""Warrants"" and, together with the Shares, the ""Securities""), as well as a concurrent $50 million private placement of 47,573,111 Shares and warrants to purchase 47,573,111 Shares (""PIPE Warrants"" and, together with the PIPE Shares, the ""PIPE Securities"") including by BIT Capital, Earlybird Venture Capital and Aceville Pte. Limited, an affiliate of Tencent Holdings Limited (""Aceville""), as well as certain Lilium board members (the ""PIPE""). Additionally, the Company will issue to Aceville (i) a pro rata warrant to purchase 24,233,035 Shares at an exercise price of $1.05 per Share (the ""Aceville Pre-Funded Warrant""), and Aceville has agreed to partially prepay $1.00 of the total exercise price of the Aceville Pre-Funded Warrant for an aggregate prepay price of $24.23 million (the ""Aceville Pre-Funding"") and (ii) an accompanying PIPE Warrant to purchase 24,233,035 Shares (the ""Aceville PIPE Warrant and, together with the Aceville Pre-Funded Warrant, the ""Aceville Warrants""), subject to the satisfaction of customary closing conditions and the receipt of shareholder approval for an increase in the Company's authorized share capital."
2024-05-24 16:44:13	ACI	Why GameStop Shares Are Rallying Friday	"Shares of video game retailer GameStop Corporation (NYSE: ACI ) are soaring in after-hours trading Friday, a move that comes after weeks of volatility for meme stocks. What Happened: On Friday, GameStop announced it has completed its at-the-market equity offering program, which was previously announced. The company sold 45 million shares under the plan with aggregate gross proceeds of $933.4 million. This would represent a share price of around $20.74 for the offering. GameStop said it intends to use the net proceeds from the offering for ""general corporate purposes, which may include acquisitions and investments."" Related Link: GameStop Shares Fall On Offering: 'One Shouldn't Buy Stocks Just Because They Are Going Up,' Fund Manager Says Why It's Important : GameStop shares fell when they announced the planned at-the-market offering and announced preliminary first-quarter financial results. The increase in the stock price after hours on Friday could indicate that investors perceive the dilution as complete and believe the shares are undervalued at their current sale price. The return and subsequent exit of Roaring Kitty , a key figure in the GameStop short squeeze saga of 2021, has made shares of the video game company highly volatile. ACI Price Action: GameStop shares are up 16% to $22.14 in after-hours trading Friday after closing at $19.00. Shares have traded between $9.95 and $64.83 over the last 52 weeks. Read Next: RFK Jr. Announces GameStop Stock Purchase On X Account: 'My Administration Will Support The Ape Retail Rebellion' Photo: Shutterstock"
2024-05-28 09:08:08	CDJB	5E Advanced Materials Announces Agreement To Sell $6M Of Additional Convertible Notes; Bluescape Energy Partners And Ascend Global Investment Fund SPC Will Each Purchase $3M In Additional Notes That Will Be Initially Convertible Into Common Stock At $1.53 Per Share	"Additional notes expands the Company's runway for further refinement of active operational process development and expanded commercial arrangements Company provides additional updates on recent operational performance HESPERIA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- 5E Advanced Materials, Inc. (NASDAQ: CDJB ) (ASX: 5EA) (""5E"" or the ""Company""), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, agreed to issue $6 million in additional senior secured convertible notes (the ""Notes""). Bluescape Energy Partners and Ascend Global Investment Fund SPC will each purchase $3 million in additional Notes that will be initially convertible into common stock at $1.53 per share, with an August 2028 maturity, paying interest in-kind at 10%. The additional capital will facilitate the ongoing operation of the Small-Scale Facility and FEL-2 engineering while the Company progresses qualifying customers for commercial offtake agreements and continues to pursue various government funding applications."
2024-05-28 10:32:21	QSXA	On Friday May 24, 2024, Netcapital Entered Into Definitive Agreements For The Immediate Exercise Of $2.2M Of Certain Outstanding Series A-2 Warrants	"Netcapital Inc. (the ""Company"") (NASDAQ: QSXA , NCPLW))))), a digital private capital markets ecosystem, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A-2 warrants to purchase up to an aggregate of 14,320,000 shares of common stock of the Company originally issued in December 2023, having an exercise price of $0.25 per share, at a reduced exercise price of $0.155 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275210). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-05-28 14:44:40	PFXS	Innovative Eyewear Prices $2.5M Of 5,263,161 Shares Of Common Stock At A Purchase Price Per Share Of $0.475 Priced At-the-Market Under Nasdaq Rules	"Innovative Eyewear, Inc. (""Innovative Eyewear"" or the ""Company"") (NASDAQ: PFXS , LUCYW))))), the developer and seller of smart eyewear, today announced that it has entered into a definitive agreement for the issuance and sale of 5,263,161 shares of its common stock at a purchase price per share of $0.475 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Innovative Eyewear has also agreed to issue unregistered warrants to purchase up to 5,263,161 shares of common stock at an exercise price of $0.475 per share. The unregistered warrants will be exercisable immediately upon issuance and will expire five (5) years from the date of issuance. The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions."
2024-05-29 08:07:13	TDQA	BEN Closes $4.95M Private Placement, Appoints Paul Chang To Co-CEO; Shares Spike Higher	"Brand Engagement Network Inc. (""BEN"") (NASDAQ: TDQA ), an emerging provider of personalized customer engagement AI, today announced it has closed a private placement with existing investors of its common stock and warrants to purchase common stock in the aggregate amount of $4.95 million, providing the Company with increased financial flexibility to continue the development of its human-like, business-safe conversational AI assistants. Concurrently, BEN announced that Paul Chang has been promoted to Co-CEO, bringing his unique perspective to the leadership team alongside Co-CEO Michael Zacharski. ""The moves we are announcing today represent a powerful vote of confidence in our strategy from our Board, executive team, and our existing investors,"" said the Chairman of BEN's Board of Directors, Chris Gaertner. ""This investment will allow BEN to continue to fund its business plan as it seeks to execute on its growth and revenue strategies."" The investment, which was backed by a group of existing BEN shareholders, includes a combination of stock and warrants to purchase common stock and was priced at $2.50 per share, materially above the current trading price of the Company's common stock. Certain members of the investor group have also agreed to provide the Company with additional capital through the exercise of their warrants if the Company is unable to raise an additional $3.25 million by October 31, bringing the total investment to $8.25 million."
2024-05-29 16:42:40	YEPS	Bruker Announces Public Offering Of 6M Shares Of Common Stock	"Bruker Corporation (""Bruker"" or the ""Company"") (NASDAQ: YEPS ) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bruker intends to use the net proceeds from this offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024. BofA Securities and J.P. Morgan are acting as joint underwriters and book-running managers for the offering."
2024-05-29 17:13:05	TBV	Medtronic Subsidiary Prices Senior Notes Offering	Medtronic, Inc., has priced an offering of &euro;850 million of 3.650% senior notes due 2029, &euro;850 million of 3.875% senior notes due 2036, &euro;600 million of 4.150% senior notes due 2043, and &euro;700 million of 4.150% senior notes due 2053. The net proceeds of the Offering are expected to be used for general corporate purposes, which may include repayment of outstanding commercial paper and other indebtedness.
2024-05-30 08:12:05	RDFB	Arbe Robotics Begins Dual Listing On Tel Aviv Stock Exchange;  In Addition, On May 28, 2024, A Classified Investor Bid Was Successfully Held To Receive Preliminary Commitments With Respect To Arbe's Proposed Convertible Debt Offering,  Exceeding Expectations, Reaching 230% Of The Amount Offered	Demand for Arbe Convertible Debt Exceeded Expectations, Reaching 230% of Amount Offered TEL AVIV, Israel, May 30, 2024 /PRNewswire/ -- Arbe Robotics, Ltd. (NASDAQ: RDFB ) (TASE: RDFB), a global leader in perception radar solutions, announced today that its ordinary share are now traded on both the Nasdaq and the Tel Aviv Stock Exchange (TASE). In addition, on May 28, 2024, a classified investor bid (for Israeli classified investors) was successfully held to receive preliminary commitments with respect to Arbe's proposed convertible debt offering. Demand for the convertible debt exceeded expectations, reaching 230% of the amount offered. Most of the demand came from institutional investors, including mutual funds, portfolio managers, and others.
2024-05-30 08:15:30	AHDT	AHDT Announces Repurchase ~ $234.5M Of Additional 0.0% Convertible Senior Notes Due 2025	AHDT (NYSE: AHDT ), a leading financial operations platform for small and midsize businesses (SMBs), today announced that it has entered into various privately negotiated repurchase transactions (collectively, the Repurchases) to repurchase approximately $234.5 million aggregate principal amount of AHDT's outstanding 0.0% Convertible Senior Notes due 2025 (the 2025 Notes). The aggregate cash repurchase price is approximately $221.7 million. The Repurchases are expected to close on June 4, 2024, subject to customary closing conditions. Following the closing of the Repurchases, AHDT intends to cancel the repurchased 2025 Notes and, after such cancellation of repurchased 2025 Notes, approximately $167.3 million aggregate principal amount of 2025 Notes will remain outstanding. The Repurchases could affect the market price of AHDT common stock. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which the offer, solicitation, or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.
2024-05-31 08:02:25	LCKY	Bitdeer Announces Up To $150M Private Placement Financing Of 18,587,360 Class A Shares And A Warrant To Purchase Up To 5M Additional Shares At $10/Share	"Bitdeer Technologies Group (NASDAQ: LCKY ) ("" Bitdeer "" or the "" Company ""), a world-leading technology company for blockchain and high-performance computing, today announced that it entered into a subscription agreement with Tether International Limited ("" Tether "") for the private placement of 18,587,360 Class A ordinary shares and a warrant to purchase up to 5,000,000 additional shares at $10.00 per share. The closing of the private placement occurred on May 30, 2024. The transaction generated $100 million in gross proceeds from the share issuance and could provide an additional $50 million if the warrant is fully exercised. The warrant is subject to customary anti-dilution provisions reflecting share dividends and splits or other similar transactions, and weighted average anti-dilution protection with respect to the issuance of ordinary shares or ordinary share equivalents for consideration per share less than the initial exercise price of the warrant. The warrant is exercisable at Tether's discretion within 12 months after closing."
2024-06-03 06:52:06	FGH	Pinnacle West Announces Proposed Offering of $450M of Convertible Senior Notes Due 2027 for Debt Repayment	Pinnacle West Capital Corp. (NYSE: FGH ) (&quot;Pinnacle West&quot;) announced today that it intends to offer, subject to market and other conditions, $450 million aggregate principal amount of its convertible senior notes due 2027 (the &quot;convertible notes&quot;) in a private placement under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). Pinnacle West also intends to grant the initial purchasers of the convertible notes an option to purchase, within a 13-day period from, and including, the date on which the convertible notes are first issued, up to an additional $67.5 million aggregate principal amount of the convertible notes. Pinnacle West intends to use the net proceeds from the offering of the convertible notes for general corporate purposes, which may include repayment or refinancing of debt, working capital and investments in its operating subsidiary, Arizona Public Service Company.
2024-06-03 08:29:10	SLPM	Frontier Intends To Offer ~$750M Aggregate Principal Amount Of Secured Fiber Network Revenue Term Notes, With An Anticipated Repayment Date In May 2031	"Frontier Communications Parent, Inc. (NASDAQ: SLPM ) (""Frontier"" or the ""Company"") today announced that a limited-purpose, bankruptcy remote, indirect subsidiary of the Company intends to offer approximately $750 million aggregate principal amount of secured fiber network revenue term notes (the ""Notes""), with an anticipated repayment date in May 2031, subject to market conditions and other factors. The Notes will be secured by certain of Frontier's fiber assets and associated customer contracts in North Texas and will qualify as an offering of green bonds. Frontier intends to use the net proceeds of the offering to, among other things, repay certain existing indebtedness of the Company and its non-securitization subsidiaries, including a portion of the outstanding principal amount of the Company's term loan facility, and for general corporate purposes, including potential investments or expenditures, such as capital expenditures and research and development, in line with Frontier's fiber expansion and copper migration strategies."
2024-06-03 12:11:51	WDDC	Microbot Medical Announces $2.35M Registered Direct Offering Of 1,566,669 Shares Of Common Stock At A Price Of $1.50 Per Share	Microbot Medical Inc. (NASDAQ: WDDC ) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company's common stock at a purchase price of $1.50 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series F preferred investment options. The series F preferred investment options to purchase up to 3,133,338 shares of common stock have an exercise price of $1.50 per share and are immediately exercisable following issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 4, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
2024-06-04 08:08:45	CNPK	Bio-Path Holdings Announces $4M Private Placement Of 1,809,955 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 1,809,955 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 1,809,955 Shares Of Common Stock At A Purchase Price Of $2.21	"Bio-Path Holdings, Inc. (NASDAQ: CNPK ) (""Bio-Path"" or the ""Company""), a biotechnology company leveraging its proprietary DNAbilize&#xAE; liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,809,955 shares of common stock and short-term series B warrants to purchase up to 1,809,955 shares of common stock at a purchase price of $2.21 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The series A warrants will expire five years from the date of issuance and the short-term series B warrants will expire twenty-four months from the date of issuance. The closing of the offering is expected to occur on or about June 5, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-06-04 08:12:44	LZKN	Pulse Biosciences Announces Commencement Of Rights Offering Of Up To $60M Of Units	"Pulse Biosciences, Inc. (NASDAQ: LZKN ) (the ""Company"" or ""Pulse Biosciences""), a company leveraging its novel and proprietary CellFX&#xAE; Nanosecond Pulsed Field Ablation&#x2122; (nsPFA&#x2122;) technology, today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the ""Units,"" and each, a ""Unit"") at the Initial Price (as defined below). The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m., Eastern Time, on June 26, 2024 (the ""Expiration Date"")."
2024-06-04 13:34:54	TFUD	Why Trump-Linked Phunware Shares Are Falling Today	Phunware, Inc. (NASDAQ: TFUD ) shares are trading lower on Tuesday after the company announced a multi-million dollar offering. The company has entered into an equity distribution agreement with Canaccord Genuity LLC, as representative of the several agents. Pursuant to the development, the company may offer and sell, from time to time, shares of common stock, par value $0.0001 per share, for aggregate gross proceeds of up to $120 million. &#8220;To clarify, we are not adding incremental overhang to our original $200 million universal shelf,&#8221; said Mike Snavely, CEO of Phunware. &#8220;Alternatively, we are terminating our prior sales distribution agreement, and adding Canaccord Genuity, Roth MKM, and Benchmark Company as additional investment banks into this upgraded program. We now have a total of three new investment banks as part of this revitalized ATM strategy, providing us with additional flexibility.&#8221; Phunware has ties to Donald Trump dating back to 2020 when the company announced that it was working on the development, launch and ongoing management of the Trump-Pence 2020 Reelection Campaign's mobile application portfolio. According to Benzinga Pro , TFUD stock has lost over 80% in the past year. In April, the company disclosed the renewal or extension of several healthcare and hospitality customer contracts . These renewals underscore the value customers are receiving from Phunware's mobile solutions to enhance the visitor experience for hospital patients and hotel guests. The Phunware-powered hospitality app generates six figures plus annual ancillary guest revenue for a typical customer, the company said in a press release in April. Price Action: TFUD shares are trading lower by 10.1% to $5.70 at last check Tuesday.
2024-06-05 09:14:12	NWY	X Financial Commences a Tender Offer To Buyback ~$9.04M Of Its ADSs	"X Financial (NYSE: NWY) (the ""Company"" or ""we""), a leading online personal finance company in China, announced today that it has commenced a tender offer (the ""Tender Offer"") to purchase up to 2 million American Depositary Shares (the ""ADSs"") of the Company, each representing six Class A ordinary shares, par value $0.0001 per share, at a price of $4.52 per ADS (the ""Purchase Price""), less any applicable withholding taxes, less a cancellation fee of $0.05 per ADS accepted for purchase in the Tender Offer that will be paid to The Bank of New York Mellon, the Company's ADS depositary (the ""ADSs Depositary""), and without interest. The Tender Offer will expire at 5:00 P.N., New York City time, on July 12, 2024, unless extended or earlier terminated. As previously announced, the Company's Board of Directors (the ""Board"") approved a share repurchase program of up to $20 million (the ""2024 Repurchase Program"") in May 2024. The repurchase of ADSs in the Tender Offer is being made pursuant to the 2024 Repurchase Program."
2024-06-05 16:27:16	GASI	Actelis Entered Into A $3M Definitive Agreement For The Immediate Exercise Of Certain Outstanding Warrants To Purchase Up To An Aggregate Of 999,670 Shares Of Common Stock	"Actelis Networks, Inc. (NASDAQ: GASI ) (""Actelis"" or the ""Company""), a market leader in cyber-hardened, rapid deployment networking solutions for IoT applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 999,670 shares of common stock of the Company originally issued in May 2023 and September 2023 having an exercise price of $2.75 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276425). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3 million, prior to deducting placement agent fees and estimated offering expenses. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-06-06 07:52:06	HDQ	Dorian HDQ Ltd Priced Public Offering of 2M Common Shares at $44.50/Share	Dorian HDQ Ltd. (NYSE: HDQ ) (the &quot;Company&quot;, &quot;Dorian HDQ&quot;, &quot;we&quot;, &quot;us&quot; and &quot;our&quot;) announced today that it has priced its previously announced underwritten public offering (the &quot;Offering&quot;) of 2,000,000 shares of common stock, par value $0.01 per share (&quot;Common Shares&quot;), at $44.50 per share. The net proceeds of the Offering are expected to be used for general corporate purposes. The Company has granted the underwriters a 30-day option to purchase up to an additional 300,000 Common Shares.
2024-06-07 07:01:08	ACI	GameStop Plans To Sell Up To 75M Shares Of Common Stock In Addition To 45M Shares Filed On May 17, 2024	On June 7, 2024, GameStop Corp., a Delaware corporation (the &ldquo;Company&rdquo;), filed a prospectus supplement (the &ldquo;Prospectus Supplement&rdquo;) with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection with the Company&rsquo;s &ldquo;at-the-market offering&rdquo; program (the &ldquo;Offering&rdquo;) for the offer and sale from time to time through Jefferies LLC (the &ldquo;Sales Agent&rdquo;) of up to 75,000,000 shares of the Company&rsquo;s Class A common stock, par value $0.001 per share (the &ldquo;Common Shares&rdquo;), pursuant to the Company&rsquo;s existing Open Market Sale AgreementSM (the &ldquo;Sales Agreement&rdquo;) with the Sales Agent, dated May 17, 2024. Prior to the date hereof, the Company has sold an aggregate of 45,000,000 shares of its common stock for aggregate gross proceeds of approximately $933.4 million pursuant to the Sales Agreement.
2024-06-07 08:11:28	ROKW	Gorilla Prices $12M Registered Direct Offering Of With Existing Institutional Investors For The Purchase And Sale Of 2,142,858 Ordinary Shares And Warrants At A Combined Price Of $5.60	"Gorilla Technology Group Inc. (""Gorilla"" or the ""Company"") (NASDAQ: ROKW ), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence, and IoT technology, today announced that it has entered into securities purchase agreements with existing institutional investors for the purchase and sale of 2,142,858 ordinary shares of the Company and warrants to purchase up to 2,142,858 ordinary shares pursuant to a registered direct offering (the ""Offering"") at a combined purchase price of $5.60 per ordinary share and accompanying warrant to purchase ordinary shares. The warrants will have an exercise price of $5.90 per share, will be immediately exercisable upon issuance and will expire 5 years from issuance. The gross proceeds to Gorilla from this Offering, before deducting the placement agents' fees and other offering expenses, will be approximately $12 million. Gorilla intends to use the net proceeds from the Offering for working capital needs. The closing of the Offering is expected to occur on or about June 10, 2024, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering."
2024-06-07 09:10:14	QKNP	Sify Technologies Announces Commencement  Of Its Previously Announced Rights Offering	"Sify Technologies Ltd. (NASDAQ: QKNP ) (the ""Company""), a leading integrated information communications technology (or ICT) Solutions and Services provider in India, today announced the commencement of its previously announced rights offering. In the rights offering, the Company will distribute, at no charge, (1) to the holders of its equity shares, transferable rights to subscribe for new equity shares and, (2) through Citibank, N.A., the depositary for the ADSs (the ""Depositary""), to holders of ADSs, transferable rights to subscribe for new equity shares in the form of ADSs. Holders of ADSs will receive 1.36364 ADS rights for each ADS owned of record at 5:00 p.m. (New York City time) on May 31, 2024, which is the ADS record date. One (1) ADS right will entitle the holder of such right to subscribe for and purchase one new ADS at a price of US$0.14 per ADS (the ""ADS Subscription Price""). The ADS Subscription Price includes the Depositary fee of US$0.02 per new ADS subscribed in the rights offering. Holders of equity shares will receive 1.36364 equity share rights for each equity share owned of record at 6:00 p.m. (Chennai, India time) on May 31, 2024, which is the equity share record date. One (1) equity share right will entitle a holder of such right to subscribe for and purchase one new equity share at a subscription price of Rs. 10 per new equity share, which is the Indian Rupee equivalent of the U.S. dollar price per new ADS, translated based on the exchange rate in effect as of March 31, 2024, minus the Depositary fee."
2024-06-10 07:46:20	AJKH	Virtu Financial, Announces Proposed Opportunistic Private Offering of $500M of Senior First Lien Notes Due 2031 For Debt Repayment	Virtu Financial, Inc. (NASDAQ: AJKH ) (&quot;Virtu&quot;) announced today that its subsidiaries, VFH Parent LLC (the &quot;Issuer&quot;) and Valor Co-Issuer, Inc. (the &quot;Co-Issuer&quot; and, together with the Issuer, the &quot;Issuers&quot;), intend to offer (the &quot;Offering&quot;) $500 million aggregate principal amount of senior first lien notes due 2031 (the &quot;notes&quot;) in an opportunistic private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The notes will be fully and unconditionally guaranteed on a senior secured first-lien basis by Virtu Financial LLC (&quot;Virtu Financial&quot;) and each of Virtu Financial's existing and future wholly owned domestic subsidiaries (other than the Issuers) that guarantee, or are borrowers under, the Issuer's senior secured first lien credit facilities. The Offering remains subject to market and other customary conditions. The Issuers intend to use the proceeds of the Offering to repay $500 million aggregate principal amount outstanding under the Issuer's existing senior secured first lien term loan facility (the &quot;existing term loan facility&quot;). Concurrently with the consummation of the Offering, the Issuer intends to amend its existing credit agreement to (i) provide for a $1,245 million senior secured first lien term loan facility (the &quot;new term loan facility&quot;), (ii) increase the commitments under its existing senior secured first lien revolving credit facility to $300 million and extend the maturity thereof (the &quot;extended revolving credit facility&quot; and, together with the new term loan facility, the &quot;amended credit facilities&quot;) and (iii) amend certain other provisions of its existing credit agreement. If the closing of the amended credit facilities is successfully consummated, the Issuer intends to use the proceeds from the new term loan facility to repay all remaining amounts outstanding under the existing term loan facility. The Issuer intends to use cash on hand to pay discounts, fees, commissions and expenses of the Offering, the closing of the amended credit facilities and the refinancing of the existing term loan facility. The closing of the amended credit facilities remains subject to market and other customary conditions. The consummation of the Offering is not contingent upon the closing of the amended credit facilities. The closing of the amended credit facilities is not contingent upon the consummation of the Offering.
2024-06-10 11:15:35	WALV	What's Going On With DraftKings Stock?	DraftKings Inc (NASDAQ: WALV ) shares are trading higher Monday. The company filed for a mixed shelf offering on Friday before being named a top pick by Morgan Stanley this week . What To Know: After the market close on Friday, DraftKings filed a prospectus supplement for the proposed sale of up to 7.5 million shares of its Class A common stock by selling stockholders. All of the shares being offered would be sold by the selling stockholders for their respective accounts. DraftKings will not receive any of the proceeds from the sales by the selling stockholders. DraftKings shares traded lower following the filing, but the stock is bouncing back in early trading Monday. The upward momentum appears to be due to reports indicating DraftKings was added to Morgan Stanley's Top Picks list on Monday. Several reports suggest Morgan Stanley argued in a new note to clients that recent tax increase concerns could be overdone. The firm reportedly sees earnings upside on the horizon. Morgan Stanley reiterated DraftKings with an Overweight rating and a price target of $51. See Also: Caitlin Clark Not Selected For US Olympic Basketball Team Roster, WNBA Rookie Will Miss Paris How To Buy WALV Stock Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in DraftKings' case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. WALV Price Action: DraftKings shares were up 1.82% at $37.56 at the time of publication, according to Benzinga Pro . Photo: courtesy of DraftKings.
2024-06-10 13:56:34	KMN	Trump Media & Technology Group Stock Is Sliding Monday: What's Going On?	Trump Media & Technology Group Corp (NASDAQ: KMN ) shares are trading lower Monday after the company filed an amended S-1 with the U.S. Securities and Exchange Commission . What Happened: Trump Media & Technology Group, the company behind former President Donald Trump's Truth Social, has filed a prospectus for the issuance of up to 14.4 million common shares upon the warrant exercise and resale of 146.1 million shares by selling stockholders, including 78.8 million shares held by Trump. The amended registration statement amends the registration statement filed on April 15 following the company's business combination with Digital World Acquisition Corp. Trump Media will not receive any proceeds from the sale, except in connection with any possible future exercise of any outstanding warrants for cash. &#8220;I want to thank SMC for serving as our independent auditor and enabling us to file an Amended Registration Statement, which we hope the SEC will promptly review,&#8221; said Devin Nunes , CEO of Trump Media & Technology. Check This Out: Trump's Economic Lead Over Biden Narrows in Latest Poll How To Buy KMN Stock Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in Trump Media & Technology's case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. KMN Price Action: Trump Media shares were down 6.19% at $41.83 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-06-10 17:18:57	TKHQ	Atour Lifestyle Reveals Proposed Offering Of 10M ADSs By Entities Affiliated With Legend Capital	Each ADS representing three Class A ordinary shares. The underwriters in the proposed Secondary Offering have a 30-day option to purchase up to 1.50 million additional ADSs from Legend Capital. Immediately after the completion of this Secondary Offering, Legend Capital will beneficially own approximately 7.6% of issued and outstanding share capital, assuming the underwriters do not exercise the option to purchase additional ADSs. Hongbin Zhou, a director of company previously appointed by Legend Capital, has tendered his resignation as director, effective upon completion of this Secondary Offering.
2024-06-11 09:07:58	HPZX	China Jo-Jo Drugstores Announces $3.37M Registered Direct Offering Of 1.98M Shares At A Price Of $1.70/Share	"China Jo-Jo Drugstores, Inc. (NASDAQ: HPZX ) (""Jo-Jo Drugstores"" or the ""Company""), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into definitive agreements with a number of investors providing for the issuance of 1,980,000 million ordinary shares, at a purchase price of $1.70 per share, in a registered direct offering for an aggregate gross proceeds of approximately $3.37 million. The closing of the sale of the securities is expected to occur on or about June 26, 2024, subject to satisfaction of customary closing conditions. Jo-Jo Drugstores intends to use the net proceeds from the offering for general corporate purposes and working capital."
2024-06-12 07:37:04	VASE	Navigator Gas Prices Upsized Secondary Public Offering of 7M Shares by Selling Shareholder at $15/Share	Navigator Holdings Ltd. (NYSE: VASE ) (&quot;Navigator Gas,&quot; the &quot;Company,&quot; &quot;we,&quot; or &quot;our&quot;) announced today the upsize and pricing of the previously announced public offering (the &quot;Secondary Offering&quot;) of a total of 7,000,000 shares of the Company's common stock (the &quot;Offered Shares&quot;) by LW Group Limited, as the selling shareholder of the Company (the &quot;Selling Shareholder&quot;), at a public offering price of $15.00 per share. The Secondary Offering is expected to close on or about June 13, 2024, subject to customary closing conditions.
2024-06-13 16:01:56	TRZA	Rezolute Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Size Or Amount Disclosed	"Rezolute, Inc. (NASDAQ: TRZA ) (""Rezolute"" or the ""Company""), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. All of the shares in the public offering are being offered by the Company. Jefferies and Cantor are acting as the book-running managers for the public offering."
2024-06-13 16:46:26	NUUT	Gain Therapeutics Plans To Offer And Sell Shares Of Its Common Stock (Or Pre-funded Warrants In Lieu Thereof) In Public Offering	Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. All of the securities are being offered by the Company. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate SK-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes.
2024-06-14 08:07:46	WNDE	MicroStrategy Prices Its Offering Of $700M Aggregate Principal Amount Of 2.25% Convertible Senior Notes Due 2032	"MicroStrategy&#xAE; Incorporated (NASDAQ: WNDE ) (""MicroStrategy"") today announced the pricing of its offering of $700 million aggregate principal amount of 2.25% convertible senior notes due 2032 (the ""notes""). The notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). MicroStrategy also granted to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $100 million aggregate principal amount of the notes. The offering was upsized from the previously announced offering of $500 million aggregate principal amount of notes. The offering is expected to close on June 17, 2024, subject to satisfaction of customary closing conditions."
2024-06-14 10:06:12	FQTF	Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering	Vaxart, Inc. (NASDAQ: FQTF ) shares traded higher in the premarket session on Friday , up more than 23% at one point. Vaxart's average session volume was about 1.6 million. Friday premarket's session volume had exceeded four million at the time of writing. Yesterday, Vaxart obtained a project award worth $453 million through the Rapid Response Partnership Vehicle, supported by the Biomedical Advanced Research and Development Authority under the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The funding from the award will be disbursed in two installments, with an initial sum of about $65.7 million accessible immediately to facilitate ongoing study start-up endeavors. These funds are designated for conducting a Phase 2b comparative study, which will assess Vaxart's oral pill COVID-19 vaccine candidate against an FDA-approved mRNA vaccine comparator. Vaxart expects to commence enrollment as soon as summer 2024, with a potential interim analysis of vaccine efficacy compared to an approved mRNA comparator by the first quarter of 2025. This funding from BARDA will assist us in determining whether we can bring a transformational, next-generation approach to global vaccination,&#8221; said Steven Lo, Vaxart's Chief Executive Officer. That's not all! Vaxart also announced an underwritten offering of 50 million shares of its common stock at an offering price of $0.80 per share . This represents a premium of over 6% to the last closing price of $0.75 per share. The offering by Vaxart is anticipated to generate gross proceeds of approximately $40 million prior to deductions for underwriting discounts, commissions, and estimated offering expenses. It is projected to conclude around June 17, 2024, pending standard closing conditions. Price Action: FQTF shares are trading lower by 7.68% to $0.69 at last check on Friday. Disclaimer : This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. November 18th, 2023 Read Next: JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
2024-06-14 12:31:58	GCIU	La Rosa Files Request For Withdrawal Of Registration Statement On Form S-1; Registration Statement Has Not Been Declared Effective By The SEC, And No Securities Have Been Sold In Connection With The Offering Described In The Registration Statement.	"La Rosa Holdings Corp. (NASDAQ: GCIU) (""La Rosa"" or the ""Company""), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it has filed a Request for Withdrawal of the Registration Statement with the U.S. Securities and Exchange Commission (""SEC"") with respect to the Company's Registration Statement on Form S-1 that it filed with the SEC originally on June 11, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement."
2024-06-17 16:49:31	EWZW	UroGen Pharma Announces Public Offering Of Ordinary Shares And Pre-Funded Warrants; No Size Or Amount Disclosed	UroGen Pharma Ltd. (NASDAQ: EWZW ), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of ordinary shares (including those underlying pre-funded warrants) offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All of the ordinary shares and pre-funded warrants to be sold in the proposed offering will be offered by UroGen.
2024-06-18 08:34:50	HNSN	HNSN Technologies Secures Up To $2.8M In Senior Notes To Fund Previously Announced Acquisition Of Myrtle Recovery Centers And Provide Additional Working Capital	"HNSN Technologies Inc. (NYSE: HNSN ) (the ""Company"" or ""HNSN""), today announced that it has secured up to $2.8 million in Senior Notes from an institutional investor (""Investor"") to fund the previously announced acquisition of Myrtle Recovery Centers, Inc. as well as provide additional working capital to support the Company's growth strategy."
2024-06-18 09:49:07	CQX	NextEra Energy Announces Sale Of $2B Equity Units To Wells Fargo Securities And BofA Securities, Expected To Close On June 20, 2024	NextEra Energy, Inc. (NYSE: CQX ) announced today that it has agreed to sell $2.0 billion of equity units to Wells Fargo Securities and BofA Securities. The transaction is expected to close on June 20, 2024. Each equity unit will be issued in a stated amount of $50. Each equity unit will consist of a contract to purchase NextEra Energy common stock in the future and a 5% undivided beneficial ownership interest in a NextEra Energy Capital Holdings, Inc. debenture due June 1, 2029, to be issued in the principal amount of $1,000. The debentures will be guaranteed by NextEra Energy Capital Holdings' parent company, NextEra Energy, Inc. Total annual distributions on the equity units will be at the rate of 7.299%, consisting of interest on the debentures and payments under the stock purchase contracts.
2024-06-21 09:20:20	IKM	What's Going On With Hertz Global Stock Today?	Hertz Global Holdings, Inc (NASDAQ: IKM ) shares are trading lower on Friday premarket. The company revealed the upsize and pricing of $1 billion offerings, which comprised $750 million of First Lien Senior Secured Notes, which represents an upsize from the previously announced $500 million. The First Lien Notes will be issued at par and will bear interest at a rate of 12.625% per annum. It is payable semi-annually in cash in arrears on January 15 and July 15 of each year, beginning on January 15, 2025, and will mature on July 15, 2029. The offering also comprises $250 million of exchangeable senior second-Lien Secured PIK Notes issued by its unit, The Hertz Corporation. The exchangeable notes will bear PIK interest at a rate of 8%. The initial exchange price of the exchangeable notes represents a premium of approximately 89% to the $3.51 closing price of the Common Stock on the Nasdaq Global Select Market on June 20. The offerings are each expected to close on or about June 28, subject to customary closing conditions. Hertz Corp. intends to use the net proceeds of the offerings to pay down a portion of its $2.0 billion committed revolving credit facility, improving liquidity. Price Action: IKM shares are trading lower by 1.42% to $3.46 premarket at last check Friday. Read Next: Recreation Products Maker Winnebago Struggles In Q3 With Lower Earnings, But New Product Launches Offer Hope: Details Photo via Shutterstock
2024-06-24 07:20:24	TAWP	Entrada Therapeutics To Raise $100M Via Registered Direct Offering of 3.4M Shares At $14.85/Share To Fund The Ongoing Clinical Development	Entrada Therapeutics, Inc. (NASDAQ: TAWP ) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stock in a registered direct offering for aggregate gross proceeds of approximately $100 million. The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm. The purchase price for the common stock is $14.85 per share and the purchase price for the pre-funded warrants is $14.8499 per warrant, which represents the per share purchase price for the common stock less the $0.0001 exercise price for the pre-funded warrant. The offering is expected to close on or about June 25, 2024, subject to the satisfaction of customary closing conditions. Entrada expects to use the net proceeds from the offering to fund the ongoing clinical development of each of ENTR-601-44 and ENTR-601-45 through initiation of our planned Phase 2b clinical trials and ENTR-601-50 through initiation of our planned Phase 2 multiple ascending dose trial, the ongoing research and development of our development pipeline (including our neuromuscular and ocular franchises), and the remainder for working capital and other general corporate purposes.
2024-06-24 07:37:44	FDGT	CPI Card Group To Raise $285M Via Private Offering Of Senior Secured Notes	CPI Card Group Inc. (NASDAQ: FDGT ) (&quot;CPI&quot; or the &quot;Company&quot;) today announced the commencement of a private offering by its wholly-owned subsidiary, CPI CG Inc. (the &quot;issuer&quot;), of $285 million aggregate principal amount of senior secured notes due 2029 (the &quot;notes&quot;). The offering is subject to market and other conditions, and there is no assurance that the offering will be completed or, if completed, the terms on which it will be completed. The issuer intends to use the net proceeds from the offering, together with cash on hand, to redeem all of the issuer's outstanding 8.625% senior secured notes due 2026 (the &quot;2026 notes&quot;) and to pay related fees, premiums and expenses. The notes are expected to be general senior secured obligations of the issuer and guaranteed by the Company and all of its current and future wholly-owned domestic subsidiaries (other than the issuer) and will be secured by substantially all of the assets of the issuer and the guarantors, subject to customary exceptions. The notes and related guarantees will be offered only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or outside the United States to certain non-U.S. persons in compliance with Regulation S under the Securities Act. The issuance and sale of the notes and related guarantees have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction, and the notes and related guarantees may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws.
2024-06-24 17:00:08	YIMO	Why Birkenstock's Stock Is Down	"Birkenstock Holding Plc (NYSE: YIMO ) shares are trading lower Monday after the company announced the launch of a secondary public offering of up to 14 million ordinary shares. The Details Birkenstock said the selling shareholder intends to grant the underwriters a 30-day option to purchase up to 2.1 million additional ordinary shares. Following the completion of the proposed offering and without giving effect to the underwriters' option to purchase additional shares, the selling shareholder will hold approximately 137,543,181 ordinary shares, or 73.2% of the ordinary shares outstanding. &#8220;Supported by the positive outlook and strong performance of our business, the intended Secondary Offering is an opportunity for us to further broaden our investor base and to increase the liquidity of our stock. As with our GIP, we will look to partner with investors that have a long-term perspective, understand our unique investment case and contribute a sustainable value to the Company,"" said Oliver Reichert , CEO of Birkenstock. Related News: Clover Health's $1 Million Insider Buy: What's Going On With The Stock? Is YIMO A Good Stock To Buy? An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages  like Birkenstock Holding 's page, for example  there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter. These are known as capital allocation programs. Birkenstock Holding does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company. For example, if you're looking to earn an annualized return of 19.77%, you'll need to buy a share of Dividend Growth Split by June 28, 2024. Once done, you can expect to receive a nominal payout of $0.10 on July 15, 2024. Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Birkenstock Holding will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand. YIMO Price Action: According to Benzinga Pro , Birkenstock shares ended Monday's regular session 2.75% lower at $59.78 and are down another 3.90% after-hours at $57.45 at the time of publication. Photo: nateen08650 from Pixabay"
2024-06-24 17:56:34	GN	Waste Management Prices Public Offering Of $1.50B Of Senior Notes	$750,000,000 aggregate principal amount of 4.950% senior notes due July 3, 2027; and $750,000,000 aggregate principal amount of 4.950% senior notes due July 3, 2031. The Company intends to use the net proceeds from the offering to repay borrowings under its commercial paper program used for working capital, which is fully supported by the Company's $3.5 billion revolving credit facility, and the remainder, if any, for general corporate purposes.
2024-06-25 09:22:18	KTYY	SolarEdge Technologies Stock Is Tumbling Tuesday: What's Going On?	SolarEdge Technologies Inc (NASDAQ: KTYY ) shares are trading lower Tuesday after the company announced a private offering of $300 million convertible senior notes due 2029 . What Happened: After the market close on Monday, SolarEdge said it intends to offer $300 million aggregate principal amount of Convertible Senior Notes due 2029 in a private offering to people reasonably believed to be qualified institutional buyers. The initial purchasers are expected to be granted a 13-day option to purchase up to an additional $45 million aggregate principal amount of the notes on the same terms and conditions. The final terms of the Notes, including the initial conversion price, interest rate and certain other terms, will be determined at the time of pricing of the offering. In connection with the pricing of the notes, SolarEdge expects to enter into capped call transactions with one or more of the initial purchasers. SolarEdge noted that it intends to use net proceeds from the offering to pay the cost of its capped call transactions. See Also: Pool Lowers FY24 EPS Forecast, Joins SolarEdge Technologies, Spirit AeroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session How To Buy KTYY Stock Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in SolarEdge Technologies' case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. KTYY Price Action: SolarEdge shares were down 17.3% at $27.50 at the time of publication, according to Benzinga Pro . Photo: Andreas from Pixabay.
2024-06-26 07:03:38	KTYY	SolarEdge Technologies Reports Pricing Of $300M Of 2.25% Convertible Senior Notes Due 2029 In Private Offering	In connection with the Offering, SolarEdge has granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $45 million aggregate principal amount of the Notes on the same terms and conditions. The sale of the Notes to the initial purchasers is expected to settle on June 28, 2024, subject to customary closing conditions. The Notes will bear interest at a rate of 2.25% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2025. The Notes will mature on July 1, 2029, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.
2024-06-26 08:04:32	QEWE	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement of 568K Shares At $2.45/Share	CNS Pharmaceuticals, Inc. (NASDAQ: QEWE ) (&quot;CNS&quot; or the &quot;Company&quot;), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a registered direct offering and warrants to purchase up to 568,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the &quot;Offering&quot;) at a combined purchase price of $2.45 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $2.32 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date. The closing of the Offering is expected to occur on or about June 27, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $1.39 million before deducting financial advisory fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.
2024-06-26 08:17:40	QXFG	DiaMedica Therapeutics Announces $11.8M Private Placement, Will Issue A Total Of 4.72M Common Shares At A Purchase Price Of $2.50 Per Share	DiaMedica Therapeutics Inc. (NASDAQ: QXFG ), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement. Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 4,720,000 common shares at a purchase price of $2.50 per share. The private placement is expected to close on or about June 28, 2024, subject to the satisfaction of customary closing conditions.
2024-06-26 09:19:43	RBPS	Taysha Gene Therapies Announces Pricing Of ~$75M Public Offering Of 14,361,113 Shares Of Its Common Stock At A Price To The Public Of $2.25 Per Share	Taysha Gene Therapies, Inc. (NASDAQ: RBPS ), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering at the public offering price, less the underwriting discount. The gross proceeds from the offering to Taysha are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriter's option to purchase additional shares. The offering is expected to close on or about June 27, 2024, subject to customary closing conditions. Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, and Cantor is also serving as a book-running manager for the offering.
2024-06-26 13:40:39	YAJ	UPDATED: Nexalin Technology Files Prospectus For The Offering Of Up To $7M Of Common Stock At An Assumed Price Of $2.26 Per Share	- SEC Filing We are offering on a reasonable best effort basis up to $7,000,000 of our common stock, $0.001 par value per share. We are offering each share of common stock at an assumed public offering price of $2.26 per share. The securities will be offered at a fixed price and are expected to be issued in a single closing. The offering will terminate on [], 2024, unless completed sooner or unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We expect this offering to be completed not later than two business days following the commencement of sales in this offering (after the effective date of the registration statement of which this prospectus forms a part) and we will deliver all securities to be issued in connection with this offering delivery versus payment or receipt versus payment, as the case may be, upon receipt of investor funds received by us. Accordingly, neither we nor the Placement Agent (as defined below) have made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent will not receive investor funds in connection with the sale of the securities offered hereunder.v
2024-06-26 16:02:29	DFBX	Addus HomeCare Commences Proposed Public Offering Of 1.50M Shares Of Its Common Stock	Addus expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 225,000 shares of its common stock. Addus intends to use approximately $81.4 million of the net proceeds it receives from this offering for the repayment of all indebtedness outstanding under its credit facility and the remainder for general corporate purposes, including the Company's previously announced acquisition of the personal care assets of Gentiva and any future acquisitions or investments. There are no selling stockholders in the offering.
2024-06-27 08:20:58	NEH	NEH Bio Announces Pricing Of $4M Public Offering; Potential Additional Gross Proceeds To The Co From The Series Warrants, If Fully Exercised On A Cash Basis, Will Be ~$8M	"NEH Bio, Inc. (NASDAQ: NEH ) (""NEH Bio"" or the ""Company""), a biotechnology company advancing an innovative pipeline of Natural Killer F (""NKT"") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 2,185,793 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,185,793 shares of common stock and Series C-2 warrants to purchase up to 2,185,793 shares of common stock (all the warrants, collectively, the ""Series Warrants""), at a combined public offering price of $1.83 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants will have an exercise price of $1.83 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series Warrants. The Series C-1 warrants will expire on the five-year anniversary of the initial exercise date. The Series C-2 warrants will expire on the eighteen month anniversary of the initial exercise date. The closing of the offering is expected to occur on or about June 28, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-06-27 09:07:10	ARGM	Siyata Mobile Announces Pricing Of ~$6 Million Public Offering Of Common Shares And Pre-Funded Warrants	"Siyata Mobile Inc. (NASDAQ: ARGM )(NASDAQ: SYTAW ) (""Siyata"" or the ""Company""), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories,announces the pricing of its public offering of approx. $6 million of common shares, and/or pre-funded warrants to purchase common shares at a public offering price of $0.58 per share (minus $0.01 per pre-funded warrant). The Company intends to use the proceeds of the offering for working capital, general corporate purposes, payments to a third-party marketing agency for services related to marketing and advertising, strategic investments, and any additional future acquisition (if any). Dominari Securities LLC is acting as the sole placement agent in connection with the offering."
2024-06-27 12:05:51	CILG	On June 21, 2024, Energy Focus Entered Into A ~$0.85M Securities Purchase Agreement With Sander Electronics Who Agreed To Issue And Sell In A Private Placement 534,592 Shares Of Common Stock For A Purchase Price Per Share Of $1.59	"On June 21, 2024, Energy Focus, Inc. (the ""Company"") entered into a securities purchase agreement (the ""Purchase Agreement"") with Sander Electronics Inc. (the ""Purchaser""), a shareholder of the Company controlled by Chiao Chieh (Jay) Huang, CEO of the Company, pursuant to which the Company agreed to issue and sell in a private placement (the ""Private Placement"") an aggregate of 534,592 shares (the ""Shares"") of the Company's common stock, par value $0.0001 per share (the ""Common Stock""), for a purchase price per share of $1.59. Aggregate gross proceeds to the Company in respect of the Private Placement is approximately $0.85 million, before offering expenses payable by the Company. The Private Placement was closed on June 21, 2024."
2024-06-27 16:10:11	LMCF	Elicio Therapeutics Announces Proposed Public Offering; No Size Or Amount Disclosed	"Elicio Therapeutics, Inc. (NASDAQ: LMCF , ""Elicio Therapeutics"" or ""Elicio""))))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants. All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Elicio intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, for the advancement of its development pipeline, as well as for working capital and general corporate purposes. Jones is acting as the sole book-running manager for the offering."
2024-06-28 08:05:07	LZKN	Pulse Biosciences Announces Preliminary Results For Its Rights Offering Expected To Generate $60M In Immediate Gross Proceeds For The Co	"Based on a preliminary tabulation by Broadridge Corporate Issuer Solutions, Inc. (the ""Subscription Agent""), as of the Expiration Date, the Company received basic subscriptions and over-subscriptions in excess of $83 million, equal to approximately 138% of the $60 million limit in the rights offering, and subscriptions from over 800 accounts, including those of the Company's Executive Chairman, Robert Duggan. Available Units will therefore be allocated proportionately among those rights holders who exercised their over-subscription right based on the number of Units each rights holder subscribed for under its basic subscription rights, in accordance with the procedures described in the prospectus relating to the rights offering, as amended, and the remaining oversubscription amounts will be returned by the Subscription Agent to the investors. The common stock and warrants comprising the Units will separate upon the closing of the rights offering and will be issued individually. The Company expects the Subscription Agent to distribute such shares and warrants, as well as the sale proceeds, as soon as practical upon the closing of the rights offering. The Company expects to receive aggregate gross proceeds from the rights offering of $60 million, excluding additional proceeds of up to $66 million from the exercise of warrants issued in the rights offering (if any such exercises occur). The results of the rights offering are preliminary and subject to change pending finalization of subscription procedures by the Subscription Agent."
2024-06-28 08:39:05	BFPC	Safety Shot President Jordan Schur Invests $1M Private Placement In The Company Through His Family Fund, Core 4 Capital Corp.	"This Private Placement Investment Comes in Addition to a $5 Million Investment from Core 4 Capital Corp Which Closed in April JUPITER, HK, June 28, 2024 (GLOBE NEWSWIRE) -- Safety Shot , Inc. (NASDAQ: BFPC ) (the ""Company) is pleased to announce that Safety Shot President Jordan Schur has invested in a $1 million private placement in the Company through his family investment group, Core 4 Capital Corp. The investment is in addition to the $5 million private placement from the investment group that closed in April of 2024 upon Schur's appointment as President of the Company."
2024-06-28 08:50:43	WXVO	Savara Announces Pricing Of $100M Underwritten Offering Of Common Stock Of 26,246,720 Shares Of Its Common Stock At A Price Of $3.81 Per Share	Savara Inc. (NASDAQ: WXVO ), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million. All of the securities to be sold in the offering are being sold by Savara. The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazier Life Sciences, Wellington Management, Nantahala Capital, TCGX and First Light Asset Management, among others. The offering is expected to close on July 1, 2024, subject to the satisfaction of customary closing conditions. Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the lead manager for the offering.
2024-06-28 09:08:38	CQXY	Allurion Announces Pricing Of $17.3M Public Offering Of 14,406,508 Shares Of Its Common Stock At A Price Of $1.20 Per Share And $2.7M Concurrent Private Placement To Sell To Funds Affiliated With RTW Investments; Aggregate Proceeds Expected To Be ~$20M	"Allurion Technologies, Inc. (NYSE: CQXY ) (""Allurion"" or the ""Company""), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the ""Shares""), and warrants to purchase 14,406,508 Shares (the ""Warrants"" and, together with the Shares, the ""Securities"") at a public offering price of $1.20 per share, for total gross proceeds of $17.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriters for the offering. Roth Capital Partners is acting as co-manager for the offering. The Company has granted the underwriters a 30-day option to purchase additional Securities in an amount equal to 15% of the Securities offered in the offering. The Company agreed to sell to funds affiliated with RTW Investments (""RTW""), in a concurrent private placement subject to the consummation of the public offering and satisfaction of customary closing conditions, a newly created series of preferred stock, Series A convertible preferred stock (the ""Series A Preferred Stock"") and private placement warrants, at the public offering price, for total gross proceeds of approximately $2.7 million. The Series A Preferred Stock will not have any voting rights and will automatically convert into Shares upon stockholder approval of such conversion. The securities sold in the concurrent private placement are being issued pursuant to the exemptions provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the ""Securities Act""), have not been registered under the Securities Act or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdiction's securities laws. The aggregate gross proceeds from the public offering and the concurrent private placement are expected to be approximately $20.0 million, before underwriting discounts and commissions and other offering expenses payable by Company, and without giving effect to any exercise by the underwriters of their option to purchase additional shares. The public offering and concurrent private placement are expected to close on or about July 1, 2024, subject to the satisfaction of customary closing conditions."
2024-06-28 09:16:19	BCLU	Cingulate Announces Exercise Of Warrants For $1.86M Of Gross Proceeds	"Cingulate Inc. (the ""Company"") (NASDAQ: BCLU ), a biopharmaceutical company utilizing its proprietary Precision Timed Release&#x2122; (PTR&#x2122;) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 2,125,000 shares of common stock of the Company and Series B warrants to purchase up to an aggregate of 1,062,500 shares of common stock of the Company originally issued in February 2023, having an exercise price of $2.00 per share, at a reduced exercise price of $0.585 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276502). The offering is expected to close on or about July 1, 2024, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series C warrants to purchase up to 4,250,000 shares of common stock and new unregistered Series D warrants to purchase up to 2,125,000 shares of common stock. The new warrants will have an exercise price of $0.585 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the new warrants. The Series C warrants will expire five years from the effective date of stockholder approval, and the Series D warrants will expire two years from the effective date of stockholder approval."
2024-06-28 09:23:05	JBMN	Aptevo Therapeutics Announces $2.75M Offering Of 5,339,806 Shares Of Its Common Stock Or Pre-funded Warrants In Lieu Thereof And Warrants To Purchase Up To An Aggregate Of 10,679,612 Shares Of Its Common Stock At A Purchase Price Of $0.515 Per Share And Associated Warrant	"Aptevo Therapeutics Inc. (NASDAQ: JBMN ), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR&#x2122; and ADAPTIR-FLEX&#x2122; platform technologies, today announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the ""Common Warrants"") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock. The Common Warrants will have an exercise price of $0.515 per share, are exercisable upon stockholder approval, and will expire five years following the date stockholder approval. The offering is expected to close on or about July 1, 2024, subject to customary closing conditions. Roth Capital Partners is acting as placement agent of the offering. Dawson James Securities, Inc. is acting as co-agent. Gross proceeds, before deducting placement agent fees and commissions and offering expenses, are expected to be approximately $2.3 million. The company intends to use the net proceeds from the offering for the continued clinical development of its product candidates, working capital, and other general corporate purposes."
2024-06-28 11:41:35	LMCF	Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?	Thursday, Elicio Therapeutics Inc (NASDAQ: LMCF ) released new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P . The preliminary data showed patients receiving ELI-002 7P at the Phase 2 dose of 4.9mg AMP-peptide were yet to reach the median disease-free survival (DFS) endpoint as of the May 24, 2024 data cutoff date. The AMPLIFY-7P study is evaluating the 7-peptide formulation ELI-002 7P in patients with mKRAS-driven solid tumors following standard locoregional treatment. Data were based on May 24, 2024, data cutoff date of 14 patients with minimal residual disease who enrolled in the Phase 1 cohort of the AMPLIFY-7P study, with a median follow-up for the DFS endpoint of 29.1 weeks: The median DFS has not yet been reached (n=14). The median disease-free survival (mDFS) has not been reached in patients receiving the 4.9mg AMP-peptide dose (n=8) vs. 12.6 weeks for patients receiving the 1.4mg AMP-peptide dose (n=6). Patients achieving a reduction in their tumor biomarker levels had no progression events, compared to an mDFS of 11.0 weeks for patients whose tumor biomarker did not respond to ELI-002 7P. Patients with an above-median F-cell response to ELI-002 have had no progression events. The company expects to share additional clinical data updates from the AMPLIFY Phase 1 trials later in 2024 and the randomized Phase 2 interim analysis in the first quarter of 2025. ELI-002 2P (2-peptide formulation) is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors following surgery and chemotherapy. ELI-002 7P (7-peptide formulation) is currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer. Concurrently, Elicio Therapeutics priced its approximately $11.5 million public offering of 500k shares and accompanying warrants to purchase 500k shares at a combined price of $5.00 . Price Action: LMCF shares are down 36.9% at $4.345 at last check Friday. Image by PDPics from Pixabay
2024-07-01 08:06:03	HCBN	NextDecade Subsidiary Rio Grande HPJ Announces Issuance Of $1.115B Senior Secured Notes Due 2047	Note proceeds will be utilized to reduce outstanding borrowings and commitments under existing Rio Grande HPJ, LLC term loan facilities NextDecade Corporation (NextDecade or the Company) (NASDAQ: HCBN ) announced today that its subsidiary Rio Grande HPJ, LLC (Rio Grande HPJ) has issued $1.115 billion of senior secured notes in a private placement. These senior secured notes will accrue interest at a fixed rate of 6.58%. Proceeds from the notes will be used to reduce outstanding borrowings and commitments under Rio Grande HPJ's existing term loan facilities for Phase 1 at the Rio Grande HPJ Facility.
2024-07-01 09:09:58	QTYC	Purple Biotech Exercises Warrants For $2M Gross Proceeds	"Purple Biotech Ltd. (""Purple Biotech"" or ""the Company"") (NASDAQ/TASE: QTYC), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3 (File Nos. 333-268710, 333-235327 and 333-215037). The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-07-01 11:06:54	KHHN	XTI Aerospace Secures ~$55M Investment To Boost TriFan Aircraft Production - What's On The Radar?	XTI Aerospace, Inc. (NASDAQ: KHHN ) announced a strategic equity investment agreement with FC Imperial Limited , an affiliate of the FinExic Concordia Group, for up to $55 million in convertible preferred stock. The investment values XTI at $275 million post-money and aims to accelerate the development of its innovative TriFan aircraft. Anindya Chakraborty, leading the investment structuring for the Investment Consortium, said, &#8220;The Trifan is unique and perhaps the most efficient, practical, versatile and commercially viable VTOL aircraft with clear attributes of ushering in a game changing reality to the aviation industry.&#8221; The investment will support several key milestones, including the preliminary and critical design reviews and the assembly of XTI's first test aircraft. XTI CEO Scott Pomeroy said, &#8220;Assuming the completion of the proposed investment, we believe the additional capital will help accelerate the development of the TriFan through several major milestones including completion of the updated preliminary design review along with launching the critical design review phase in preparation for the assembly of XTI's Test Aircraft No. 1.&#8221; The $275 million valuation aligns with a fairness opinion provided prior to XTI's merger with Inpixon. This valuation reflects the progress made since the last capital raise based on a $100 million valuation. Anindya Chakraborty highlighted the TriFan's potential for widespread adoption across emerging aviation markets, including India, Southeast Asia, and the Middle East. The VTOL aircraft is poised to serve diverse applications such as healthcare, emergency services, para-military operations, corporate mobility, and luxury travel. The agreement details a structured capital distribution process, with convertible preferred stock to be issued up to $55 million, converting to common stock through defined exchange events. Price Action : KHHN shares are trading lower by 6.31% at $0.4141 at the last check Monday. Disclaimer : This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image: Courtesy of XTI Aerospace, Inc.
2024-07-01 17:29:49	TIA	Aspira Women's Health Reveals Private Placement Equity Financing Of $1.935M	The company announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1.264 million shares of its common stock and warrants to purchase an equal number of shares of Common Stock at a combined offering price of $1.53 per share and warrant through a private placement financing. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. Net proceeds from the Offering will support Aspira's ongoing commercial activities as well as general corporate purposes and working capital.
2024-07-02 08:12:19	CJRK	Checkpoint Therapeutics Announces $12M Registered Direct Offering Of 5,853,659 Shares Of Its Common Stock At A Purchase Price Of $2.05 Per Share Priced At-The-Market Under Nasdaq Rules	"Checkpoint Therapeutics, Inc. (""Checkpoint"") (NASDAQ: CJRK ), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 5,853,659 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.05 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 5,853,659 shares of common stock. The warrants will have an exercise price of $2.05 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrant and will expire five years following the issuance date. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The closing of the offering is expected to occur on or about July 3, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $12 million. Checkpoint intends to use the net proceeds of this offering for working capital and general corporate purposes."
2024-07-02 08:32:02	XBOC	Blackboxstocks Announces $1.25M Private Placement Offering Priced At $4.00 per Share	"Blackboxstocks Inc. (NASDAQ: XBOC ), (""Blackbox"" or the ""Company""), a financial technology and social media hybrid platform offering real-time proprietary analytics for stock and options traders of all levels, announced that it has closed a private placement of its common stock for aggregate proceeds in the amount of $1.25 million priced at $4.00 per share. Blackbox will invest $1.15 million into Evtec Aluminium and retain $100,000 for working capital for Blackbox.io, Inc., the Company's wholly owned operating subsidiary. Blackbox is working with Evtec Aluminium to provide custom analytics and enterprise software solutions for their manufacturing operations. Evtec Aluminium will use the proceeds to fund its growth initiatives including capital expenditures to increase production capacity. Blackbox and Evtec amended the Share Exchange Agreement dated December 12, 2023, to increase the Blackbox percentage ownership of the combined company from 26.2% to 29.4% to reflect the investments into Blackbox and Evtec Aluminium and preserve the value for their shareholders. The private placement was led by a $1.15 million investment by Quadrofoglio LLC. Blackbox CEO Gust Kepler is also participating in the private placement with an investment of $100,000."
2024-07-02 08:34:33	XLVO	Datasea Announces Pricing Of $2.25M Registered Direct Offering To Purchase 692,308 Shares Of Its Common Stock At An Offering Price Of $3.25 Per Share	"Datasea Inc., (NASDAQ: XLVO ) (""Datasea"" or the ""Company""), a Nevada corporation engaged in innovative businesses in high-tech intelligent acoustics and 5G-Artificial Intelligence (""AI"") multimodal communication technology in the United States and China, today announced that it entered into a share purchase agreement with a certain institutional investor to purchase 692,308 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $3.25 per share of common stock (or common stock equivalents in lieu thereof) in a registered direct offering. The offering is expected to close on or about July 3, 2024, subject to satisfaction of customary closing conditions. Datasea intends to use the net proceeds from the offering for research and development, market development and for general corporate purposes. EF Hutton LLC is acting as the exclusive placement agent for the offering."
2024-07-02 08:51:28	CLGG	Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M	Tuesday, Cartesian Therapeutics Inc (NASDAQ: CLGG ) announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG) . Descartes-08, Cartesian's lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor F-cell therapy (mRNA CAR-F) directed against the B cell maturation antigen. It is designed to be administered as an outpatient treatment without requiring lymphodepleting chemotherapy to achieve activity with conventional CAR-F cell therapies. The trial achieved its primary endpoint with statistical significance in the pre-specified mITT efficacy population, with 71% (10/14) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MG Composite (MGC) score at Month 3 compared to 25% (3/12) of patients treated with placebo (p=0.018). MGC score aims to assess the disease severity. In addition, the trial also achieved its primary endpoint with statistical significance in the per-protocol population, with 69% (11/16) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MGC score compared to 33% (5/15) of patients treated with placebo (p=0.048). Descartes-08 responders experienced deep improvements across the MG severity scales. The improvements seen at Month 3 persisted or improved in patients evaluated at Month 4 (n=5) and Month 6 (n=3) follow-up visits. Descartes-08 demonstrated a favorable safety profile and was tolerated well, and adverse events were transient and mostly mild. There were no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome cases. Cartesian also announced updated results from two patients enrolled in the Phase 2a open-label portion of the trial. Both retreated patients experienced rapid improvement in clinical scores and maintained minimal symptom expression for up to one year after receiving a second treatment cycle. The time course and magnitude of treatment response upon retreatment were similar to those seen when the patients were first treated. Four of the seven patients from the Phase 2a portion of the trial maintained clinically meaningful responses for at least one year following initial dosing. Cartesian Therapeutics has also dosed the first patient in its Phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus. The Phase 2 open-label trial will enroll up to 30 adult patients . Concurrently, Cartesian Therapeutics has entered into a private investment in public equity financing of approximately $130 million . The company is selling 3.56 million shares and 2.94 million Series B Non-Voting Convertible Preferred Stock at a purchase price of $20.00 per share. Price Action: CLGG shares are down 17.6% at $20.00 during the premarket session at last check Tuesday. Photo via Shutterstock
2024-07-02 16:36:07	VBFZ	REPAY Announces Launch Of Convertible Notes Offering Of $260M Aggregate Principal Amount Of Its Convertible Senior Notes Due 2029	"Repay Holdings Corporation (NASDAQ: VBFZ ) (""REPAY"" or the ""Company"") today announced that it intends to offer, subject to market and other conditions, $260 million aggregate principal amount of its convertible senior notes due 2029 (the ""Convertible Notes""). The Company also intends to grant to the initial purchasers of the Convertible Notes an option to purchase up to an additional $27.5 million aggregate principal amount of the Convertible Notes for settlement within a 13-day period beginning on, and including, the first day on which the Convertible Notes are issued."
2024-07-03 11:14:58	QEWE	CNS Pharmaceuticals Announces Pricing Of $1.98M Registered Direct Offering And Concurrent Private Placement Of 1.425M Shares Of Common Stock At A Combined Purchase Price Of $1.39 Per Share	CNS Pharmaceuticals, Inc. (NASDAQ: QEWE ) (&quot;CNS&quot; or the &quot;Company&quot;), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 1,425,000 shares of common stock in a registered direct offering and warrants to purchase up to 1,425,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the &quot;Offering&quot;) at a combined purchase price of $1.39 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.26 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date. The closing of the Offering is expected to occur on or about July 5, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $1.98 million before deducting financial advisory fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.
2024-07-08 07:21:19	EYPB	Welltower  Looks To Raise $750M Via Announces Private Placement Of Exchangeable Senior Notes	Welltower&reg; Inc. (NYSE: EYPB ) (&quot;Welltower&quot; or the &quot;Company&quot;) announced today that its operating company, Welltower OP LLC (&quot;Welltower OP&quot;), launched an offering (the &quot;Offering&quot;), subject to market conditions and other factors, of $750 million aggregate principal amount of exchangeable senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). Welltower OP also intends to grant the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of notes.
2024-07-09 16:24:40	WHR	Cinemark USA Announces Pricing Of $500M Senior Notes Due 2032	"Cinemark Holdings, Inc. (NYSE: WHR ) (""Cinemark"" or the ""Company"") announced today that its wholly-owned subsidiary, Cinemark USA, Inc. (""Cinemark USA""), priced a private offering (the ""Offering"") that is exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""), to eligible purchasers of $500 million aggregate principal amount of its 7.0% Senior Notes due 2032 (the ""Notes"") at the initial offering price of 100.000% of the principal amount plus accrued and unpaid interest from July 18, 2024. The Offering is expected to close on July 18, 2024, subject to customary closing conditions."
2024-07-11 08:05:57	HDTQ	Entero Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement For $1.9M Gross Proceeds	"Entero Therapeutics, Inc. (""Entero"" or the ""Company"") (NASDAQ: HDTQ ), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1,921,315, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules. Roth Capital Partners is acting as the Company's financial advisor for this transaction."
2024-07-11 08:28:52	KFIW	Onconetix Announces Exercise Of Warrants For $1.11M Gross Proceeds	"Onconetix, Inc. (""Onconetix"" or the ""Company"") (NASDAQ: KFIW ), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares of its common stock originally issued in August 2022 and August 2023, having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The transaction is expected to close on or about July 12, 2024, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. The aggregate gross proceeds from the exercise of the existing warrants are expected to be approximately $1.11 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes."
2024-07-11 13:28:52	ZYSE	Volcon Announces Pricing Of $12M Registered Direct Offering Of 3,287,671 Shares Of Common Stock And/ Or Pre-Funded Warrants To Acquire Common Stock In A Registered Direct Offering. The Purchase Price Of Each Share Is $3.65	"Volcon Inc. (NASDAQ: ZYSE ), (""Volcon"" or the ""Company""), the first all-electric, off-road powersports company, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 3,287,671 shares of common stock and/or pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share is $3.65. The purchase price for the pre-funded warrants is identical to the purchase price for the shares, less the exercise price of $0.00001. The aggregate gross proceeds to the Company are expected to be approximately $12 million. The transaction is expected to close on or about July 12, 2024, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as exclusive placement agent for the offering. ArentFox Schiff LLP is acting as counsel to the Company for the offering. Kaufman & Canoles, P.C. is acting as counsel to Aegis for the offering."
2024-07-12 08:03:54	KUZQ	Phio Pharmaceuticals Announces Exercise Of Warrants For $3.1M Gross Proceeds	"Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: KUZQ ) (the ""Company""), a clinical stage biotechnology company whose proprietary INTASYL&#xAE; siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 545,286 shares of common stock of the Company originally issued in February 2020 through December 2023, having exercise prices between $324.00 and $9.72 per share, at a reduced exercise price of $5.45 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (Nos. 333-234032, 333-238204, 333-239779, 333-271521, 333-272526 and 333-276146) and Form S-3 (No. 333-252588). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $136,321.50 in the aggregate, which are included in the gross proceeds to the Company), the exercising holders will receive new unregistered warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the ""1933 Act""). The new warrants will be exercisable for an aggregate of up to 1,090,572 shares of common stock, at an exercise price of $5.45 per share and will be immediately exercisable upon issuance. 583,098 of the new warrants will have a term of five and one-half years from the issuance date and 507,474 of the new warrants will have a term of eighteen months from the issuance date."
2024-07-12 14:14:15	OOP	Nano Nuclear's $18M Upsized Offering: Eyes Funding for Advanced Micro Nuclear Reactor Designs	Nano Nuclear Energy Inc. (NASDAQ: OOP ) shares are trading lower after the company announced the pricing of an $18 million upsized offering of 900,000 shares of common stock and warrants to purchase 450,000 shares of common stock. Each share and associated warrant is being sold at a public offering price of $20.00. Furthermore, Nano Nuclear has given the underwriter a 30-day option to buy up to 135,000 additional shares of common stock and/or warrants for 67,500 shares at the public offering price, minus underwriting fees. While the shares and associated warrants were marketed as a unit, such units have no stand-alone rights and will not be certificated or issued as stand-alone securities. Also Read: Toyota Plans To Integrate RoboSense LiDAR In Lexus Electric Models, Future Expansion Across Other Brands Expected The warrants can be exercised immediately, have a five-year term, and an exercise price of $20.00 per share. They are not tradable on any market, the company said. Nano Nuclear plans to allocate the net proceeds from this offering towards advancing the research and development of its proprietary micro nuclear reactor designs, ZEUS and ODIN. Additionally, funds will support the development of a U.S. domestic source for HALEU fuel fabrication, crucial for both Nano Nuclear's microreactors and the broader advanced nuclear reactor industry. These funds will also be utilized for business development initiatives, as well as general corporate purposes and working capital. Price Action: OOP shares are trading lower by 6.52% to $24.53 at last check Friday. Photo via Shutterstock Read Next: Wells Fargo Q2 Earnings: Net Interest Margin Slides, Average Loans Decline, Stock Falls
2024-07-12 16:18:31	SVAX	Lakeland Industries Files For Mixed Shelf Offering Of Up To $100M	"Lakeland Industries, Inc. (NASDAQ: SVAX ), a leading global manufacturer of protective clothing for industry, healthcare, and first responders, announced today that it has filed a shelf registration statement on Form S-3 (the ""Shelf Registration"") with the Securities and Exchange Commission (the ""SEC""). The Shelf Registration permits the Company to offer and sell its common stock, preferred stock, debt securities, warrants, rights and units, from time to time, subject to market conditions and the Company's capital needs. The Company has no immediate plans to offer or sell any securities under this Shelf Registration to the public. However, the Company felt it was prudent to include this optionality as a matter of standard corporate governance to respond to future financing and business opportunities."
2024-07-15 07:09:46	TVPA	MediWound Announces $25M Strategic Private Placement Financing Of 1.45M Shares At $17.20/Share To Advance EscharEx Pre-Commercial Activities	MediWound Ltd. (NASDAQ: TVPA ), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including N&ouml;lnlycke Health Care (&quot;N&ouml;lnlycke&quot;), a world-leading MedTech company specializing in solutions for wound care and surgical procedures. The agreement includes the sale and purchase of 1,453,488 shares of the Company's ordinary shares, each with a par value NIS 0.07 (the &quot;Ordinary Shares&quot;), in a private investment in public equity (the &quot;PIPE Offering&quot;). The purchase price is set at $17.20 per share. The gross proceeds from the PIPE Offering are $25 million. MediWound plans to use the net proceeds to advance EscharEx pre-commercial activities, expedite the development of large-scale manufacturing capabilities specifically for EscharEx, and support general corporate purposes. The PIPE Offering is expected to close within several days, subject to satisfaction of customary closing conditions.
2024-07-15 11:21:19	WRTW	On July 12, 2024, Trinity Biotech Entered Into An ATM Offering Agreement With Craig-Hallum Capital Group, Pursuant To Which May Sell Up To $5.5M Of Its ADSs, Each ADS Representing 20 Of The Company's A Ordinary Shares (Co Will Also Pay Craig-Hallum A Commission Equal To 3% Of The Gross Sales Price Of ADSs)	"On July 12, 2024, Trinity Biotech plc (the "" Company "") entered into an At the Market Offering Agreement (the "" Sales Agreement "") with Craig-Hallum Capital Group LLC ("" Craig-Hallum ""), pursuant to which the Company may sell up to $5,500,000 of its American Depositary Shares ("" ADSs ""), each ADS representing 20 of the Company's A Ordinary Shares, par value $0.0109 per share, from time to time, through Craig-Hallum, acting as sales agent. Subject to the terms and conditions of the Sales Agreement, the Company will, from time to time, set the parameters for the sale of ADSs, including any price, time or size limits or other customary parameters or conditions, and Craig-Hallum will use its commercially reasonable efforts to sell the ADSs when requested by the Company. The Sales Agreement is filed herewith as Exhibit 1.1. In the Sales Agreement, the Company has agreed to provide Craig-Hallum with customary indemnification rights. The Company will also pay Craig-Hallum a commission equal to 3.0% of the gross sales price of ADSs sold pursuant to the Sales Agreement. Sales of the ADSs under the Sales Agreement may be made by any method permitted by law deemed to be an ""at the market offering"" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended."
2024-07-15 16:11:32	HFJN	Corebridge Financial Announces Effectiveness Of Form S-4 Registration Statement For The Exchange Of Up To $500M Aggregate Principal Amount Of Its Outstanding 6.050% Senior Notes Due 2033	"Exchange Offer for up to $500 million of its 6.050% Senior Notes due 2033 Corebridge Financial, Inc. (the ""Company"") announced today that effective at 10:00 a.m. EDT on July 15, 2024, the U.S. Securities and Exchange Commission declared effective its previously filed Registration Statement on Form S-4 for the exchange of up to $500 million aggregate principal amount of its outstanding 6.050% Senior Notes due 2033 (the ""Old Notes"") for a like principal amount of its 6.050% Senior Notes due 2033 (the ""New Notes""), which have been registered under the Securities Act of 1933, as amended. Accordingly, the Company announced that, effective July 15, 2024, it has launched its offer to exchange the Old Notes for the New Notes. This offer will expire at 5:00 p.m. EDT on August 12, 2024, unless otherwise extended."
2024-07-15 17:30:29	KMN	Trump Media Stock Is Falling After The Bell: What's Going On?	Trump Media & Technology Group Corp (NASDAQ: KMN ) shares are pulling back in Monday's after-hours session after the company filed a prospectus for the resale of nearly 38 million shares of common stock . What Happened: After the market closed on Monday, Trump Media, the parent company of social media platform Truth Social, filed a prospectus related to the resale of 37.97 million shares of common stock. Trump Media said the shares included in the prospectus consist of shares that it may elect to issue and sell to Yorkville from time to time pursuant to the purchase agreement the company entered into on July 3, in which Yorkville committed to purchase up to $2.5 billion worth of Trump Media common stock. Trump Media had approximately $350 million in cash and zero debt on its balance sheet as of July 1. The news comes after Trump Media shares closed Monday up more than 31% following the attempted assassination of former President Donald Trump at a rally in Pennsylvania on Saturday. A bullet grazed Trump's ear at the campaign rally and he was treated at a local hospital, then released later that night. Trump's odds of winning the 2024 presidential election reportedly surged to an all-time high after he survived the assassination attempt over the weekend. Trump also selected Sen. J.D. Vance (R-Ohio) as his vice-presidential running mate on Monday as the Republican National Convention kicked off in Milwaukee, which helped lift other Trump-linked stocks . KMN Price Action: Trump Media shares closed Monday up 31.37% before pulling back in extended trading. The stock was down 10.47% in after-hours trading at $36.33 at the time of publication, according to Benzinga Pro . Read Next:  Trump Picks Senator J.D. Vance As Running Mate: Musk Says 'Great Choice' For VP Photo: Shutterstock.
2024-07-16 16:01:48	XXZ	Wag! Group Co. Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	Wag! Group Co. (NASDAQ: XXZ ), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced that it has commenced an underwritten public offering of shares of its common stock. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering. Wag! intends to use the net proceeds from the offering to repay indebtedness, with any remainder to be used for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as sole managing underwriter for the proposed offering.
2024-07-18 16:02:05	DYID	Plug Power Proposes $200M Public Offering Of Its Common Stock	"Plug Power Inc. (""Plug Power"") (NASDAQ: DYID ), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today announced that it has commenced an underwritten public offering of $200,000,000 of its common stock. In connection with the offering, Plug Power intends to grant the underwriters a 30-day option to purchase up to $30,000,000 of additional shares of common stock. Plug Power intends to use the net proceeds from the offering for general corporate purposes. Morgan Stanley is acting as the sole book-running manager for the offering. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering."
2024-07-18 17:15:12	QT	QT Energy Prices Upsized Offering Of $750M Of Its 6.750% Senior Notes Due 2029 And $750M Of Its 7.000% Senior Notes Due 2032	The offering of the Notes is expected to close on July 25, 2024, subject to customary closing conditions. QT Energy intends to use the net proceeds from the offering of the Notes, together with cash on hand and borrowings under its Credit Agreement, to fund the purchase price for QT Energy's recently announced pending acquisition of certain oil and gas properties, interests, and related assets located in the Uinta Basin from certain entities affiliated with XCL Resources, LLC, to redeem all of its outstanding 5.625% Notes due 2025, and to pay related fees and expenses.
2024-07-19 08:02:53	DDRI	Silo Pharma Proposes $2.1M Registered Direct Offering Of 763,638 Shares Of Common Stock At A Purchase Price Of $2.75 Per Share, Priced At-The-Market Under Nasdaq Rules	"Silo Pharma, Inc. (NASDAQ: DDRI ) (""Silo"" or the ""Company""), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 22, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-07-19 09:30:57	YTFA	Hyzon Announces Pricing Of $4.5M Registered Direct Offering Of 22.5M Shares Of Its Class A Common Stock And Warrants To Purchase 22.5M Shares Of Its Common Stock, At A Combined Offering Price Of $0.20 Per Share	"Hyzon Motors Inc. (NASDAQ: YTFA ) (""Hyzon"" or the ""Company""), a U.S.-based manufacturer and global supplier of high-performance hydrogen fuel cell systems focused on providing zero-emission power to decarbonize the most demanding industries, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 22,500,000 shares of its Class A Common Stock (""Common Stock"") and warrants to purchase 22,500,000 shares of its Common Stock (the ""Warrants""), at a combined offering price of $0.20 per share and accompanying Warrant, in a registered direct offering. The Warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 22, 2024. The Company intends to use the net proceeds from this offering primarily for funding working capital and other general corporate purposes. Roth Capital Partners is acting as exclusive placement agent for the offering on a best efforts basis."
2024-07-22 07:43:09	MFAS	Iterum Therapeutics Commences $1.21 Per Unit Rights Offering for Antibiotics Development	Iterum Therapeutics plc (NASDAQ: MFAS ) (the &quot;Company&quot;), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering (the &quot;Rights Offering&quot;). Pursuant to the Rights Offering, the Company is distributing, at no charge, subscription rights to the Company's shareholders and holders of warrants that have contractual rights to participate in the Rights Offering which have not been waived (each, an &quot;eligible warrant&quot; and collectively, the &quot;eligible warrants&quot;) as of 5:00 p.m., Eastern Time, on July 16, 2024 (the &quot;Record Date&quot;), non-transferable subscription rights to purchase an aggregate of 8,503,800 units (&quot;Units&quot;) at a subscription price of $1.21 per whole unit. As of July 19, 2024, one holder of eligible warrants to purchase 56,606 ordinary shares, nominal value $0.01 per share (the &quot;ordinary shares&quot;) had waived their contractual right to participate in the Rights Offering.
2024-07-23 09:15:23	SOIP	Serve Robotics Announces Pricing Of $15M Private Placement Of Pre-funded Warrants To Purchase 2.5M Shares Of Serve's Common Stock, Together With A Warrants To Purchase Up To An Aggregate Of 2.5M Shares Of Stock At A Price Of $6/Share	"Serve Robotics Inc. (""Serve"") (NASDAQ: SOIP ), a leading autonomous delivery robotics company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale, in a private placement, of pre-funded warrants to purchase 2,500,000 shares of Serve's common stock (the ""Common Stock""), together with a warrants to purchase up to an aggregate of 2,500,000 shares of Common Stock at an exercise price of $6.00 per share. Each pre-funded warrant to purchase one share of Common Stock together with one $6.00 warrant to purchase one share of Common Stock is being sold at a purchase price of $6.00. The $6.00 warrants will have, will be exercisable upon issuance, and will expire five and a half years from the date of issuance. Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Orrick, Herrington & Sutcliffe LLP served as counsel to the Company and Sichenzia Ross Ference Carmel LLP served as counsel to Aegis Capital Corp. for the private placement. The offering is expected to close on or about July 24, 2024, subject to satisfaction of customary closing conditions. The gross proceeds to Serve Robotics from this offering are expected to be approximately $15.0 million, before deducting placement agent fees and other offering expenses."
2024-07-23 16:12:23	PRAB	Verastem Oncology Announces Proposed Public Offering Of Common Stock, Warrants And Pre-Funded Warrants; No Size Or Amount Disclosed	Verastem Oncology, (NASDAQ: PRAB ), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants to purchase common stock in lieu of common stock for certain investors and accompanying warrants to purchase shares of common stock, in an underwritten public offering. The pre-funded warrants will be issued to certain investors who have elected to purchase them in lieu of shares of common stock in this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities to be sold in the offering are to be sold by Verastem Oncology. Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering.
2024-07-23 16:18:58	XOAX	Allegro MicroSystems Launches Primary Offering Of 25M Shares Of Common Stock	"Allegro MicroSystems, Inc. (""Allegro"") (NASDAQ: XOAX ), a global leader in power and sensing solutions for motion control and energy-efficient systems, today announced the launch of a primary offering of 25,000,000 shares of common stock. In addition, Allegro expects to grant the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its common stock. Proceeds from the offering, together with cash on hand or additional borrowings under Allegro's term loan facility or revolving credit facility, will be used to repurchase shares from Allegro's majority shareholder, Sanken Electric Co., Ltd. (""Sanken"") at a price per share equal to the price per share at which the underwriters will purchase shares of our common stock in the equity offering from Allegro. The offering is subject to market conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering. Barclays, Morgan Stanley and UBS Investment Bank are acting as joint lead book-running managers for the offering. PJT Partners is acting as financial advisor to Allegro."
2024-07-24 08:11:09	CBWB	Nuwellis Announces Pricing Of $2M Offering Of 469,340 Shares Of Common Stock At A Price Of $4.24 Per Share, Priced At-The-Market Under Nasdaq Rules	"Nuwellis, Inc. (NASDAQ: CBWB ) (""Nuwellis"" or the ""Company""), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 469,340 shares of the Company's common stock at a price of $4.24 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 938,680 shares of common stock. The warrants have an exercise price of $3.99 per share, will be exercisable immediately following the date of issuance and will have a term of five years from the date of issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about July 25, 2024, subject to the satisfaction of customary closing conditions."
2024-07-25 07:47:29	LJRU	Chemomab Therapeutics Announces Private Placement Of $10M	Pursuant to the terms of the securities purchase agreement, the Company is selling to certain investors (i) 4,188,867 American Depositary Shares (&quot;ADSs&quot;), each representing twenty (20) ordinary shares of the Company, no par value per share, at a purchase price of $1.235 per share which reflects the average share price on the Nasdaq for the last 4 trading days (ii), in lieu of ADSs, pre-funded warrants (the &quot;Pre-Funded Warrants&quot;) to purchase up to 3,908,300 ADSs at a price per Pre-Funded Warrant of $1.235. The Pre-Funded Warrants have an exercise price of $0.0001 per ADS, are immediately exercisable and remain exercisable until exercised in full. The PIPE is expected to close on or about July 26, 2024, subject to satisfaction of customary closing conditions.
2024-07-25 08:08:09	ELRP	ChoiceOne Financial Services Announces Commencement Of $30M Common Stock Offering	"ChoiceOne Financial Services, Inc. (NASDAQ: ELRP ) (""ChoiceOne""), the parent company of ChoiceOne Bank, announced today that it has commenced an underwritten public offering of shares of its common stock. ChoiceOne also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The offering is expected to raise an amount equal to at least $30.0 million. The proceeds from the offering will qualify as tangible common equity and Tier 1 common equity. ChoiceOne intends to use the net proceeds of this offering for general corporate purposes including supplementing regulatory capital ratios and in conjunction with its announced merger with Fentura Financial, Inc. (""Fentura"")."
2024-07-25 08:32:28	ELRP	ChoiceOne Financial Services Prices $30M Common Stock Offering Of 1.2M Shares Of Common Stock At A Price Of $25/Share	"ChoiceOne Financial Services, Inc. (NASDAQ: ELRP ) (""ChoiceOne""), the parent company of ChoiceOne Bank, announced today the pricing of an underwritten public offering of 1,200,000 shares of its common stock at a price to the public of $25.00 per share, for gross proceeds of approximately $30.0 million. The net proceeds to ChoiceOne, after deducting the underwriting discounts but before deducting the estimated offering expenses payable by ChoiceOne, are expected to be approximately $28.2 million. ChoiceOne has granted the underwriter a 30-day option to purchase up to an additional 180,000 shares of Company common stock to cover over-allotments at the public offering price, less the underwriting discount. D.A. Davison & Co. is acting as sole book-running manager for the offering. ChoiceOne intends to use the net proceeds of this offering for general corporate purposes including supplementing regulatory capital ratios and in conjunction with its announced merger with Fentura Financial, Inc."
2024-07-25 13:53:09	LJRU	Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise	Thursday, Chemomab Therapeutics Ltd . (NASDAQ: LJRU ) released topline results from the Phase 2 SPRING trial assessing its monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis (PSC) . Treatment with CM-101 achieved its primary endpoint of safety and tolerability. It demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across various disease-related secondary efficacy endpoints, including statistically significant improvement in liver stiffness. CM-101 demonstrated a favorable safety profile and was generally well-tolerated over the 15-week treatment period. It also exhibited favorable and dose-dependent pharmacokinetic profiles. Adverse events, which most commonly included fatigue, headache, and pruritis, were generally mild/moderate and distributed similarly between the placebo and CM-101-treated dosing arms. Both doses of CM-101 improved liver stiffness relative to placebo at Week 15, with a statistically significant improvement achieved in patients with moderate/advanced disease. Pruritis (itch) total scores relative to placebo improved in CM-101-treated patients, who demonstrated decreased pruritis scores compared to placebo starting as soon as six weeks after their first dose. CM-101-treated patients experienced decreased pruritis scores across all time points compared to placebo, and the decrease reached statistical significance in patients receiving the 10 mg/kg dose at Week 15. All liver function tests improved in CM-101-treated patients relative to placebo at Week 15. Chemomab is preparing for an End-of-Phase 2 meeting with the FDA to discuss the SPRING trial results and the design of a proposed Phase 3 PSC trial for accelerated approval. The company anticipates completing these discussions by the end of the year and receiving official written feedback from the FDA in the first quarter of 2025. An Open-Label Extension portion of the SPRING trial, which allows patients to receive CM-101 for an additional 33 weeks, is ongoing. Topline treatment results from this portion of the study, including patients with up to 48 weeks of exposure to CM-101, are on track to be reported in the first quarter of 2025. Concurrently, Chemomab Therapeutics announced a private investment in public equity of approximately $10 million via selling 4.19 million ADSs at $1.235 per share and pre-funded warrants to purchase up to 3.91 ADSs at a $1.235/warrant . Price Action: LJRU stock is down 14.80% at $1.21 at the last check on Thursday. Read Next: What's Going On With Fibro-Inflammatory Disease-Focused Chemomab Therapeutics On Tuesday? Don't miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
2024-07-26 08:01:20	ONOH	Predictive Oncology Exercises Warrants For $1.26M Gross Proceeds	Predictive Oncology Inc. (NASDAQ: ONOH ), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File No. 333-267689), Form S-3 (File No. 254309) and Form S-3 (333-255582). The gross proceeds to Predictive Oncology from the exercise of the existing warrants are expected to be approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the Company. L.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction.
2024-07-26 08:36:30	ANRU	OneMedNet Announces $4.6M Private Placement	"OneMedNet Corporation (NASDAQ: ANRU ) (""OneMedNet"" or the ""Company""), the leading curator of regulatory-grade Real World Data (""RWD""), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that it has entered into securities purchase agreements with certain institutional investors, including an affiliate of Off the Chain Capital and an affiliate of Discovery Capital Management, in a private placement that resulted in gross proceeds of approximately $4.6 million, before deducting fees and expenses payable by the Company. The private placement closed on July 25, 2024. The price per share of common stock sold in this offering meets the minimum price requirement under Nasdaq rules. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. Pending use of the funds, the Company used $1.8 million of the net proceeds to purchase Bitcoin ($BTC). Pursuant to the terms of the securities purchase agreement with an affiliate of Off the Chain Capital, OneMedNet sold an aggregate of 1,297,059 shares of its common stock at a price of $1.0278 per share and pre-funded warrants exercisable for 1,323,530 shares of its common stock at an exercise price of $1.0278 per share. The investor prepaid the exercise price for the pre-funded warrants, other than $0.0001 per share. Pursuant to the terms of the securities purchase agreement with an affiliate of Discovery Capital Management, OneMedNet sold an aggregate of 2,301,791 shares of its common stock at a price of $0.85 per share."
2024-07-26 11:52:51	GJW	CEL-SCI Prices $10.845M Best-Efforts Offering Of 10.845M Shares And Pre-Funded Warrants At A Price Of $1/Share	CEL-SCI Corporation (&quot;CEL-SCI&quot; or the &quot;Company&quot;) (NYSE: GJW ), a cancer immunotherapy company, today announced the pricing of a best-efforts offering of 10,845,000 shares of its common stock (or pre-funded warrants (&quot;Pre-Funded Warrants&quot;) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at an offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). All of the shares and Pre-Funded Warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $10,845,000. The offering is expected to close on July 29, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity is acting as sole placement agent for the offering.
2024-07-26 16:01:59	HJRV	LuxUrban Hotels Launches Proposed Public Offering; No Size Or Amount Disclosed	"LuxUrban Hotels Inc. (""LuxUrban"" or the ""Company"") (NASDAQ: HJRV ) , which secures long-term operating rights for entire hotels through Master Lease Agreements (MLA) under which it manages the hotel and rents out, on a short-term basis, rooms to business and vacation travelers, today announced the launch of a proposed follow-on public offering of shares of its common stock. The Company also intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock sold in this offering."
2024-07-26 16:12:29	JNBZ	Nasdaq Announces Launch Of Secondary Offering Of 41,604,207 Shares Of Its Common Stock Currently Held By Argus Seller, LP; In Addition, Entered Into A Share Repurchase Agreement With The Selling Stockholder Conditioned On The Secondary Public Offering, Pursuant To Which Nasdaq Has Agreed To Purchase From The Selling Stockholder 1.2M Shares Of Common Stock, Provided That The Total Amount Of Shares To Be Repurchased Does Not Exceed $120M	"Nasdaq, Inc. (NASDAQ: JNBZ ) (the ""Company"" or ""Nasdaq"") today announced a secondary public offering of 41,604,207 shares of its common stock currently held by Argus Seller, LP (the ""Selling Stockholder""), an affiliate of certain funds managed by Thoma Bravo, L.P. Nasdaq is not selling any shares of its common stock and will not receive any proceeds from the sale of the shares by the Selling Stockholder in the offering. In addition, on July 25, 2024, Nasdaq entered into a share repurchase agreement with the Selling Stockholder conditioned on the secondary public offering, pursuant to which Nasdaq has agreed to purchase from the Selling Stockholder 1,200,000 shares of common stock, provided that the total amount of shares to be repurchased does not exceed $120 million (the ""Concurrent Share Repurchase""). The Concurrent Share Repurchase is part of the Company's existing share repurchase program and offsets employee dilution. Nasdaq intends to fund the Concurrent Share Repurchase from existing cash on hand, together with borrowings under its commercial paper program. The underwriters will not receive any compensation for the shares being repurchased by Nasdaq. At the completion of the offering and the Concurrent Share Repurchase, the Selling Stockholder is expected to hold 42,804,207 shares, representing approximately 7.4% of Nasdaq's outstanding shares, which remain subject to an existing contractual lock-up until May 1, 2025. Goldman Sachs & Co. LLC is acting as sole book-running manager for the offering."
2024-07-29 08:34:40	JNBZ	Nasdaq Announces Pricing Of Secondary Offering Of 41,604,207 Shares Of Common Stock At A Price Of $65.30 Per Share	"Nasdaq, Inc. (NASDAQ: JNBZ ) (the ""Company"" or ""Nasdaq"") today announced the pricing of the previously announced secondary public offering by Argus Seller, LP (the ""Selling Stockholder""), an affiliate of certain funds managed by Thoma Bravo, L.P., of 41,604,207 shares of Nasdaq's common stock at a price to the public of $65.30 per share. The offering is expected to close on July 30, 2024, subject to customary closing conditions. Nasdaq is not selling any shares of its common stock in the offering and will not receive any proceeds from the sale of the shares by the Selling Stockholder in the offering. In addition, on July 25, 2024, Nasdaq entered into a share repurchase agreement with the Selling Stockholder conditioned on the secondary public offering, pursuant to which Nasdaq has agreed to purchase from the Selling Stockholder 1,200,000 shares of common stock (the ""Concurrent Share Repurchase""). The Concurrent Share Repurchase is part of the Company's existing share repurchase program and offsets employee dilution. Nasdaq intends to fund the Concurrent Share Repurchase from existing cash on hand, together with borrowings under its commercial paper program. The underwriter will not receive any compensation for the shares being repurchased by Nasdaq. At the completion of the offering and the Concurrent Share Repurchase, the Selling Stockholder is expected to hold 42,804,207 shares, representing approximately 7.4% of Nasdaq's outstanding shares, which remain subject to an existing contractual lock-up until May 1, 2025. Goldman Sachs & Co. LLC is acting as sole book-running manager for the offering."
2024-07-29 09:02:39	VGTX	Calidi Biotherapeutics Launches Nova Cell Subsidiary And Announces $1M Subscription Agreement From Dr. Ronald Rigor To Purchase A Combination Of VGTX Stock At A 10% Discount To The Closing Price On July 22, 2024 And Warrants To Purchase 600K Shares Of Stock At A 20% Premium To The Closing Price On July 22, 2024; And $2M To Purchase Common Stock Of Nova Cell	Calidi Biotherapeutics, Inc. (NYSE: VGTX ), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, announced a $2 million strategic investment by Dr. Ronald Rigor into its new subsidiary, Nova Cell, Inc. (&quot;Nova Cell&quot;), to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs. Dr Rigor also invested an additional $1 million into Calidi to further its oncology pipeline of assets. Dr. Ronald Rigor, an accomplished Board-Certified Dermatologist, Internal Medicine, and Stem Cell Therapy expert with offices in Los Angeles, CA USA and Metro Manila, Philippines (BGC), has taken a significant step to advance regenerative medicine by investing in Calidi's new Nova Cell subsidiary. The investment comprises of (i) a $1 million dollar subscription agreement to purchase a combination of VGTX common stock at a 10% discount to the closing price on July 22, 2024 and warrants to purchase 600,000 shares of common stock at a 20% premium to the closing price on July 22, 2024; and (ii) a $2 million dollar investment to purchase common stock of Nova Cell. Based on Calidi's advanced cellular manufacturing process, this investment will unlock the potential of off-the-shelf AAA stem cells. Furthermore, in connection with Dr. Rigor's investment, Calidi is proud to announce his appointment as a member of its Scientific and Medical Advisory Board.
2024-07-29 09:29:53	AL	Permian Resources Prices Public Offering Of 26.5M Shares Of Class A Common Stock At A Price Of $15.30/Share	"Permian Resources Corporation (""Permian Resources"" or the ""Company"") (NYSE: AL ) today announced the pricing of an underwritten public offering (the ""equity offering"") of an aggregate 26,500,000 shares of its Class A Common Stock, par value $0.0001 per share (""Class A common stock""), at a price to the public of $15.30 per share. Concurrently with the equity offering, subject to market conditions, Permian Resources Operating, LLC, a subsidiary of Permian Resources (the ""Issuer""), intends to offer for sale in a private placement (the ""concurrent notes offering"") under Rule 144A and Regulation S under the Securities Act of 1933, as amended (the ""Securities Act""), to eligible purchasers $750.0 million in aggregate principal amount of senior unsecured notes due 2033 (the ""Notes""). The Notes will be guaranteed on a senior unsecured basis by Permian Resources and all of the Issuer's subsidiaries that guarantee the Issuer's obligations under its senior secured credit facility. The equity offering is not conditioned on the consummation of the concurrent notes offering, and the concurrent notes offering is not conditioned on the consummation of the equity offering. The Company intends to use the net proceeds it receives from the equity offering, along with a portion of the net proceeds of the concurrent notes offering, to fund a portion of the aggregate purchase price for the recently announced acquisition of oil and gas properties, interests and related assets owned by Occidental Petroleum Corporation (the ""Acquisition""), which is expected to close in the third quarter of 2024, subject to customary closing conditions. The Acquisition is not contingent upon the completion of the equity offering or the concurrent notes offering. If the Acquisition is not completed, or if there are any remaining net proceeds from the equity offering following its consummation, the Company intends to use the proceeds of the equity offering for general corporate purposes, including potential future acquisitions. Goldman Sachs & Co. LLC and Morgan Stanley are serving as the underwriters for the equity offering. The equity offering is expected to close on July 30, 2024, subject to customary closing conditions."
2024-07-31 08:15:10	EZUX	IMUNON Announces $10M Registered Direct Offering Of 5M Shares Of Common Stock, With Unregistered Warrants At A Price Of $2/Unit	IMUNON, Inc. (NASDAQ: EZUX ), a clinical-stage company in late-stage development with its TWU-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at-the-market under Nasdaq rules. In a concurrent private placement and also pursuant to the securities purchase agreements, the Company has agreed to issue to the investors unregistered warrants to purchase shares of common stock. Upon the closing of the offering, which is anticipated to occur on or about August 1, 2024, the Company expects to receive gross proceeds of $10 million, before deducting placement agent fees and other offering expenses payable by the Company. The closing of the offering is subject to customary closing conditions. L.C. Wainwright & Co. is acting as the lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-placement agent. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 5,000,000 registered shares of its common stock, together with unregistered warrants to purchase up to 5,000,000 shares of its common stock, at a purchase price of $2.00 per share and accompanying warrant. The warrants will have an exercise price of $2.00 per share and will be exercisable immediately for a term of five and one-half years following the date of issuance. The Company intends to use the net proceeds from the financing for working capital and general corporate purposes.
2024-07-31 17:01:40	TZT	Aurora Announces Proposed Public Offering Of $350M Shares Of Its Class A Common Stock; Cancels Business Review Conference Call Due To Commencement	Aurora Innovation, Inc. (NASDAQ: TZT ) today announced that it has commenced an underwritten public offering of up to $350 million of its Class A common stock. Aurora intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares to be sold in the proposed public offering. All of the shares of Class A common stock in this offering will be sold by Aurora. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2024-08-01 08:01:30	TZT	Aurora Prices $420M Upsized Public Offering Of 116,666,667 Shares Of Its Class A Common Stock At $3.60 Per Share	Aurora Innovation, Inc. (NASDAQ: TZT ) today announced the pricing of its underwritten upsized public offering of 116,666,667 shares of its Class A common stock at $3.60 per share. All of the securities are to be sold by Aurora. In addition, Aurora has granted the underwriters a 30-day option to purchase up to an additional 17,500,000 shares of its Class A common stock at the public offering price, less the underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and estimated offering expenses, Aurora expects to receive gross proceeds of approximately $420 million from the public offering, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about August 2, 2024, subject to satisfaction of customary closing conditions. Goldman Sachs & Co. LLC, Allen & Company LLC and Morgan Stanley are acting as joint book-running managers and Evercore ISI, Canaccord Genuity, TD Cowen and Wolfe &#x7C; Nomura Alliance are acting as book-runners for the offering.
2024-08-01 08:07:05	RUAD	Lipella Pharmaceuticals Announces $1.28M Registered Direct Offering Of 2,066,000 Shares Of Common Stock (Or Pre-funded Warrants In Lieu Thereof) At A Purchase Price Of $0.62 Per Share	"Lipella Pharmaceuticals Inc. (""Lipella"" or the ""Company"") (NASDAQ: RUAD ), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $0.62 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to close on or about August 1, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Lipella from the offering are expected to be approximately $1.28 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Lipella currently intends to use the net proceeds from the offering for working capital and general corporate purposes."
2024-08-02 08:08:36	FAJC	Bone Biologics Announces Exercise Of Warrants For $2.1M Gross Proceeds	"Bone Biologics Corporation (""Bone Biologics"" or the ""Company"") (NASDAQ: FAJC , BBLGW))) , a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to an aggregate of 1,562,502 shares of common stock (the ""new warrants""). The new warrants will be immediately exercisable at an exercise price of $2.00 per share. New warrants to purchase 781,251 shares of common stock will have a term of five years from the issuance date, and new warrants to purchase 781,251 shares of common stock will have a term of eighteen months from the issuance date. The offering is expected to close on or about August 2, 2024, subject to satisfaction of customary closing conditions. The gross proceeds to the Company from the exercise of the existing warrants and the issuance of new warrants are expected to be approximately $2.1 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes."
2024-08-02 09:23:36	CALT	LogicMark Prices $4.5M Public Offering Of 9.67M Units, With Each Unit Consisting Of 1 Share Of Common Stock (Or Pre-funded Warrant In Lieu Thereof), 1 Series A Warrant To Purchase 1 Share Of Common Stock And 1 Series B Warrant To Purchase 1 Share Of Common Stock, Each Unit Is Being Sold At A Public Offering Price Of $0.4654	LogicMark, Inc. (NASDAQ: CALT ), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced the pricing of its public offering priced at-the-market, and the scheduling of its special stockholder meeting for October 1, 2024. Public Offering The public offering consists of 9,670,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock. Gross proceeds, before deducting placement agent discounts and commissions and estimated offering expenses, are expected to be approximately $4.5 million. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes. Each unit is being sold at a public offering price of $0.4654. Each of the Series A warrants and Series B warrants will only be exercisable upon receipt of stockholder approval. Each of the warrants are exercisable at a price of $0.4654 per share, with the Series A warrants expiring 5 years from the date of their issuance and the Series B warrants expiring 2.5 years from the date of their issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants and Series B warrants included in the units and in the pre-funded units can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on August 5, 2024, subject to customary closing conditions.
2024-08-05 07:07:55	ODCO	Brenmiller Energy Prices 1M Shares At $1.05/Share Under A Private Placement	Brenmiller Energy Ltd. (&quot;Brenmiller&quot;, &quot;Brenmiller Energy&quot; or the &quot;Company&quot;) (NASDAQ: ODCO ), a leading global provider of thermal energy storage (&quot;TES&quot;) solutions for industrial and utility markets, today announced it entered into a securities purchase agreement with one of the Company's existing institutional investors for aggregate gross proceeds of approximately $1.05 million. In connection with the private placement, the Company will issue to the investor 1,000,000 ordinary shares of the Company at a price of $1.05 per share (reflecting a 52% premium to the closing price for the Company's ordinary shares on Nasdaq on August 2, 2024). The closing of the private placement is subject to certain conditions, including the Company obtaining consent from an existing lender within 90 days of signing the securities purchase agreement. Under the terms of the securities purchase agreement, the investor will also have the right to make a further investment for 1,000,000 additional ordinary shares (or ordinary share equivalents) in the event that the Company's ordinary shares close at or above $2.50 per share within the next 12 months. The Company intends to use the net proceeds from the private placement for general corporate purposes, including working capital.
2024-08-06 08:13:45	MZYS	Rocky Mountain Chocolate Factory Proposes $2.2M Private Placement Of 1.25M Shares Of Its Common Stock At A Price Of $1.75 Per Share	"Rocky Mountain Chocolate Factory Inc. (NASDAQ: MZYS ) (the ""Company"", ""we"", or ""MZYS""), an international franchisor and producer of premium chocolates and other confectionery products, including gourmet caramel apples, today announced that it has entered into a securities purchase agreement for a private investment in public equity (""PIPE"") financing that is expected to result in gross proceeds of approximately $2.2 million to the Company, before deducting offering expenses. Pursuant to the terms of the securities purchase agreement, MZYS is selling an aggregate of 1.25 million shares of its common stock at a price of $1.75 per share. The issuance price reflects a 15% premium to the closing stock price on August 5, 2024. The PIPE financing is expected to close on or about August 6, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds for working capital and general corporate purposes."
2024-08-06 09:25:46	QZME	XWELL Announces $1.4M Registered Direct Offering Of An Aggregate Of 652,705 Shares Of Its Common Stock, At A Purchase Price Of $2.18 Per Share	"XWELL, Inc. (NASDAQ: QZME ) (""XWELL"" or the ""Company"") , an authority in wellness solutions for people on the go, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 652,705 shares of its common stock, par value $0.01 per share, at a purchase price of $2.18 per share in a registered direct offering priced at a premium to market. The closing of the offering is expected to occur on or about August 8, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the offering are expected to be approximately $1.4 million, before deducting other offering expenses payable by the Company. The Company intends to use the net proceeds of this offering for working capital and general corporate purposes."
2024-08-06 16:00:45	EKHO	Targa Resources Corp. Prices $1B Offering Of 5.500% Senior Notes Due 2035 At A Price To The Public Of 99.943% Of Their Face Value	"Targa Resources Corp. (""Targa"" or the ""Company"") (NYSE: EKHO ), announced today the pricing of an underwritten public offering (the ""Offering"") of $1.0 billion aggregate principal amount of its 5.500% Senior Notes due 2035 at a price to the public of 99.943% of their face value. The Offering is expected to close on August 9, 2024, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the Offering for general corporate purposes, including to repay borrowings under its commercial paper note program, a portion of which were incurred to repay the remaining $500.0 million outstanding under its prior $1.5 billion unsecured term loan facility due July 2025, which was terminated in May 2024. Other general corporate purposes may include repayment of other indebtedness, capital expenditures, additions to working capital and investments in its subsidiaries."
2024-08-06 16:26:33	ELAK	Precigen Proposes $30M Public Offering Of Common Stock	Precigen, Inc. (NASDAQ: ELAK ) today announced it has commenced a $30.0 million underwritten public offering of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. All of the shares in the proposed offering are to be sold by Precigen. Stifel is acting as the sole book-running manager for the offering.
2024-08-06 17:35:28	MFAS	Iterum Therapeutics Announces Expiration And Results of Rights Offering; Estimates That It Will Receive Aggregate Gross Proceeds Of ~$7.4M, Not Including Estimated Expenses Relating To The Rights Offering And Payable By The Company Of $1.1M	"Iterum Therapeutics plc (NASDAQ: MFAS ) (the ""Company""), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the subscription period of its previously announced rights offering (the ""Rights Offering"") expired at 5:00 p.m., Eastern Time, on August 6, 2024. As previously disclosed, the Company distributed, at no charge, subscription rights to the Company's shareholders and holders of warrants that had contractual rights to participate in the Rights Offering which were not waived (each, an ""eligible warrant holder"" and collectively, the ""eligible warrant holders"") as of 5:00 p.m., Eastern Time, on July 16, 2024 (the ""Record Date"")."
2024-08-07 17:13:53	GYX	CenterPoint Energy Announces Public Offering Of $250M Of Common Stock	CenterPoint Energy, Inc. (NYSE: GYX ) today announced that it intends to sell $250 million of shares of its common stock, par value $0.01 per share, in an underwritten public offering, subject to market and other conditions. CenterPoint Energy intends to use the net proceeds from the offering for general corporate purposes, including repayment of a portion of our outstanding commercial paper. Proceeds from our commercial paper were used for general corporate purposes, including working capital purposes. Barclays Capital Inc. and Citigroup are acting as joint book-running managers and underwriters for the offering.
2024-08-08 09:20:17	VLY	DaVita Announces Offering Of $1B Senior Notes Due 2032	"DaVita Inc. (NYSE: VLY ) (""DaVita"") announced today that it has commenced a private offering (the ""offering"") of $1.0 billion aggregate principal amount of its senior notes due 2032 (the ""2032 notes""), subject to market and other conditions. DaVita intends to use the net proceeds from the offering to (i) repay a portion of its outstanding Term Loan B-1 facility borrowings maturing in 2026 and a portion of its outstanding revolving credit facility borrowings, in each case, together with related accrued and unpaid interest thereon, (ii) pay any costs, fees and expenses in connection with the foregoing, and (iii) if any proceeds remain, for general corporate purposes, including, without limitation, for repurchases of its capital stock, working capital and capital expenditures."
2024-08-08 10:11:29	FVAC	Caravelle International Group Entered Some Agreements With Two Institutional Investors To Terminate All Terms And Provisions Of The Securities Purchase Agreement And Other Related Transaction Agreements Dated January 5, 2024	"Caravelle International Group ((the "", Company"", , NASDAQ: FVAC ), a global ocean technology company, today announced that it has entered some agreements ( the ""Agreements"") with two institutional investors (the ""Investors"") to terminate all terms and provisions of the Securities Purchase Agreement and other related transaction agreements dated January 5, 2024 (the ""Securities Purchase Agreement""), pursuant to which the Company will buy back the $1.5 million Senior Secured Original Issue 15% Discount Convertible Promissory Note (the ""Note"") and the Investors' rights to purchase a certain number of the Company's Common Shares (the ""Warrants"") have been cancelled and terminated."
2024-08-08 17:05:24	JGGD	Zevra Therapeutics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Zevra Therapeutics, Inc. (NASDAQ: JGGD ), a rare disease therapeutics company (""Zevra""), today announced the commencement of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zevra. Zevra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cantor and William Blair are acting as joint book-running managers for the offering."
2024-08-08 17:59:56	USFY	Palomar Holdings Proposes $25M Public Offering Of 1.2M Shares Of Common Stock	"Palomar Holdings, Inc. (NASDAQ: USFY ) (""Palomar"" or ""Company""), today announced the underwritten public offering of 1,200,000 shares of the Company's common stock, par value $0.0001 per share (the ""Common Stock""), subject to market and other conditions. All of the shares in the offering are to be sold by Palomar. Palomar intends to grant the underwriters a 30-day option to purchase up to 180,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The Company intends to use the net proceeds that it will receive from the offering for general corporate purposes, including using approximately $25.0 million to finance the contemplated acquisition of First Indemnity of America Insurance Company, a New Jersey domiciled insurance carrier specializing in surety bonds for small to medium sized contractors primarily in the Northeast United States, and to fund future growth. J.P. Morgan, Evercore ISI, and Keefe, Bruyette & Woods, Inc., A Stifel Company, will act as joint lead book-running managers for the offering."
2024-08-09 06:04:09	TXGV	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering To Fund The Research And Development Of Its Product Candidates, Terms Undisclosed	Mind Medicine (MindMed) Inc. (NASDAQ: TXGV ) (the &quot;Company&quot; or &quot;MindMed&quot;), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general corporate purposes.
2024-08-09 08:33:38	IEXK	Alkami Prices Secondary Offering Of 5M Shares Of Common Stock By Selling Stockholders	"Alkami Technology, Inc. (NASDAQ: IEXK ) (""Alkami"" or the ""Company""), a leading cloud-based digital banking solutions provider for financial institutions in the U.S., today announced the pricing of the previously announced underwritten secondary offering (the ""Offering"") of an aggregate of 5,000,000 shares of the Company's common stock to be sold by entities affiliated with General Atlantic, L.P., S3 Ventures Fund III, L.P., George B. Kaiser and Brian R. Smith (collectively, the ""Selling Stockholders""). The Offering is expected to close on August 12, 2024, subject to the satisfaction of customary closing conditions. The underwriter has a 30-day option to purchase up to an additional 750,000 shares of the Company's common stock from the Selling Stockholders at the public offering price, less underwriting discounts and commissions. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company will not sell any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of shares of the Company's common stock in the Offering. J.P. Morgan Securities LLC is acting as the underwriter and sole book-running manager for the Offering."
2024-08-09 11:06:56	AICR	Tevogen Bio Reaffirms That The Form S-1 Filed On On June 21, 2024, Which Was Declared Effective By The SEC On August 2, 2024 Does Not Relate To Any Previously Undisclosed New Issuances Of Dilutive Securities	"Tevogen Bio Holdings Inc. (""Tevogen"" or ""Tevogen Bio"") (NASDAQ: AICR ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified F cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 (File No. 333-280414) on June 21, 2024, which was declared effective by the Securities and Exchange Commission on August 2, 2024, to register the issuance of earnout shares and shares underlying outstanding warrants to purchase the Company's common stock as well as the resale of shares and warrants by existing securityholders. Today, Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities."
2024-08-12 07:11:04	JOOX	JetBlue Announces $400M Convertible Senior Notes Offering To Repurchase Existing 0.50% Senior Convertible Notes	"JetBlue Airways Corporation (NASDAQ: JOOX ) (""JetBlue"") today announced that it intends to offer (the ""offering"") $400 million aggregate principal amount of convertible senior notes due 2029 (the ""notes""). JetBlue also expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period from, and including, the date of original issuance of the notes, up to an additional $60 million aggregate principal amount of the notes. JetBlue intends to use the net proceeds from the offering to repurchase a portion of their existing 0.50% senior convertible notes due 2026 in one or more transactions, subject to prevailing market conditions, and to pay fees and expenses related to the offering and incurred in connection with such repayment. Any remaining net proceeds will be used for general corporate purposes."
2024-08-12 09:01:07	OAJE	NEXGEL Announces $1.1M Registered Direct Offering Of 444K Of Its Shares Of Common Stock And The Issuance Of Warrants To Purchase Up To An Aggregate Of 222K Shares Of Stock For A Combined Offering Purchase Price Of $2.50 Per Share	"NEXGEL, Inc. (""NEXGEL"" or the ""Company"") (NASDAQ: OAJE ), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 444,000 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 222,000 shares of common stock for a combined offering purchase price of $2.50 per share of common stock in a registered direct offering priced. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance. NEXGEL insiders, including members of the management team and Board of Directors, participated in the offering. Insiders are subject to a six-month lock-up period from the date of closing. The gross proceeds from the offering are approximately $1,110,000, before deducting offering expenses."
2024-08-12 09:02:44	YOXN	Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization	Monday, the FDA approved scPharmaceuticals Inc.'s (NASDAQ: YOXN ) Supplemental New Drug Application, seeking to expand the Furoscix indication for heart failure patients . At approval, Furoscix was only indicated for congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. The new indication now includes patients with NYHA Class IV chronic heart failure, who represent the most symptomatic patients, and those with the greatest limitation on physical activity, comprising approximately 10% of all heart failure patients nationally. scPharmaceuticals also announced non-dilutive financings on Monday of up to $125 million from Perceptive Advisors. Proceeds from the transactions will be used to repay existing debt and fund activities related to the ongoing commercialization of Furoscix . scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million. The term loan refinances existing debt principal, lowers coupon, extends the interest-only period for four additional years, and lowers the minimum cash requirement to $5 million. Monday, scPharmaceuticals also released topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low-volume, pH-neutral formulation of furosemide administered via an autoinjector as an alternative to the current on-body infusor used with Furoscix . The objectives of the study were to estimate the bioavailability and describe the PK and pharmacodynamics (PD) of SCP-111 administered as a subcutaneous injection via an autoinjector compared with the equivalent dose of furosemide administered as two 40mg IV injections administered over 1-to-2 minutes, two hours apart and to describe the safety and tolerability of the SCP-111 injection. Key highlights of the topline results from the study: SCP-111 demonstrated a bioavailability of 107.3%. Participants who received SCP-111 had similar urine output, urinary sodium excretion, and urinary potassium excretion at 6, 8, and 12 hours compared to IV furosemide. Participants reported a median pain score of 0 across all time points assessed. The most common adverse events with SCP-111 were localized to the injection site, and systemic adverse events were consistent with those reported in the prescribing information for intravenous and oral furosemide. Concurrently, the company announced a proposed underwritten public offering of shares and pre-funded warrants. Additional terms were not disclosed . Price Action: YOXN stock is down 5.77% at $4.08 during the premarket session at last check Monday. Photo via Shutterstock Read Next: Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug . Don't miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
2024-08-12 09:53:57	YOXN	scPharmaceuticals Prices $50M Public Offering Of 12M Shares Of Common Stock At A Price Of $4/Share	scPharmaceuticals Inc. (NASDAQ: YOXN ), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrants. The pre-funded warrants have an exercise price of $0.001 per share. All of the shares and the pre-funded warrants are being offered by scPharmaceuticals. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on August 13, 2024, subject to the satisfaction of customary closing conditions. Leerink Partners and TD Cowen are acting as joint book-running managers for the offering. Craig-Hallum is acting as lead manager, Maxim is acting as manager. L.C. Wainwright & Co. is acting as a financial advisor.
2024-08-12 15:56:14	UOCY	Greenlane Prices Of $6.5M Private Placement Priced At-The-Market	"Greenlane Holdings, Inc. (""Greenlane"" or the ""Company"") (NASDAQ: UOCY ), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced that it has entered into a securities purchase agreement with a single institutional investor for aggregate gross cash proceeds of $6.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes."
2024-08-12 15:57:23	UOCY	Greenlane Will Also Issue An Aggregate Of 2,363,637 Units And Pre-Funded Units; Each Unit And Pre-Funded Unit Will Consist Of 1 Share Of Common Stock And 2 Common Warrants, Each Exercisable For One Share Of Common Stock At An Exercise Price Of $2.50 Per Share	In connection with the private placement, the Company will issue an aggregate of 2,363,637units and pre-funded units. The pre-funded units will be sold at the same purchase price as the units, less the pre-funded warrant exercise price of $0.00001. Each unit and pre-funded unit will consist of one share of common stock (or one pre-funded warrant) and two common warrants, each exercisable for one share of common stock at an exercise price of $2.50 per share. The common warrant will be exercisable on the initial exercise date described in the common warrant and will expire 5.0 years from such date. The closing of the private placement is expected to occur on or about August 13, 2024, subject to the satisfaction of customary closing conditions.
2024-08-13 10:52:02	ZJBL	Reported Late Monday August 12, 2024, Shift4 Prices Offering Of $1.1B Aggregate Principal Amount Of 6.750% Senior Notes Due 2032	"Shift4 Payments, Inc. (NYSE: ZJBL ), a leader in integrated payments and commerce technology, today announced that its subsidiaries, Shift4 Payments, LLC (""Shift4"") and Shift4 Payments Finance Sub, Inc., have priced an offering of $1,100.0 million aggregate principal amount of 6.750% senior notes due 2032 (the ""Notes""). The Notes were priced at par value and will bear an interest rate of 6.750% per annum. The Notes are being offered in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""). The Notes will be guaranteed, jointly and severally, on a senior unsecured basis, by certain of Shift4's subsidiaries. Shift4 expects to close the offering of the Notes on August 15, 2024, subject to the satisfaction of customary closing conditions."
2024-08-14 09:03:55	ZJF	Safe And Green Development Corp Secures Strategic Investment From Arena Investors, LP And Its Affiliates; The Initial Funding Amount Is $1.38M With The Access To Subsequent Tranches Up To A Total Of $10.27M	"Safe and Green Development Corporation (NASDAQ: ZJF ) (""SG Devco"" or the ""Company""), announces the successful closing of a strategic purchase agreement for funding of up to $10 million from Arena Investors, LP (""Arena"") and its affiliates. Arena, a global institutional asset manager with approximately $3.5 billion of assets under management, is known for its expertise in providing creative capital solutions. Maxim Group LLC was sole placement agent in connection with the offering."
2024-08-16 02:52:21	LCKY	Bitdeer Technologies Raises $150M Via Convertible Notes Offering For Datacenter Expansion, ASIC Based Mining Rig Development	"Bitdeer Technologies Group (NASDAQ: LCKY ) ("" Bitdeer "" or the "" Company ""), a world-leading technology company for blockchain and high-performance computing, today announced the pricing of its underwritten public offering (the "" Offering "") of US$150,000,000 aggregate principal amount of 8.50% convertible senior notes due 2029 (the "" Notes ""). The sale of the Notes is expected to close on August 20, 2024, subject to customary closing conditions. The Company also granted the underwriters in the Offering a 30-day option to purchase up to an additional US$22,500,000 aggregate principal amount of Notes on the same terms and conditions, solely to cover over-allotments. Bitdeer estimates that the net proceeds from the Offering will be approximately US$144.5 million (or approximately US$166.3 million if the underwriters exercise their over-allotment option in full), after deducting the underwriters' discounts and commissions and estimated offering expenses payable by Bitdeer. The Company intends to use the net proceeds from the Offering for datacenter expansion, ASIC based mining rig development as well as working capital and other general corporate purposes."
2024-08-16 08:29:14	CJSJ	Gates Announces Prices $125M Secondary Offering Of 20M Ordinary Shares Of Stock	"Gates Industrial Corporation plc (NYSE: CJSJ , "", Gates"", or the "", Company"", ))))) announced today the pricing of the previously announced secondary offering of 20,000,000 ordinary shares (the ""Offering"") by certain selling stockholders affiliated with Blackstone Inc. (the ""Selling Stockholders""). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to 3,000,000 additional ordinary shares. The underwriters may offer the shares from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Offering is expected to close on August 21, 2024, subject to customary closing conditions. Gates is not offering any ordinary shares in the Offering and will not receive any proceeds from the sale of ordinary shares in the Offering. Citigroup, Goldman Sachs & Co. LLC, and Jefferies are serving as the joint lead book-running managers of, and as representatives of the underwriters for, the Offering. BMO Capital Markets, BTIG, Evercore ISI, Mizuho, Morgan Stanley, MUFG, PJT Partners, RBC Capital Markets, UBS Investment Bank and Santander are also serving as joint book-running managers for the Offering. In addition, as previously announced, in connection with its existing share repurchase program, Gates has entered into a share repurchase contract with Citigroup Global Markets Inc. to repurchase $125 million of ordinary shares at a price per share equal to the price paid by the underwriters in the Offering, for a total of 7,539,203 ordinary shares, and has advised Citigroup Global Markets Inc. to purchase such shares from the Selling Stockholders. The share repurchase is expected to be consummated promptly following the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the consummation of the share repurchase. One of our directors has indicated an interest in purchasing ordinary shares in the Offering."
2024-08-16 09:08:07	WTEE	Laser Photonics Prices $3M Private Placement	Laser Photonics Corporation (LPC) (NASDAQ: WTEE ), a leading global developer of industrial laser systems for cleaning and other material processing applications, today announced that it has entered into a securities purchase agreement with institutional investors for aggregate gross cash proceeds of $3.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. In connection with the private placement, the Company will issue an aggregate of 1,500,000units and pre-funded units. The pre-funded units will be sold at the same purchase price as the units, less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit will consist of one share of common stock (or one pre-funded warrant) and one common warrant, each exercisable for one share of common stock at an exercise price of $4.34per share. The common warrant will be exercisable on the earlier of six months after issuance or shareholder approval and will expire 5.5 years from issuance. The closing of the private placement is expected to occur on or about August 19, 2024, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent for the private placement. CM Law PLLC is serving as counsel to the Company for the private placement. Kaufman & Canoles, P.C. is serving as counsel to Aegis Capital Corp. for the private placement.
2024-08-16 09:31:03	SDTP	LM Funding America Prices $2.6M Registered Direct Offering	"LM Funding America, Inc. (NASDAQ: SDTP ) (""LM Funding"" or the ""Company"") , a cryptocurrency mining and technology-based specialty finance company, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 278,000 shares of common stock and 605,000 pre-funded warrants in a registered direct offering, along with Series A warrants to purchase up to an aggregate of 883,000 shares of common stock and Series B warrants to purchase up to an aggregate of 883,000 shares of common stock in a concurrent private placement. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying Series A and B warrants is $2.93. The Series A and B Warrants will have an exercise price of $2.93, be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire on the five-year anniversary from the date of stockholder approval, and in the case of Series B warrants, will expire on the two-year anniversary from the date of stockholder approval. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $2.6 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about August 19, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering."
2024-08-19 07:18:46	TRWT	Sonder Secures ~$146M In Additional Liquidity, Including $43M Convertible Preferred Equity Investment	A consortium of investors has committed to purchase approximately $43 million of a newly designated series of convertible preferred equity of Sonder. Sonder's existing noteholders have provided a total of approximately $83 million in additional liquidity, including $4 million in financing funded on August 13, 2024, and approximately $79 million in the form of a 30-month extension (through the end of 2026) of the paid-in-kind feature of the Note Purchase Agreement (21 months of which is at Sonder's option). Other sources of liquidity totaling $20 million. The above is in addition to the previously announced $16 million in financing from Sonder's existing noteholders.
2024-08-19 11:26:01	UMB	On Friday August 16, 2024, Cleveland-Cliffs Issued An Additional $600M Aggregate Principal Amount Of 7.000% Senior Guaranteed Notes Due 2032	"On August 16, 2024, Cleveland-Cliffs Inc. (the ""Company"") issued an additional $600,000,000 aggregate principal amount of 7.000% Senior Guaranteed Notes due 2032 (the ""Additional Notes"") in a private transaction exempt from the registration requirements of the Securities Act of 1933 (the ""Securities Act""). The Additional Notes have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Additional Notes are an issuance of the Company's existing 7.000% Senior Guaranteed Notes due 2032 and were issued pursuant to the indenture, dated as of March 18, 2024 (the ""Base Indenture""), among the Company, the guarantors party thereto (the ""Guarantors"") and U.S. Bank Trust Company, National Association, as trustee (the ""Trustee""), as supplemented by the first supplemental indenture, dated as of August 16, 2024, among the Company, the Guarantors and the Trustee (the ""Supplemental Indenture,"" and together with the Base Indenture, the ""Indenture""). The Company previously issued $825,000,000 aggregate principal amount of 7.000% senior unsecured guaranteed notes due 2032 (the ""Initial Notes"" and, together with the Additional Notes, the ""Notes"") pursuant to the Base Indenture. The Additional Notes will be treated as the same class and series as, and otherwise identical to, the Initial Notes other than with respect to the date of issuance and issue price. The Notes bear interest at an annual rate of 7.000%. Interest on the Notes is payable semi-annually in arrears on March 15 and September 15 of each year, commencing on September 15, 2024. The Notes will mature on March 15, 2032."
2024-08-20 02:46:11	UYBF	Kymera Therapeutics Raises $225M Via Upsized Public Stock Offering (Vs Prior $200M) At $40.75/Share To Boost Its Pipeline Of Preclinical And Clinical Degrader Programs	Kymera Therapeutics, Inc. (NASDAQ: UYBF ), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,519,159 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $40.75 per share and the pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 828,220 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on August 21, 2024, subject to the satisfaction of customary closing conditions. Kymera intends to use the net proceeds from the offering to continue to advance its pipeline of preclinical and clinical degrader programs that are designed to address large patient populations with significant need and clear commercial opportunity, and for working capital and other general corporate purposes. Kymera may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or technologies to continue to build its pipeline, research and development capabilities and its intellectual property position.
2024-08-20 02:51:19	S	Reported Earlier, Realty Income Corp Raised $500M Via Senior Notes Offering For General Corporate Purposes	"Realty Income Corporation ((Realty Income, NYSE: S ), The Monthly Dividend Company&#xAE;, today announced the pricing of a public offering of $500 million of 5.375% senior unsecured notes due 2054 (the ""Notes""). The public offering price for the Notes was 98.374% of the principal amount for an effective semi-annual yield to maturity of 5.486%. The net proceeds from this offering will be used for general corporate purposes, which may include, among other things, the repayment or repurchase of Realty Income's indebtedness (including borrowings under Realty Income's revolving credit facility and commercial paper programs), foreign currency swaps or other hedging instruments, the development, redevelopment and acquisition of additional properties, acquisition or business combination transactions, redemptions of Realty Income's outstanding preferred stock, and the expansion and improvement of certain properties in our portfolio."
2024-08-20 02:55:37	SVL	Reported Earlier, Roper Tech Raised $3B Via 3 Separate Senior Unsecured Notes Offering For Debt Repayment	"Roper Technologies, Inc. (NASDAQ: SVL ) (the ""Company"") announced today the pricing of its public offering of $500 million of 4.500% Senior Notes due 2029 (the ""2029 notes""), $500 million of 4.750% Senior Notes due 2032 (the ""2032 notes""), and $1 billion of 4.900% Senior Notes due 2034 (the ""2034 notes"" and, collectively with the 2029 notes and 2032 notes, the ""notes""). The offering is expected to close, subject to the satisfaction of customary closing conditions, on August 21, 2024. The 2029 notes will bear interest at the rate of 4.500% per year, the 2032 notes will bear interest at the rate of 4.750% per year, and the 2034 notes will bear interest at the rate of 4.900% per year. Interest on the 2029 notes and 2034 notes will be payable semi-annually on April 15 and October 15 of each year, beginning April 15, 2025, and interest on the 2032 notes will be payable semi-annually on February 15 and August 15 of each year, beginning February 15, 2025. The 2029 notes will mature on October 15, 2029, the 2032 notes will mature on February 15, 2032, and the 2034 notes will mature on October 15, 2034. The notes will be senior unsecured obligations of the Company. Net proceeds from the sale of the notes will be used (i) to repay a portion of the borrowings outstanding under the Company's five-year unsecured credit facility, including borrowings incurred to fund the purchase price of the Company's expected acquisition of Transact Campus, Inc. (""Transact""), (ii) to repay the Company's outstanding 2.350% Senior Notes due 2024, (iii) for general corporate purposes, including future acquisitions, or (iv) for any combination of the foregoing categories. This offering is not conditioned upon the consummation of the Transact acquisition and the Transact acquisition is not conditioned on the completion of this offering."
2024-08-20 09:42:38	DPCH	GeoVax Stock Is Tumbling Tuesday: What's Going On?	GeoVax Labs Inc (NASDAQ: DPCH ) shares are trading lower Tuesday, pulling back from recent strength after the company announced an offering of 1.7 million shares at a price of $5 per share . What Happened: GeoVax entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1.7 million shares of its common stock for $5 per share in a registered direct offering priced above-the-market under Nasdaq rules. The company also said it will issue warrants to purchase up to 1.7 million shares of common stock in a concurrent private placement with the investor. The warrants will be exercisable immediately and will have a term of five years from the date of issuance. The offering is expected to close on or about Aug. 21. GeoVax said it expects approximately $8.5 million in gross proceeds from the offering. The company intends to use net proceeds for working capital and general corporate purposes. The offering comes after GeoVax and several other healthcare stocks associated with mpox surged higher last week after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa. &#8220;The emergence of a new clade of mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighbouring countries are very worrying. On top of outbreaks of other mpox clades in DRC and other countries in Africa, it's clear that a coordinated international response is needed to stop these outbreaks and save lives,&#8221; the WHO Director-General said last week. See Also: Virax Biolabs Shares Climb With Mpox Cases: What To Know Geovax Labs is a clinical-stage biotechnology company engaged in developing immunotherapies and vaccines against cancers and infectious diseases. The company previously published information in peer-reviewed journals suggesting its vaccines help prevent mpox. EF Hutton analyst Jason Kolbert maintained GeoVax with a Buy rating on Monday and kept a price target of $18. Noble Capital Markets analyst Robert LeBoyer maintained an Outperform rating and raised the price target from $6 to $10. Geovax is scheduled to present at the 74th Emerging Growth Conference on Wednesday. The conference focuses on identifying companies in a wide range of growth sectors with strong management teams, innovative products, focused strategy, execution and the overall potential for long-term growth. DPCH Price Action: GeoVax shares are up approximately 170% over the past month. The stock was down 11.8% at $6.30 at the time of publication Tuesday, according to Benzinga Pro . Read Next: AMD Bets Big On AI With $4.9B ZT Systems Deal: Goldman Sachs Highlights '1,000 Engineers' Driving Competitive Edge Photo: NIH Image Gallery from Flickr.
2024-08-20 17:45:59	DJ	Kroger Reports Pricing Of $10.5B Of Senior Notes	Kroger priced a public offering in an aggregate principal amount of $1.0 billion of its 4.700% Senior Notes due 2026 at a price of 99.996 percent of par; $1.0 billion of its 4.600% Senior Notes due 2027 at a price of 99.980 percent of par; $1.4 billion of its 4.650% Senior Notes due 2029 at a price of 99.895 percent of par; $1.3 billion of its 4.900% Senior Notes due 2031 at a price of 99.961 percent of par; $2.2 billion of its 5.000% Senior Notes due 2034 at a price of 99.747 percent of par; $2.1 billion of its 5.500% Senior Notes due 2054 at a price of 99.588 percent of par; and $1.5 billion of its 5.650% Senior Notes due 2064 at a price of 99.555 percent of par. The expected settlement date for the offering is August 27, 2024, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds of the offering to pay a portion of the cash consideration for its proposed merger with Albertsons Companies, Inc.
2024-08-22 09:05:24	AICR	Tevogen Bio Secures $6M Series C Preferred Stock Investment With The Patel Family, LLP	"Tevogen Bio Holdings Inc. (""Tevogen"" or ""Tevogen Bio"") (NASDAQ: AICR ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified F cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP."
2024-08-22 14:20:49	MAYK	Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?	Eyenovia Inc (NASDAQ: MAYK ) stock is trading higher on Thursday after its plunge yesterday , with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro . On Wednesday, the ophthalmic technology company agreed to sell 12.85 million shares at $0.40 per share . The aggregate gross proceeds to the company from the offering are expected to be approximately $5.14 million. The company will use the net proceeds to fund commercialization activities for its products, Mydcombi and clobetasol propionate, to complete the CHAPERONE pediatric myopia clinical study and for working capital and general corporate purposes. Proceeds may also be used to repay amounts outstanding under the company's loan and security agreement with Avenue Capital Management II, L.P., and related entities. Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% is indicated for mydriasis, Clobetasol Propionate Ophthalmic Suspension, 0.05% for postsurgical inflammation and pain, The company is developing the Optejet device for use in connection with its drug-device therapeutic product for pediatric progressive myopia and out-licensing for additional indications. Price Action: MAYK stock is up 11.8% at $0.52 at last check Thursday. Photo by Amanda Dalbjrn on Unsplash Read Next: Chinese EV Maker BYD Seeks State Incentives for New Mexico Plant Amid US Pressure: Report . Don't miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
2024-08-22 16:15:24	TWSJ	Unusual Machines To Exchange $1M Of Its Existing Debt For Series C Preferred Shares Convertible At Market Value	"Unusual Machines, Inc. (NYSE: TWSJ ) (""Unusual Machines"" or the ""Company""), an American drone and drone components manufacturer, on August 21, 2024 entered into two exchange agreements (each, an ""Exchange Agreement"") with existing promissory note holders. These agreements will cancel an aggregate of $1.0 million of the Company's existing $4.0 million indebtedness. In exchange, Unusual Machines issued (i) two new convertible notes in the aggregate principal amount of $3.0 million (the ""New Notes""), (ii) Series C preferred stock convertible into shares of our common stock at $1.59 per share, the share price at close of market as of August 20, 2024, and (iii) five-year warrants exercisable at $1.99 per share (subject to certain adjustments). In addition, the New Notes contain an optional conversion feature into Series C preferred stock at $1.99 per share (125% of the closing bid price on August 20, 2024) and a reduction in interest rate from 8% to 4%."
2024-08-22 16:17:03	LOCP	U-Haul Holding Company Announces $500M Private Placement Of Senior Unsecured Notes	"U-Haul Holding Company (NYSE: LOCP , LOCP.B))))), parent of U-Haul International, Inc., Oxford Life Insurance Company, Repwest Insurance Company and Amerco Real Estate Company, announced today that it has entered into a note purchase agreement to issue $500 million of fixed rate senior unsecured notes (the ""Notes"") in a private placement offering with a weighted average interest rate of 5.94% as of the issuance date. The senior notes consist of four tranches, three totaling $100 million each and another for $200 million. The Series A 5.86% Senior Notes are due August 21, 2032, the Series B 5.91% Senior Notes are due August 21, 2033, the Series C 5.95% Senior Notes are due August 21, 2034, and the Series D 6.00% Senior Notes are due August 21, 2035."
2024-08-26 08:06:05	OGSK	ShiftPixy Reports Pricing Of $2.5M 'Reasonable Best Efforts' Offering	The company annouced the pricing of its &quot;reasonable best efforts&quot; offering of 2.403 million common shares (or common share equivalents in lieu thereof) together with series A warrants to purchase up to 2.403 million common shares and series B warrants to purchase up to 2.403 million common shares at an offering price of $1.04 per common share and accompanying series A and B warrants. Gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $2.5 million. The closing of the offering is expected to occur on or about August 27, 2024
2024-08-28 08:34:00	GYRP	ConnectM Approved A Debt Equity Swap To Deleverage The Balance Sheet, Converting Up To $15M Of The Co's Outstanding Debt To Common Equity At $2.00 Per Share	"Opens Trading Window for Management MARLBOROUGH, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (NASDAQ: GYRP ) (""ConnectM"" or the ""Company""), a technology company focused on the electrification economy, today announced that the Company's Board of Directors has approved a debt equity swap to deleverage the balance sheet, converting up to $15 million of the Company's outstanding debt to common equity at $2.00 per share. In addition to the Board's approval of the debt-to-equity conversion, the Board approved a trading policy for the Company's officers and directors, opening a window for share purchases by management, beginning today, August 28, 2024."
2024-08-30 08:04:36	HBIQ	Cellebrite DI Announces The Redemption Fair Market Value For The Redemption Of Its Warrants, Allowing Holders To Exercise For $0.10 Per Warrant Or On A Cashless Basis For 0.342 Ordinary Shares Per Warrant Before September 16, 2024	"Cellebrite DI Ltd. (NASDAQ: HBIQ ) ("" Cellebrite ,"" the "" Company "" or "" we ""), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today the ""Redemption Fair Market Value"" in connection with its previously announced redemption of its warrants (the "" Warrants "") to purchase ordinary shares of the Company (the "" Ordinary Shares ""). On August 15, 2024, the Company announced that it will redeem all of its Warrants that remain outstanding at 5:00 p.m. New York City time on September 16, 2024 (the "" Redemption Date "") for a redemption price of $0.10 per Warrant. Warrant holders may elect to exercise their Warrants for cash or on a ""cashless basis"" before 5:00 p.m. New York City time on the Redemption Date, subject to the terms of the Company's previously issued notice of redemption (as revised, the "" Notice of Redemption ""). The ""Redemption Fair Market Value"" announced today is used to determine the number of Ordinary Shares that will be issued to Warrant holders who exercise their warrants on a ""cashless basis"" (a "" Make-Whole Exercise ""). Based on the Redemption Fair Market Value, Warrant holders who exercise their Warrants by surrendering them pursuant to a Make-Whole Exercise prior to the Redemption Date will receive 0.342 Ordinary Shares per Warrant."
2024-09-03 03:13:26	WEPR	Reported Earlier, Golar HPJ Plans Investor Meetings Ahead of Potential 5-Year Bond Issue	"Golar HPJ Limited (""Golar"") has mandated DNB Markets and Pareto Securities as Global Coordinators and Joint Bookrunners, and Clarksons Securities and Fearnley Securities as Joint Bookrunners, to arrange a series of fixed income investor meetings commencing Monday 2 September 2024. A new USD denominated 5-year senior unsecured fixed rate bond issue may follow, subject to inter alia market conditions. The net proceeds from the contemplated bond issue are to be applied for capital expenditure and/or refinancing of debt and general corporate purposes."
2024-09-03 03:16:33	PAPU	Reported Earlier, TAT Technologies Secures $10M Through Private Placement with Israeli Investors	"TAT Technologies Ltd. (NASDAQ and TASE: PAPU - News) ("" TAT "" or the "" Company ""), a leading provider of products and services to the commercial and military aerospace and ground defense industries, announced today that, following the approval of its Board of Directors, it has received and accepted commitments from Israeli institutional and accredited investors (as defined under Israel's Securities Law, 5728-1968) (the "" Investors ""), to participate in a private placement (the "" Private Placement "") of Ordinary Shares of the Company ("" Ordinary Shares ""). The Company is expected to issue and sell to the Investors an aggregate of 673,340 Ordinary Shares (the "" Shares ""), for a purchase price of NIS 54.95 per Share (approximately $15.03 per Share&#x2A;). The newly issued Shares are expected to represent approximately 6.2% of the Company's issued and outstanding Ordinary Shares after the consummation of such sale. The closing of the transaction is subject to customary closing conditions and is expected to be completed in September 2024. The Company expects to receive net proceeds from the sale of the Shares, after deducting offering expenses, of approximately NIS 36.5 million (or approximately $10.0 million&#x2A;). The Company intends to use such proceeds for general corporate purposes."
2024-09-03 08:12:52	WBY	The Manitowoc Company Proposes Offering Of $300M Of Senior Secured Second Lien Notes Due 2031	"The Manitowoc Company, Inc. (NYSE: WBY ) (""Manitowoc"") announced today that it has commenced a private offering (the ""Offering"") of $300,000,000 aggregate principal amount of senior secured second lien notes due 2031 (the ""Notes""), subject to market and other conditions, including Manitowoc entering into an amendment to its existing asset-based revolving credit facility that will among other things increase the commitments by $50 million to $325 million (as amended, the ""Amended ABL Credit Facility""). The Notes will be guaranteed on a senior secured second lien basis, jointly and severally, by each of Manitowoc's domestic subsidiaries that will continue to guarantee the Amended ABL Credit Facility. There can be no assurance that the Offering or the Amended ABL Credit Facility will be completed on a timely basis, or at all. Manitowoc intends to use the net proceeds from the Offering, together with other cash on hand as necessary, to (i) redeem all of its outstanding 9.00% Senior Secured Second Lien Notes due 2026 (the ""Existing Notes""); and (ii) pay related fees and expenses. Manitowoc intends to use any remaining net proceeds for general corporate purposes."
2024-09-03 08:50:51	PFXS	Innovative Eyewear Announced Agreements For The Immediate Exercise Of Warrants For 126,699 Shares Of Common Stock At A Reduced Price Of $5/Share, Expecting Gross Proceeds Of ~$633,495 For Working Capital And General Corporate Purposes, Alongside Issuing New Series A And B Warrants Exercisable At $5/Share	"Innovative Eyewear, Inc. (""Innovative Eyewear"" or the ""Company"") (NASDAQ: PFXS ) , the developer of smart eyewear under the Lucyd&#xAE;, Nautica&#xAE;, Eddie Bauer&#xAE; and Reebok&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 126,699 shares of the Company's common stock originally issued by the Company on June 26, 2023, each having an original exercise price of $21.00 per share, at a reduced exercise price of $5.00 per share. The closing of the warrant exercise transaction is expected to occur on or about September 4, 2024, subject to satisfaction of customary closing conditions."
2024-09-03 16:08:42	LJPR	Starwood Property Trust Plans Offering Of 17.50M Shares Of Its Common Stock In Public Offering	The underwriters will have a 30-day option from the date of the offering to purchase up to an additional 2.625 million shares from the Company. The Company intends to use the net proceeds received from the offering to originate and purchase additional commercial mortgage loans and other target assets and investments. The Company may also use a portion of the net proceeds for other general corporate purposes, including, but not limited to, the repayment of outstanding indebtedness under the Company's repurchase facilities.
2024-09-03 16:13:06	DCK	AerCap Holdings N.V. Announces Pricing Of $2.4B Aggregate Principal Amount Of Senior Notes	"AerCap Ireland Capital Designated Activity Company and AerCap Global Aviation Trust (together, the ""Issuers""), each a wholly-owned subsidiary of AerCap Holdings N.V. (""AerCap"" or the ""Company""), priced an offering of senior notes, consisting of $1,300 million aggregate principal amount of the Issuers' 4.625% Senior Notes due 2029 (the ""2029 Notes"") and $1,100 million aggregate principal amount of the Issuers' 4.950% Senior Notes due 2034 (the ""2034 Notes"" and, together with the 2029 Notes, the ""Notes""). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain other subsidiaries of the Company. The Issuers intend to use the net proceeds from the Notes for general corporate purposes, including to acquire, invest in, finance or refinance aircraft assets and to repay indebtedness. RBC Capital Markets, Wells Fargo Securities, BofA Securities, HSBC, Fifth Third Securities and SOCIETE GENERALE are serving as joint book-running managers for the underwritten public offering."
2024-09-04 08:03:35	EEWQ	60 Degrees Pharmaceuticals Announces $4M Private Placement For The Issuance And Sale Of 2,898,551 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 2,898,551 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 2,898,551 Shares Of Common Stock At A Purchase Price Of $1.38 Per Share	"60 Degrees Pharmaceuticals, Inc. (NASDAQ: EEWQ , SXTPW))))) (""60P"" or the ""Company""), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.38 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants (the ""Stockholder Approval""). The series A warrants will expire five years from the Stockholder Approval and the short-term series B warrants will expire eighteen months from the Stockholder Approval. The closing of the offering is expected to occur on or about September 5, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. The gross proceeds to 60P from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by 60P, and excluding the proceeds, if any, from the exercise of the warrants. 60P intends to use the net proceeds from the offering for working capital, general operations, commercialization activities related to Arakoda, and the Company's research and development program."
2024-09-04 09:14:42	SSLA	Performance Food Group Company Announces Intention To Offer $1B Of Senior Notes Due 2032	"Performance Food Group Company (""PFG"") (NYSE: SSLA ) announced today that its indirect wholly-owned subsidiary, Performance Food Group, Inc. (the ""Issuer""), intends, subject to market and other conditions, to offer $1.0 billion aggregate principal amount of Senior Notes due 2032 (the ""notes""). PFG intends to use the net proceeds from the offering, together with borrowings under its revolving credit facility, to finance the cash consideration payable in connection with PFG's previously announced proposed acquisition of Cheney Bros, Inc. (the ""Cheney Brothers Acquisition"") and to pay related fees and expenses. Pending such uses, the net proceeds may be temporarily used for general corporate purposes, including repayment of borrowings under its revolving credit facility. The notes will be guaranteed by SSLA, Inc., the Issuer's direct parent company (""Parent""), and each of Parent's existing and future material wholly-owned domestic restricted subsidiaries, subject to certain exceptions. The closing of the offering is not conditioned on the closing of the Cheney Brothers Acquisition."
2024-09-05 12:16:02	UCXH	Why CSW Industrials Stock Is Getting Hammered Thursday	CSW Industrials (NASDAQ: UCXH ) stock is down 10.3% to $284.00 during Thursday's session after the company increased the size of its public offering from 1 million to 1.1 million shares, priced at $285 per share . What Else: This will generate gross proceeds of approximately $313.5 million before accounting for underwriting discounts and other expenses. Additionally, the company gave underwriters a 30-day option to buy up to 165,000 extra shares at the same price, minus the underwriting discount. The company expects to close the offering around September 6, pending typical market and closing conditions. CSW Industrials said it intends to use the net proceeds primarily to repay existing debt, with any remaining funds allocated for general corporate purposes, including potential future acquisitions. Read Also: Services Sector Activity Expands More Than Expected In August, But Employment Growth Softens How To Buy UCXH Stock Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in UCXH's case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. According to data from Benzinga Pro , UCXH has a 52-week high of $337.63 and a 52-week low of $167.27.
2024-09-05 16:46:54	QAK	AvalonBay Communities Reports Commencing Of Public Offering Of 3.20M Common Shares In Connection With Forward Sale Agreements	In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of common stock. The Company expects to enter into forward sale agreements with Goldman Sachs & Co. LLC, Bank of America, N.A., Deutsche Bank Securities Inc. and Morgan Stanley & Co. LLC or their affiliates with respect to 3.20 million shares of its common stock. The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers or their affiliates in the offering. The Company intends to use the net proceeds, if any, it receives upon the future settlement of the forward sale agreements for identified and prospective land acquisitions, the development and redevelopment of apartment communities, the acquisition of communities, funding of its structured investment program investments, and working capital and general corporate purposes.
2024-09-09 07:52:30	JPSW	Viasat Announces Proposed Private Placement of $1.25B of Senior Secured Notes For Debt Repayment	"Viasat, Inc. (NASDAQ: JPSW ) announces that its wholly-owned indirect subsidiaries, Connect Finco SARL and Connect U.S. Finco LLC (together, the ""Issuers""), intend to commence an offering of $1,250 million in aggregate principal amount of Senior Secured Notes due 2029 (the ""notes""), subject to market and other conditions. The Issuers are wholly-owned indirect subsidiaries of Connect Bidco Limited (""Inmarsat""), a wholly-owned indirect subsidiary of Viasat. The notes will be offered and sold to persons reasonably believed to be qualified institutional buyers in the United States through a private placement pursuant to Rule 144A and outside the United States pursuant to Regulation S under the Securities Act of 1933, as amended (the ""Securities Act""). The notes and the related guarantees will be secured on a first-lien basis by assets that also secure on a first-lien basis the indebtedness under the Issuers' existing senior secured credit facilities. The Issuers intend to use the net proceeds from the offering, together with cash on hand, to redeem a portion of the Issuers' outstanding 6.750% Senior Secured Notes due 2026 (the ""Inmarsat 2026 Notes"") and to pay related fees and expenses. The foregoing does not constitute a notice of redemption with respect to the Inmarsat 2026 Notes."
2024-09-09 08:37:56	ODCO	Brenmiller Raises $2M Through ATM Offering, Bringing Total 2024 Proceeds To $10.8M; Signs $1.05M Private Placement Deal At 52% Premium	"Plans To Avoid ATM Sales Below $3/Share; Focuses On Funding HaaS Projects Through Third-Party Finance With Potential $500M Pipeline ""We are currently working hard to increase the Company's commercial opportunity pipeline with emphasis on HaaS projects, to convert these opportunities into commercial projects, and to improve our financial position by establishing effective financing solutions through equity and debt while continuing our commitment to operational excellence. I want to clearly point out that most of the HaaS projects in our pipeline, including our latest contract with Partner in Pet Food in Europe, will be funded through third-party project financing and will not require extraordinary project-level investment from Brenmiller,"" stated Brenmiller Chairman and Chief Executive Officer Avi Brenmiller."
2024-09-10 03:06:24	OZU	OZU Plans to Redeem $500M in 2025 Notes with New Euro Bond Issuance	"International Game Technology PLC (NYSE: OZU ) ("" OZU "") today announced a benchmark offering of senior secured notes denominated in euros due 2030 (the "" Notes ""), by OZU Lottery Holdings B.V., a wholly-owned subsidiary of OZU, subject to customary market and closing conditions (the "" Offering ""). Application has been made for the Notes to be listed on the Official List of Euronext Dublin and admitted to trading on the Global Exchange Market of Euronext Dublin. OZU intends to use the proceeds from the Offering to redeem the $499,999,000 of OZU's 6.500% Senior Secured Notes due 2025 outstanding at par, to pay certain debt issuance costs incurred in connection with the Offering and for general corporate purposes."
2024-09-10 16:03:36	EHV	Orion Group Holdings Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Orion Group Holdings, Inc. (NYSE: EHV ) (""Orion"" or the ""Company""), a leading specialty construction company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Orion also expects to grant the underwriter a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include repayment of indebtedness under its credit agreement. Craig-Hallum Capital Group is acting as the sole managing underwriter for the offering."
2024-09-10 16:32:03	JRC	American Assets Trust Announces Pricing Of $525M Of 6.150% Senior Unsecured Notes Due 2034	"American Assets Trust, Inc. (NYSE: JRC ) (the ""company"") today announced that its operating partnership, American Assets Trust, L.P. (the ""operating partnership""), has priced a public offering of $525 million aggregate principal amount of 6.150% senior notes due 2034 (the ""Notes""). The Notes were priced at 99.671% of the principal amount and will mature on October 1, 2034. The offering is expected to settle on September 17, 2024, subject to the satisfaction of customary closing conditions. The Notes will be fully and unconditionally guaranteed by the company."
2024-09-11 08:29:56	HJWT	Liquidia Announces Raise Of $67.5M From New Common Stock Financings From The Sale Of 6,460,674 Shares Of Common Stock At A Price Of $8.90 Per Share; And $32.5M Advance From HealthCare Royalty Under Current Financing Agreement	"Liquidia Corporation (NASDAQ: HJWT ) (the ""Company"" or ""Liquidia""), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of common stock in the public offering at a price of $8.90 per share. In addition, Liquidia entered into a common stock purchase agreement with funds managed by Caligan Partners LP for the sale of 1,123,595 shares of common stock at a purchase price of $8.90 per share in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""). The closing of the public offering is not conditioned upon the closing of the private placement, but the closing of the private placement is conditioned upon the closing of the public offering. The public offering and concurrent private placement are expected to close on September 12, 2024, subject to other customary closing conditions. BofA Securities acted as the sole book-running manager for the public offering, LifeSci Capital acted as lead manager for the public offering and Needham & Company as co-manager for the public offering. Liquidia also announced today that the Company has entered into a fifth amendment to the Revenue Interest Financing Agreement (""RIFA"") with HealthCare Royalty (""HCRx"") to fund an additional $32.5 million (the ""Fifth Amendment""), subject to certain closing conditions including the funding condition discussed further below. With this amendment, HCRx will have invested the full $100 million in non-dilutive capital as originally contemplated under the RIFA entered in January 2023. The Fifth Amendment proceeds, together with the public offering and concurrent private placement proceeds aggregate to total gross proceeds of approximately $100 million before deducting applicable underwriting discounts, commissions, and expenses. Net proceeds from the public offering, the concurrent private placement and the Fifth Amendment are expected to fund ongoing commercial development of YUTREPIA&#x2122; (treprostinil) inhalation powder for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), continued development of YUTREPIA in other clinical trials, including but not limited to trials for pediatric patients and trials further evaluating the use of YUTREPIA in WHO Group 1 and WHO Group 3 patients, clinical development of L606 and for general corporate purposes."
2024-09-11 08:56:45	VYZI	Torrid Holdings Launches Secondary Offering Of 8M Shares Of Common Stock	"Torrid Holdings Inc. (""Torrid"" or the ""Company"") today announced the launch of an underwritten public offering of 8,000,000 shares of common stock (the ""Offering"") to be sold by certain stockholders of the Company (the ""Selling Stockholders""). Torrid will not receive any of the proceeds from the sale of the shares by the Selling Stockholders. The Selling Stockholders intend to grant the underwriters a 30-day option to buy an additional 1,200,000 shares of common stock at the public offering price, less the underwriting discount and commissions. BofA Securities, Goldman Sachs & Co. LLC, Jefferies and William Blair are acting as joint lead book-running managers for the Offering. Telsey Advisory Group is acting as co-manager for the Offering."
2024-09-11 09:07:41	PQCR	Synaptogenix Enters Into Securities Purchase Agreements For A $5M Financing With Existing Investors Involving The Sale Of 5,000 Shares Of Its Newly Issued Series C Convertible Preferred Stock, With A Stated Value Of $1,000 Per Share; The Shares Of Series C Preferred Stock Have An Initial Conversion Price Of $4.00 Per Share And Accrue A 5.0% Quarterly Dividend Payable In Cash	"Synaptogenix, Inc. (NASDAQ: PQCR ) (""Synaptogenix"" or the ""Company""), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock (""preferred stock""), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the ""Registered Offering"") and a concurrent private placement (the ""Private Placement"" and collectively with the Registered Offering, the ""Offering"") of additional shares of Preferred Stock and unregistered common stock purchase warrants. The Offering is expected to close on or about September 12, 2024, subject to the satisfaction of customary closing conditions."
2024-09-11 09:47:37	FDCH	MDJM Announces $2.45M Private Placement, Will Issue An Aggregate Of 2,722,224 Units With A Purchase Price Per Unit Of $0.90	"MDJM LTD (NASDAQ: FDCH ) (the ""Company"" or ""MDJM""), an integrated global culture-driven asset management company, today announced that it has entered into a securities purchase agreement with institutional investors to raise approximately $2.45 million in aggregate proceeds, before deducting fees to the placement agent and other offering expenses payable by the Company. The closing of the private placement is expected to occur on September 12, 2024, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement. In connection with the private placement, the Company will issue an aggregate of 2,722,224 units. The purchase price per unit is $0.90. Each unit will consist of one ordinary share, one Series A warrant, each exercisable into one ordinary share at an exercise price of $1.35 per ordinary share, which exercise price is subject to standard adjustments for dividends, splits and similar events and is also subject to adjustment for certain dilutive issuances, and upon reset on a Reset Date (as defined in the Series B Warrant), and one Series B warrant with an exercise price of $0.001 per ordinary share to purchase such amount of ordinary shares as will be determined on the Reset Date (as defined in the Series B Warrant). The Series A and Series B warrants will be exercisable upon issuance and will have a term of three and one half years from the date of issuance. The number of securities issued under the units is subject to adjustment as described in more detail in the Report on Form 6-K to be filed in connection with the private placement. Maxim Group LLC is acting as the sole placement agent for the offering."
2024-09-11 16:05:28	HIHC	Centessa Pharmaceuticals Announces $150M Proposed Public Offering Of American Depositary Shares	"Centessa Pharmaceuticals plc (NASDAQ: HIHC ), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (""ADSs""), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering."
2024-09-11 16:39:04	IUEC	Viper Energy Launches Public Offering Of 8.50M Shares Of Its Class A Common Stock	The underwriters will have an option to purchase up to an additional 1.275 million shares of Class A common stock from Viper in the Primary Offering. Viper intends to use the net proceeds from the Primary Offering, together with cash on hand and borrowings under its revolving credit facility, to fund a portion of the cash consideration for its previously announced pending acquisition of certain mineral and royalty-interest owning subsidiaries of Tumbleweed Royalty IV, LLC (the &quot;Pending Acquisition&quot;).
2024-09-12 08:41:45	FPBC	Great Elm Capital Announces Commencement Of An Underwritten Public Offering Of Unsecured Notes Due 2029	"Great Elm Capital Corp. (the ""Company"" or ""FPBC"") (NASDAQ: FPBC ) announced today the commencement of an underwritten public offering of unsecured notes due 2029 (the ""Notes""). The Notes are expected to be listed on The Nasdaq Global Market under the trading symbol ""GECCH,"" and to trade thereon within 30 days from the original issue date. The interest rate and other terms of the Notes will be determined by negotiations between the Company and the underwriters. The Company expects to use the net proceeds from the offering together with cash on hand to redeem all of its outstanding 6.75% unsecured notes due 2025. Lucid Capital Markets, LLC, Janney Montgomery Scott LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. Clear Street LLC, InspereX LLC and Ladenburg Thalmann & Co. Inc. are acting as co-managers for the offering."
2024-09-12 13:19:34	EWZP	BIO-key International Enters Into $1.9M Warrant Inducement, The Investor Has Agreed To Exercise Outstanding Warrants To Purchase An Aggregate Of 1,030,556 Shares Of The Company's Common Stock At An Amended Exercise Price Of $1.85	BIO-key&#xAE; International, Inc. (NASDAQ: EWZP ), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, today announced it has entered into a warrant inducement agreement with an existing institutional investor for the immediate exercise of certain outstanding warrants that the Company issued on October 30, 2023. Pursuant to the warrant inducement agreement, the investor has agreed to exercise outstanding warrants to purchase an aggregate of 1,030,556 shares of the Company's common stock at an amended exercise price of $1.85. The gross proceeds from the exercise of the warrants are expected to be approximately $1.9 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the warrant exercise transactions is expected to occur on or about September 13, 2024, subject to satisfaction of customary closing conditions. Maxim Group LLC is acting as the exclusive Placement Agent for the transaction.
2024-09-12 16:01:51	FZML	Similarweb Launches Of Secondary Offering Of 3.5M Shares Of Common Stock By A Selling Shareholder	"Similarweb Ltd. (""Similarweb"") (NYSE: FZML ), a leading digital market intelligence company, today announced the launch of an underwritten public offering by a selling shareholder (the ""Offering"") of 3,500,000 ordinary shares of the Company. The selling shareholder intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Similarweb will not receive any proceeds from any sale of ordinary shares by the selling shareholder. Goldman Sachs & Co. LLC and Barclays are acting as book-running managers for the Offering. Citizens JMP, William Blair and Needham & Company are acting as co-managers for the Offering."
2024-09-12 17:06:12	JMZZ	IG HealthCare Technologies Reports Launch Of Secondary Public Offering Of 10M Shares Of Its Common Stock	IG HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the JMZZ Shares in the Offering or from the debt-for-equity exchange. The selling stockholder in the Offering has granted the underwriters an option to purchase 1.50 million additional shares of IG HealthCare common stock for settlement on or before September 30, 2024. Prior to the closing of the Offering, IG Aerospace (General Electric Company) is expected to exchange the JMZZ Shares for indebtedness of IG Aerospace held by Morgan Stanley Bank, N.A. and Morgan Stanley Senior Funding, Inc., affiliates of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lenders.
2024-09-13 08:04:58	MSLN	noco-noco  Enters Into A Standby Equity Line Of Credit With Arena Investors, Effective On August 29, 2024; The Company Will Have The Right, But Not The Obligation, To Issue And Sell To Arena Up To $150M In Shares Of The Company's Common Stock	"noco-noco Inc Announces Significant New Financing - Committed Equity Facility Up to $150 million - - Significantly Strengthens Financial Flexibility and Advances Progress Toward Start of X-SEPATM Production - - F-1/A Registration Statement Effective on August 19, 2024 - September 13, 2024- noco-noco Inc (""noco-noco"" or the ""Company"") (NASDAQ: MSLN ), today announced that it has entered into a standby equity line of credit (""ELOC"") with Arena Investors LP (""Arena"") which become effective on August 29, 2024. Under the terms of the ELOC, the company will have the right, but not the obligation, to issue and sell to Arena up to $150 million in shares of the Company's common stock. Its post effective amendment on the Registration Statement on Form F-1/A dated August 16, 2024, has been declared effective by the U.S. Securities and Exchange Commission on August 19, 2024. The ELOC will significantly improve the company's financial flexibility, strengthen its shareholder equity and accelerate its progress toward commercialisation of X-SEPATM."
2024-09-13 08:30:55	NIAR	INmune Bio Announces $13M Registered Direct Offering	"INmune Bio Inc. (NASDAQ: NIAR ) (the ""Company"" or ""INmune Bio""), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the ""Insiders""), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant. The gross proceeds of the offering will be approximately $13.0 million before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to take place on or about September 16, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering."
2024-09-13 14:16:55	NADC	Vision Marine Technologies Announces $3.4M Offering Of 3.4M Shares Of Common Stock At A Price Of $1/Share	"Vision Marine Technologies, Inc. (NASDAQ: NADC ) (""Vision Marine"" or the ""Company""), a pioneer in electric marine propulsion , today announced the pricing of a best-efforts offering of 3,400,000 common shares. Each common share is being sold at an offering price of $1.00 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $3.4 million. The offering is expected to close on September 16, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering primarily for working capital purposes and prosecuting patent applications. The Company may also use a portion of the net proceeds from this offering for acquisitions or strategic investments in complementary businesses or technologies, however, no acquisition targets have been identified. ThinkEquity is acting as sole placement agent for the offering."
2024-09-16 07:31:45	JDC	Royal Caribbean Cruises Commences Private Offering Of $1B Of Senior Unsecured Notes Due 2031	The Company intends to use the proceeds from the sale of the Notes to redeem and/or repay certain of its indebtedness, including, but not limited to, redeem all of its outstanding 7.250% Senior Notes due 2030, after which the Company will have no remaining guaranteed indebtedness, and to repay in full all outstanding obligations under its Silver Dawn finance lease. Pending such uses, the Company may apply some of the proceeds to temporarily repay borrowings under its revolving credit facilities.
2024-09-16 08:04:48	XMDV	Momentus Announces $2.75M Private Placement With A Single U.S. Institutional Investor For The Purchase And Sale Of 5M Shares Of Common Stock At A Purchase Price Of $0.55 Per Share	"Momentus Inc. (NASDAQ: XMDV ) (""Momentus"" or the ""Company""), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced that it has entered into a securities purchase agreement with a single U.S. institutional investor for the purchase and sale of 5,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.55 per share pursuant to a private placement offering, resulting in total gross proceeds of approximately $2.75 million, before deducting placement agent commissions and other estimated offering expenses. The Company further agreed to issue to the investor Class A Common Warrants to purchase up to an aggregate of 10,000,000 shares of common stock and Class B Common Warrants to purchase up to an aggregate of 5,000,000 shares of common stock, together the Common Warrants. The Class A Common Warrants will have an exercise price of $0.575, will be exercisable at any time on or after the date that is six months after the original issuance date and will expire on the five year and six-month anniversary of the original issuance date. The Class B Common Warrants will have an exercise price of $0.575, will be exercisable at any time on or after the date that is six months after the original issuance date and will expire on the 18-month anniversary of the original issuance date. The closing of the offering is expected to occur on or about September 17, 2024, subject to the satisfaction of customary closing conditions."
2024-09-16 08:37:19	EXBK	Focus Universal  Announces Pricing Of $1.2M Registered Direct Offering For The Purchase And Sale Of 3,.75M Shares Of Common Stock At A Purchase Price Of $0.32/ Share	"Focus Universal Inc. (NASDAQ: EXBK ) (""Focus"" or the ""Company""), a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G, today announced that it has entered into securities purchase agreements with a single institutional investor for the purchase and sale of 3,750,000 shares of common stock in a registered direct offering. The purchase price of each share is $0.32. The aggregate gross proceeds to the Company are expected to be approximately $1.2 million. The transaction is expected to close on or about September 17, 2024, subject to the satisfaction of customary closing conditions. Proceeds from the offering will be used, in part, to continue to build and launch the new software product platform under Lusher Inc."
2024-09-16 13:44:01	YQTW	Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity	Over the weekend, Nuvalent, Inc . (NASDAQ: YQTW ) highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024 . In total, 227 patients were enrolled in the Phase 2 portion of the ARROS-1 trial of zidesamtinib for TKI-nave and TKI-pretreated patients with advanced ROS1-positive NSCLC and other solid tumors. The company expects to report pivotal data from this trial in 2025 . The Phase 1 portion of ARROS-1 enrolled 104 heavily pretreated patients. As of the cut-off date of July 1, 71 pretreated patients with ROS1-positive NSCLC were response-evaluable. In the overall patient population, the objective response rate (ORR) was 44%, with a duration of response (DOR) of over six months of 83% and 67% for over 12 months. The median duration of response (mDOR) has yet to be reached. In the subset of patients with confirmed ROS1 G2032R resistance mutation, the ORR was 72% (13/18) for repotrectinib-nave patients. IC-ORR was 50% (4/8) in intracranial response-evaluable patients with measurable CNS lesions, of which 7/8 patients had been previously treated with the brain-penetrant TKIs lorlatinib and/or repotrectinib. The mIC-DOR was not reached, with no CNS progression observed among confirmed CNS responders. Also Read: Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold . The Phase 2 portion of the ALKOVE-1 trial of NVL-655 for TKI-nave and TKI-pretreated patients with advanced AKT-positive NSCLC and other solid tumors enrolled 229 patients. Pivotal data is expected in 2025. The Phase 1 portion of ALKOVE-1 enrolled 133 patients who received doses ranging from 15 to 200 mg QD, and 150 mg QD was selected as the recommended Phase 2 dose (RP2D). In the overall patient population, the ORR was 38% at RP2D and at all doses, with a DOR of over six months of 78% at all doses and 100% at RP2D. The median duration of response (mDOR) has yet to be reached for RP2D and reached 14.4 months for all doses. The company says the data in heavily pretreated patients could potentially to translate to deep, durable responses in the front-line setting. The company plans to initiate the Phase 3 ALKAZAR study with registrational intent for TKI-nave patients in the first half of 2025. On Monday, Nuvalent commenced an underwritten public offering of $350 million . Price Action: YQTW stock is up 22.6% at $107.26 at last check Monday. Photo via Shutterstock Read Next: Walgreens Agrees To $106.8M Settlement Over Alleged False Billing Claims .
2024-09-17 08:16:21	LLIQ	Sky Harbour Group Corporation Announces A Securities Purchase Agreement To Issue 3,352,106 PIPE Shares For Net Proceeds Of About $31.8M, On A Net Purchase Price Of $9.50 Per Share With Potential For Additional $63M By December 2024; Proceeds To Fund Aviation Infrastructure Expansion Plan Through 2026, Supporting Development Of 6-7 New Airport Campuses	"Sky Harbour Group Corporation (NYSE: LLIQ , LLIQ WS))))) (""SHG"" or the ""Company""), an aviation infrastructure company building the first nationwide network of Home-Basing campuses for business aircraft, announced it has entered a securities purchase agreement with certain investors to issue 3,352,106 PIPE shares of Class A Common Stock for aggregate net proceeds of approximately $31.8 million, on a net purchase price of $9.50 per share in an initial closing expected to occur no earlier than October 15, 2024 and no later than October 25, 2024, subject to customary closing conditions. In addition, the Company granted each investor the option to purchase one additional share of Class A Common Stock for each initial PIPE Share purchased in the initial closing at the same net price of $9.50 per share. These associated options to purchase additional PIPE Shares at a second closing expire on December 4th, 2024. Any PIPE Shares purchased at the second closing would be issued on or prior to December 20, 2024. At any time prior to the initial closing, at the Company's sole discretion, we may allow additional investors to purchase additional PIPE Shares and the associated option to purchase PIPE Shares at the second closing date, by executing a joinder to the securities purchase agreement. The price per share may be equal to or greater than $9.50, and the amount of PIPE Shares that may be purchased at the second closing may be equal to or less than the number of additional PIPE Shares purchased by such additional investors in the initial closing. The financing includes participation from investors in the Company's November 2023 PIPE, including affiliates of Altai Capital and Raga Partners, as well as Boulderado, the family office of SHG Board member Alex Rozek. The Company plans to leverage the potential proceeds of approximately $63 million of this PIPE financing from both closings, and other cash on hand, with the previously announced incremental $150 million in private activity debt financing, the latter expected to be issued in the first semester of 2025. The combined proceeds of approximately $240 million is intended to support the phase 1 development projects at approximately 6-7 new airport campuses (or approximately 800,000 additional rentable square feet), beyond the approximately one million rentable square feet already funded. As recently announced, the Company is forecasting to announce another eight ground leases by the end of 2025, bringing the portfolio to 22 airports. Discussions with the various potential debt providers continue, with fixed income markets continuing to improve in the Company's direction in terms of yield spreads and overall interest rates."
2024-09-17 09:18:09	GSMK	Lumen Announces Early Tender Results Of Exchange Offers For Unsecured Notes Of Lumen And Level 3	"Lumen Technologies, Inc. (NYSE: GSMK ) (""Lumen"") announced the early results of its offers to exchange newly-issued secured notes for certain of its outstanding unsecured senior notes. In addition, Lumen also announced the early results of the offers by Level 3 Financing, Inc., its indirect, wholly-owned subsidiary (""Level 3"" and, together with Lumen, the ""Issuers""), to exchange newly-issued second lien notes for certain of its outstanding unsecured senior notes. Lumen Exchange Offers As previously announced, Lumen has offered to exchange (collectively, the ""Lumen Exchange Offers"") up to $500,000,000 (the ""Lumen Notes Cap"") maximum aggregate principal amount of its newly-issued 10.000% Secured Notes due 2032 (the ""New Lumen Notes"") and certain cash consideration, as applicable, for its outstanding: 5.125% Senior Notes due 2026 (the ""2026 Lumen Notes""); 4.000% Senior Secured Notes due 2027 (Unsecured) (the ""2027 Lumen Notes""); 6.875% Debentures, Series G, due 2028 (the ""2028 Lumen Notes""); and 4.500% Senior Notes due 2029 (the ""2029 Lumen Notes"" and, together with the 2026 Lumen Notes, the 2027 Lumen Notes and the 2028 Lumen Notes, the ""Subject Lumen Notes""); subject to the terms and conditions set forth in Lumen's private offering memorandum, dated September 3, 2024 (the ""Lumen Offering Memorandum""), including the $100,000,000 limit (the ""New Notes Series Cap"") on the maximum aggregate principal amount of New Lumen Notes that Lumen may issue in exchange for the 2029 Lumen Notes."
2024-09-17 16:03:23	DBIR	Casella Waste Systems Commences Proposed Public Offering Of $400M Of Its Class A Common Stock	Casella also intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its Class A common stock sold in the public offering. All of the shares in the offering are to be sold by Casella. Casella intends to use the net proceeds from the offering to finance its previously announced acquisition of Royal Carting and Welsh Sanitation, to repay borrowings under its revolving credit facility and for general corporate purposes.
2024-09-17 17:11:29	VKYO	Altamira Therapeutics Reports Pricing Of Up To $12M Public Offering; $4M Upfront With Up To Additional $8M Of Aggregate Gross Proceeds Upon Exercise Of Milestone-linked Warrants	The company announced the pricing of a public offering of an aggregate of 5.55 million common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5.55 million common shares and Series A-2 common warrants to purchase up to 5.55 million common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant.
2024-09-18 08:13:17	WNDE	MicroStrategy Announces Pricing Of Its Offering Of $875M Aggregate Principal Amount Of 0.625% Convertible Senior Notes Due 2028	"MicroStrategy&#xAE; Incorporated (NASDAQ: WNDE ) (""MicroStrategy"") today announced the pricing of its offering of $875 million aggregate principal amount of 0.625% convertible senior notes due 2028 (the ""notes""). The notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). MicroStrategy also granted to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $135 million aggregate principal amount of the notes. The offering was upsized from the previously announced offering of $700 million aggregate principal amount of notes. The offering is expected to close on September 19, 2024, subject to satisfaction of customary closing conditions."
2024-09-19 09:31:27	ZCT	Haoxi Health Technology Limited Announces Pricing Of A $12M Underwritten Follow-On Public Offering Of 4M Units At A Price Of $3/Unit	"Haoxi Health Technology Limited (the ""Company"" or ""ZCT""), an online marketing solution provider headquartered in Beijing, China, today announced the pricing of its underwritten follow-on public offering (the ""Offering"") of 4,000,000 units (each a ""Unit,"" and collectively, the ""Units"") at an offering price of $3.00 per Unit (the ""Public Offering Price"") for total gross proceeds of $12,000,000, before deducting underwriting discounts and other offering expenses. Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the ""Class A Ordinary Share"") (or one pre-funded warrant to purchase one Class A Ordinary Share (the ""Pre-Funded Warrant"")), (ii) one Series A warrant to purchase one Class A Ordinary Share (the ""Series A Warrant"") (subject to certain adjustments therein), and (iii) one Series B warrant to purchase such number of Class A Ordinary Share described in the prospectus of the Offering (the ""Series B Warrant"", together with the Series A Warrant, the ""Warrants""). The Warrants will have a term of 5 years from the closing date of the Offering (the ""Closing Date""). The Series A Warrant is exercisable immediately upon issuance, or the Closing Date. The Series B Warrant is exercisable at any time on or after the sixteenth (16th) calendar day from the Closing Date (the ""Series B Exercise Date""). The Series A Warrants have an initial exercise price of $3.00 per Class A Ordinary Share. On the Series B Exercise Date, the exercise price of the Series A Warrant will be adjusted to $0.60 and the maximum number of Class A Ordinary Shares issuable upon exercise of the Series A Warrants will be adjusted to 20,000,000 shares. The exercise price of the Series B Warrants is $0.0001 per Class A Ordinary Share. The maximum number of shares issuable upon exercise of the Series B Warrants will be 16,000,000 shares. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Class A Ordinary Shares, the Pre-Funded Warrants, and related Warrants are immediately separable and will be issued separately in the Offering."
2024-09-19 13:29:41	IW	What's Going On With Hawaiian Electric Shares On Thursday?	Hawaiian Electric Industries, Inc. (NYSE: IW ) shares are trading lower on Thursday. Hawaiian Electric entered into an Equity Distribution Agreement to issue common shares of up to $ 250 million. The company is issuing shares through several agents Wells Fargo Securities, LLC, Barclays Capital Inc., and Guggenheim Securities, LLC. via an &#8220;at the market offering.&#8221; The agents will follow the company's instructions and receive up to 1% commission on gross sales proceeds, with customary indemnification provided. Last month, Hawaiian Electric and its subsidiary reached an agreement in principle to settle tort-related claims from the Maui windstorm and wildfires litigation for $1.91 billion. This amount, reduced by a $75 million credit, will be paid in four annual installments starting in mid-2025. The settlement is pending final documentation and court approval. HEI previously accrued a $1.71 billion loss for these liabilities, which may be adjusted as the settlement process evolves. Apart from this, Hawaiian Electric and UWM Hawaii Refining extended their Petroleum Fuels Supply Agreement through January 31, 2029, with automatic one-year renewals unless terminated with 120 days' notice. Price Action : IW shares are trading lower by 10.1% at $10.84 at the last check Thursday. Image via Shutterstock Read Next: WKD' Kuihelani Facility: Biggest Solar Plant In Hawaii Flips the Switch on Clean Energy Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
2024-09-19 16:42:57	CPEH	Chewy Announces A $500M Underwritten Offering Of Shares By Its Largest Shareholder, Buddy Chester Sub LLC; Chewy Will Concurrently Repurchase $300MOf Its Stock From The Selling Stockholder At The Offering Price, Separate From Its Existing Share Repurchase Program	"Chewy, Inc. (NYSE: CPEH ) (""Chewy""), a trusted destination for pet parents and partners everywhere, announced today the commencement of an underwritten offering of $500 million of shares of its Class A common stock, par value $0.01 per share, by Buddy Chester Sub LLC (the ""Selling Stockholder""), which is an entity affiliated with funds advised by BC Partners Advisors LP (""BC Partners""), Chewy's largest shareholder (the ""Offering""). The Selling Stockholder intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of Class A common stock. Chewy will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholder. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed. In addition, Chewy has agreed to purchase from the Selling Stockholder $300 million of Chewy's Class A common stock at a price per share equal to the per share purchase price to be paid by the underwriters in the Offering specified above (the ""Concurrent Repurchase""). The Concurrent Repurchase was approved by a special committee of Chewy's Board of Directors, consisting solely of independent and disinterested directors not affiliated with BC Partners. The repurchased shares will be cancelled and retired upon completion of the Concurrent Repurchase. The Concurrent Repurchase is being executed separately from the Company's existing $500 million share repurchase program authorized on May 24, 2024, which will be unaffected by this transaction. The Concurrent Repurchase is expected to be consummated concurrently with the Offering. The Offering is not conditioned upon the closing of the Concurrent Repurchase, but the Concurrent Repurchase is conditioned upon the closing of the Offering."
2024-09-19 16:56:41	XQKG	Diamondback Energy Announces Launch Of Secondary Common Stock Offering Of 11.27M Shares Of Common Stock; Diamondback Has Authorized The Purchase From The Underwriters Of 2M Shares Of Common Stock Offered In The Secondary Offering As Part Of Its Existing Repurchase Program	"Diamondback Energy, Inc. (NASDAQ: XQKG ) (""Diamondback"") announced today the launch of an underwritten public offering of 11,270,000 shares of its common stock by certain Legacy Endeavor Stockholders (the ""Selling Stockholders""), subject to market and other conditions (the ""Secondary Offering""). Diamondback will not receive any proceeds from the sale of the shares by the Selling Stockholders. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1,390,500 shares of common stock. In addition, Diamondback has authorized the purchase from the underwriters of 2,000,000 shares of common stock offered in the Secondary Offering (the ""Share Repurchase""). The Share Repurchase is part of the Diamondback's existing share repurchase program. Diamondback intends to fund the Share Repurchase from existing cash on hand. The underwriters will not receive any compensation for the shares being repurchased by Diamondback in the Share Repurchase. Evercore ISI, Citigroup and J.P. Morgan are acting as joint book-running managers for the Secondary Offering."
2024-09-19 17:10:49	CPEH	Chewy Stock Is Sliding After Hours: What's Going On?	Chewy Inc (NYSE: CPEH ) shares are trading lower in Thursday's after-hours session after the company announced a public offering by a selling stockholder and a concurrent share repurchase . What Happened: After the market close, Chewy announced an underwritten offering of $500 million of its common stock by Buddy Chester Sub LLC , which is an entity affiliated with funds advised by Chewy's largest shareholder BC Partners Advisors LP . The selling stockholder expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of Chewy common stock. The online pet retailer will not sell any shares in the offering or receive any proceeds. Chewy also agreed to purchase $300 million worth of its common stock from the selling stockholder at a price equal to the price paid by the underwriters in the offering. The repurchased shares will be canceled and retired upon completion of the concurrent repurchase. Chewy noted that its existing $500 million share repurchase program will not be affected by this transaction. Don't Miss: FedEx Q1 Earnings: Revenue Miss, EPS Miss, Lowered Guidance  'Challenging Quarter' CPEH Price Action: Chewy shares were down 3.09% in after hours, trading at $30.15 at the time of publication Thursday, according to Benzinga Pro . Photo: huoadg5888 from Pixabay.
2024-09-23 03:15:03	CU	Reported Friday, Empire Petroleum Announces $10M Rights Offering, Record Date Set for September 30	"Empire Petroleum Corporation (NYSE: CU ) (""Empire"" or the ""Company""), an oil and gas company with current producing assets in New Mexico, North Dakota, Montana, Texas, and Louisiana, announced today that its Board of Directors has fixed the close of business on September 30, 2024 as the record date (the ""Record Date"") for a subscription rights offering (""Rights Offering"") pursuant to which it intends to raise gross proceeds of up to approximately $10 million. The Company will distribute at no charge to holders of its common stock, par value $0.001 per share (""Common Stock""), as of the close of business on the Record Date one subscription right for each share of Common Stock held. Each subscription right will entitle the holder to purchase 0.063 shares of Common Stock at a subscription price of $5.05 per share. If fully subscribed, this would result in the issuance of an aggregate of approximately 1.98 million shares of Common Stock. The subscription rights are non-transferable, and will not be listed for trading on any stock exchange or market. In addition, holders of subscription rights who fully exercise their subscription rights will be entitled to over-subscribe for additional shares of Common Stock, subject to proration. The Rights Offering is expected to expire at 5:00 p.m., Eastern Time, on October 16, 2024 (""Expiration Date""), subject to extension or earlier termination."
2024-09-23 07:42:23	YUTP	Mativ Holdings To Raie $400M Via Proposed Private Offering of Senior Notes To Repay Debt	"Mativ Holdings, Inc. (""Mativ"" or the ""Company"") (NYSE: YUTP ) today announced that it has commenced a private offering that is exempt from registration under the Securities Act of 1933, as amended (the ""Securities Act""), subject to market and other conditions, of $400,000,000 in aggregate principal amount of senior notes due 2029 (the ""Notes""). The Notes will be senior unsecured obligations of the Company and will be guaranteed by each of the Company's existing and future wholly owned subsidiaries that is a borrower under or that guarantees obligations under its credit agreement or that guarantees certain other indebtedness, subject to certain exceptions. The Company intends to use the net proceeds from the offering (i) to redeem its 6.875% Senior Notes due 2026 (""2026 Notes"") and (ii) to repay approximately $43 million aggregate principal amount of outstanding borrowings under the term loan B facility under its credit agreement. The Notes and the related guarantees will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements under the Securities Act and any applicable securities laws of any other jurisdiction."
2024-09-23 07:57:05	ACK	Pebblebrook Hotel Trust To Raise $350M Via Proposed Offering of Senior Notes For Debt Repayment	"RepaymenrtPebblebrook Hotel Trust (NYSE: ACK ) (the ""Company"") today announced that its operating partnership, Pebblebrook Hotel, L.P. (the ""Operating Partnership""), and a wholly owned subsidiary of the Operating Partnership, ACK Finance Corp.(together with the Operating Partnership, the ""Issuers""), intend to offer, in a private placement, subject to market conditions and other factors, $350 million aggregate principal amount of senior notes due 2029 (the ""Notes""). The Notes will be senior unsecured obligations of the Issuers and will initially be fully and unconditionally guaranteed by the Company and the Operating Partnership's subsidiaries that guarantee the existing credit facilities of the Operating Partnership. The Operating Partnership intends to use the net proceeds from the offering as follows: (i) with at least $253.0 million, to pay down in whole or in part one or more of the Operating Partnership's unsecured term loans and (ii) with the balance, which may be up to $87.4 million, to pay down part of one or more of the Operating Partnership's other unsecured term loans and/or repurchase a portion of the convertible senior notes of the Company."
2024-09-23 08:24:13	PFXS	Innovative Eyewear Announces Exercise Of Warrants For $2.6M Gross Proceeds For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 263,160 Shares Of Common Stock Originally Issued By The Company On May 29, 2024, Each Having An Original Exercise Price Of $9.50 Per Share, At An Exercise Price Of $9.875 Per Share	"Innovative Eyewear, Inc. (""Innovative Eyewear"" or the ""Company"") (Nasdaq: PFXS ) , the developer of smart eyewear under the Lucyd&#xAE;, Nautica&#xAE;, Eddie Bauer&#xAE; and Reebok&#xAE; brands, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 263,160 shares of the Company's common stock originally issued by the Company on May 29, 2024, each having an original exercise price of $9.50 per share, at an exercise price of $9.875 per share. The closing of the warrant exercise transaction is expected to occur on or about September 24, 2024, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-279873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.6 million, prior to deducting placement agent fees and offering expenses. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes."
2024-09-23 08:25:20	QQBO	Matthews International Announced A Proposed Private Offering Of Senior Secured Second Lien Notes Due 2027	"Matthews International Corporation (NASDAQ GSM: QQBO) (the ""Company"") today announced a proposed private offering of senior secured second lien notes due 2027 (the ""Notes""). At or prior to the closing of the offering of the Notes, the Company intends to amend its senior credit facility to, among other things, permit the Notes to be secured by a second priority lien on substantially all of our and certain of our domestic subsidiaries' assets, and the Company and certain of its domestic subsidiaries intend to enter into a second amended and restated pledge and security agreement pursuant to which the Company and such subsidiaries will grant to the secured parties under the senior credit facility a first priority lien on substantially all of the Company's and such subsidiaries' assets. The Company intends to use the net proceeds of the offering, together with borrowings under the Company's senior credit facility, to redeem all of its outstanding 5.25% senior notes due December 1, 2025 (the ""Existing 2025 Notes"") on or about October 25, 2024, and to pay accrued and unpaid interest on the Existing 2025 Notes to, but not including, the date of redemption, and to satisfy and discharge the indenture governing the Existing 2025 Notes."
2024-09-23 08:47:19	MKOJ	Elevai Labs Inc. Announces Pricing Of $8M Public Offering Of 28,571,425 Shares Of Common Stock (Or Pre-Funded Warrants In Lieu Of Shares Of Common Stock). Each Share Of Common Stock Or Pre-Funded Warrant Will Be Sold With One Series A Warrant To Purchase One Share Of Common Stock At An Exercise Price Of $0.38/Share	"Elevai Labs, Inc. (NASDAQ: MKOJ ) (""Elevai"" or the ""Company""), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. The offering is comprised of 28,571,425 shares of the Company's common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.38 per share (the ""Series A Warrants"") and one Series B Warrant to purchase one share of common stock at an exercise price of $0.38 per share or, pursuant to an alternative cashless exercise option, three shares of common stock (the ""Series B Warrants"" and, together with the Series A Warrants, the ""Warrants""). The Series A Warrants will be exercisable beginning on the date of completion of the requisite waiting period following the filing of the Information Statement related to the approval by the stockholders of the Company (the ""Initial Exercise Date"" or ""Effective Shareholder Approval Date"") of the issuance of shares upon exercise of the Warrants, among other things (the ""Shareholder Approval""). The Series B Warrants will be exercisable beginning on the Effective Shareholder Approval Date. The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date and the Series B Warrants will expire on the two and one-half-year anniversary of the Initial Exercise Date. The purchase price of each share of common stock and accompanying Warrants is $0.28, and the purchase price of each pre-funded warrant and accompanying Warrants will be equal to such price minus $0.0001. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital and investments. This offering is expected to close on or about September 24, 2024, subject to satisfaction of customary closing conditions. Univest Securities, LLC is acting as sole placement agent for the offering."
2024-09-23 16:17:02	HGJ	Seaport Entertainment Commences Previously Announced $175M Rights Offering To Purchase Up To 7M Shares Of Its Common Stock	The Rights Offering is being backstopped by investment funds advised by Pershing Square. Pershing Square has agreed to (i) exercise its pro rata subscription Right with respect to the Rights Offering and (ii) purchase from the Company, subject to the terms and conditions thereof, at the Rights Offering subscription price of $25.00 per share, any shares of the Company's common stock not purchased upon the expiration of the Rights Offering, up to $175.0 million in the aggregate, such that the aggregate gross proceeds to the Company of the Rights Offering would be $175.0 million.
2024-09-23 16:36:00	OBO	Simon Property Group Sells $1B Aggregate Principal Amount Of Its 4.750% Notes Due 2034	"Simon&#xAE;, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, announced today that its majority-owned operating partnership subsidiary, Simon Property Group, L.P. (the ""Operating Partnership""), has agreed to sell $1.0 billion aggregate principal amount of its 4.750% Notes due 2034. The new issue of senior notes has a term of 10 years and a coupon rate of 4.750%. The offering is expected to close on September 26, 2024, subject to customary closing conditions. The Operating Partnership intends to use the net proceeds of the offering for general corporate purposes, including to repay other unsecured indebtedness."
2024-09-23 16:49:08	DBBV	Snowflake Stock Dips On Offering After-Hours: What To Know	Snowflake Inc. (NYSE: DBBV ) shares are trading lower in Monday's after-hours session after the company announced a $2 billion private placement of senior convertible notes. The Details: Snowflake announced it intends to offer $1 billion aggregate principal amount of its convertible senior notes due 2027 and a $1 billion aggregate principal amount of its convertible senior notes due 2029. The company also intends to grant the initial purchasers of the notes options to purchase up to an additional $150 million aggregate principal amount of the 2027 notes and up to an additional $150 million aggregate principal amount of the 2029 notes. Read Next: Homebuilder Lennar Reports Better-Than-Expected Q3 Results: Details According to data from Benzinga Pro , Snowflake shares are trading below the stock's 50-day moving average of $121.30 and near its 52-week low of $107.13. Will DBBV Stock Go Up? When trying to assess whether or not Snowflake will trade higher from current levels, it's a good idea to take a look at analyst forecasts. Wall Street analysts have an average 12-month price target of $166.93 on Snowflake. The Street high target is currently at $220 and the Street low target is $121. Of all the analysts covering Snowflake, 19 have positive ratings, nine have neutral ratings and no one has negative ratings. In the last month, no analysts have adjusted price targets. Here's a look at recent price target changes [Analyst Ratings] . Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Snowflake have performed in recent history. Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Snowflake is 40.11% down year-to-date. The average analyst price target suggests the stock could have further upside ahead. For a broad overview of everything you need to know about Snowflake, visit here . If you want to go above and beyond, there's no better tool to help you do just that than Benzinga Pro . Start your free trial today. DBBV Price Action: According to Benzinga Pro , Snowflake shares are down 2.62% after-hours at $110.29 at the time of publication Monday. Read Also: Shipping Giants FedEx, UPS Stocks Slip Friday: What's Going On? Image: Shutterstock
2024-09-23 16:59:03	ACI	GameStop Stock Jumps Monday After The Bell: What's Going On?	GameStop Corp (NYSE: ACI ) shares are rising in extended trading Monday after the company announced the completion of its at-the-market offering program . What Happened: After the market close on Monday, GameStop said it completed its previously announced offering program. On Sept. 10, GameStop updated its prospectus to allow the company to offer and sell up to 20 million shares of its common stock from time to time. The video game retailer announced Monday it sold the maximum number of shares registered under the program for gross proceeds of approximately $400 million. GameStop expects to use net proceeds for general corporate purposes, which may include acquisitions and investments. GameStop stock is extremely popular among retail investors, which has helped spark some wild swings in the stock in recent years. GameStop management has taken advantage of the volatility by raising cash several times along the way. GameStop had $4.204 billion in cash, cash equivalents and marketable securities as of the end of the second quarter. Don't Miss: Trump's Historic Bitcoin Transaction, Ethereum Co-Founder Backs Trump Over Harris For Crypto, Gamestop Customer's Bitcoin Windfall, And More: This Week In Cryptocurrency ACI Price Action: GameStop shares were up 1.34% in after-hours, trading at $22.31 at the time of publication Monday, according to Benzinga Pro . Photo: JJBers from Flickr.
2024-09-24 02:54:33	XOV	Reported Earlier, InvenTrust Properties Raised $224M Via Upsized Secondary Stock Offering Of 8M Shares (Prior $6.5M Shares) At $28/Share	"InvenTrust Properties Corp. (""InvenTrust"" or the ""Company"") (NYSE: XOV ) today announced it has priced an underwritten registered public offering of 8,000,000 shares of its common stock at a price to the public of $28.00 per share for total gross proceeds of $224.0 million. As part of the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of the Company's common stock at the public offering price, less the underwriting discount. The offering is expected to close on September 25, 2024 subject to customary closing conditions. J.P. Morgan, BofA Securities, and Wells Fargo Securities are acting as joint-book-running managers for the public offering. Jefferies and KeyBanc Capital Markets are acting as additional bookrunners for the public offering. BTIG and Fifth Third Securities are acting as co-managers for the public offering. The Company intends to use the net proceeds for general corporate purposes, including, but not limited to, funding the acquisition of additional properties, repayment of short-term and long-term indebtedness (including mortgage loans, including a $72.5 million loan with Bank of America, N.A, and amounts outstanding from time to time under the Company's revolving credit facility) and providing for working capital."
2024-09-24 02:57:15	ZLDA	Reported Earlier, BioVie Raised $3M VIa Secondary Stock Offering Of 1.96M Shares At $1.53/Share	"BioVie Inc. (NASDAQ: ZLDA ), (""BioVie"" or the ""Company""), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (""Pre-funded Warrants"") in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $3,000,000, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock (or Pre-funded Warrants) and associated warrants are being offered by the Company. The offering is expected to close on September 25, 2024, subject to satisfaction of customary closing conditions."
2024-09-24 03:07:26	FZGH	Reported Earlier, New Mountain Finance Raised $300M Via Secondary Offering Of Unsecured Notes Due 2027	"New Mountain Finance Corporation (the ""Company,"" ""we,"" ""us"" or ""our"") (NASDAQ: FZGH ) today announced that it has priced an underwritten public offering of $300 million in aggregate principal amount of 6.200% unsecured notes due 2027 (the ""Notes""). The Notes will mature on October 15, 2027, and may be redeemed in whole or in part at the Company's option at any time prior to October 15, 2027, at par plus a ""make-whole"" premium plus accrued interest. The Notes will bear interest at a rate of 6.200% per year payable semi-annually on April 15 and October 15 of each year, beginning April 15, 2025. The offering is expected to close on September 26, 2024, subject to the satisfaction of customary closing conditions."
2024-09-24 03:10:38	CMFJ	Reported Earlier, F-Mobile To Raise $2.5B Via Senior Notes Offering	"F-Mobile US, Inc. (NASDAQ: CMFJ ) (""F-Mobile"") announced today that F-Mobile USA, Inc., its direct wholly-owned subsidiary (""F-Mobile USA"" or the ""Issuer""), has agreed to sell $700,000,000 aggregate principal amount of its 4.200% Senior Notes due 2029 (the ""2029 Notes""), $900,000,000 aggregate principal amount of its 4.700% Senior Notes due 2035 (the ""2035 Notes"") and $900,000,000 aggregate principal amount of its 5.250% Senior Notes due 2055 (the ""2055 Notes,"" and collectively with the 2029 Notes and the 2035 Notes, the ""notes"") in a registered public offering. The offering of the notes is scheduled to close on September 26, 2024, subject to satisfaction of customary closing conditions. F-Mobile USA intends to use the net proceeds from the offering for general corporate purposes, which may include among other things, share repurchases, any dividends declared by F-Mobile's Board of Directors and refinancing of existing indebtedness on an ongoing basis."
2024-09-24 03:14:14	NJH	Reported Earlier, First American Financial Raised $450M Via Senior Notes Offering For Debt Repayment	First American Financial Corporation (NYSE: NJH ), a premier provider of title, settlement and risk solutions for real estate transactions, today announced the pricing of a public offering of $450 million of its 5.450 percent senior notes due 2034. The offering is expected to close on September 30, 2024, subject to customary conditions. The notes will be general senior unsecured obligations of the company and will rank equally in right of payment with the company's existing and future senior unsecured indebtedness. Interest will be paid semi-annually on March 30 and September 30, beginning March 30, 2025. The company intends to use the net proceeds from the sale of the notes for repayment at maturity of the company's 4.60% senior notes due 2024 and for general corporate purposes, which may include, among other possible uses, acquisitions, funding for working capital, repurchase of the company's capital stock and other capital expenditures. The company may also use the net proceeds for temporary investments until it needs them for general corporate purposes.
2024-09-24 08:19:32	GN	GN Announces Successful Early Tender Results In Private Exchange Offer And Consent Solicitation For Any And All Of Stericycle $500M Outstanding 3.875% Senior Notes Due 2029	"Waste Management, Inc., a Delaware corporation (NYSE: GN ) (""GN""), announced today that it has received, on behalf of Stericycle, Inc., a Delaware corporation (""SRCL""), the requisite consents to amend the 3.875% Senior Notes due 2029 (the ""SRCL Notes"") issued by SRCL and the indenture governing the SRCL Notes (the ""SRCL Indenture"") to eliminate substantially all of the restrictive covenants and events of default, other than payment-related, guarantee-related and bankruptcy-related events of default (collectively, the ""Proposed Amendments""), based on the early tender results in connection with GN's previously announced (i) private offer to exchange (the ""Exchange Offer"") any and all of the $500 million aggregate principal amount outstanding of SRCL Notes held by eligible holders for a series of new notes to be issued by GN (the ""GN Notes""), and (ii) GN's related solicitation of consents, on behalf of SRCL (the ""Consent Solicitation""), to adopt the Proposed Amendments, pursuant to the terms and subject to the conditions set forth in an exchange offer memorandum and consent solicitation statement, dated September 10, 2024 (the ""Offering Memorandum"")."
2024-09-24 10:00:59	IW	Why Hawaiian Electric Stock Is Down Today	Hawaiian Electric Industries, Inc. (NYSE: IW ) shares are trading lower Tuesday after the company announced a secondary offering of 54 million shares of its common stock at a price of $9.25 per share . The Details: Hawaiian Electric said the offering is expected to close on Sept. 25 subject to customary closing conditions. The company has granted the underwriters of the offering an option to purchase up to an additional 8.1 million shares of common stock at the public offering price. HEI intends to use the net proceeds from the offering to fund its contribution to the expected Maui wildfire tort litigation settlement and for general corporate purposes. Read Next: Snowflake Stock Dips On Offering After-Hours: What To Know Hawaiian Electric shares are moving on heavy volume Tuesday with more than 5.6 million shares traded before the opening bell. According to data from Benzinga Pro , the stock is moving below its 50-day moving average of $13.25 and is approaching its 52-week low of $7.60. Will IW Stock Go Up? When trying to assess whether or not Hawaiian Electric will trade higher from current levels, it's a good idea to take a look at analyst forecasts. Wall Street analysts have an average 12-month price target of $15.0 on Hawaiian Electric Indus. The Street high target is currently at $16 and the Street low target is $14. Of all the analysts covering Hawaiian Electric Indus, no one has positive ratings, 3 have neutral ratings and one has a negative rating. In the last month, no analysts have adjusted price targets. Here's a look at recent price target changes [Analyst Ratings] . Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Hawaiian Electric Indus have performed in recent history. Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Hawaiian Electric Indus is 29.22% down year-to-date. The average analyst price target suggests the stock could have further upside ahead. For a broad overview of everything you need to know about Hawaiian Electric Indus, visit here . If you want to go above and beyond, there's no better tool to help you do just that than Benzinga Pro . Start your free trial today. IW Price Action: According to Benzinga Pro , Hawaiian Electric Industries shares are down 10.1% at $9.79 at the time of publication Tuesday. Read Also: What Happened With Palantir Stock Today? Image: Shutterstock
2024-09-24 16:01:51	UJJ	Wave Life Sciences Announces $175M Proposed Public Offering Of Ordinary Shares and Pre-Funded Warrants	Wave Life Sciences Ltd. (NASDAQ: UJJ ), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences. J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering. Truist Securities and Mizuho are acting as book-runners for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2024-09-25 02:39:06	OTFE	Reported Earlier, Rithm Capital Raised $342.9M Via Secondary Stock Offering Of 30M Shares	"Rithm Capital Corp. (NYSE: OTFE , ""Rithm"" or the ""Company""))))) announced today that it priced its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of approximately $342.9 million, before deducting estimated underwriting discounts and commissions and estimated offering expenses. In connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 4,500,000 shares of common stock. The underwriters may offer the shares from time to time for sale in negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The offering is expected to close on September 26, 2024, subject to customary closing conditions. The Company intends to use the net proceeds from this offering for general corporate purposes."
2024-09-25 02:43:55	P	Reported Earlier, Wayfair Raised $800M (Prior $700M) Via Upsized Secondary Senior Secured Notes Offering For Debt Repayment	"Wayfair Inc. (NYSE: P ) (the ""Company,"" ""we"" or ""Wayfair"") today announced the pricing by its subsidiary, Wayfair LLC (the ""Issuer""), of its private offering of $800 million in aggregate principal amount of 7.250% senior secured notes due 2029 (the ""Notes""). The offering size was increased to $800 million from the previously announced offering size of $700 million in aggregate principal amount of Notes. The Notes will mature on October 31, 2029, unless earlier repurchased or redeemed in accordance with their terms. The Notes oering is expected to close on October 8, 2024, subject to customary closing conditions. We intend to use the net proceeds from the Notes oering, together with cash on hand, for the repayment of certain of Wayfair's existing convertible senior notes and general corporate purposes."
2024-09-25 08:23:16	CRRM	Post Holdings Intends To Commence A Private Offering To Eligible Purchasers $500M In Aggregate Principal Amount Of Senior Notes Due 2034	"Post Holdings, Inc. (NYSE: CRRM ) (the ""Company"" or ""Post"") today announced it intends to commence a private offering to eligible purchasers, subject to market and other conditions, of $500.0 million in aggregate principal amount of senior notes due 2034 (the ""Notes""). The Notes will be unsecured, senior obligations of the Company and will be guaranteed by the Company's existing and subsequently acquired or organized domestic subsidiaries (other than immaterial subsidiaries, certain excluded subsidiaries and subsidiaries designated as unrestricted subsidiaries). The Company intends to use the net proceeds from the Notes offering to pay the costs, fees and expenses associated with the Notes offering and to redeem all of the Company's outstanding 5.625% senior notes due 2028, including payment of any premiums, fees, costs and expenses associated therewith. To the extent there are any remaining net proceeds, the Company intends to use such proceeds for general corporate purposes, which could include, among other things, acquisitions, share repurchases, retirement or repayment of existing debt, capital expenditures and working capital. The final terms and amounts of the Notes are subject to market and other conditions and may be materially different than expectations. The offering is not conditioned upon the consummation of the redemption of the Company's 5.625% senior notes due 2028, which is expected to occur on or after December 1, 2024."
2024-09-26 02:53:03	UJJ	Reported Earlier, Wave Life Sciences Raised $200M Via Secondary Stock Offering Of 23.1M Shares At $8/Share	Wave Life Sciences Ltd. (NASDAQ: UJJ ), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. All of the securities in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about September 27, 2024, subject to customary closing conditions.
2024-09-26 08:46:59	ANRU	OneMedNet Announces Additional $1.7M Private Placement, Before Deducting Fees And Expenses Payable By The Company; OneMedNet Sold An Aggregate Of 1,918,591 Shares Of Its Common Stock At A Price Of $0.65 Per Share	"OneMedNet Corporation (NASDAQ: ANRU ) (""OneMedNet"" or the ""Company""), the leading curator of regulatory-grade Real World Data (""RWD""), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, today announced that it has entered into a securities purchase agreement with an affiliate of Off the Chain Capital (collectively, ""Off the Chain"") in a follow-on private placement that resulted in gross proceeds of approximately $1.7 million, before deducting fees and expenses payable by the Company. OneMedNet previously consummated a private placement with Off the Chain Capital on July 24, 2024 that resulted in gross proceeds of $2.7 million. The private placement closed on September 25, 2024. The price per share of common stock sold in this offering meets the minimum price requirement under Nasdaq rules. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. Pending use of the funds, the Company plans to use a portion of the net proceeds to purchase Bitcoin ($BTC). Pursuant to the terms of the securities purchase agreement, OneMedNet sold an aggregate of 1,918,591 shares of its common stock at a price of $0.65 per share, warrants exercisable for 133,095 shares of its common stock at an exercise price of $0.325 per share and pre-funded warrants exercisable for 743,314 shares of its common stock at an exercise price of $0.65 per share. The investor prepaid the exercise price for the pre-funded warrants, other than $0.0001 per share. The terms of the transaction were otherwise generally consistent with the previous Off the Chain private placement."
2024-09-27 02:46:05	YHA	Cue Biopharma's $12M Public Offering Includes Pre-Funded Warrants at $0.50/Share	Cue Biopharma, Inc. (NASDAQ: YHA ), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific F cells, today announced the pricing of an underwritten public offering of (i) 11,564,401 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 2,891,100 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 12,435,599 shares of common stock and accompanying common stock warrants to purchase an aggregate of 3,108,900 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.50, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.499. The aggregate gross proceeds of the offering are expected to be approximately $12.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.50 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about September 30, 2024, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.
2024-09-27 02:49:22	BCBI	enVVeno Medical's $15M Public Offering of 4.3M Shares At $3.50/Share Aims to Fund VenoValve and enVVe Development	"enVVeno Medical Corporation (NASDAQ: BCBI ) (""enVVeno"" or the ""Company""), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public offering led by existing institutional investors of 4,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The purchase price of each pre-funded warrant sold in the offering will be equal to the price at which a share of common stock is sold in the offering, minus $0.0001, and the exercise price of each pre-funded warrant will equal $0.0001 per share. In connection with the offering, enVVeno has granted the underwriter a 30-day option to purchase up to an additional 642,857 shares of common stock from the Company at the public offering price, less underwriting discounts and commissions. Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. enVVeno expects to receive aggregate gross proceeds from the offering, excluding the exercise of the underwriter's option, if any, of approximately $15.0 million, excluding underwriting discounts and commissions and other offering-related expenses. The offering is expected to close on or about September 30, 2024, subject to customary closing conditions. enVVeno intends to use the net proceeds from the offering primarily for the continued development of enVVeno's two lead products, VenoValve and enVVe, and for general corporate purposes, including working capital."
2024-09-27 02:52:40	KSK	Pagaya Priced Upsized $140M Exchangeable Senior Notes Offering (Up From Prior Size Of $125M) For Debt Repayment	"Pagaya Technologies LTD. (NASDAQ: KSK ) (""Pagaya"" or the ""Company""), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced that its wholly owned subsidiary, Pagaya US Holding Company LLC (""Pagaya US""), priced its offering of $140 million aggregate principal amount of exchangeable senior notes due 2029 (the ""notes"") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). The offering size was increased from the previously announced offering size of $125 million aggregate principal amount of notes as a result of strong demand on the offering. The issuance and sale of the notes is scheduled to settle on October 1, 2024, subject to customary closing conditions. Pagaya US also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $20 million principal amount of notes. Pagaya intends to use the net proceeds from the offering of the notes to repay higher-cost debt facilities and reduce interest expense costs with the remainder for general corporate purposes. The notes will be senior, unsecured obligations of Pagaya US, and will accrue interest at a rate of 6.125% per annum, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2025. The notes will mature on October 1, 2029, unless earlier repurchased, redeemed or exchanged. Prior to the close of business on the business day immediately preceding July 2, 2029, the notes will be exchangeable at the option of the holders of notes only upon the satisfaction of specified conditions and during certain periods. On or after July 2, 2029 until the close of business on the second scheduled trading day immediately preceding the maturity date, the notes will be exchangeable at the option of the holders of the notes at any time regardless of these conditions. Subject to certain conditions, Pagaya US may settle exchanges of the notes by paying or delivering, as applicable, cash, Class A ordinary shares of Pagaya or a combination of cash and Class A ordinary shares of Pagaya, at the election of Pagaya US. The notes will be fully and unconditionally guaranteed, on a senior unsecured basis, by Pagaya. The initial exchange rate is 71.4669 Class A ordinary shares of Pagaya per $1,000 principal amount of notes, which represents an initial exchange price of approximately $13.99 per Class A ordinary share of Pagaya. The initial exchange price represents a premium of approximately 45% over the last reported sale price of $9.65 per Class A ordinary share of Pagaya on September 26, 2024. The exchange rate and exchange price will be subject to adjustment upon the occurrence of certain events. If a ""make-whole fundamental change"" (as defined in the indenture for the notes) occurs, Pagaya US will, in certain circumstances, increase the exchange rate for a specified time for holders who exchange their notes in connection with that make-whole fundamental change. The notes will not be redeemable prior to October 5, 2027. The notes will be redeemable, in whole or in part (subject to certain limitations on partial redemptions), for cash at the option of Pagaya US at any time, and from time to time, on or after October 5, 2027 and on or before the 41st scheduled trading day immediately before the maturity date, but only if the last reported sale price per Class A ordinary share of Pagaya exceeds 130% of the exchange price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If Pagaya US calls any or all notes for redemption, holders of notes called for redemption may exchange their notes during the related redemption exchange period, and any such exchange will also constitute a ""make-whole fundamental change"" with respect to the called notes so exchanged. If a ""fundamental change"" (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Pagaya US to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. The offering price of the notes is 95% of the principal amount of notes. Pagaya estimates that the net proceeds from the offering will be approximately $128.1 million (or approximately $146.5 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers' discounts and commissions and Pagaya's estimated offering expenses."
2024-09-27 02:55:42	BHGL	Theriva Biologics Priced $2.5M Offering with New Warrants At $1.75/Share, Eyes Unmet Cancer Needs	"Theriva Biologics, Inc. (NYSE: BHGL ) (""Theriva"" or the ""Company""), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its ""reasonable best efforts"" public offering for the purchase and sale of up to 1,428,600 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,428,600 shares of common stock at a combined offering price of $1.75 per share and accompanying warrant (the ""Offering""). The Company expects to receive aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $2.00 per share, will be exercisable immediately and will expire five years from the issuance date."
2024-09-27 03:08:44	KEYV	KEYV Plans to Pay Down Debt With Proceeds From $150M Unsecured Notes Offering	"KEYV Investment Corporation (NYSE: KEYV ) (the ""Company"" or ""KEYV"") announced today that it has priced an underwritten public offering of $150.0 million aggregate principal amount of unsecured notes due 2029 (the ""Notes""), which will result in net proceeds to the Company of approximately $145.4 million after the payment of underwriting discounts and commissions and estimated offering expenses payable by the Company. The Notes will mature on December 30, 2029 and may be redeemed in whole or in part at any time or from time to time at the Company's option on or after December 30, 2026. The Notes will be issued in denominations of $25 and integral multiples of $25 in excess thereof and will bear interest at a rate of 7.50% per year, payable quarterly, with the first interest payment occurring on December 30, 2024. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of Notes to cover overallotments, if any. The offering is expected to close on October 3, 2024, subject to customary closing conditions. The Company intends to list the Notes on the New York Stock Exchange under the symbol ""CICB."" The Company intends to use the net proceeds of the offering of the Notes to pay down borrowings under the Company's senior secured credit facility with JPMorgan Chase Bank, National Association."
2024-09-27 08:33:18	MAYK	Eyenovia, Inc. Announces Pricing Of $4M Offering For The Purchase And Sale Of 8,695,653 Shares Of Its Common Stock And Warrants In A Registered Direct Offering At A Combined Offering Price Of $0.46 Per Share And Accompanying Warrant	"Eyenovia, Inc. (NASDAQ: MAYK ) (""Eyenovia"" or the ""Company""), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,695,653 shares of common stock in a registered direct offering at a combined offering price of $0.46 per share and accompanying warrant. The warrants have an exercise price of $0.50 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about September 30, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering will be approximately $4 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, which may include the repayment of a portion of existing indebtedness. A.G.P./Alliance Global Partners is acting as the lead placement agent for the offering and Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as a co-placement agent for the offering."
2024-09-27 08:40:10	XEUX	VCI Global Announces Termination Of Its At-the-Market Offering Program; As Of The Termination Date, The ATM Program Has Generated Total Gross Proceeds Of ~1.77M	"VCI Global Limited (NASDAQ: XEUX ) (Frankfurt: H0T) (""VCI Global,"" ""XEUX,"" or the ""Company"") today announced the termination of its At-The-Market equity offering program (""ATM program"") with L.C. Wainwright & Co., LLC as sales agent. The ATM program, which was initiated to offer shares totaling approximately US$4.96 million from time to time, was formally terminated on September 25, 2024. As of the termination date, the ATM program has generated total gross proceeds of approximately US$1.77 million. The Company views this as an opportunity to explore more favorable financing options that better align with its long-term growth objectives. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any province, state, or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state, or jurisdiction."
2024-09-27 08:51:58	VJLF	MidWestOne Financial Group Announces Pricing Of $103.5M Offering Of 4.347M Shares Of Common Stock At A Price Of $25/Share	"MidWest One Financial Group, Inc. (NASDAQ: VJLF ) (the ""Company""), parent company of MidWest One Bank (the ""Bank""), today announced the pricing of its previously announced underwritten public offering of 4,347,000 shares of its common stock at a public offering price of $25.00 per share. The expected proceeds to the Company, after deducting underwriting discounts and commissions but before deducting operating expenses payable by the Company, are approximately $103.5 million. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 652,050 shares of Company common stock at the public offering price, less underwriting discounts, and commissions. The Company intends to invest all of the net proceeds from this offering into the Bank, to support the Bank's capital ratios in connection with the potential repositioning of a substantial portion of its available-for-sale and held-to-maturity securities portfolio. Keefe, Bruyette & Woods, Inc., A Stifel Company (""KBW""), is serving as the sole manager for the offering."
2024-09-27 09:03:50	XIJ	Color Star Technology Announces Pricing Of Initial $7M Tranche Of Up To $33M Registered Senior Secured Convertible Notes	"Color Star Technology Co., Ltd. (NASDAQ: XIJ ) (""Color Star"" or the ""Company""), an entertainment technology company with a global network that focuses on the application of technology and artificial intelligence in the entertainment industry, today announced it has entered into securities purchase agreements with certain institutional investors (the ""Investors"") to purchase senior secured convertible notes in the aggregate principal amount of $7.6 million (the ""First Closing""), having an original issue discount of 8% and a maturity of twelve months from issuance, resulting in net proceeds to the Company of approximately $7,000,000 (the ""Convertible Notes""). The Convertible Notes will bear an interest rate of 6.0% per annum and will be convertible 45 days after the date of the First Closing, subject to certain conditions, into Class A Ordinary Shares of the Company (the ""Ordinary Shares"") at an initial conversion price equal to the lower of $1.60, or the Alternative Conversion Price, as set forth in the Convertible Notes. This First Closing is expected to occur on or about September 30, 2024, subject to the satisfaction of customary closing conditions. Under the terms of the securities purchase agreements, the Convertible Notes will be issued to the Investors, together with registered warrants to purchase up to an aggregate of approximately 2.9 million Ordinary Shares. The warrants to be issued at the First Closing will be exercisable 45 days after issuance, subject to certain conditions (the ""Initial Exercise Date""), will expire on the five-year anniversary of the Initial Exercise Date, and will have an exercise price of $1.60 per share and contain certain anti-dilution provisions. Maxim Group LLC is acting as the sole placement agent in connection with the offering."
2024-09-27 16:09:18	XHET	US Foods Announces Pricing Of Private Offering Of $500M Aggregate Principal Amount Of 5.75% Senior Unsecured Notes Due 2033	"US Foods Holding Corp. (NYSE: XHET ) today announced that its wholly-owned subsidiary, US Foods, Inc. (""US Foods""), has priced the previously announced notes offering and has agreed to issue and sell $500 million aggregate principal amount of 5.75% senior unsecured notes due 2033 (the ""Notes""). US Foods intends to use the net proceeds of the Notes offering to repay a portion of the amounts outstanding under its term loan facility. The Notes will be the senior unsecured obligations of US Foods and will be guaranteed by all of US Foods' existing and future wholly-owned domestic subsidiaries that guarantee US Foods' obligations under its existing term loan credit facility. The closing of the sale of the Notes is scheduled for October 3, 2024, subject to customary closing conditions."
2024-09-30 02:54:15	YCBJ	Reported Earlier, Mesoblast Secures $50M Convertible Note Deal, Prepares for Ryoncil FDA Approval and Launch	"Mesoblast Limited (NASDAQ: YCBJ , ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into a convertible note subscription agreement with its largest shareholder Gregory George (""Investor"") for issue, at its sole discretion, up to US$50.0 million (A$72.7 million) convertible notes on approval by the United States Food and Drug Administration (FDA) of Mesoblast's lead product candidate Ryoncil&#xAE; (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). The funding is available at Mesoblast's option and will enable the Company to seamlessly implement its go-to-market commercial strategy. Mesoblast anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025. Mesoblast Chief Executive Silviu Itescu said: ""We appreciate the ongoing support from our major shareholder in ensuring that the Company is well capitalized for commercial product launch and can hit the ground running immediately following approval of RYONCIL by FDA."" Activities For Go to Market Strategy for RYONCIL in children with SR-aGvHD Hiring of select senior positions to build targeted commercial team has commenced. Key Pre-Launch Activities include: Market Access initiates payer outreach Medical provides education to payers Corporate leadership initiates engagement with Top 15 centers Regional sales directors lead center profiling Ongoing KOL engagement with greatest experience using RYONCIL at highest volume centers Non-promotional activities including profiling high-volume centers, education on disease awareness & unmet needs, and payer engagement Post-launch - Staged approach based on centers with highest volume and experience with product. Targeted sales force with experience in bone marrow transplant centers - 15 highest volume centers account for ~50% of patients. Key terms of the Convertible Notes Mesoblast at its sole discretion, to issue up to US$50 million of convertible notes in tranches of US$10 million at any time following an FDA approval of RYONCIL for a 90-day period. The convertible notes have a coupon of 5% per annum on the face value of issued notes. A commitment fee comprising 2 million warrants to subscribe for up to 2 million ordinary shares (or 200,000 Mesoblast ADRs) is payable on signing of the convertible note subscription agreement and a further commitment fee comprising 3 million warrants to subscribe for up to 3 million ordinary shares (300,000 Mesoblast ADRs) is payable on the first issue of convertible notes. The warrants have an exercise price of US$9.06 per ADR and a maturity date of 4 years from the date of first issuance of the warrants. The conversion price of the convertible notes will be US$9.06 per ADR (American Depository Receipt) equivalent to A$1.32 per ASX-listed share, representing a 25% premium to Mesoblast's 5-day volume weighted average share price (""VWAP"") up to and including the close of trading on NASDAQ on Friday, September 27th, 2024. The maturity date of the convertible notes will be 4 years after the first issuance of notes (unless redeemed or converted earlier). At any time up to the maturity date, the Investor may elect to convert convertible notes issued into fully paid ordinary shares or ADRs of Mesoblast, at the conversion price. The convertible notes will be unsecured and be subordinated to the Company's two existing secured financing facilities. The conversion price is subject to adjustment mechanisms in the event of future share issues, capital reductions, share consolidations and other corporate actions in accordance with customary adjustment rules."
2024-09-30 07:28:46	SAL	Terex Seeks $1.25B Term Loan and $750M Senior Notes Offering for Dover Unit Purchase	"Terex Corporation (""Terex"") (NYSE: SAL ) today announced that it intends to offer, subject to market and other conditions, $750 million in aggregate principal amount of senior notes due 2032 (the ""Notes"") in a private offering (the ""Private Offering"") that is exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""). Terex intends to use the proceeds from the Private Offering, together with the new term loan borrowings described below and cash on hand, to consummate Terex's previously announced acquisition (the ""Acquisition"") of the subsidiaries and assets of Dover Corporation (""Dover"") that constitute Dover's Environmental Solutions Group (""ESG""), and to pay related fees, costs and expenses. The Notes and the related guarantees will be offered and sold only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act and to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been, and will not be, registered under the Securities Act, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and the rules promulgated thereunder. Concurrently with the Private Offering, Terex is also seeking to amend (the ""Amendment"") its existing credit agreement (i) to increase the size of its revolving credit facilities to $800 million from $600 million and to extend the maturity of its revolving credit facilities to the fifth anniversary of the closing of the Acquisition and (ii) to provide for a new term loan facility which will mature on the seventh anniversary of the closing of the Acquisition and pursuant to which Terex expects to incur term loans in an aggregate amount of up to $1,250 million. There can be no assurance that Terex will be able to complete the Private Offering or the Amendment on terms and conditions favorable to it or at all."
2024-09-30 08:48:44	AKT	Alaska Air Group Has Launched A Private Offering Of Senior Secured Notes Due 2029 And Senior Secured Notes Due 2031	"Alaska Air Group, Inc. (the ""Company"") today announced that it has launched a private offering (the ""Offering"") of senior secured notes due 2029 and senior secured notes due 2031 (together, the ""Notes"") by AS Mileage Plan IP Ltd. (""Loyalty Issuer""), an exempted company incorporated with limited liability under the laws of the Cayman Islands and an indirect, wholly-owned subsidiary of the Company. The Notes will be (i) fully and unconditionally guaranteed on a senior secured basis, jointly and severally, by Alaska Airlines, Inc. (""Alaska"") and AS Mileage Plan Holdings Ltd. and on an unsecured basis by the Company (together, the ""Guarantors"") and (ii) secured, on a senior, first-priority basis by the Guarantors' (other than the Company) right, title and interest in certain collateral associated with Alaska's customer loyalty program, Alaska Airlines Mileage Plan&#x2122;."
2024-09-30 09:01:43	JHJ	JHJ ImmunoTech Announces Pricing Of $1.26M Registered Direct Offering Of 4,653,036 Shares Of Common Stock At A Purchase Price Of $0.27 Per Share	"JHJ ImmunoTech Inc. (NYSE: JHJ ) (""JHJ"" or the ""Company"") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered direct offering at a purchase price of $0.27 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class C warrants to purchase up to an aggregate of 4,653,036 shares of common stock and, unregistered Class D warrants to purchase up to an aggregate of 4,653,036 shares of common stock. The Class C and Class D warrants will each have an exercise price of $0.28, will be exercisable six months from the date of issuance and, in the case of the Class C warrants, will expire on the eighteen-month anniversary from the initial exercise date, and in the case of the Class D warrants, will expire on the five-year anniversary from the initial exercise date. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $1.26 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. Maxim Group LLC is acting as the sole placement agent in connection with the offering."
2024-09-30 09:09:51	SFZR	Hepsiburada Announces The Second Issuance Of Asset-backed Securities Amounting To TRY 350 Million	"D-MARKET Electronic Services & Trading (d/b/a ""Hepsiburada"") (NASDAQ: SFZR ), a leading Turkish e-commerce platform, today announced the second issuance of asset-backed securities amounting to TRY 350 million. The second issuance of asset-backed securities amounting to TRY 350 million, within the scope of the TRY 2 billion limit given by the Capital Markets Board to Pasha Yatrm Bank Hepsiburada Varlk Finansman Fonu, settled on September 27, 2024. In this structure, Hepsiburada participated as the originating entity with respect to its BNPL receivables. The issue consists of six tranches with an average maturity of 84 days and at an annual average interest rate of 51.00%. Hepsiburada intends to use the funds raised through this issue to sustainably grow its BNPL business and reduce its impact on working capital."
2024-09-30 13:58:55	OUFO	VivoPower Closes F-1 Offering, Raising $4M From Institutional Investors To Reduce Debt And Fund Inventory; Transition To Capital-Light Model Reduces Future Funding Requirements	"Issue of common stock only Funds will be used to reduce debt and fund inventory for customer orders Transition to capital light business model significantly reduces funding requirements LONDON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: OUFO ) (""VivoPower""), a global sustainable energy solutions company, is pleased to announce it has closed its F-1 offering, after the issuance of an aggregate of 3,200,000 Ordinary Shares to institutional investors. The offering was terminated and closed after market on September 27, 2024. The offering provides the Company with approximately $4 million in gross proceeds, which will be used for reducing debt and to fund inventory for customer orders. With the Company now having transitioned to a capital light business model leveraging its strategic supply chain across Asia, there is no longer a requirement for it to build out assembly and manufacturing facilities. Chardan acted as the sole placement agent in connection with this offering."
2024-09-30 16:10:35	FDGT	CPI Card Group Announces Proposed Secondary Public Offering Of 1M Shares Of Common Stock By Majority Stockholder	"CPI Card Group Inc. (NASDAQ: FDGT ) (""CPI"" or the ""Company""), a payments technology company and leading provider of credit, debit and prepaid card and digital solutions, including Software-as-a-Service (SaaS) based instant issuance, today announced that certain stockholders affiliated with Parallel49 Equity (the ""selling stockholders"") have commenced an underwritten secondary public offering of 1,000,000 shares of the Company's common stock. In addition, the selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 150,000 shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. The selling stockholders will receive all proceeds from the offering. The Company is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of common stock by the selling stockholders. D.A. Davidson & Co. is acting as sole book-running manager for the offering."
2024-09-30 16:11:42	DODS	Biohaven Announces Proposed $250M Public Offering Of Common Shares	Biohaven Ltd. (NYSE: DODS ), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $250 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $37.5 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Biohaven intends to use the net proceeds received from the offering for general corporate purposes. J.P. Morgan and Morgan Stanley are acting as book-running managers of the offering.
2024-10-01 02:58:55	FDGT	CPI Card Group Selling Stockholders Priced $25.2M Secondary Public Offering of 1.2M Shares At $21/Share	"CPI Card Group Inc. (NASDAQ: FDGT ) (""CPI"" or the ""Company""), a payments technology company and leading provider of credit, debit and prepaid card and digital solutions, including Software-as-a-Service (SaaS) based instant issuance, today announced the pricing of a registered underwritten secondary public offering of 1,200,000 shares of the Company's common stock to be sold by certain stockholders affiliated with Parallel49 Equity (the ""selling stockholders""), at a public offering price of $21.00 per share. The underwriters were also granted a 30-day option to purchase up to an additional 180,000 shares of common stock from the selling stockholders at the public offering price, less the underwriting discount. The offering is expected to close on or about October 2, 2024, subject to the satisfaction of customary closing conditions. The Company is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of common stock by the selling stockholders. Total gross proceeds from the offering to the selling stockholders, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $25.2 million."
2024-10-01 06:34:04	AFK	Acadia Realty Trust Priced Upsized Offering of 5M Shares (Up From Prior $4.5M) At $23.25/Share For Settlement of Forward Sale Agreements	"Acadia Realty Trust (NYSE: AFK ) (""Acadia"" or the ""Company"") announced today the pricing of an upsized underwritten offering of 5,000,000 common shares of beneficial interest at a price to the public of $23.25 per share. The underwriters have been granted a 30-day option to purchase up to an additional 750,000 common shares. This reflects an upsizing of the previously announced offering of 4,500,000 common shares. The offering is expected to close on October 2, 2024, subject to customary closing conditions. Wells Fargo Securities, Goldman Sachs & Co. LLC and Jefferies are acting as joint book-running managers for the offering. The Company has entered into forward sale agreements with each of Wells Fargo Bank, National Association, Goldman Sachs & Co. LLC and Jefferies or their affiliates (the ""forward purchasers"") with respect to 5,000,000 of its common shares. In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow and sell to the underwriters an aggregate of 5,000,000 common shares that will be delivered in the offering. Subject to its right to elect cash or net share settlement, which right is subject to certain conditions, the Company intends to deliver, upon physical settlement of such forward sale agreements on one or more dates specified by the Company occurring no later than September 30, 2025, an aggregate of 5,000,000 common shares to the forward purchasers in exchange for cash proceeds per share equal to the applicable forward sale price, subject to certain adjustments as provided in the forward sale agreements. If the underwriters and forward sellers exercise their option to purchase additional shares, the Company will enter into one or more additional forward sale agreements with each of the forward purchasers in respect of the number of common shares that are subject to exercise of the option to purchase additional shares. The Company will not initially receive any proceeds from the sale of common shares by the forward purchasers or their affiliates in the offering. The Company intends to use the net proceeds, if any, it receives upon the future settlement of the forward sale agreements for general corporate purposes, including funding potential investment transactions, working capital and the repayment of outstanding indebtedness. Pending such usage, the Operating Partnership expects to invest the net proceeds in short-term instruments."
2024-10-01 14:57:37	QHY	New Fortress Energy Stock Is Rising Tuesday: What's Going On?	New Fortress Energy Inc (NASDAQ: QHY ) shares are trading higher, bouncing off of recent 52-week lows. The company on Tuesday announced a $400 million offering of common stock . What To Know: New Fortress Energy announced that it priced its underwritten public offering of 46.35 million shares of its Class A common stock at a public offering price of $8.63 per share. New Fortress chairman and CEO Wesley Edens has agreed to purchase 5,793,742 shares in this offering at the public offering price on the same terms as the other purchasers, which may be helping lift shares Tuesday. The offering is expected to close on Oct. 2. The company expects to use any net proceeds for general corporate purposes. The news comes after New Fortress Energy shares hit new 52-week lows on Monday after the company decided to delay the payment of its common stock dividend of 10 cents per share. New Fortress said it expected to reach an agreement with noteholders in the near future and would reevaluate its dividend payment at that time. See Also: Tesla Stock Speeds Ahead Of Mag7 Peers, Can October's Robotaxi Reveal Keep The Momentum? In a separate press release on Monday, New Fortress also provided an update on its initial Fast HPJ asset located offshore Altamira, Mexico. The company said the asset achieved its first full cargo and sail away as it heads for Europe. &#8220;This is a significant milestone for our Fast HPJ installation. Natural gas and power supply are critical components of a sustainable, affordable, and cleaner energy system and we're excited to be able to provide our own gas supply to the world markets and our customers,&#8221; Edens said. New Fortress Energy also appears to be getting a lift Tuesday as energy stocks move higher amid heightening Middle East tensions . Iran reportedly launched an attack on Israel following the recent killing of Hezbollah leader Hassan Nasrallah . Bloomberg reportedly that Iran fired between 100 and 200 missiles towards Israel on Tuesday. QHY Price Action: New Fortress Energy shares were up 16.9% at $10.63 at the time of publication, according to Benzinga Pro . Photo: Csaba Nagy from Pixabay.
2024-10-02 08:53:06	WC	A2Z Cust2Mate Solutions Corp. Announces Aggregate $4.06M Registered Direct Offering Of 5.41M Shares, Priced At $0.75/Share, With No Warrants	"A2Z Cust2Mate Solutions Corp. (the ""Company"" or ""A2Z"") (NASDAQ: WC ), a global leader in innovative technology solutions, today announced that it has entered into a definitive securities purchase agreement with certain accredited investors to issue, in a registered direct offering, up to 5,409,999 common shares at a purchase price of US$0.75 per share. Subject to customary closing conditions, the transaction is expected to close on or around Wednesday, October 2, 2024. A2Z anticipates that the net proceeds from this offering, after deducting offering expenses, will be used for working capital and general corporate purposes. No placement agent was used or participated in the offering."
2024-10-02 09:15:30	LNB	Caesars Entertainment, Inc. Announces That The Company Intends To Offer, Subject To Market And Other Conditions, $1B Aggregate Principal Amount Of Senior Notes Due 2032	"Caesars Entertainment, Inc. (NASDAQ: LNB ) (the ""Company"") today announced that the Company intends to offer, subject to market and other conditions, $1,000.0 million aggregate principal amount of senior notes due 2032 (the ""Notes"") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""), and to persons outside the United States under Regulation S of the Securities Act. The Company intends to use the proceeds of the offering of the Notes to (i) tender, redeem or repurchase (the ""2027 Notes Redemption"") a portion of the Company's existing 8.125% Senior Notes due 2027 and (ii) to pay fees and expenses in connection with the offering of the Notes and the 2027 Notes Redemption. The Notes will be offered to persons reasonably believed to be qualified institutional buyers under Rule 144A of the Securities Act and to persons outside the United States under Regulation S of the Securities Act. The Notes will not be registered under the Securities Act, and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws."
2024-10-03 09:09:46	KFIW	Onconetix Announces Financing Through A $2M Private Placement Of Series C Preferred Stock And Warrants; Establishes A $25 Million Equity Line Of Credit	"Onconetix, Inc. (NASDAQ: KFIW ) (""Onconetix"" or ""the Company"") (formerly Blue Water Biotech, Inc. (RFS)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced the signing and closing of a private placement of (i) 3,499 shares of the Company's Series C Convertible Preferred Stock, $0.00001 par value (the ""Series C Preferred Stock""), and (ii) warrants (the ""Warrants"") to acquire up to an aggregate of 591,856 additional shares of the Company's common stock, $0.00001 par value per share (the ""Common Stock""), for aggregate gross proceeds of approximately $2.0 million. The Series C Preferred Stock are initially convertible into an aggregate of 776,590 shares of Common Stock, subject to certain anti-dilution adjustments. The Warrants will have an exercise price of $4.38 per share, subject to customary adjustments, and are exercisable beginning six months and one day after the issuance date (the ""Initial Exercisability Date"") and expiring on the third anniversary of the Initial Exercisability Date. The Company has filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 3, 2024, with additional details of the transaction. The Company agreed to seek stockholder approval for the issuance of all of the shares of Common Stock issuable upon conversion of the Series C Preferred Stock and exercise of the Warrants in accordance with the rules and regulations of the Nasdaq Stock Market. The Company intends to use the gross proceeds from the private placement for working capital and general corporate purposes. Tungsten Advisors (through its broker-dealer, Finalis Securities, LLC), served as financial advisor to Onconetix."
2024-10-07 09:28:57	VPJL	VPJL Announces The Completion Of A Strategic Investment Of $11M Of A New Class Of Preferred Stock In VPJL, With A Conversion Price Of $2/Share, With An 8% Annual Dividend, Led By Lance Shaner, Chairman & CEO Of Shaner Hotel Group, Joined By Other Strategic And Key VPJL Investors	"Management Emphasizes That It Has Sufficient Cash to Achieve Its Goals Including Recently Announced Collaborations and Being Cash Flow Positive During 2025 The $11 Million Investment includes Leading Builders and Hotel Developers MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- VPJL Platforms Corp. (NASDAQ: VPJL ) (d/b/a VPJL Technologies) (the ""Company"" or ""VPJL""), a highly disruptive smart platform technology company with more than 97 issued and pending patents globally and over 60 lighting and home dcor websites, today announced the completion of a strategic investment of $11 million of a new class of preferred stock in VPJL, with a conversion price of $2.00 per common share, with an 8% annual dividend, led by Lance Shaner, Chairman & CEO of Shaner Hotel Group, joined by other strategic and key VPJL investors."
2024-10-07 09:54:15	ZURG	Scilex Holding Company Announces Signing Of A $50M Registered Convertible Financing To Purchase Up To 7.5M Shares Of Common Stock In A Registered Direct Offering, To Refinance And Restructure Existing Debt & Strengthen Financial Profile	"Affiliates of Murchinson, 3i LP, and existing senior debt holder, Oramed Pharmaceuticals, Inc. (""Oramed""), are expected to participate in the $50 million convertible note offering, which is expected to close on or about October 7, 2024. The offering involves a refinancing and restructuring of existing debt and is expected to position Scilex for sustainable, long-term growth, as part of its multi-year plan to transform into a potential global and leading non-opioid pain management company. Scilex will receive from Oramed in consideration for the newly issued convertible note issued to Oramed an exchange and reduction of the principal balance under the Company's existing Senior Secured Promissory Note with Oramed (the ""Oramed Note""). Over the past 12 months, Scilex has aggressively addressed and restructured the debt on our balance sheet with payments of more than $80 million. The new financing will allow Scilex to retire the revolving facility with eCapital Healthcare Corp. in its entirety. As previously announced, on June 11, 2024, Scilex has successfully eliminated a $10.0 million loan with FSF 33433 LLC. PALO ALTO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ: ZURG , ""Scilex"" or the ""Company""))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a definitive agreement with affiliates of Murchinson, 3i LP and with Oramed for the purchase and sale of new tranche B senior secured convertible notes in the aggregate principal amount of $50 million (the ""New Financing"") and warrants to purchase up to 7,500,000 shares of the Company's common stock in a registered direct offering."
2024-10-08 08:09:50	XKSO	Algorhythm Holdings Announces Termination Of Its At-the-Market Equity Program	"Algorhythm Holdings, Inc. (""Algorhythm"") (NASDAQ: XKSO ), an AI-driven technology and consumer electronics holding company, announced it has terminated its ""at-the-market"" ("" ATM "") equity program with Ascendiant Capital, LLC, as sales agent (the "" Agent ""). The Company elected to terminate the ATM because it had achieved its objective of raising capital under the ATM. Through the utilization of the most recently amended ATM, the Company raised approximately $1.4 million in gross proceeds, selling approximately 2.16 million shares of common stock at an average share price of $0.65 per share."
2024-10-08 16:03:04	NNKE	Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed	"Cardiol Therapeutics Inc. (NASDAQ: NNKE ) (TSX: NNKE ) (""Cardiol"" or the ""Company"") , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "" Supplement "") to its short form base shelf prospectus dated July 12, 2024 (the "" Base Prospectus "") in connection with a proposed public offering (the "" Offering "") of Class A common shares (the "" Common Shares ""). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "" SEC ""), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses. Canaccord Genuity is acting as the sole bookrunner in connection with the Offering."
2024-10-08 16:05:57	AJK	Delek Logistics Partners, LP Announces $150M Proposed Public Offering Of Common Units	"Delek Logistics Partners, LP (NYSE: AJK ) (""Delek Logistics"") announced today that it has commenced an underwritten public offering of $150,000,000 of common units representing limited partner interests in Delek Logistics pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the ""SEC""). A preliminary prospectus supplement relating to the offering will also be filed with the SEC. Delek Logistics intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of common units. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Delek Logistics intends to use the net proceeds from the offering (including any net proceeds from the underwriters' exercise of their option to purchase additional common units) to redeem its outstanding convertible preferred units and to repay outstanding borrowings under its revolving credit agreement. Avigal Soreq, our President and Chief Executive Officer, and certain other of our executives (collectively, the ""Executives""), have indicated an interest in purchasing up to $300,000 of the common units offered in the offering at the price offered to the public. Because this indication is not a binding agreement or commitment to purchase, the Executives may elect not to purchase any units in the offering, or the underwriters may elect not to sell any units in the offering to the Executives."
2024-10-08 16:47:02	UMB	Cleveland-Cliffs Upsizes And Prices $900M Of Senior Guaranteed Notes Due 2029 And $900M Of Senior Guaranteed Notes Due 2033	The 2029 Notes will bear interest at an annual rate of 6.875% and will be issued at par. The 2033 Notes will bear interest at an annual rate of 7.375% and will be issued at par. The Notes offering is expected to close on October 22, 2024, subject to the satisfaction of customary closing conditions. Cliffs intends to use the net proceeds from the Notes offering to finance a portion of the cash consideration payable in connection with the previously announced acquisition of Stelco Holdings Inc., which Cliffs expects to complete in the fourth quarter of 2024 following the satisfaction or waiver of applicable conditions.
2024-10-09 08:03:24	NNKE	Cardiol Therapeutics Announces Pricing Of $13.5M Public Offering Of 8,437,500 Common Shares At A Price Of $1.60/Share	"Cardiol Therapeutics Inc. (NASDAQ: NNKE ) (TSX: NNKE ) (""Cardiol"" or the ""Company"") , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "" Offering "") of 8,437,500 Class A common shares of the Company (the "" Common Shares "") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering. The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses. Canaccord Genuity is acting as the sole bookrunner in connection with the Offering."
2024-10-09 08:14:18	HJRV	LuxUrban Hotels Files Prospectus To Sell Up To 23.63M Shares Of Common Stock	"LUXURBAN HOTELS INC. 23,628,324 shares of Common Stock offered by the Selling Stockholders This prospectus is part of a registration statement that registers the resale by the selling stockholders (the ""Selling Stockholders"") identified herein (and their permitted transferees) from time to time of up to an aggregate of 23,628,324 shares (""Selling Stockholder Shares"") of our common stock, par value $0.00001 per share (""common stock""). We are not selling any securities under this prospectus and will not receive any of the proceeds from the sales of our common stock by the Selling Stockholders. The Selling Stockholders may sell or otherwise dispose of the common stock described in this prospectus in a number of different ways and at varying prices. See "" Plan of Distribution "" for more information. We shall bear all fees and expenses incurred in connection with the registration statement of which this prospectus is a part, and all expenses incurred in performing or complying with our other obligations under the registration rights agreements and other registration rights pursuant to which such registration statement has been filed. See ""Plan of Distribution."" Our common stock is listed on the Nasdaq Capital Market, under the symbol ""HJRV."" Our Series A preferred stock is listed on the Nasdaq Capital Market under the symbol ""LUXHP""."
2024-10-09 09:20:03	IPZ	Inhibikase Therapeutics Announces Pricing Of $110M Private Placement To Advance IkT-001Pro, Into A Late-Stage Trial In Pulmonary Arterial Hypertension; Aggregate Investment Of Up To ~$275M By Healthcare-Focused Investment Funds, Led By Soleus Capital	"-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IPZ ) (""Inhibikase"" or the ""Company""), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately $110 million private placement financing, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in pulmonary arterial hypertension (""PAH"") and for general corporate purposes. The private placement was led by new investor Soleus Capital, with participation from new investors including Sands Capital, Fairmount, Blackstone Multi-Asset Investing, Commodore Capital, Perceptive Advisors, ADAR1 Capital Management, BSQUARED Capital, Nantahala Capital, Stonepine Capital Management and Spruce Street Capital. In connection with and to be effective immediately prior to the closing of this financing, two current members of the Board of Directors, Ms. Gisele Dion and Dr. Paul Grint, will resign and four new directors will join the Company's board: Roberto Bellini (former Chief Executive of BELLUS Health Inc. and current Managing Partner of BSQUARED Capital), Amit Munshi (current Chief Executive of Orna Therapeutics and former CEO of Arena Pharmaceuticals), Arvind Kush (current CFO of Candid Therapeutics and former CFO of RayzeBio) and David Canner (Partner at Soleus Capital). In addition, Mr. Bellini will serve as Independent Chairperson of the Board of Directors. The Company is selling an aggregate of 58,310,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 21,985,000 shares of common stock, along with accompanying Series A-1 warrants to purchase an aggregate of 40,139,474 shares of common stock (or, in lieu thereof, additional pre-funded warrants) (the ""Series A-1 Warrants"") and accompanying Series B-1 warrants to purchase an aggregate of 73,813,529 shares of common stock (or, in lieu thereof, additional pre-funded warrants) (the ""Series B-1 Warrants""). The purchase price for each share of common stock and accompanying warrants is $1.37 (provided, the purchase price for each pre-funded warrant and accompanying warrants is $1.369). The pre-funded warrants have an exercise price of $0.001 per share and are exercisable at any time after their original issuance and will not expire. The accompanying Series A-1 and Series B-1 Warrants will become exercisable at the earlier of (a) the 75th calendar day following the initial filing of the resale registration statement covering the resale of the shares of common stock issuable upon the exercise of the warrants, if the United States Securities and Exchange Commission (the ""SEC"") notifies the Company that it will review the resale registration statement and (b) the 5th business day after the date the Company is notified by the SEC that the resale registration statement will not be subject to further review. Each Series A-1 Warrant will be exercisable for approximately 0.5 shares of common stock and will expire 30 days following the later of (a) the date of the Company's public announcement of the safety and tolerability of IkT-001Pro for PAH and (b) the Company both obtaining stockholder approval to and filing an amendment to its charter to increase the number of authorized shares of common stock to a number of shares of common stock sufficient to allow for the full exercise of the warrants (the Charter Amendment""). Each Series B-1 Warrant will be exercisable for approximately 0.92 shares of common stock, will become exercisable by an investor once all of such investor's A-1 Warrants have been exercised and will expire 30 days following the later of (a) the Company's public announcement of its Phase 2b efficacy readout for IkT-001Pro with respect to PAH and (b) the Charter Amendment. The Series A-1 Warrants have an exercise price of $1.37 per share and the Series B-1 Warrants have an exercise price of $1.49 per share. The PIPE is expected to close on October 21, 2024, subject to customary closing conditions. Jefferies is acting as the lead placement agent for the private placement. Maxim Group LLC is acting as a co-placement agent."
2024-10-10 13:33:31	KDLF	Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?	On Thursday, Immatics N.V. (NASDAQ: KDLF ) stock is trading lower after the company commenced an underwritten public offering of $150 million . The company also announced updated Phase 1b data on ACTengine IMA203 TCR-F targeting PRAME in melanoma patients and provided an update on SUPRAME, the upcoming Phase 3 trial to evaluate IMA203 in metastatic melanoma patients . As of August 23, 2024, 28 heavily pretreated patients with metastatic melanoma were treated with IMA203 at the recommended Phase 2 dose (RP2D, 1 to 10 billion total TCR-F cells) during the Phase 1b dose expansion part of the clinical trial. IMA203 monotherapy has maintained a favorable tolerability profile with no treatment-related Grade 5 adverse events in the safety population, even at doses up to ~10&#215;10 power 9 TCR-F cells. The data presented demonstrate a significant positive shift in median progression-free survival (PFS) and median overall survival (OS) between melanoma patients treated during Phase 1a and patients treated in Phase 1b. In addition, approximately half of all patients in the Phase 1b trial have a deep response (>50% tumor reduction). This subgroup of patients was observed to have a median PFS of more than one year, while patients with <50% tumor reduction (including patients with tumor size increase) were still observed with a more than 2 times longer median PFS compared to patients treated in dose escalation with suboptimal doses. Translational data from patients across Phase 1a and Phase 1b indicate that IMA203 F cells rapidly engrafted in all patients after a single dose and show a persistence of more than two years. The Phase 3 trial will evaluate IMA203 targeting PRAME in 360 HLA-A&#x2A;02:01-positive patients with second-line or later unresectable or metastatic melanoma. The Phase 3 trial is on track to commence in December 2024 and patient enrollment is forecasted to be completed in 2026. A pre-specified interim analysis is planned for early 2026. The company aims to submit an FDA marketing application in early 2027 for full approval. Price Action: KDLF stock is down 11.1% at $9.841 at last check Thursday. Photo via Shutterstock Read Next: Cloudflare Taps ServiceNow Executive To Drive $5B Growth Ambition &#8211; What's Going On?
2024-10-10 14:06:08	CUI	FangDD Announces Pricing Of $4.5M Registered Direct Offering, At A Price Of $0.88 Per Share	"Fangdd Network Group Ltd. (NASDAQ: CUI ) (""FangDD"" or the ""Company""), a customer-oriented property technology company in China, today announced that it has entered into a securities purchase agreement with certain investors (the ""Purchase Agreement"") for the issuance and sale by the Company of US$4.5 million of Class A ordinary shares (or pre-funded warrants in lieu thereof), at a price of US$0.88 per share (or US$0.8794375 per pre-funded warrant), in a registered direct offering. The Purchase Agreement contains representations, warranties and other provisions customary for transactions of this nature. The offering is expected to close on or about October 11, 2024, subject to the satisfaction of customary closing conditions. FangDD intends to use the net proceeds from this offering for general corporate purposes. The Company has engaged MM Global Securities, Inc. as its exclusive placement agent in connection with this offering."
2024-10-10 14:43:25	ZGAZ	Jet.AI Announces Pricing Of $2.4M Registered Direct Offering Of 26.6M Shares Of Common Stock At A Price Of $0.09/Share	"Jet.AI Inc. (""Jet.AI"" or the ""Company"") (NASDAQ: ZGAZ ) , an innovative private aviation and artificial intelligence company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase approximately 26.6 million shares of common stock in a registered direct offering at a purchase price of $0.09 per share. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $2.4 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about October 11, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the exclusive placement agent for the offering."
2024-10-10 16:16:34	FOGF	Carlyle Secured Lending Prices Public Offering Of $300M 6.750% Unsecured Notes Due 2030	"Carlyle Secured Lending, Inc. (NASDAQ: FOGF ) (the ""Company"") today announced that it has priced an underwritten public offering of $300 million in aggregate principal amount of 6.750% unsecured notes due 2030 (the ""Notes""). The Notes will mature on February 18, 2030 and may be redeemed in whole or in part at the Company's option at the applicable redemption price. The offering is expected to close on October 18, 2024, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to repay the Company's outstanding debt including the revolving credit facility, the Company's 4.750% unsecured notes and 4.500% unsecured notes in the aggregate principal of approximately $190.0 million, each of which is scheduled to mature on December 31, 2024, and to fund new investment opportunities, and for other general corporate purposes. J.P. Morgan, Barclays, BofA Securities, Morgan Stanley, Citigroup, Deutsche Bank Securities, Goldman Sachs & Co. LLC, HSBC Securities (USA) Inc. and R. Seelaus & Co., LLC are acting as joint book-running managers for this offering. ICBC Standard Bank, TCG Capital Markets L.L.C., B. Riley Securities, Keefe, Bruyette & Woods, A Stifel Company and Raymond James are acting as co-managers for this offering."
2024-10-10 17:08:19	ZGAZ	What Happened With Jet.AI Stock Today?	Jet.AI Inc. (NASDAQ: ZGAZ ) shares fell Thursday after the company announced it entered into an agreement with certain institutional investors to purchase approximately 26.6 million shares of common stock in a registered direct offering. The Details: Jet.AI announced the pricing of the offering will be nine cents per share with gross proceeds of approximately $2.4 million to the company before deducting the estimated offering expenses. The offering is expected to close on or about Oct. 11. Read Next: What's Going On With SoFi Stock? Jet.AI shares reached an intraday high of 25 cents before reversing in afternoon trading when the direct offering was announced. The stock moved lower on heavy trading volume with more than 805 million shares traded in Thursday's session, according to data from Benzinga Pro . How To Buy ZGAZ Stock Besides going to a brokerage platform to purchase a share  or fractional share  of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in Jet AI's case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. ZGAZ Price Action: According to Benzinga Pro , Jet.AI shares are up 8.57% after-hours at 8 cents after falling 11.77% in regular trading Thursday. Read Also: What Happened With Celsius Holdings Stock Today? Image: Shutterstock
2024-10-11 16:11:08	WC	A2Z Cust2Mate Solutions Announces Aggregate $1.8M Registered Direct Offering Of 642,860 Common Shares Priced At $2.80/Share, With No Warrants	"A2Z Cust2Mate Solutions Corp. (the ""Company"" or ""A2Z"") (NASDAQ: WC ), a global leader in innovative technology solutions, today announced that it has entered into a definitive securities purchase agreement with certain accredited investors to issue, in a registered direct offering, up to 642,860 common shares at a purchase price of US$2.80 per share. Subject to customary closing conditions, the transaction is expected to close on or around Tuesday, October 15, 2024. A2Z anticipates that the net proceeds from this offering, after deducting offering expenses, will be used for working capital and general corporate purposes. No placement agent was used or participated in the offering."
2024-10-15 08:11:36	KWU	Western Asset Global High Income Fund Announced The Final Results Of Its Transferable Rights Offering; The Final Subscription Price Per Share Was $6.60. The Offer Will Result In The Issuance Of 7,574,935 Shares Of Common Stock. The Gross Proceeds Of The Offer Are Expected To Be ~$50M. The Shares Of Common Stock Subscribed For Are Expected To Be Issued On Or About October 16, 2024. The Fund Will Return To Subscribing Investors The Full Amount Of Any Excess Payments.	"Western Asset Global High Income Fund Inc. (NYSE: KWU ) (""KWU"" or the ""Fund"") announced the final results of its transferable rights offering (the ""Offer""). The Offer expired at 5:00 PM Eastern Time on October 8, 2024 (the ""Expiration Date"") and the Rights no longer trade on the New York Stock Exchange (""NYSE""). The final subscription price per share was $6.60, which was equal to 90% of the Fund's net asset value per share of common stock at the close of trading on the NYSE on October 8, 2024. The Offer will result in the issuance of 7,574,935 shares of common stock. The gross proceeds of the Offer are expected to be approximately $50.0 million. The shares of common stock subscribed for are expected to be issued on or about October 16, 2024. The Fund will return to subscribing investors the full amount of any excess payments."
2024-10-15 08:41:52	QBI	GLOBAL MOFY AI LIMITED Announces $2.5M Private Placement Financing	"Global Mofy AI Limited (the ""Company"" or ""Global Mofy"") (NASDAQ: QBI ), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that it has entered into a Securities Purchase Agreement (the ""SPA"") with certain non-U.S. investors (each individually, a ""Purchaser"", and collectively, the ""Purchasers""). Pursuant to the SPA, the Company will sell and issue up to 5,000,000 units (each a ""Unit"", and collectively, the ""Units"") to the Purchasers in a private placement financing transaction (the ""Offering"") at an offering price of $0.50 per unit. Each Unit consists of (i) one Class A ordinary share, par value $0.000002 per share (the ""Class A Ordinary Share"") (or one pre-funded warrant to purchase one Class A Ordinary Share (the ""Pre-Funded Warrant"")), (ii) two warrants, each exercisable for one Class A Ordinary Share at an exercise price of $3.00 per share (each a ""Ordinary Warrant"", and collectively, the ""Ordinary Warrants""). The exercise price and number of Class A Ordinary Share issuable upon exercise of the Ordinary Warrants are subject to adjustment as described in the Ordinary Share Purchase Warrant. The Ordinary Warrants will be exercisable upon issuance and will have a term of 5 years from the issuance date. The gross proceeds of the Offering are expected to be approximately $2.5 million, before the deduction of customary expenses. The Company intends to use the net proceeds from the Offering, together with the Company's existing cash, cash equivalents, and marketable securities, to provide financing for its generative AI platform, general research and development, administrative expenses, talent acquisition, and working capital needs."
2024-10-15 09:46:10	GDIF	Sidus Space Plans Public Offering Of Up To 3.75M Shares	"Up to 3,745,318 Shares of Class A Common Stock Up to 3,745,318 Pre-Funded Warrants to Purchase up to 3,745,318 Shares of Class A Common Stock Sidus Space, Inc. We are offering up to 3,745,318 shares of our Class A common stock at an assumed public offering price of $2.67 (which is the last sale price of our Class A common stock as reported by The Nasdaq Capital Market on October 10, 2024) on a firm commitment basis. The actual public offering price per share of Class A common stock will be determined between us and the underwriters at the time of pricing and may be at a discount to this assumed offering price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price of the shares of Class A common stock. We are also offering to each purchaser whose purchase of shares of our common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of Class A common stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, Pre-Funded Warrants to purchase shares of Class A common stock (""Pre-Funded Warrants""), in lieu of shares of Class A common stock. The purchase price of each Pre-Funded Warrant is equal to the price per share of Class A common stock being sold to the public in this offering, minus $0.001. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell, the number of shares of Class A common stock that we are offering will be decreased on a one-for-one basis. Our Class A common stock is listed on The Nasdaq Capital Market under the symbol ""GDIF"". On October 10, 2024, the closing price as reported on The Nasdaq Capital Market was $2.67 per share. There is no established trading market for the Pre-Funded Warrants and we do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. We are an ""emerging growth company"" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements."
2024-10-15 12:34:30	GDIF	What's Going On With Sidus Space Stock Today?	Sidus Space, Inc. (NASDAQ: GDIF ) shares are trading lower on Tuesday. In an SEC filing , the company announced an offering of 3.75 million shares at an assumed price of $2.67 per share. The offering also contains up to 3.745 million pre-funded warrants to purchase up to 3.745 million shares of Class A common stock. Per Sidus Space, the net proceeds from this offering will be approximately $8.9 million. The firm will use the net proceeds from this offering for sales and marketing, operational costs, product development, manufacturing expansion, and working capital, along with other general corporate purposes. Also Read: Oil Prices Take Largest Plunge In Over A Year As Israel Vows To Spare Iranian Facilities: Energy Stocks Sink, Airlines, Cruise Lines Rally In a press release, Sidus Space announced that the U.S. Federal Communications Commission (FCC) has approved its operation of a micro constellation of remote sensing, multi-mission satellites in Low Earth Orbit (LEO). This regulatory milestone is a significant step in Sidus Space's plans for on-orbit expansion and underscores its strategic commitment to enabling new missions while delivering flexible, cost-effective data acquisition solutions through its innovative data-as-a-service model. The company retains ownership of the data collected by its LizzieSat sensors for all missions, giving customers a distinct advantage in accessing valuable data streams. The FCC approval marks a significant milestone for Sidus Space as it expands its on-orbit presence and enhances its capacity to provide a variety of industries with improved real-time, space-based data services. According to Benzinga Pro , GDIF stock has lost over 79% in the past year. Price Action : GDIF shares are trading lower by 11.2% to $2.335 at last check Tuesday. Read Next: State Street Q3 Earnings: AUM Soars To $4.7T, Announces CFO Eric Aboaf's Departure In 2025
2024-10-16 07:56:29	NV	Why Is Versus Systems Stock Rocketing Over 300% Premarket On Wednesday?	Versus Systems Inc. (NASDAQ: NV ) shares are rocketing premarket on Wednesday. The company disclosed that it has entered into two major agreements with Aspis Cyber Technologies, Inc. (ASPIS) . ASPIS is affiliated with Cronus Equity Capital Group, LLC, which holds approximately 39.5% of the company's outstanding common stock. The first is a Business Funding Agreement, which includes an investment of $2.5 million from ASPIS in Versus Systems. ASPIS has initially invested $500,000, with the remaining $2 million due by November 15, 2024. In return, Versus Systems issued an unsecured convertible promissory note for $2.5 million. The Note can be converted into units, each consisting of one common share and a warrant for half a share at an exercise price of $4.00. The company plans to seek shareholder approval at its annual meeting in December 2024. The second agreement allows ASPIS to license Versus Systems' gamification, engagement, and QR code technology for its cybersecurity solutions in sectors like government, finance, gaming, and social media. ASPIS will pay a monthly licensing fee and compensate for any technology updates or innovations. These agreements support Versus Systems' compliance plan submitted to Nasdaq on October 7, 2024, to maintain the required $2.5 million in shareholders' equity for continued listing on The Nasdaq Capital Market. The company aims to exceed this minimum to ensure compliance until at least September 30, 2025. Under the agreements, if Versus Systems receives shareholder approval for the equity issuance and its redomiciling to Delaware, ASPIS could convert the Note and exercise the warrants to receive approximately 2.155 million shares of common stock and warrants for an additional 1.077 million shares at a final price of $1.16. This would give ASPIS about 45.8% of Versus Systems' outstanding common stock, not including shares from warrant exercises or conversions of accrued cash interest into units. The License Agreement establishes a monthly fee of $165,000, starting in January 2025, allowing ASPIS to use any modifications to the licensed technology for cybersecurity. Nasdaq will review the company's compliance plan, if its not accepted or compliance isn't met by February 18, 2025, delisting proceedings may begin. In such cases, Versus reserves the right to request a hearing for an additional extension. Price Action : NV shares are up 300% at $4.60 premarket at the last check Wednesday. Read Next : eBay's Circular Fashion Fund Expands To US And Germany, Fueling Eco-Friendly Fashion Revolution
2024-10-16 17:29:43	TQJB	Lucid Stock Is Tumbling Wednesday: What's Driving The Action?	Lucid Group Inc (NASDAQ: TQJB ) shares are trading lower in Wednesday's after-hours session after the company announced an offering and corresponding investment from an affiliate of the Public Investment Fund (PIF) . What Happened: Lucid said it commenced a public offering of 262,446,931 shares of its common stock. The company intends to grant the underwriter a 30-day option to purchase up to 39,367,040 additional shares. In connection with the offering, Lucid announced that majority shareholder and PIF affiliate Ayar Third Investment Company has agreed to purchase 374,717,927 shares of common stock from Lucid in a private placement. Ayar expects to maintain approximately 58.8% ownership of Lucid following the purchases. Lucid said it will use the net proceeds from the public offering and concurrent private placement for general corporate purposes, which may include capital expenditures and working capital. Lucid ended the second quarter with $4.28 billion in total liquidity, including $1.35 billion in cash and cash equivalents. The EV maker announced the date for its third-quarter earnings release this week: Lucid will report quarterly results after the market close on Nov. 7. Analysts anticipate a loss of 30 cents per share and revenue of $194.981 million, according to Benzinga Pro . TQJB Price Action: Lucid shares were down 10.98% in after-hours, trading at $2.92 at the time of publication Wednesday, according to Benzinga Pro . Read Next: Elon Musk's Tesla Waving Goodbye To Bitcoin? $760M Sent To Unknown Wallets Photo: Courtesy of Lucid Group.
2024-10-17 09:01:42	HFSH	Lottery.com Outlines Future Growth Plans Following Registration Statement On Form S-1 Effectiveness; The Registration Statement Also Provides For An Offering By The Company Of Up To 50M Shares Of Common Stock At $3/Share	"Lottery.com Inc. (NASDAQ: HFSH , LTRYW))))) (""Lottery.com"" or the ""Company""), a leading technology company in digital lottery and sports entertainment, is pleased to announce that the U.S. Securities and Exchange Commission (""SEC"") has declared the Company's Form S-1 Registration Statement effective on October 16, 2024 (""Registration Statement"") (File Number: 333-281925). The Company's turnaround efforts which began in late 2022, were designed to address numerous operational and financial challenges, which included regulatory inquiries; regaining full compliance with Nasdaq listing and SEC reporting requirements; staff restructuring; as well as overall capital shortages. With the successful registration of the Company's registration statement, Lottery.com is now poised to enter a new phase of strategic growth and market expansion. The Registration Statement, while effective, allows the covered selling securityholders to publicly resell the securities covered by the Registration Statement, subject to the satisfaction by selling securityholders of certain SEC requirements in connection with any such resale. The Registration Statement also provides for an offering by the Company of up to 50 million shares of Common Stock at $3.00 per share. Copies of the prospectus that is included in the Registration Statement may be obtained from Lottery.com by email at ir@lottery.com or by visiting https://ir.lottery.com or at the SEC's website www.sec.gov . Key milestones and strategic initiatives include: 1. Lottery.com Expansion: The Company is now poised to work to operationalize its US operations across multiple states anticipated by the end of 2025. International expansion is also planned, with the intent to introduce a new gaming model in 2025 aimed at revolutionizing the global lottery market. 2. Sports.com Growth: Earlier this year, the Company launched the new Sports.com platform in partnership with S&MI Ltd, the innovative technology company behind the Sportlocker brand, which has been rebranded as the Sports.com site and app. The Company completed its acquisition of S&MI on September 1, 2024. The platform is designed to deliver immersive live sports content enhanced by cutting-edge 3D technology, with rollouts planned in the U.S., Europe, and the Middle East by mid-2025. The Registration Statement is one key component of the Company's partnership strategy, which, when financing through sales of stock, will help to springboard Sports.com's position to becoming a major player in global sports media and entertainment. Financial Outlook Lottery.com is focused on developing proprietary technology and pursuing a ""buy and build"" growth strategy with its common stock as the primary consideration for acquisitions. With a clear roadmap, Lottery.com is working to enter this next phase with confidence, backed by a highly experienced leadership team and committed funding and business partners."
2024-10-17 09:27:23	TQJB	What's Going On With Lucid Stock Thursday?	Lucid Group Inc (NASDAQ: TQJB ) shares are trading lower Thursday morning after the company announced the pricing of an offering and corresponding investment from an affiliate of the Public Investment Fund (PIF) . What To Know: Lucid shares turned sharply lower in extended trading Wednesday after the company said it commenced a public offering of 262,446,931 shares of its common stock. Lucid priced the offering Thursday morning, noting that it anticipates gross proceeds of approximately $1.67 billion. In connection with the offering, Lucid announced that majority shareholder and PIF affiliate Ayar Third Investment Company agreed to purchase 374,717,927 shares of common stock from Lucid in a private placement. Ayar expects to maintain approximately 58.8% ownership of Lucid following the purchases. Ayar will purchase the shares from Lucid at the same price initially paid by the underwriter in the public offering. Lucid intends to grant the underwriter a 30-day option to purchase up to 39,367,040 additional shares. The offering is expected to close on or about Oct. 18. Lucid said it will use the net proceeds from the public offering and concurrent private placement for general corporate purposes, which may include capital expenditures and working capital. See Also: Tesla Promotes Key Executives And Gives Them More Responsibilities In Leadership Shuffle Lucid ended the second quarter with $4.28 billion in total liquidity, including $1.35 billion in cash and cash equivalents. Lucid reported third-quarter deliveries earlier this month. The company said it produced 1,805 vehicles and delivered 2,781 vehicles during the period. Lucid also scheduled its third-quarter results for after the market close on Nov. 7. Analysts are calling for a loss of 30 cents per share on revenue of $194.981 million, according to estimates from Benzinga Pro . TQJB Price Action: Lucid shares are down about 22% year-to-date. The stock was down 17.1% at $2.72 at the time of publication Thursday, according to Benzinga Pro . Photo: courtesy of Lucid.
2024-10-18 09:33:33	CHSK	Bullfrog AI Announces Pricing Of $3.13M Registered Direct Offering Of 1.565M Shares At A Price Of $2/Share And Concurrent Private Placement	"BullFrog AI Holdings, Inc. (NASDAQ: CHSK , BFRGW))))) (""Bullfrog AI"" or the ""Company""), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and, in a concurrent private placement, common warrants to purchase up to 1,565,000 shares of common stock (together with the registered direct offering) at a combined purchase price of $2.00. The warrants will have an exercise price of $2.00 per share, are initially exercisable on the date that is six months from the date of issuance and will expire five years from such initial exercise date. The closing of the offering is expected to occur on or about October 21, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to from the offering are expected to be approximately $3.13 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting the placement agent's fees and other offering expenses payable by the Company. WallachBeth Capital, LLC is acting as sole placement agent for the registered direct offering and private placement."
2024-10-18 14:00:49	ZGAZ	Jet.AI Announces Pricing Of $1.5M Registered Direct Offering Of 15.6M Shares Of Common Stock At A Price Of $0.096/Share	"Jet.AI Inc. (""Jet.AI"" or the ""Company"") (NASDAQ: ZGAZ ) , an innovative private aviation and artificial intelligence company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase approximately 15.6 million shares of common stock in a registered direct offering at a purchase price of $0.096 per share. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $1.5 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about October 21, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the exclusive placement agent for the offering."
2024-10-21 07:13:08	DMVL	Onity Group Announces $475M Senior Notes Offering to Redeem Outstanding Debt	"Onity Group Inc. (NYSE: DMVL ) (""Onity""), a leading non-bank mortgage servicer and originator, today announced that PHH Escrow Issuer LLC (""Escrow Issuer""), a wholly-owned special purpose subsidiary of PHH Corporation (""PHH""), plans to offer $475 million aggregate principal amount of Senior Notes due 2029 (the ""Notes""), subject to market and other conditions. The Notes will initially be issued by Escrow Issuer. The net proceeds from the sale of the Notes, together with additional cash from Onity, are expected to be placed into escrow pending the satisfaction of certain conditions, including, but not limited to, the consummation of the recently announced sale by Onity of its 15% ownership interest in MSR Asset Vehicle LLC to certain funds affiliated with Oaktree Capital Management, L.P. (the ""MAV Sale""). Upon satisfaction of the escrow conditions, the escrowed proceeds will be released to PHH Corporation, and at that time PHH Corporation, along with Onity and certain subsidiaries of PHH, will enter into a supplement to the indenture governing the Notes pursuant to which PHH will become a co-issuer of the Notes and Onity and such subsidiaries will become guarantors of the Notes. Upon their release from escrow, the net proceeds from the offering will be used, together with the net proceeds from the MAV Sale and cash on hand, to redeem all of PHH Mortgage Corporation's outstanding 7.875% Senior Notes due 2026 and all of Onity's outstanding 12.00%/13.25% Senior Second Lien Notes due 2027."
2024-10-21 07:18:53	EVJU	Prospect Capital Upsizes Preferred Stock Offering to $1.8B With 7.28% Dividend	"Prospect Capital Corporation (NASDAQ: EVJU ) (""Prospect"", ""our"", or ""we"") announced today an upsize to Prospect's preferred stock offering (the ""Preferred Stock"" or the ""Offering"") with Preferred Capital Securities (""PCS""). The Offering has seen strong demand from the private wealth, institutional, and Registered Investment Advisor channels, with $1.8 billion in aggregate liquidation preference issuances since the initial closing in the quarter ending December 31, 2020. ""Prospect's non-traded preferred stock offers investors recurring cash income with a stable stated value, ongoing liquidity, management alignment, leverage caps, and over $3.7 billion of junior common equity credit support,"" said Grier Eliasek, President of Prospect. ""Prospect is the number one market share issuer of non-traded preferred stock in 2023 and 2024 year-to-date, with each of institutional, registered investment advisor, wirehouse, independent private wealth, and international investor channels having invested in Prospect's preferred stock. With interest rates declining, we believe our A4/M4 preferred stock series, with a current 7.28% annualized floating rate dividend structure and 6.50% dividend rate floor, offers an attractive option for income-oriented investors."" PCS is a securities broker dealer and the dealer manager for the ongoing offering of the Series A4 and M4 Preferred Stock. PCS has raised $5.0 billion of capital since its formation in 2011."
2024-10-21 08:00:18	FZU	Life Time Announces $1.4B Refinancing Plan with New Notes and Loans	"Life Time Group Holdings, Inc. (NYSE: FZU ) (""Life Time"" or the ""Company"") announced today that its indirect subsidiary, Life Time, Inc. (the ""Issuer""), has commenced an offering (the ""Offering"") for $400 million aggregate principal amount of senior secured notes due 2031 (the ""Notes""). Concurrently with the Offering, the Issuer intends to amend its existing credit agreement to incur new term loans in an aggregate principal amount of $1,000 million (the ""New Term Loan Facility"" and, together with the Offering, the ""Refinancing"") and amend certain other provisions of its existing credit agreement. The Issuer intends to use the net proceeds from the Refinancing and cash from its balance sheet to fund the satisfaction and discharge of the Issuer's 5.750% Senior Secured Notes due 2026 and 8.000% Senior Notes due 2026, as well as pay related fees and expenses."
2024-10-21 12:40:47	KAR	On Saturday October 19, 2024, Rumble Filed Prospectus For Mixed Shelf Of Up To $300M	"Rumble Inc. Class A Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units From time to time, we may offer up to $300,000,000 aggregate dollar amount of shares of our Class A common stock, $0.0001 par value per share (""Class A Common Stock""), preferred stock, debt securities, warrants to purchase our Class A Common Stock, preferred stock or debt securities, subscription rights to purchase our Class A Common Stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination, together or separately, in one or more offerings, in amounts, at prices and on the terms that we will determine at the time of the offering and which will be set forth in a prospectus supplement and any related free writing prospectus. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. The total amount of these securities will have an initial aggregate offering price of up to $300,000,000."
2024-10-22 08:30:07	ZJIO	UP Fintech Announces Proposed Follow-on Public Offering Of 15M American Depositary Shares	"UP Fintech Holding Limited (NASDAQ: ZJIO ) (""UP Fintech"" or the ""Company""), a leading online brokerage firm focusing on global investors, today announced that it intends to offer and sell 15,000,000 American Depositary Shares (""ADSs""), each representing 15 Class A ordinary shares of the Company, subject to market and other conditions, in an underwritten public offering. The underwriters have an option to purchase up to an aggregate of 2,250,000 additional ADSs from the Company at the public offering price, less underwriting discounts and commissions, exercisable within 20 days from the date of the prospectus supplement. The Company expects to use the net proceeds from the proposed ADS offering for strengthening the Company's capital base and furthering the Company's business development initiatives. Deutsche Bank AG, Hong Kong Branch, China International Capital Corporation Hong Kong Securities Limited and US Tiger Securities, Inc. will act as the joint bookrunners for the proposed ADS offering."
2024-10-22 09:14:02	KBR	Inspire Veterinary Partners Announces $2.5M Registered Direct Offering Of 10M Shares Of Common Stock At A Price Of $0.25/Share	"Inspire Veterinary Partners, Inc. (NASDAQ: KBR ) (""Inspire"" or the ""Company""), an owner and provider of pet health care services throughout the U.S., today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of 10,000,000 million shares of Class A common stock in a registered direct offering, at a price per share of $0.25. The offering is expected to close on or about October 23, 2024, subject to the satisfaction of customary closing conditions. Spartan Capital Securities, LLC is acting as sole placement agent in connection with this offering. The gross proceeds of the offering are expected to be $2.5 million, prior to deducting placement agent's fees and other offering expenses payable by Inspire. Inspire intends to use the net proceeds from the offering for working capital, general corporate purposes, strategic investments, and any additional future acquisition (if any)."
2024-10-22 09:16:00	OOP	Nano Nuclear Stock Is Trading Lower Tuesday: What's Going On?	Nano Nuclear Energy Inc (NASDAQ: OOP ) shares are trading lower Tuesday after the company announced an offering . What To Know: After the market close on Monday, Nano Nuclear filed to sell 1,398,602 units, with each unit consisting of one share of common stock and one 2024 B warrant to purchase up to 0.5 shares of common stock. The warrants will not be listed on any exchanges, therefore the company said the liquidity of the warrants will be limited and should be considered illiquid. Nano Nuclear also said it will grant the underwriters a 30-day option to purchase up to an additional 209,790 shares and/or additional warrants to purchase up to 104,895 shares. Check This Out: Oklo CEO Highlights 'Mind-Blowing' Demand For AI Power, Says Google's Nuclear Deal Only 'Tip Of The Iceberg' The offering comes after nuclear stocks rallied in recent weeks as big tech companies increasingly turn to nuclear to meet the rising energy demands of data centers related to the rapid advancement of AI . Amazon Web Services (AWS) announced plans last week to invest over $500 million to support the development of nuclear energy projects just a few days after Google announced a deal to purchase power from a fleet of SMRs from Kairos Power. Google's first reactor is expected to be online by 2030, with more reactors anticipated through 2035. Nano Nuclear shares have traded higher in recent sessions alongside several other nuclear names . Despite Tuesday's pullback on the offering, the stock is still up nearly 100% over the past month. Nano Nuclear shares were down 6.10% at $25.69 at the time of publication, according to Benzinga Pro . Photo: Shutterstock.
2024-10-22 16:02:18	ENGW	ProQR Therapeutics Commences Public Offering Of Its Ordinary Shares; No Terms Disclosed	All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. ProQR intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to primarily fund research and development and clinical development to support the advancement of its current or future product candidates and the expansion of its research and development programs, and the remainder for working capital, capital expenditures and other general corporate purposes.
2024-10-23 12:07:54	ZSAY	WISeKey International Announces That It Has Signed Convertible Notes Subscription Agreements For Up To $30M, Via Private Placements With A Select Group Of Institutional Investors	"WISeKey Enters Into $30 Million Convertible Notes Subscription Agreements Geneva, Switzerland  October 23, 2024:  Ad-Hoc announcement pursuant to Art. 53 of SIX Listing Rules  WISeKey International Holding Ltd. (""WISeKey"") ((SIX: WIHN, NASDAQ: ZSAY ), a global leader in cybersecurity, digital identity and Internet of Things (IoT) innovations operating as a holding company, today announced that it has signed Convertible Notes Subscription Agreements (""Agreements"") for up to $30 million, via private placements with a select group of institutional investors (the ""Investors""). Under terms of the Agreements, WISeKey will initially issue convertible notes in the aggregate principal amount of $2,500,000 for subscription by the Investors. WISeKey has the right to request the Investors to subscribe for additional tranches, each additional tranche will be in the aggregate principal total amount of $1,250,000 per Investor, at the date and time determined by WISeKey, subject to certain cool-down and volume-related criteria. Each of the convertible notes under the Agreements has a maturity date of 12 months after the relevant issue date and is convertible at any time at the election of the Investors into WISeKey Class B Shares. The conversion price under the Agreements is equal to the lower of a fixed conversion price as determined in the Agreements and 94% of the lowest daily VWAPs of one Class B Share, as applicable, during the ten (10) consecutive trading days preceding the relevant conversion date."
2024-10-23 15:26:49	ZLDA	BioVie Prices Registered Direct Offering And Concurrent Private Placement, Raising $6M Through 2.67M Shares At $2.25 Per Share	"BioVie Inc. (NASDAQ: ZLDA ), (""BioVie"" or the ""Company""), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share, resulting in total gross proceeds of $6,000,750, before deducting the placement agent's fees and offering expenses. The Company also agreed to issue to the investors unregistered warrants to purchase up to 2,667,000 shares of common stock in a concurrent private placement. The warrants will have an exercise price of $2.12 per share of common stock, will be exercisable beginning six months from the date of issuance and will expire five years following the initial exercise date. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock and associated warrants are being offered by the Company. The registered direct offering and concurrent private placement are expected to close on or about October 24, 2024, subject to the satisfaction of customary closing conditions. ThinkEquity is acting as sole placement agent for the offering."
2024-10-23 16:41:46	THSW	Allied Gaming & Entertainment And Yellow River Capital Group Have Entered Into A Strategic Relationship, Including An Investment Of $6.6M By Yellow River By Subscribing To 6M Shares Of The Co's Common Stock; Yellow River Will Receive A Warrant To Purchase Up To 6M Shares Of Common Stock Over The Next 5-Years With An Exercise Price Of $1.80 Per Share	"Allied Gaming & Entertainment, Inc.(NASDAQ: THSW ) (the ""Company"" or ""THSW""), a global experiential entertainment company, today announced a strategic investment by Yellow River Global Capital (""Yellow River""), an alternative private equity manager with deep expertise in large-scale, long-term investments in digital technologies, new media and entertainment. In addition to the financial investment, Yellow River will provide THSW with strategic resources, networking opportunities, and industry expertise that will be extremely valuable as the Company advances its strategic initiatives forward. ""We are very excited to close this investment from Yellow River, who has expertise across a variety of industries and is adept at connecting, and growing businesses,"" said Yinghua Chen, CEO of THSW. ""Yellow River's investment in THSW will further enhance our ability to identify growth opportunities in location-based entertainment chains and the creation and acquisition of entertainment content intellectual property (IP). We are extremely confident that this partnership will bolster our growth potential as we continue building out the Allied ecosystem."" Terms of Investment THSW and Yellow River Capital Group have entered into a strategic relationship, including an investment of $6,600,000 by Yellow River by subscribing to 6,000,000 shares of the Company's common stock, par value $0.0001 per share (the ""Common Stock""). In addition, Yellow River will receive a warrant to purchase up to 6,000,000 shares of Common Stock over the next five years with an exercise price of $1.80 per share, which represents a 50% premium to THSW's closing price on October 17, 2024. As part of the agreement, Yellow River received the right to appoint one Class A Director to the Company's Board of Directors and has selected Mr. Zongmin (Philip) Ding."
2024-10-24 08:02:39	OOP	NANO Nuclear Energy Announces Pricing Of Upsized $36M Underwritten Offering Of 2,117,646 Shares Of Common Stock And Common Stock Purchase Warrants To Purchase 1,058,823 Shares Of Common Stock; Each Share And Associated Warrant Is Being Sold At A Public Offering Price Of $17.00	"NANO Nuclear Energy Inc. (NASDAQ: OOP ) (""NANO Nuclear""), a vertically integrated advanced nuclear energy and technology company developing portable clean nuclear energy solutions, today announced that it has priced an upsized firm commitment, registered underwritten public offering of 2,117,646 shares of common stock and common stock purchase warrants to purchase 1,058,823 shares of common stock. Each share and associated warrant is being sold at a public offering price of $17.00, for gross proceeds of approximately $36 million, before deducting underwriting discounts and offering expenses. In addition, NANO Nuclear has granted the underwriter a 30-day overallotment option to purchase up to an additional 317,646 shares common stock and/or common stock purchase warrants to purchase 158,823 shares of common stock at the public offering price for gross proceeds of up to $5.4 million, less underwriting discounts and expenses. While the shares and associated warrants were marketed as a unit, such units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The warrants are exercisable immediately, have a term of five years, and have an exercise price of $17.00 per share. The warrants will not trade on any market. The Benchmark Company, LLC is acting as sole book-running manager for the offering."
2024-10-24 10:38:49	TQJB	Lucid Capital Raise Should Be 'Zero Surprise To Anyone,' CEO Says	"Shares of luxury EV maker Lucid Group (NASDAQ: TQJB ) dropped after the company announced a nearly $1.75 billion capital raise last week . Lucid CEO Peter Rawlinson told CNBC the move was intended to prevent the need for a &#8220;going concern&#8221; disclosure. In other words, the company's financial runway is dwindling. The CEO also said that investors should have seen the stock offering coming. ""We'd signaled that we had a cash runway to Q4 next year. As a Nasdaq company, we have to avoid a going concern. And a going concern is issued within 12 months of your financial runway,"" Rawlinson said. ""So, it should have been no surprise to anybody."" Read Next: Bank Of America CEO Cautions Fed Not To 'Go Too Fast Or Too Slow' On Interest Rate Cuts Lucid's most recent public offering of 262.44 million shares came only two months after Saudi Arabia's Public Investment Fund injected $1.5 billion in cash into the electric vehicle maker to extend its cash runaway through the end of 2025. Investors and Wall Street analysts were surprised by the timing and size of Lucid's offering. RBC Capital Markets analyst Tom Narayan predicted a sharp decline in the share price following the company's announcement last week. ""We suspect that investors will wonder why TQJB is raising more capital just after it secured the PIF capital in August, and at currently depressed share price levels,"" Narayan reportedly wrote in an investor note. Rawlinson said the company is in a capital-intensive period as it prepares to launch its second electric vehicle, the Lucid Gravity SUV. The U.S.-based EV maker is also building a second factory in Saudi Arabia while expanding its Arizona factory and building its retail vehicle and service network. Lucid's CEO told CNBC the company now has a cash runway into 2026 and will continue to raise capital ""opportunistically."" ""This is exactly as expected. It is exactly to the playbook. It should have come as zero surprise to anyone,"" he said. ""And why did I choose this moment? Because I didn't want to string it out to the end, because I didn't have to."" Price Action: Lucid shares have fallen 28% following the announcement of the offering. They are trading slightly higher, up 0.6% at $2.50 at the time of publication Thursday, according to Benzinga Pro . Read Also: Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk's Political Views And Taking Business From Tesla Image: Courtesy of Lucid Group, Inc."
2024-10-24 14:11:54	AAAZ	Mustang Bio Announces Exercise of Warrants For $4M Gross Proceeds; Entered Into A Definitive Agreement For The Exercise Of Certain Existing Warrants To Purchase An Aggregate Of 16,877,638 Shares Of Its Common Stock Having An Exercise Price Of $0.237 Per Share	"Mustang Bio, Inc. (""Mustang"" or the ""Company"") (NASDAQ: AAAZ ), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 16,877,638 shares of its common stock having an exercise price of $0.237 per share, originally issued in May 2024. The issuance or resale of the shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-278006). The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $4 million, prior to deducting placement agent fees and offering expenses payable by the Company. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
2024-10-24 14:16:24	QN	TuanChe Announces Pricing Of $1.1M Registered Direct Offering And Concurrent Private Placement; Co To Purchase Up To An Aggregate Of 761,719 ADS; The Combined Effective Offering Price For Each ADS And Accompanying Warrant Is $1.449 Per ADS	"TuanChe Limited (""TuanChe,"" ""Company,"" ""we"" or ""our"") (NASDAQ: QN ), a leading integrated automotive marketplace in China, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 761,719 of the Company's American Depositary Shares (""ADSs"") (or pre-funded warrants to purchase ADSs (""ADS Equivalents"") in lieu thereof). In a concurrent private placement, the Company agreed to issue and sell unregistered warrants to purchase up to an aggregate of 761,719 ADSs. The combined effective offering price for each ADS (or ADS Equivalent) and accompanying warrant is $1.449 per ADS. The private placement warrants will be immediately exercisable, will expire five years from the date of issuance and will have an exercise price of $1.449 per share. The transaction is expected to close on or about October 28, 2024, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the exclusive Placement Agent."
2024-10-24 16:15:39	SHU	Agree Realty Announces Common Stock Offering Of 4M Shares Of Common Stock	"Agree Realty Corporation (NYSE: SHU) (the ""Company"") today announced that it commenced an underwritten public offering of 4,000,000 shares of its common stock in connection with the forward sale agreements described below. In connection with the offering, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock. Citigroup and Wells Fargo Securities are acting as joint book-running managers for the offering."
2024-10-24 16:39:07	BZNJ	Foremost Clean Energy Announces Brokered Private Placement For Gross Proceeds Of Up To C$7M, Including Participation Of Denison Mines	"Foremost Clean Energy Ltd. (NASDAQ: BZNJ ) ("" Foremost "" or the "" Company ""), an emerging North American uranium and lithium exploration company, is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. to act as lead agent and sole bookrunner on behalf of a syndicate of agents (the "" Agents "") in connection with a best efforts private placement (the "" Marketed Offering "") for aggregate gross proceeds of up to approximately C$7,000,000 from the sale of the following: gross proceeds of up to C$3,500,001 from the sale of up to 1,166,667 units of the Company (the "" Units "") at a price of C$3.00 per Unit (the "" Unit Price ""); and gross proceeds of up to C$3,500,000 from the sale of any combination of (i) flow-through units of the Company (the "" FT Units "") at a price of C$3.50 per FT Unit, and (ii) FT Units to be sold to charitable purchasers (the "" Charity FT Units "", and together with the Units and FT Units, the "" Offered Securities "") at a price of C$4.55 per Charity FT Unit. The Agents will have an option, exercisable in full or in part, up to 48 hours prior to the closing of the Offering, to sell up to an additional C$1,000,000 in any combination of Units, FT Units and Charity FT Units at their respective offering prices (the "" Agents' Option "", and together with the Marketed Offering, the "" Offering "")."
2024-10-25 08:03:21	WBLV	enGene Announces That It Has Agreed To Sell 6,758,311 Of Its Common Shares At A Price Per Share Of $8.90; Anticipates The Gross Proceeds From The Private Placement To Be ~$60M	enGene Holdings Inc. (NASDAQ: WBLV ), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Gurin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of its common shares at a price per share of $8.90. The financing is expected to close on October 29, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be approximately $60 million, before deducting any offering-related expenses. The financing included participation from new and existing investors, including Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital and Venrock Healthcare Capital Partners.
2024-10-25 08:35:57	OFGD	Catheter Precision Announces Exercise of Warrants For $4.9M Of Gross Proceeds; Entered Into A Definitive Agreement For The Immediate Exercise Of Certain Outstanding Warrants To Purchase Up To An Aggregate Of 5,347,981 Shares Of Stock At A Reduced Exercise Price Of $0.70	"Catheter Precision, Inc. (NYSE: OFGD ), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F, Series G, Series L and Series I warrants (collectively, the ""Existing Warrants"") to purchase up to an aggregate of 5,347,981 shares of the Company's stock at a reduced exercise price of $0.70 for total gross proceeds of approximately $3.7 million. An additional $1,185,000 of gross proceeds were received through the exercise of warrants over the last week in accordance with their original terms. Ladenburg Thalmann & Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants. In consideration for the immediate exercise of the Existing Warrants, the Company will issue new unregistered Series K warrants to purchase up to 10,695,962 shares of common stock. The new warrants will have an exercise price of $0.70, will be exercisable only after shareholder approval of their exercise has been obtained, and will have a term of 5.5 years from the date of exercisability."
2024-10-25 16:29:28	SHU	Agree Realty Announces $1.25B At-The-Market Equity Distribution Agreement	"On October 25, 2024, Agree Realty Corporation (the "" Company "") and Agree Limited Partnership (the "" Operating Partnership ""), for which the Company is the sole general partner, entered into an at-the-market ("" ATM "") equity distribution agreement with each of Wells Fargo Securities, LLC ("" Wells Fargo ""), Robert P. Baird & Co Incorporated ( ""Baird"" ), BofA Securities, Inc. ("" BofA Securities ""), BTIG, LLC ("" BTIG ""), Citigroup Global Markets Inc. ("" Citigroup ""), Evercore Group L.L.C. ("" Evercore ""), Jefferies LLC ("" Jefferies ""), J.P. Morgan Securities LLC ( ""J.P. Morgan"" ), Mizuho Securities USA LLC ("" Mizuho ""), Morgan Stanley & Co. LLC ("" Morgan Stanley ""), Samuel A. Ramirez & Company, Inc. ("" Ramirez "") , Raymond James & Associates, Inc. ("" Raymond James ""), Regions Securities LLC ("" Regions ""), SMBC Nikko Securities America, Inc. ("" SMBC "") and Stifel, Nicolaus & Company, Incorporated ("" Stifel "") (we refer to these entities, when acting in their capacity as sales agents, individually as ""sales agent"" and collectively as ""sales agents""), and the forward purchasers (as defined below), pursuant to which the Company may issue and sell from time to time shares of the Company's common stock, $0.0001 par value per share, having an aggregate offering price of up to $1,250,000,000 (the "" Shares ""). In addition to the issuance and sale of common stock by us through a sales agent acting as a sales agent or directly to the sales agent acting as principal for its own account at a price agreed upon at the time of sale, we have entered into forward sale agreements, between us and each of Wells Fargo National Association, Baird, Bank of America N.A., Citibank, N.A. (or an affiliate thereof), Jefferies, JPMorgan Chase Bank, National Association, Mizuho Markets Americas LLC, Morgan Stanley, Nomura Global Financial Products, Inc., Raymond James, Regions and Stifel, or their respective affiliates or agents (we refer to these entities, when acting in such capacity, each as a "" forward purchaser "" and, collectively, as the "" forward purchasers ""). We refer to the sales agents, or their affiliates, when acting as agents for forward purchasers, individually as a "" forward seller "" and collectively as the "" forward sellers ,"" except with respect to Nomura Global Financial Products, Inc., in which case the relevant forward seller is Nomura Securities International, Inc. (acting through BTIG as its agent). Upon entering into the ATM equity distribution agreement, the Company simultaneously terminated the equity distribution agreement the Company entered into in connection with a prior ATM offering program established in February 2024."
2024-10-28 06:44:46	ZO	Boeing Launches $5B Preferred Stock Offering and 90M Common Shares, Eyes Debt Reduction and Growth Funding	"The Boeing Company (NYSE: ZO ) (""Boeing"" or the ""Company"") announced today the launch of concurrent separate underwritten public offerings of (i) 90,000,000 shares of common stock, par value $5.00 per share (""Common Stock"") of the Company and (ii) $5 billion of depositary shares (""Depositary Shares""), each representing a 1/20th interest in a share of newly issued Series A Mandatory Convertible Preferred Stock, par value $1.00 per share (""Preferred Stock""), of the Company (together, the ""Offerings""). Boeing expects to grant to the underwriters of the Offerings a 30-day option to purchase up to an additional (i) 13,500,000 shares of Common Stock and (ii) $750 million of Depositary Shares, solely to cover over-allotments, if any. Boeing intends to use the net proceeds from the Offerings for general corporate purposes, which may include, among other things, repayment of debt, additions to working capital, capital expenditures, and funding and investments in the Company's subsidiaries. Holders of the Depositary Shares will be entitled to a proportional fractional interest in the rights and preferences of the Preferred Stock, including conversion, dividend, liquidation and voting rights, subject to the provisions of a deposit agreement. The Preferred Stock is expected to have a liquidation preference of $1,000 per share. Unless earlier converted, each share of Preferred Stock will automatically convert, for settlement on or about October 15, 2027, into a variable number of shares of Common Stock based on the applicable conversion rate, and each Depositary Share will automatically convert into a number of shares of Common Stock equal to a proportionate fractional interest in such shares of Common Stock. The dividend rate, conversion terms and other terms of the Preferred Stock will be determined at the time of pricing of the offering of the Depositary Shares. Currently, there is no public market for the Depositary Shares or the Preferred Stock. Boeing intends to apply to list the Depositary Shares on the New York Stock Exchange under the symbol ""ZO.PRA."""
2024-10-28 17:35:09	JOM	Keurig Dr Pepper Reveals Secondary Offering Of 60M Shares Of Its Common Stock By JAB Subsidiary	JAB has also granted the underwriter a 30-day option to purchase up to an additional 9 million shares. Following the completion of the offering, JAB will beneficially own approximately 16.5% of JOM's outstanding common stock, or approximately 15.8% assuming full exercise of the underwriter's option to purchase additional shares. The remaining shares beneficially owned by JAB will be subject to a 90-day lock-up agreement with the underwriter. Additionally, to fill the vacancy on the JOM Board of Directors left by JAB Partner Lubomira Rochet, who notified the Company of her immediate resignation, the Board has appointed Frank Engelen, Managing Partner and CFO of JAB, as a director.
2024-10-29 08:08:31	MVIP	Biora Therapeutics Announces $3M Registered Direct Offering  For The Purchase And Sale Of 745,342 Shares Of Common Stock At An Offering Price Of $4.025 Per Share Of Common Stock, Priced At-The-Market Under Nasdaq Rules	Biora Therapeutics, Inc. (NASDAQ: MVIP ), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company's common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing of the offering is expected to occur on or about October 29, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Biora from this offering are expected to be approximately $3 million, before deducting the placement agent's fees and other offering expenses. Biora intends to use the net proceeds from this offering to support its operations, make further investments in the development of its oral biotherapeutics platforms, and for working capital and general corporate purposes.
2024-10-29 10:29:20	TEBE	Protagenic Therapeutics Announces Pricing Of $1.275M Private Placement For The Purchase And Sale Of An Aggregate Of 1,948,295 Shares Of Common Stock; The Purchase Price Of Each Share Of Common Stock And Associated Common Stock Purchase Warrants Will Be $0.64	"Protagenic Therapeutics, Inc. (NASDAQ: TEBE ) (""Protagenic Therapeutics"" or the ""Company""), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the ""Purchase Agreement"") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants will be $0.64 ($0.89 in the case of insiders). The closing of the offering is expected to occur on or before November 4, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $1.275 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the sale of the securities for working capital purposes. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as sole placement agent for the private placement."
2024-10-29 12:34:22	JOM	Why Keurig Dr Pepper Shares Are Sliding Tuesday	Keurig Dr Pepper Inc. (NASDAQ: JOM ) shares are trading lower Tuesday after the company announced the pricing of a secondary offering. Here's what you need to know. What Happened: Keurig Dr Pepper announced it will offer 60 million shares at $32.85 per share in a secondary sale through a subsidiary of JAB Holding Company. The underwriters will also be granted an option to purchase an additional 9 million shares. Following the offering, JAB's ownership of Keurig Dr Pepper will drop to approximately 16.5%. See Also: Corning Q3 Earnings Beat Expectations with 8% Core Sales Growth, Optical Communications Segment Shines How To Buy JOM Stock Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. For example, in Keurig Dr Pepper's case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. JOM Price Action: Keurig Dr Pepper shares were down 2.57% at $32.99 at the time of writing, according to Benzinga Pro. Image: Shutterstock.
2024-10-29 13:18:53	TWSJ	Unusual Machines Announces Pricing Of $1.96M Private Placement For An Aggregate Of 1,286,300 Units At A Per Unit Price Of $1.52 Per Unit	"Unusual Machines, Inc. (NYSE: TWSJ ) (""Unusual Machines"" or the ""Company""), a drone and drone components manufacturer, today announced the pricing of a private placement with certain institutional investors. The aggregate gross cash proceeds were approximately $1.96 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the private placement for general corporate purposes and working capital. In connection with the private placement, the Company will issue an aggregate of 1,286,300 units at a per unit price of $1.52 per unit. Each unit consists of one share of common stock and one warrant, each exercisable for one share of common stock at an exercise price of $1.99 per share. The warrants are exercisable beginning 180 days after the closing date. The warrants have a term of 5 years from the closing date. The exercise price and number of shares of common stock issuable upon exercise of the warrants are subject to adjustment upon future dilutive issuances and stock splits, subject to a floor, as described in more detail in the Current Report on Form 8-K to be filed in connection with the private placement. Allan Evans, the Company's Chief Executive Officer and Sanford Rich and Robert Lowry, each a member of the Company's Board of Directors, will invest an aggregate of $250,000 in the private placement on identical terms. The closing of the private placement is expected to close on October 30, 2024."
2024-10-29 16:25:47	PQIO	Thryv Holdings Announces $75M Public Offering Of Common Stock	"Thryv Holdings, Inc. (""Thryv"" or the ""Company"") (NASDAQ: PQIO ) announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock, subject to market and other conditions. In connection with the proposed offering, Thryv intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Thryv intends to use the net proceeds from this offering to fund a portion of the purchase price for its previously announced acquisition of Infusion Software, Inc. (d/b/a Keap). RBC Capital Markets, LLC is acting as sole book-running manager for the offering. RBC Capital Markets may offer the shares of common stock from time to time for sale in one or more transactions on the Nasdaq exchange, in the over-the-counter market, through negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices."
2024-10-30 08:30:43	UHFO	iSpecimen Announces Pricing Of $5M Public Offering Of Common Stock And Pre-Funded Warrants	"iSpecimen Inc. (NASDAQ: UHFO ) (""iSpecimen"" or the ""Company""), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering of approximately $5 million of the Company's common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of proceeds will be used for working capital purposes. WestPark Capital, Inc. is acting as the exclusive placement agent in connection with the offering."
2024-10-30 16:46:13	BSOR	Enovix Announces Proposed $100M Public Offering Of Common Stock	"Enovix Corporation (""Enovix"") (NASDAQ: BSOR ) , a global high-performance battery company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock, subject to market and other conditions. In connection with the offering, Enovix expects to grant the underwriter a 30-day option to purchase up to an additional $15.0 million of the shares of common stock offered in the public offering. There can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares of common stock in the offering will be sold by Enovix. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. Enovix intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments, for general corporate purposes, and for working capital and capital expenses to achieve high-volume manufacturing at its high-volume production facility ""Fab2"" in Penang, Malaysia."
2024-10-30 17:13:28	MXLP	CalciMedica Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"CalciMedica, Inc. (""CalciMedica"" or the ""Company"") (NASDAQ: MXLP ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (""CRAC"") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it has commenced an underwritten public offering of its shares of common stock. All of the shares to be sold in the underwritten public offering are to be sold by the Company. In connection with the proposed offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jones is acting as the sole book-running manager for the offering."
2024-10-31 04:09:49	XJUJ	Reported Earlier, Harmony Biosciences Shareholders Sell 8M Shares at $31 Each in Public Offering	"Harmony Biosciences Holdings, Inc. (NASDAQ: XJUJ ) (the ""Company"") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share (""Common Stock""), by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the ""Selling Shareholders"") at a public offering price of $31.00 per share. The Selling Shareholders have granted the underwriter a 30-day option to purchase an additional 1,200,000 shares of Common Stock from the Selling Shareholders at the public offering price, less underwriting discounts and commissions. The Company is not offering any shares of Common Stock in the offering and will not receive any proceeds from the sale of shares in the offering. The offering is expected to close on November 1, 2024, subject to customary closing conditions."
2024-10-31 04:12:26	HTYW	Reported Earlier, Tiziana Life Sciences Secures $5M in Direct Offering Of 5.3M Shares At $0.95/ Share for Immunotherapy Development	"Tiziana Life Sciences, Ltd. (NASDAQ: HTYW ) (""Tiziana"" or the ""Company""), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,263,158 common shares at a purchase price of $0.95 per share pursuant to a registered direct offering, resulting in gross proceeds of approximately $5 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about November 1, 2024, subject to the satisfaction of customary closing conditions. In addition, the Company has issued the investor an option to acquire up to an additional 5,263,158 common shares at a price of $0.95 per share until the date that is 75 days from the date of the closing of the offering, resulting in additional gross proceeds of up to approximately $5 million, at the election of the investor. The Company intends to use the net proceeds from the offering towards (i) its Phase 2a clinical trial for the intranasal delivery of foralumab in patients with non-active secondary progressive multiple sclerosis, (ii) expediting the clinical development of foralumab in Alzheimer's disease, (iii) developing foralumab for other indications, and (iv) for working capital and other general corporate purposes."
2024-10-31 04:15:27	FBF	Reported Earlier, Camping World Launches $300M Stock Offering Via Sale Of 14.6M Shares At $20.50/Share to Bolster Growth, Reduce Debt	"Camping World Holdings, Inc. (NYSE: FBF ) (""Camping World"" or the ""Company"") announced today the pricing of an underwritten public offering of 14,634,146 shares of its Class A common stock (the ""Class A Common Stock"") at a public offering price of $20.50 per share pursuant to a registration statement filed on Form S-3 with the Securities and Exchange Commission (the ""SEC""). Additionally, the Company has granted the underwriters a 30-day option to purchase up to an aggregate of 2,195,121 additional shares of Class A Common Stock. The proceeds of the offering will be used by Camping World to purchase 14,634,146 common units (or 16,829,267 common units if the underwriters exercise their option in full to purchase additional shares of Class A Common Stock) directly from CWGS Enterprises, LLC (""CWGS, LLC""), at a price per unit equal to the public offering price per share of Class A common stock in the offering, less the underwriting discounts and commissions. CWGS, LLC intends to use the net proceeds from the sale of common units to Camping World for general corporate purposes, including strengthening the balance sheet, working capital for growth and debt pay down."
2024-10-31 04:18:04	MXLP	Reported Earlier, CalciMedica Launches $10.2M Stock Offering Of 2.72M Shares At $3.75/Share to Advance Inflammatory Disease Research	"CalciMedica, Inc. (""CalciMedica"" or the ""Company"") (NASDAQ: MXLP ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (""CRAC"") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the pricing of an underwritten public offering of 2,720,000 shares of its common stock at a price to the public of $3.75 per share. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $10,200,000. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 408,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by the Company. The offering is expected to close on or about November 1, 2024, subject to satisfaction of customary closing conditions."
2024-10-31 04:20:46	FRCZ	Reported Earlier, CareTrust REIT Launches $32/Share Upsized Stock Offering of 13.8M Shares (Prior 11.50M) to Fund Nursing Facility Acquisitions	"CareTrust REIT, Inc. (NYSE: FRCZ ) (""CareTrust REIT"" or the ""Company"") announced the pricing of its upsized underwritten public offering of 13,800,000 shares of common stock at a price to the public of $32.00 per share. The offering is expected to close on November 1, 2024, subject to customary closing conditions. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,070,000 shares of common stock. The Company intends to contribute the net proceeds to CTR Partnership, L.P., its operating partnership, which will in turn use the proceeds from this offering to fund new investments, including to acquire 31 skilled nursing facilities through a joint venture arrangement."
2024-10-31 08:23:04	OYFJ	PALLADYNE AI CORP. Announces Pricing Of $7M Registered Direct Offering And Concurrent Private Placements	"Palladyne AI Corp. (NASDAQ: OYFJ ) (""Palladyne AI""), a developer of artificial intelligence software for robotic platforms in the commercial and defense sectors, today announced that it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 2,790,700 shares of its common stock (the ""shares"") in a registered direct offering at a purchase price of $2.15 per share. In a concurrent private placement, the Company also agreed to issue to the same investor warrants to purchase up to 2,790,700 shares of common stock (the ""common warrants""). The common warrants have an exercise price of $2.30 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance. In a separate concurrent private placement, the Chief Executive Officer and certain other members of the board of directors of the Company (the ""Insiders"") purchased 430,105 shares of common stock at a price per share of $2.20 per share, which represents the consolidated closing bid price on October 30, 2024, and common warrants to purchase up to 430,105 shares of common stock. These common warrants were purchased at a price of $0.125 per common warrant, have an exercise price of $2.30 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance. The gross proceeds from the offerings, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $7 million. Palladyne AI expects to use the net proceeds from the offerings for general corporate purposes and working capital, including funding continued development and commercialization of our software products. A.G.P./Alliance Global Partners is acting as sole placement agent for the offerings. The offerings are expected to close on or about November 1, 2024, subject to the satisfaction of customary closing conditions."
2024-10-31 08:37:31	KKGQ	Bionano Announces $3M Registered Direct Offering Priced At-the-Market under Nasdaq Rules	"Bionano Genomics, Inc. (NASDAQ: KKGQ ) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the ""Warrants"") at a combined offering price of $0.3039 per share of common stock and accompanying Warrants, in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the ""Stockholder Approval""). The Series C warrants will expire five years following the date of the Stockholder Approval and the short-term Series D warrants will expire eighteen months following the date of Stockholder Approval. The closing of the offering is expected to occur on or about October 31, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be approximately $3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Warrants, if fully exercised on a cash basis, will be approximately $6 million. No assurance can be given that the Stockholder Approval will be achieved or that any of the Warrants will be exercised. The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and available-for-sale securities, for general corporate purposes, including working capital, research and development expenses, repayment or redemption of existing indebtedness and capital expenditures."
2024-10-31 11:45:29	BSOR	What's Going On With Enovix Stock Thursday?	"Enovix Corp (NASDAQ: BSOR ) shares are trading lower Thursday after the company announced a $100 million public offering . What Happened: Enovix announced an underwritten offering of 10,416,667 shares of its common stock for total gross proceeds of $100 million after the market close on Wednesday. The company said it plans to grant the underwriter a 30-day option to buy up to an additional 1,562,500 shares at the public offering price. All shares being offered will be sold by Enovix. The offering is expected to close on Friday. Enovix expects to use the net proceeds from the offering to achieve high-volume manufacturing at its &#8220;Fab2&#8221; production facility in Malaysia, as well as for general corporate purposes. See Also: BlackRock's Bitcoin ETF Crosses 1 Million BTC In Assets Under Management The news comes a day after Enovix shares jumped as the company reported better-than-expected financial results for the third quarter. Enovix said Fab2 is now operational and shipping samples to customers and also announced a development agreement with ""one of the leading global smartphone OEMs with top five market share in China."" Under the agreement, Enovix will develop a 100% active silicon anode battery customized for specific smartphone models. The company said it is targeting the launch of its custom battery in the fourth quarter of 2025. BSOR Price Action: Enovix shares were down 14.1%, trading at $9.01 at the time of publication Thursday, according to Benzinga Pro . Photo: Shutterstock."
2024-10-31 16:25:47	RDFB	Arbe Robotics Announces Proposed Public Offering; No Size Or Amount Disclosed	"Arbe Robotics Ltd. (NASDAQ, TASE: RDFB ) (""Arbe"" or the ""Company""), a global leader in Perception Radar Solutions, today announced that it is proposing to offer and sell, subject to market conditions, its ordinary shares (or pre-funded warrants in lieu thereof) accompanied by Tranche A Warrants to purchase ordinary shares and Tranche B Warrants to purchase ordinary shares in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Canaccord Genuity is acting as the sole bookrunner for the offering. Arbe intends to use the net proceeds from this offering for working capital and general corporate purposes."
2024-11-01 17:00:42	BOT	Equity Lifestyle Properties Enters Equity Distribution Agreements With Multiple Sales Agents; May Sell Up To $700M In Common Stock	"- SEC Filing On November 1, 2024, Equity LifeStyle Properties, Inc. (referred to herein as the ""Company,"" ""we,"" ""us"" and ""our"") and our operating partnership, MHC Operating Limited Partnership (the ""Operating Partnership""), entered into separate Equity Distribution Agreements (the ""Equity Distribution Agreements"") with each of Morgan Stanley & Co. LLC; BofA Securities, Inc.; Capital One Securities, Inc.; Goldman Sachs & Co. LLC; Jefferies LLC; RBC Capital Markets, LLC; Regions Securities LLC; Truist Securities, Inc.; and Wells Fargo Securities, LLC (collectively, the ""Sales Agents""), pursuant to which we may sell, from time to time, shares of our common stock, par value $0.01 per share (the ""Common Stock""), having an aggregate offering price of up to $700,000,000, through the Sales Agents (the ""Offering""). Upon entry into the Equity Distribution Agreements, we terminated our prior program pursuant to the equity distribution agreements, each dated as of February 28, 2024 (the ""Prior Equity Distribution Agreements""), entered into with each of Morgan Stanley & Co. LLC; BMO Capital Markets Corp.; BofA Securities, Inc.; Capital One Securities, Inc.; Goldman Sachs & Co. LLC; Jefferies LLC; Regions Securities LLC; Truist Securities, Inc.; and Wells Fargo Securities, LLC (the ""Prior Sales Agents""). At the time of the termination of the Prior Equity Distribution Agreements, an aggregate gross sales price of approximately $182.6 million of the Common Stock remained unsold under the Prior Equity Distribution Agreements. Any Common Stock sold in the Offering will be issued pursuant to a prospectus dated February 27, 2024, and a prospectus supplement filed with the Securities and Exchange Commission (the ""SEC"") onNovember 1, 2024, in connection with one or more offerings of shares under our shelf registration statement on Form S-3ASR (Registration No. 333-277426) filed with the SEC on February 28, 2024 and which was automatically effective upon filing. Sales of our Common Stock made pursuant to the Equity Distribution Agreements, if any, may be made in negotiated transactions, including block trades, in transactions that are deemed to be ""at the market"" offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the ""Securities Act""), by means of ordinary brokers' transactions at market prices prevailing at the time of sale, including sales made directly on the New York Stock Exchange, in sales made in the over-the-counter market, in sales made to or through a market maker, in sales made through other securities exchanges or electronic communications networks, or by any other means permitted by law. The Company may also sell shares of Common Stock to a Sales Agent as principal for its own account at a price agreed upon at the time of such sale. If the Company sells shares of Common Stock to a Sales Agent as principal, it will enter into a separate agreement with the Sales Agent. The Equity Distribution Agreements provide that each Sales Agent will receive from the Company a commission that will not exceed, but may be lower than, 2.0% of the gross sales price of all shares of Common Stock sold through it as Sales Agent under the Equity Distribution Agreement. We intend to use the proceeds from any sales in the Offering for general corporate purposes, which may include repayment of existing indebtedness, acquisitions of properties (including through the acquisition of individual properties, portfolios and companies), development, renovation, expansion and improvement of our existing properties, working capital and other capital expenditures. We made certain customary representations, warranties and covenants concerning the Company, the Operating Partnership and the Common Stock in each Equity Distribution Agreement and also agreed to indemnify the Sales Agents against certain liabilities, including liabilities under the Securities Act. The form of Equity Distribution Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the description of the material terms of the Equity Distribution Agreements in this Item 1.01 is qualified in its entirety by reference to such Exhibit, which is incorporated herein by reference."
2024-11-01 17:21:59	IS	NioCorp Announces Commencement Of Proposed Underwritten Public Offering Of Common Shares & Warrants; No Size Or Amount Disclosed	"NioCorp Developments Ltd. (""NioCorp"" or the ""Company"") (NASDAQ: IS ) today announced it has commenced a proposed underwritten public offering in the United States (the "" Registered Offering ""). Concurrently, the Company has also commenced a private placement (the "" Private Offering "" and, together with the Registered Offering, the "" Offerings ""). The Registered Offering consists of common shares and warrants to purchase common shares and is subject to market conditions. There can be no assurance as to whether or when the Registered Offering may be completed, or as to the actual size, pricing or other terms of the Registered Offering. In addition, the Company intends to grant the underwriter a 45-day over-allotment option to purchase up to an additional 15 percent of the number of initial common shares and/or an additional 15 percent of the number of initial warrants offered in the Registered Offering. The Private Offering consists of common shares and warrants to purchase common shares. There can be no assurance as to whether or when the Private Offering may be completed, or as to the actual size, pricing or other terms of the Private Offering. Completion of the Private Offering is not contingent on completion of the Registered Offering and completion of the Registered Offering is not contingent on the completion of the Private Offering. Maxim Group LLC is acting as sole book-running manager and underwriter for the Registered Offering. NioCorp currently intends to use the net proceeds from the Offerings for working capital and general corporate purposes, including to (i) advance its efforts to launch construction of a critical minerals project in Southeast Nebraska (the ""Elk Creek Project"") and move it to commercial operation and (ii) repay all amounts outstanding under the Company's $2.0 million non-revolving multiple draw credit facility (the ""Smith Credit Facility"") available pursuant to the Loan Agreement, dated September 11, 2024, by and between the Company and its Chief Executive Officer, President and Executive Chairman, Mark Smith. The Smith Credit Facility will continue to be available to the Company following the close of the Offerings. The Registered Offering is subject to customary closing conditions."
2024-11-04 06:17:53	PAQ	Xcel Energy Announces $1.2B Stock Sale, Plans for Corporate Funding	Xcel Energy Inc. (NASDAQ: PAQ ) (Xcel Energy) announced today the commencement of a registered underwritten offering of $1.2 billion of shares of its common stock. Subject to certain conditions, all shares are expected to be borrowed by the forward purchasers (as defined below) (or their affiliates) from third parties and sold to the underwriters and offered in connection with the forward sale agreements described below. Barclays and BofA Securities are acting as joint book-running managers for this offering. The underwriters may offer shares of Xcel Energy's common stock in transactions on the Nasdaq Stock Market LLC, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. In connection with the offering, Xcel Energy expects to enter into separate forward sale agreements with each of Barclays Bank PLC and Bank of America, N.A. (in such capacity, the forward purchasers) under which Xcel Energy will agree to issue and sell shares of its common stock to the forward purchasers at an initial forward sale price per share equal to the price per share at which the underwriters purchase the shares in the offering, subject to certain adjustments, upon physical settlement of the relevant forward sale agreement. In addition, the underwriters of the offering expect to be granted a 30-day option to purchase up to an additional $180 million of shares of Xcel Energy's common stock upon the same terms. If the underwriters exercise their option, Xcel Energy may elect to enter into additional forward sale agreements with the forward purchasers with respect to the additional shares or to issue and sell such shares directly to the underwriters. Settlement of the forward sale agreements is expected to occur on or prior to June 30, 2026. Xcel Energy may, subject to certain conditions, elect cash settlement or net share settlement for all or a portion of its rights or obligations under either of the forward sale agreements. If Xcel Energy elects physical settlement of either of the forward sale agreements, it presently expects to use the net proceeds for general corporate purposes, which may include capital contributions to its utility subsidiaries, acquisitions, and/or repayment of short-term debt.
2024-11-05 09:30:04	CBWB	Nuwellis Announces Exercise Of Warrants For $5.1M Of Gross Proceeds	"Nuwellis, Inc. (NASDAQ: CBWB ) (""Nuwellis"" or the ""Company""), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the ""Existing Warrants"") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. Ladenburg Thalmann & Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants. In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the ""Series I Warrants"") and Series II common stock purchase warrants (the ""Series II Warrants"") to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features. The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the ""Securities Act""), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the ""SEC"") or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants."
2024-11-06 14:38:01	UITW	Safe & Green Holdings Corp. Announces Entry Into Warrant Inducement Transaction, Wherein An Investor Agreed To Exercise The Existing Warrants To Purchase Up 2,758,620 Shares Of Common Stock At A Reduced Exercise Price Of $0.8718 Per Share, For $2.4M In Gross Proceeds	"Safe & Green Holdings Corp. (NASDAQ: UITW ) (""Safe & Green Holdings"" or the ""Company""), a leading developer, designer, and fabricator of modular structures, announced today that it has entered into an agreement with a single investor that is an existing holder of warrants to purchase shares of common stock of the Company for cash (the ""Existing Warrants""), wherein the investor agreed to exercise the Existing Warrants to purchase up 2,758,620 shares of common stock at a reduced exercise price of $0.8718 per share, resulting in gross proceeds of approximately $2.4 million, before deducting offering fees and other expenses payable by the Company. Aegis Capital Corp. acted as the exclusive financial advisor in connection with the transaction. In consideration for the exercise of the Existing Warrants for cash, the investor received new warrants (the ""New Warrants"") to purchase up to an aggregate of 5,517,240 shares of common stock. The New Warrants are exercisable after stockholder approval at an exercise price of $0.8718 per common share and will expire five years after stockholder approval."
2024-11-07 10:46:10	NHKB	What's Going On With Virgin Galactic Stock Thursday?	Virgin Galactic Holdings Inc (NYSE: NHKB ) shares are falling Thursday after the company announced an at-the-market equity program to fund its fleet expansion . What To Know: After the market close on Wednesday, Virgin Galactic reported mixed financial results for the third quarter. The company reported revenue of $402,000, missing estimates for revenue of $2.23 million, and a quarterly loss of $2.66 per share, beating estimates for a loss of $4.25 per share, per Benzinga Pro . Virgin Galactic reported negative free cash flow of $118 million and guided for fourth-quarter free cash flow of negative $115 million to negative $125 million. The company ended the quarter with $744 million in cash, cash equivalents and marketable securities. &#8220;Our spaceship program remains on track to begin commercial operations in 2026, and with strong progress made on the Delta program, we now have the engineering capacity to advance design work on a second mothership, which will accelerate the next phase of growth for Virgin Galactic,&#8221; said Michael Colglazier , CEO of Virgin Galactic. Check This Out: Which Musk Company Will Propel Dogecoin's Future  X, Tesla, SpaceX Or The Boring Company? A few hours after the earnings report was released, Virgin Galactic announced that it entered into a sales agreement to offer and sell up to $300 million of its common stock from time to time in an at-the-market program. The company said it expects to use the net proceeds from any sales of its common stock to further accelerate the development and production of its next-generation spaceflight fleet, including an additional mothership and Delta Class spaceships. NHKB Price Action: Virgin Galactic shares were down 11.9% at $6.27 at the time of publication, according to Benzinga Pro . Photo: courtesy of Virgin Galactic.
2024-11-08 09:20:55	QONI	Stryve Foods Announces Pricing Of $2.9M Public Offering Of 3,670,886 Shares Of Its Class A Common Stock And Commons Stock Equivalents And Warrants To Purchase Up To An Aggregate Of 7,341,722 Shares Of Its Class A Common Stock At A Combined Public Offering Price Of $0.79 Per Share	"Stryve Foods, Inc. (""Stryve"" or ""the Company"") (NASDAQ: QONI ), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today announced the pricing of a public offering priced at-market according to Nasdaq rules of 3,670,886 shares of its Class A common stock and commons stock equivalents and warrants to purchase up to an aggregate of 7,341,722 shares of its Class A common stock at a combined public offering price of $0.79 per share (or prefunded warrant) and associated common warrants. Each share of Class A common stock (or prefunded warrant) is being sold together with two warrants each to purchase one share of Class A common stock. The common warrants will have an exercise price of $0.79 per share, are exercisable following stockholder approval and have a term of exercise equal to five years following date of the stockholder approval. The closing of the offering is expected to occur on or about November 12, 2024, subject to the satisfaction of customary closing conditions. In connection with this offering, the Company also agreed to amend certain existing warrants to purchase up to 529,412 shares of its Class A common stock at an exercise price of $54.00 per share to have a reduced exercise price equal to $0.79 per share, subject to stockholder approval. Roth Capital Partners and Northland Capital Markets are acting as the co-placement agents for the offering."
2024-11-11 11:12:20	ZYFK	Houston American Energy Corp. Announces It Has Closed A Private Placement Offering For The Issuance And Sale Of 2,180,180 Shares Of Common Stock To An Accredited Investor; CEO John F. Terwilliger To Be Stepping Down, Peter F. Longo To Serve As President And CEO, Effective On November 11, 2024	"Houston American Energy Corp. (NYSE: ZYFK ) (the ""company"") today announced that the company has closed a private placement offering for the issuance and sale of 2,180,180 shares of common stock of the company (the ""private placement"") to an accredited investor. The aggregate gross proceeds to the company from the offering were approximately $2.5 million, before deducting placement agent fees and other offering expenses. Univest Securities, LLC acted as the exclusive placement agent for the private placement. The company today also announced certain management changes. John F. Terwilliger, the company's President and Chief Executive Officer, has advised the company that he would be stepping down from those positions, effective November 11, 2024. Mr. Terwilliger will provide advisory services to the company for a limited period of time to effect an orderly transition. Mr. Terwilliger will continue to serve as a director of the company. The company's board of directors has appointed Peter F. Longo to serve as President and Chief Executive Officer of the company, effective on November 11, 2024. Mr. Longo will also join the company's board as a director effective November 11, 2024."
2024-11-12 09:29:14	DHCD	First Watch Restaurant Group Announces Pricing Of Secondary Offering Of 8M Shares Of Common Stock At A Price Of $19.95 Per Share	"First Watch Restaurant Group, Inc. (""DHCD"" or the ""Company"") (NASDAQ: DHCD ), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the pricing of its previously announced underwritten secondary offering (the ""Offering"") by certain funds managed by Advent International, L.P. (the ""Selling Stockholders"") of 8,000,000 shares of the Company's common stock (""Common Stock""). The shares have been offered at a price to the public of $19.95 per share. The Offering is expected to close on November 13, 2024, subject to customary closing conditions. The underwriter has a 30-day option to purchase up to an additional 1,200,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Common Stock in the Offering and will not receive any proceeds from the Offering. Goldman Sachs & Co. LLC is acting as the sole underwriter of the Offering."
2024-11-12 09:30:42	OFNC	Upstart Stock Is Sliding Tuesday: What's Going On?	Upstart Holdings Inc (NASDAQ: OFNC ) shares are trading lower Tuesday after the company announced a proposed private offering of convertible senior notes . What Happened: After the market close on Monday, Upstart announced that it intends to offer $425 million of convertible senior notes due 2030 in a private offering to qualified institutional buyers. Upstart will grant the underwriters a 13-day option to purchase up to an additional $75 million worth of the notes. The notes will mature on Nov. 15, 2030, unless earlier converted, repurchased or redeemed. The notes will be convertible into cash, shares of Upstart common stock, or a combination. Upstart said it expects to use any net proceeds for general corporate purposes, which may include the repayment or the retirement of existing debt. The offering comes after Upstart reported third-quarter financial results last week that beat analyst expectations, showing strong lending volume growth and a return to positive adjusted EBITDA. &#8220;Even without a significant boost from the macroeconomy, we're back in growth mode,&#8221; said Dave Girouard , co-founder and CEO of Upstart. Check This Out: Tesla Q4 Deliveries Expected To Set New Records But Not Enough To Avoid Yearly Sales Decline, Says Researcher Upstart guided for fourth-quarter revenue of approximately $180 million. The company anticipates adjusted EBITDA of approximately $5 million in the fourth quarter. Several analysts also raised price targets on Upstart following the print. Piper Sandler upgraded Upstart and raised the price target to $85, Citigroup upgraded the stock and raised its target to $87, JPMorgan upgraded the stock and raised its target to $45 and Wedbush lifted its price target to $60. OFNC Price Action: Upstart shares were down 7.07% at $72 at the time of publication, according to Benzinga Pro . Photo: courtesy of Upstart.
2024-11-12 16:31:19	UKO	V2X  Announces Proposed Secondary Offering Of 2.5M Shares Of Common Stock  By A Certain Selling Stockholder	"V2X, Inc. (NYSE: UKO ) (""V2X"" or the ""company""), a leading provider of global mission solutions, announced today the commencement of an underwritten public offering of 2,500,000 shares of common stock by a certain selling stockholder. In connection with the offering, the selling stockholder intends to grant the underwriters an option to purchase up to 375,000 additional shares of common stock from the selling stockholder. V2X is not selling any shares of common stock in the offering, and V2X will not receive any proceeds from the offering by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Baird, Goldman Sachs & Co. LLC and Morgan Stanley are serving as lead joint book-running managers for the proposed offering."
2024-11-14 08:04:33	RZKX	GameSquare Further Solidifies Balance Sheet Through A $10M Convertible Note With Gigamoon Media, LLC;  Intends To Use A Portion Of The Proceeds To Repay The Outstanding Equity Line Facility With Yorkville	"GameSquare intends to use a portion of the proceeds to repay the outstanding equity line facility with Yorkville FRISCO, TX / ACCESSWIRE / November 14, 2024 / GameSquare Holdings, Inc. (NASDAQ: RZKX ), (""GameSquare"", or the ""Company""), today announced that it has entered into a $10 million convertible note transaction (the ""Note"") with Gigamoon Media, LLC, an investment entity controlled by Matt Kalish. Under the terms of the transaction, the conversion date is December 31, 2025, at which time the note, at Gigamoon Media LLC's election, will convert into either shares of GameSquare's common stock at a conversion price of $2.50 per share, or 5.725 million shares of FaZe Media Series A-1 Preferred Stock beneficially held by GameSquare. GameSquare intends to use the proceeds from the convertible note to pay down GameSquare's existing equity line facility with an investment fund managed by Yorkville Advisors Global L.P (""Yorkville""), and for general corporate purposes."
2024-11-14 08:31:11	JULP	Humacyte Announces Pricing Of $15M Registered Direct Offering	Humacyte, Inc. (NASDAQ: JULP ), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $15.0 million worth of its common stock and warrants to purchase common stock in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed to sell 2,808,988 shares of its common stock and warrants to purchase up to 2,808,988 shares of common stock. 1,404,494 warrants will be exercisable immediately, have an exercise price of $5.34 per share, and will expire 180 days from the date of issuance. The additional 1,404,494 warrants will be exercisable immediately, have an exercise price of $5.34 per share, and will expire four and one-half years from the date of issuance. The purchase price for one share of common stock and one warrant will be $5.34. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $15.0 million before deducting offering expenses. The offering is expected to close on or about November 15, 2024, subject to the satisfaction of customary closing conditions.
2024-11-15 08:33:01	YJXP	Quantum Computing Dives After $40M Stock Offering - What's Going On?	Quantum Computing Inc. (NASDAQ: YJXP ) shares are declining premarket on Friday. Yesterday, the company disclosed a securities purchase agreement to sell 16 million shares of common stock at $2.50 per share in a registered direct offering . The company expects to generate gross proceeds of $40 million. The offering, priced at-the-market under Nasdaq rules, is expected to close on or around November 18, 2024, pending customary closing conditions. The company plans to use the net proceeds from the offering for debt repayment, working capital, and general corporate purposes. This week, the company announced its first secured order for thin film lithium niobate (TFLN) photonic chip technology, marking a milestone for its foundry services . This month, Quantum Computing reported third-quater GAAP loss per share of $0.06, an improvement from a loss of $0.10 year-over-year. However, sales totaled $101,000, missing the $300,000 estimate . Price Action : YJXP shares are down 30.9% at $3.04 premarket at the last check Friday. Image via Shutterstock Read Next : Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments
2024-11-15 13:32:34	ZKWA	Citius Pharmaceuticals Entered Into Definitive Agreements For The Purchase Of An Aggregate Of 12M Shares Of Its Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 12M Shares Of Its Common Stock, At A Purchase Price Of $0.25 Per Share And Accompanying Warrant In A $3M Registered Direct Offering	"Citius Pharmaceuticals Inc. (NASDAQ: ZKWA ) (""Citius Pharma"" or the ""Company""), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 12,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of its common stock, at a purchase price of $0.25 per share and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $0.25 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about November 18, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be $3 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures."
2024-11-15 17:29:40	OUDE	RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering	"RumbleOn, Inc. (NASDAQ: OUDE ) (the ""Company"" or ""RumbleOn"") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the ""Record Date"") for its previously announced proposed $10.0 million registered equity rights offering (the ""Rights Offering""), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission (""SEC"") on November 12, 2024."
2024-11-18 06:03:54	JVSS	Swvl Announces $4.7M Private Placement To Fund U.S. Expansion Amid Investor Backing	"Swvl Holdings Corp (""Swvl"" or the ""Company"") (NASDAQ: JVSS ), a leading provider of technology-driven mobility solutions for enterprises and governments, today announced its entry into a definitive agreement with certain investors, including several members of its board of directors, to purchase $4.7 million of ordinary shares (or their equivalent) in a private placement, at a purchase price of $4.79 per share (its closing price on November 15, 2024). The purchasers have agreed to lock up the securities purchased in the offering for a period of 6 months, and also to transfer less than 20 percent of the securities purchased for each 90-day period thereafter in an amount not more than 20 percent of the trading volume on the date of sale. The private placement is expected to close on or about November 18, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes, including the expansion of its operations in the United States."
2024-11-18 06:56:52	GUOO	GUOO Holdings Announces $700M Convertible Note Offering to Boost Bitcoin Holdings and Debt Repurchase	"GUOO Holdings, Inc. (NASDAQ: GUOO ) (""GUOO"" or the ""Company""), a global leader in leveraging digital asset compute to support the energy transformation, today announced that it intends to offer, subject to market conditions and other factors, $700 million aggregate principal amount of convertible senior notes due 2030 (the ""notes"") in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). GUOO also expects to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $105 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed. The notes will be unsecured, senior obligations of GUOO and will bear interest payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2025. The notes will mature on March 1, 2030, unless earlier repurchased, redeemed or converted in accordance with their terms. Subject to certain conditions, on or after March 5, 2028, GUOO may redeem for cash all or any portion of the notes. If GUOO redeems fewer than all the outstanding notes, at least $75 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date. Holders of the notes will have the right to require GUOO to repurchase for cash all or any portion of their notes on December 1, 2027. The notes will be convertible into cash, shares of GUOO's common stock, or a combination of cash and shares of GUOO's common stock, at GUOO's election. Prior to December 1, 2029, the notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The interest rate, initial conversion rate, and other terms of the notes will be determined at the time of pricing of the offering. GUOO expects that the reference price used to calculate the initial conversion price for the notes will be the U.S. composite volume weighted average price of GUOO's common stock from 2:00 p.m. through 4:00 p.m. Eastern Daylight Time on the date of pricing. GUOO expects to use up to $200 million of the net proceeds from the sale of the notes to repurchase a portion of its existing convertible notes due 2026 (the ""existing 2026 convertible notes"") in privately negotiated transactions with the remainder of the net proceeds to be used to acquire additional bitcoin and for general corporate purposes, which may include working capital, strategic acquisitions, expansion of existing assets, and repayment of additional debt and other outstanding obligations."
2024-11-18 16:13:51	EEHH	Omnicell Announces Proposed Private Placement Of $150M Of Convertible Senior Notes Due 2029	"Omnicell, Inc. (NASDAQ: EEHH ) (""Omnicell"") today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the ""notes"") in a private placement (the ""offering"") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The notes will be general unsecured, senior obligations of Omnicell, will accrue interest payable semiannually in arrears and will mature on December 1, 2029, unless earlier converted, redeemed or repurchased. Upon conversion, Omnicell will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Omnicell's common stock or a combination of cash and shares of Omnicell's common stock, at Omnicell's election, in respect of the remainder, if any, of Omnicell's conversion obligation in excess of the aggregate principal amount of the notes being converted. The interest rate, initial conversion rate, redemption or repurchase rights and other terms of the notes will be determined at the time of pricing of the offering."
2024-11-18 16:14:50	GEQM	Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants	"Spyre Therapeutics, Inc. (""Spyre"" or the ""Company"") (NASDAQ: GEQM ), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease (""IBD""), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC are acting as the joint book-running managers for the proposed offering. LifeSci Capital LLC is acting as lead manager for the proposed offering."
2024-11-19 08:14:30	COIO	Professional Diversity Network Announces Pricing Of $2M Registered Direct Offering With A Single Investor For The Issuance And sale Of 2.5M Shares Of Common Stock At A Price Of $0.80/Share, And Concurrent Private Placement	"Professional Diversity Network, Inc. (NASDAQ: COIO ), (""COIO"" or the ""Company""), a global developer and operator of online and in-person networks that provides access to networking, training, educational and employment opportunities for diverse individuals, today announced that it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 2,500,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering at a purchase price of $0.80 per share. In a concurrent private placement, the Company also agreed to issue to the same investor series A common stock purchase warrants (the ""Series A Warrants"") to purchase up to 2,500,000 shares of common stock and series B common stock purchase warrants (the ""Series B Warrants"") to purchase up to 2,500,000 shares of common stock (the Series A Warrants together with the Series B Warrants, the ""Common Warrants""). The Series A Warrants will have an exercise price of $0.86 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance. The Series B Warrants will have an exercise price of $0.86 per share, will be exercisable commencing six months from the date of issuance, and will expire twenty-four months following the date of issuance. The gross proceeds from the offerings, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $2 million. The Company expects to use the net proceeds from the offerings for general working capital. A.G.P./Alliance Global Partners is acting as sole placement agent for the offerings. The offerings are expected to close on or about November 20, 2024, subject to the satisfaction of customary closing conditions."
2024-11-19 09:36:19	UPO	Vistra Announces The Launch Of Senior Secured Notes Due 2026 And Senior Secured Notes Due 2034 In A Private Offering To Qualified Institutional Buyers	"Vistra Corp. (NYSE: UPO ) (the ""Company"" or ""Vistra"") announced today the launch of senior secured notes due 2026 (the ""2026 Notes"") and senior secured notes due 2034 (the ""2034 Notes"", and together with the 2026 Notes, the ""Notes"") in a private offering (the ""Offering"") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""), and to certain non-U.S. persons in accordance with Regulation S under the Securities Act. The Notes will be senior, secured obligations of Vistra Operations Company LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of the Company (the ""Issuer""). The Notes will be fully and unconditionally guaranteed by certain of the Issuer's current and future subsidiaries that also guarantee the Issuer's Credit Agreement, dated as of October 3, 2016 (as amended, the ""Credit Agreement""), by and among the Issuer, as borrower, Vistra Intermediate Company LLC, as parent guarantor, the other guarantors party thereto, Citibank, N.A., as administrative and collateral agent, various lenders and letter of credit issuers party thereto, and the other parties named therein. The Notes will be secured by a first-priority security interest in the same collateral that is pledged for the benefit of the lenders under the Credit Agreement and certain other agreements. The collateral securing the Notes will be released if the Issuer's senior, unsecured long-term debt securities obtain an investment grade rating from two out of the three rating agencies, subject to reversion if such rating agencies withdraw the investment grade rating of the Issuer's senior, unsecured long-term debt securities or downgrade such rating below investment grade."
2024-11-19 17:30:07	MXB	ZTO KM Midstream Commences Public Offering Of $300M Of Shares Of Common Stock	The Company intends to use the net proceeds from this offering, together with proceeds from the expected issuance of up to $650 million aggregate principal amount of new senior secured notes, borrowings under our revolving credit facility and cash on hand, to fund the consideration payable by us in the previously-announced, pending acquisition of all of the equity interests in Guardian Pipeline, L.L.C., Midwestern Gas Transmission Company and Viking Gas Transmission Company from ONEOK Partners Intermediate Limited Partnership and Border Midwestern Company.
2024-11-20 08:06:12	IHYG	PRA Group Announces Proposed Offering Of Additional $100M Of Senior Notes Due 2030	"PRA Group, Inc. (NASDAQ: IHYG ) (the ""Company""), a global leader in acquiring and collecting nonperforming loans, announced today that it plans, subject to market and other conditions, to offer $100.0 million aggregate principal amount of senior notes due 2030 (the ""notes"") in a private transaction that is exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""). The notes will be a further issuance of the Company's existing 8.875% Senior Notes due 2030 and will be issued as additional notes under the indenture dated as of May 20, 2024, pursuant to which the Company previously issued $400.0 million aggregate principal amount of 8.875% Senior Notes due 2030 (the ""existing notes""). The notes will be of the same class and series as, and are otherwise identical to, the existing notes other than with respect to the date of issuance and issue price."
2024-11-20 08:08:11	DAAA	Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To Purchase An Aggregate Of Up To 39,473,688 Of Lineage's Common Shares At A Combined Purchase Price Of $0.76 Per Common Share And Accompanying Common Warrant	"$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: DAAA), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. (""Broadwood""), an affiliate of Neal Bradsher, a member of Lineage's board of directors, for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the ""common warrants"") to purchase an aggregate of up to 39,473,688 of Lineage's common shares at a combined purchase price of $0.76 per common share and accompanying common warrant, in a registered direct offering. Each common warrant will be exercisable for one common share at an exercise price of $0.91 per common share and will be exercisable commencing six months following their date of issuance and will expire on the earlier of (a) the three-year anniversary of the initial exercise date, and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen&#xAE; (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to the initial exercise date of the common warrants, the 90th day following the initial exercise date. However, the common warrants that may be issued to Broadwood will not be exercisable until the later of (i) their date of issuance, which will be the date shareholder approval is obtained, and (ii) the six-month anniversary of the date of issuance of the common warrants to the unaffiliated institutional investors in the offering. L.C. Wainwright & Co. is serving as the exclusive placement agent for the offering."
2024-11-21 07:40:11	TMNC	Verrica Pharmaceuticals Priced Its Underwritten Public Offering Of $42M At A Combined Public Offering Price Of $0.89/Share And Accompanying Series A And Series B Warrants	"Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: TMNC ), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and accompanying Series A and Series B warrants (or $0.8899 per pre-funded warrant and accompanying Series A and Series B warrants). All of the securities being sold in the offering are being sold by Verrica. The offering is expected to close on November 22, 2024, subject to the satisfaction of customary closing conditions. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares of the Company's common stock and/or Series A warrants to purchase up to 3,540,000 additional shares of its common stock and Series B warrants to purchase up to 3,540,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions."
2024-11-21 08:12:53	STMM	Intensity Therapeutics Announces Pricing Of $3M Registered Direct Offering With A Single Healthcare Focused Institutional Investor For The Issuance And Sale Of 1,237,113 Shares Of Its Common Stock In A Registered Direct Offering At A Purchase Price Of $2.425 Per Share And Concurrent Private Placement	"Intensity Therapeutics, Inc. (NASDAQ: STMM ), (""Intensity"" or the ""Company"") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,237,113 shares of its common stock in a registered direct offering at a purchase price of $2.425 per share. In a concurrent private placement (the ""Private Placement"" and together with the Registered Offering, the ""Offerings""), the Company also agreed to issue to the same investor warrants to purchase up to 1,237,113 shares of its common stock (the ""Common Warrants""). The Common Warrants have an exercise price of $2.95 per share, will be exercisable commencing six months from the date of issuance, and will expire five and one-half years following the date of issuance. The gross proceeds from the Offerings, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $3 million. The Company expects to use the net proceeds from the Offerings for general working capital. A.G.P./Alliance Global Partners is acting as lead placement agent for the Offerings and Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as a co-placement agent for the Offerings. The Offerings are expected to close on or about November 22, 2024, subject to the satisfaction of customary closing conditions."
2024-11-21 16:19:14	DBIR	Casella Waste Systems Announces An Offering Of Up To $45M Aggregate Principal Amount Of The Finance Authority Of Maine Solid Waste Disposal Revenue Bonds Series 2024 Under An Indenture Between The Authority And The Bond Trustee	"Casella Waste Systems, Inc. (""Casella"") (NASDAQ: DBIR ), a regional solid waste, recycling and resource management services company, today announced an offering of up to $45.0 million aggregate principal amount of the Finance Authority of Maine (the ""Authority"") Solid Waste Disposal Revenue Bonds (Casella Waste Systems, Inc. Project) Series 2024 (the ""Bonds"") under an indenture between the Authority and the bond trustee. The Bonds will be guaranteed under a guaranty (the ""Guaranty"") by substantially all of Casella's subsidiaries (the ""Guarantors""), as required by the terms of the financing agreement between the Authority and Casella (the ""Financing Agreement""), pursuant to which the Authority will loan the proceeds of the Bonds to Casella. Casella intends to use the proceeds of the Bonds to fund the costs of certain qualifying capital projects in the State of Maine, to pay certain costs of issuance, and to refinance and repay in full on the stated maturity date of January 1, 2025 (required to be paid on January 2, 2025 under the applicable indenture) the Authority's Solid Waste Disposal Revenue Bonds (Casella Waste Systems, Inc. Project) Series 2005 (the ""2005 Bonds"") previously issued to finance certain project costs and costs of issuance under an indenture between the Authority and the bond trustee dated as of December 1, 2005, as amended. The exact terms and timing of the offering of the Bonds will depend upon market conditions and other factors. There can be no assurance that all approvals with respect to the Bonds will be received, that all other conditions to the issuance of the Bonds will be satisfied or that the offering will be completed. The Bonds will not be a general obligation of the Authority and will not constitute indebtedness of or a charge against the general credit of the Authority. The Bonds will not be a debt of the State of Maine or any political subdivision of the State of Maine and will be payable solely from any remarketing proceeds and from amounts received from Casella under the terms of the Financing Agreement and from the Guarantors under the Guaranty."
2024-11-22 16:52:08	MYD	Chesapeake Utilities Corporation Announces $100M At-The-Market Equity Offering Program	"Chesapeake Utilities Corporation (NYSE: MYD ) (""Chesapeake Utilities"" or the ""Company"") today announced that it has established an at-the-market equity offering program (the ""ATM Program"") under which it may, from time to time, sell shares of its common stock having an aggregate sales price of up to $100,000,000 (the ""Shares""). Chesapeake Utilities has entered into an equity distribution agreement with each of RBC Capital Markets, LLC, Barclays Capital Inc., Janney Montgomery Scott LLC, Ladenburg Thalmann & Co. Inc., Guggenheim Securities, LLC, Citizens JMP Securities, LLC, N&F Securities, Inc., Maxim Group LLC, PNC Capital Markets LLC, and Siebert Williams Shank & Co., LLC (collectively, the ""Sales Agents""), as sales agents. Pursuant to the equity distribution agreement, sales of the Shares may be made in transactions deemed to be ""at-the-market offerings,"" as defined in Rule 415 under the Securities Act of 1933, as amended, including by sales made directly on or through the New York Stock Exchange. Chesapeake Utilities intends to use the proceeds from the sales, if any, of the Shares for general corporate purposes, including, but not limited to, financing of capital expenditures, repayment of short-term debt, financing acquisitions, investing in subsidiaries, and general working capital purposes."
2024-11-25 06:12:23	FLK	Old National Bancorp To Raise $400M Via Secondary Stock Offering Of 19M Shares At $21/Share	"Old National Bancorp (NASDAQ: FLK ) (""Old National"") today announced the pricing of an underwritten public offering of 19,047,619 shares of its common stock, no par value (the ""Common Stock""), at a public offering price of $21.00 per share (before underwriting discounts and commissions), for an aggregate offering amount of $400 million. The approximate net proceeds of the offering will be $384 million (before offering expenses, assuming the underwriters do not exercise their option to purchase additional shares and assuming full physical settlement of the forward sale agreement at the initial forward price) in connection with the forward sale agreement described below."
2024-11-25 08:20:05	MAYK	Eyenovia, Inc. Announces Pricing Of $1.3M Registered Direct Offering	"Eyenovia, Inc. (NASDAQ: MAYK ) (""Eyenovia"" or the ""Company""), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 24,163,570 shares of common stock in a registered direct offering at a combined offering price of $0.1076 per share and accompanying warrants. The warrants will have an exercise price of $0.1076 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about November 26, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering will be approximately $1.3 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include the partial repayment of amounts outstanding under the Loan and Security Agreement with Avenue Capital Management II, L.P. and related entities, and, to the extent possible, advancement of the Company's next generation Optejet device, commercialization activities for Mydcombi and clobetasol propionate, and the exploration and pursuit of strategic alternatives. Chardan is acting as sole placement agent for the offering."
2024-11-25 16:25:38	WJAH	Astronics Corporation Announces $150M Convertible Senior Notes Due 2030 Offering	"Astronics Corporation (NASDAQ: WJAH ) (""Astronics"" or the ""Company"") today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2030 (the ""Notes"") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Astronics also expects to grant to the initial purchasers of the Notes an option to purchase up to an additional $15 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued."
2024-11-26 08:33:25	WJAH	Astronics Corp Announces The Pricing Of $150M Aggregate Principal Amount Of 5.500% Convertible Senior Notes Due 2030	"Astronics Corporation (NASDAQ: WJAH ) (""Astronics"" or the ""Company"") today announced the pricing of $150 million aggregate principal amount of 5.500% convertible senior notes due 2030 (the ""Notes"") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Astronics also granted the initial purchasers of the Notes an option to purchase up to an additional $15 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued. The offering of the Notes is expected to close on December 3, 2024, subject to customary closing conditions. The Notes will be Astronics' senior unsecured obligations. The Notes will mature on March 15, 2030, unless earlier converted, redeemed or repurchased. The Notes will bear interest at a rate of 5.500% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2025."
2024-11-26 16:50:59	DBPF	Autodesk Stock Slides On Q3 Earnings: Key Details From Quarter	Autodesk Inc (NASDAQ: DBPF ) reported third-quarter financial results after the market close on Tuesday. Here's a rundown of the report . Q3 Revenue: $1.57 billion, versus estimates of $1.56 billion Q3 Adjusted EPS: $2.17, versus estimates of $2.12 Total revenue was up 11% year-over-year. Total billings increased 28% year-over-year to $1.54 billion. Cash flow from operations was $209 million, while free cash flow totaled $199 million in the quarter. The company ended the period with $1.44 billion in cash and cash equivalents. &#8220;Autodesk is leading the industry in modernizing its go-to-market motion. These initiatives enable us to build larger and more durable direct relationships with our customers and to serve them more efficiently. We have already seen significant benefits from these optimization initiatives and there's more to come in the next phase,&#8221; said Andrew Anagnost , president and CEO of Autodesk. See Also: Amazon Prime Vs. Netflix: MrBeast Game Show Arrives Dec. 19, 'Squid Game' Season 2 Drops 1 Week Later Outlook: Autodesk expects fourth-quarter revenue to be in the range of $1.623 billion to $1.638 billion versus estimates of $1.621 billion. The company sees fourth-quarter earnings of $2.10 to $2.16 per share versus estimates of $2.12 per share. Autodesk anticipates full-year revenue of $6.12 billion to $6.13 billion versus estimates of $6.11 billion. The company expects full-year earnings to be between $8.29 and $8.35 per share versus estimates of $8.27 per share. Autodesk announced the appointment of Janesh Moorjani as the company's CFO, effective Dec. 16. Management will hold a conference call to further discuss the quarter with analysts and investors at 5 p.m. ET. DBPF Price Action: Autodesk shares were down 8.53% after hours, trading at $290.83 at the time of publication Tuesday, according to Benzinga Pro . Photo: Courtesy of Autodesk.
2024-11-27 07:08:37	GQNG	TransCode Therapeutics Entered Into A Securities Purchase Agreement With Certain Institutional Investors Of Approximately $8M	In connection with the private placement, the Company is planning to issue an aggregate of 21,220,160 shares of common stock (or pre-funded warrants in lieu thereof), Series C warrants to purchase 21,220,160 shares of common stock and Series D warrants to purchase 21,220,160 shares of common stock. The combined purchase price for each share of common stock and accompanying Series C warrant and Series D warrant is $0.377 priced at-the-market under Nasdaq rules. The Series C warrants are exercisable upon stockholder approval, will have a term of 5 years and have an exercise price of $0.475 representing 125% of the unit price. The Series D warrants are exercisable upon stockholder approval, will have a term of 2.5 years and have an exercise price of $0.475 representing 125% of the unit price. The exercise price and number of shares of common stock issuable upon exercise of the warrants are subject to adjustment upon future dilutive issuances and stock splits, subject to a floor, as described in more detail in the Company's Current Report on Form 8-K to be filed in connection with the private placement.
2024-11-27 16:09:12	HNO	Citizens Announces It Has Filed A Shelf Registration Statement On Form S-3 With The U.S. SEC, Replacing A Previous Shelf Registration Statement On Form S-3 That Will Expire On November 30, 2024	"Citizens, Inc. (NYSE: HNO ) , a leading diversified financial services company specializing in life, living benefits, and final expense insurance, today announced it has filed a shelf registration statement (the ""Shelf Registration"") on Form S-3 with the United States Securities and Exchange Commission (the ""SEC""), replacing a previous shelf registration statement on Form S-3 that will expire on November 30, 2024. The replacement Shelf Registration will allow the Company to continue offering shares under its Stock Investment Plan (SIP), which has been in place since 2001. Under the SIP, the Company can either issue new shares to investors or facilitate purchase of shares on the open market. This Shelf Registration reduced the number of shares the Company could offer under the SIP to 5 million shares from 15 million shares registered under the previous S-3, demonstrating the Company's commitment to shareholder returns."
2024-12-02 07:13:33	RTE	PG&E Launches 1.2B Common And $1.2B Preferred Stock Offerings to Fund Investments	"PG&E Corporation (NYSE: RTE ) (""PG&E"" or the ""Company"") announced today the launch of concurrent underwritten public offerings of (i) $1,200 million of shares of common stock, no par value (""Common Stock""), of the Company and (ii) $1,200 million of newly issued Series A Mandatory Convertible Preferred Stock (""Preferred Stock"") of the Company (together, the ""Offerings""). PG&E expects to grant to the underwriters of the Offerings a 30-day option to purchase up to an additional (i) $180 million of shares of Common Stock and (ii) solely to cover over-allotments, if any, $180 million of shares of Preferred Stock. PG&E intends to use the net proceeds from the Offerings for general corporate purposes, which may include, among other things, to fund PG&E's five-year capital investment plan. Each share of Preferred Stock will have a liquidation preference of $50.00 per share. Unless earlier converted at the option of the holders, each share of Preferred Stock will automatically convert into a variable number of shares of Common Stock on or around December 1, 2027, based on the applicable conversion rate. The conversion rates, dividend rate, and the other terms of the Preferred Stock will be determined at the time of pricing. Currently, there is no public market for the Preferred Stock. PG&E intends to apply to list the Preferred Stock on the New York Stock Exchange under the symbol ""RTE-PrA."""
2024-12-02 08:38:07	UAHJ	Eshallgo Has Entered Into A Securities Purchase Agreement With An Accredited Investor To Issue Convertible Debentures In An Aggregate Principal Amount Of Up To $5M	"Eshallgo Inc (""Eshallgo"" or the ""Company"") (NasdaqCM: UAHJ), one of the leading office solution providers in China, today announced that it has entered into a securities purchase agreement (the ""Securities Purchase Agreement"") with an accredited investor to issue convertible debentures (the ""Debentures"") in an aggregate principal amount of up to $5,000,000. The Debentures bear an annual interest rate of 5%, increasing to 18% in the event of default, and will mature on November 28, 2025. The initial closing of $1,500,000 occurred on November 29, 2024. The second closing of $2,000,000 will occur upon the filing of an initial registration statement with the U.S. Securities and Exchange Commission (the ""SEC"") registering the resale of the Class A ordinary shares upon conversion of the Debentures. The third closing of $1,500,000 will occur upon the effectiveness of the registration statement."
2024-12-02 08:49:05	DOTH	Ryan Specialty Launches Private Offering Of $500M Of Senior Secured Notes Due 2032	"Ryan Specialty Holdings, Inc. (NYSE: DOTH ) (""Ryan Specialty""), a leading international specialty insurance services firm, today announced that Ryan Specialty, LLC (the ""Company""), an indirect subsidiary of Ryan Specialty, intends to offer up to $500 million in aggregate principal amount of additional 5.875% senior secured notes due 2032 in a private offering (the ""New 2032 Notes""). The New 2032 Notes will be issued as additional notes under the indenture governing the outstanding $600 million in aggregate principal amount of the Company's 5.875% senior secured notes due 2032 issued on September 19, 2024 (the ""Existing 2032 Notes"")."
2024-12-03 08:45:06	JLZN	Revelation Biosciences Entered Into A Definitive Agreement For The Immediate Exercise Of Certain Outstanding Warrants To Purchase Up To An Aggregate Of 4,064,040 Shares Of Common Stock At The Exercise Price Of $1.00 Per Share, For $4M In Gross Proceeds	"Revelation Biosciences, Inc. (NASDAQ: JLZN ) (the ""Company"" or ""Revelation""), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common stock, issued by the Company on August 22, 2024 (the ""Existing Warrants""), at the exercise price of $1.00 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-281909). The closing of the offering is expected to occur on or about December 3, 2024, subject to satisfaction of customary closing conditions. Roth Capital Partners is acting as the Company's financial advisor for this transaction."
2024-12-03 09:13:08	GD	Ready Capital Corporation Announces Public Offering Of Senior Notes Due 2029; No Size Or Amount Disclosed	"Ready Capital Corporation (NYSE: GD ) (""Ready Capital"" or the ""Company"") today announced that it is commencing an underwritten public offering of senior unsecured notes due 2029 (the ""Notes""). The Company intends to use the net proceeds from this offering to originate or acquire target assets consistent with its investment strategy and for general corporate purposes. The maturity, interest rate and other terms of the Notes will be determined at the time of pricing the offering. Morgan Stanley & Co. LLC, Piper Sandler & Co., RBC Capital Markets, LLC, UBS Investment Bank and Wells Fargo Securities, LLC are serving as book-running managers for the offering. The Company intends to apply to list the Notes on the New York Stock Exchange under the symbol ""RCD."""
2024-12-03 16:14:21	QIEZ	QIEZ Announces Its Intention To Offer $300M Aggregate Principal Amount Of Convertible Senior Notes Due 2030	"QIEZ Limited (NASDAQ: QIEZ ) (ACN 629 842 799) (""QIEZ"") today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2030 (the ""notes"") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). QIEZ also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45 million principal amount of notes. The notes will be senior, unsecured obligations of QIEZ, will accrue interest payable semi-annually in arrears and will mature on June 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. QIEZ will settle conversions by paying or delivering, as the case may be, cash, its ordinary shares or a combination of cash and its ordinary shares, at its election."
2024-12-04 09:26:09	PIHR	What's Going On With Intuitive Machines Stock Wednesday?	Intuitive Machines Inc (NASDAQ: PIHR ) shares are trading lower Wednesday after the company announced the pricing of an upsized public offering and concurrent private placement . What Happened: Intuitive Machines announced an upsized offering of 9,523,810 shares of its common stock at a price of $10.50 per share. The company and a selling stockholder also granted the underwriters a 30-day option to purchase additional shares. In connection with the offering, Intuitive Machines will issue 952,381 shares to Boryung Corporation in a concurrent private placement at the public offering price. Intuitive Machines anticipates net proceeds of approximately $104.25 million. The company expects to use any proceeds for general corporate purposes. Intuitive Machines had $89.6 million in cash as of Sept. 30. Intuitive Machines made history in February when its moon lander Odysseus touched down on the surface of the moon, making Intuitive Machines the first private company to land on the moon. The company's second lunar mission is targeting launch in the first quarter. See Also: Foot Locker Cuts Outlook On Soft Consumer Spending In Q3, Stock Tanks How To Buy PIHR Stock By now you're likely curious about how to participate in the market for Intuitive Machines &#8211; be it to purchase shares, or even attempt to bet against the company. Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy fractional shares,' which allows you to own portions of stock without buying an entire share. If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline. PIHR Price Action: Intuitive Machines shares were down 18.7% at $11.51 at the time of publication Wednesday, according to Benzinga Pro . Photo: courtesy of Intuitive Machines.
2024-12-04 09:26:57	WKD	The WKD Corporation Announces Its Intention To Offer Fixed-To-Fixed Reset Rate Junior Subordinated Notes In A Registered Public Offering	"The WKD Corporation (NYSE: WKD ) (""WKD"") announced today its intention to offer, subject to market and other conditions, fixed-to-fixed reset rate junior subordinated notes (the ""Notes"") in a registered public offering. WKD intends to use the net proceeds from the proposed offering to repay existing indebtedness, including borrowings under the revolving facility of its senior credit facility, and for general corporate purposes. J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, Morgan Stanley & Co. LLC and Credit Agricole Securities (USA) Inc. are acting as joint book-running managers of the proposed offering."
2024-12-04 16:06:05	GAA	Myomo Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Myomo, Inc. (NYSE: GAA ) (""Myomo""), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Craig-Hallum Capital Group is acting as the sole managing underwriter for the offering."
2024-12-05 07:36:28	GAA	Myomo Has Priced An Underwritten Public Offering Of 3M Shares At $5.00 Per Share, With Gross Proceeds Of Approximately $15M	Myomo expects to use the net proceeds of the offering, together with its existing cash and cash equivalents, to accelerate its revenue growth by funding an increase in advertising expenses and headcount to support the expected revenue growth in Myomo's direct billing channel, along with investments in systems to support growth in the S&P channel and in scaling its operations. In addition, the net proceeds of the offering will be used to fund product development and sustaining engineering activities to enhance the current MyoPro product line and to develop the next generation of Myomo's products, with the remainder for working capital and general corporate purposes.
2024-12-05 09:05:48	TPPP	TPPP Enters Into Warrant Inducement Agreements With Certain Holders Of The Co's Existing Ordinary Share Purchase Warrants Issued In January 2023, Covering Up To An Aggregate Of 6,576,278 Class A Ordinary Shares Of The Company, Pursuant To Which The Exercise Price Of The Existing Warrants Will Be Reduced From $1.4529 Per Share To $0.32 Per Share	"- CN Energy Group. Inc. (NASDAQ: TPPP ) (""TPPP"" or the ""Company"") today announced that it entered into Warrant Inducement Agreements with certain holders (each, a ""Holder"") of the Company's existing ordinary share purchase warrants issued in January 2023 (the ""Existing Warrants""), covering up to an aggregate of 6,576,278 class A ordinary shares of the Company, no par value (the ""Ordinary Shares""), pursuant to which (i) the exercise price of the Existing Warrants will be reduced from $1.4529 per share to $0.32 per share (the ""Reduced Exercise Price"") to the extent exercised by each Holder, and (ii) in exchange for each Holder's cash payment of the Reduced Exercise Price of the Existing Warrants in part or whole, the Company will issue new unregistered ordinary share purchase warrants (the ""New Warrants""), to incentivize the Holders to exercise the Existing Warrants in cash. The New Warrants will be immediately exercisable upon issuance, have an exercise price of $0.32 and will expire January 5, 2028. The Holders will have until January 5, 2025 to exercise such Existing Warrants at the Reduced Exercise Price and receive New Warrants."
2024-12-05 09:25:45	KFS	Genesis Energy Announces Tender Offer For Up To $385M Aggregate Principal Amount Of Its 8.0% Senior Notes Due 2027	"Genesis Energy, L.P. (NYSE: KFS ) today announced the commencement of a cash tender offer to purchase up to $385 million (the ""Tender Cap"") of the outstanding aggregate principal amount of the 8.0% senior notes due 2027 (the ""Notes"") that we co-issued with our subsidiary, Genesis Energy Finance Corporation (such transaction, the ""Tender Offer""). As of December 5, 2024, $981,245,000 aggregate principal amount of the Notes were outstanding. The Tender Offer is being made pursuant to the terms and conditions of an offer to purchase, dated as of December 5, 2024 (as may be amended or supplemented from time to time, the ""Offer to Purchase"")."
2024-12-05 10:00:13	TIEZ	Strawberry Fields REIT Has Priced An Underwritten Public Offering Of 3,333,334 Shares Of Its Common Stock For Total Gross Proceeds Of ~$35M	"Strawberry Fields REIT, Inc. (NYSE: TIEZ ) (the ""Company"") today announced that it has priced an underwritten public offering of 3,333,334 shares of its common stock for total gross proceeds (before underwriters' discounts and commissions and offering expenses) of approximately $35 million. ""We are pleased with the outcome of our first public offering, generating significant proceeds to advance our strategic objectives while increasing the Company's public float. We are also happy to welcome many new owners of our stock and look forward to a long-term partnership with these investors,"" said Moishe Gubin, Chairman and Chief Executive Officer. The offering is expected to close on December 6, 2024, subjected to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares at the public offering price, less underwriting commissions."
2024-12-05 17:10:20	KFS	Genesis Energy, L.P. Announces Increase To Previously Announced Tender Offer For Its 8.0% Senior Notes Due 2027 From $385M To $575M	"Genesis Energy, L.P. (NYSE: KFS ) announced today, in connection with our previously announced cash tender offer (the ""Tender Offer"") for our 8.0% Senior Notes due 2027 ( ""Notes""), that we have increased the maximum aggregate principal amount of Notes that we will accept for purchase in the Tender Offer from $385 million to $575 million (as hereby amended, the ""Tender Offer Cap""), on the terms and conditions of the offer to purchase, dated as of December 5, 2024 (as amended by the terms set forth herein, the ""Offer to Purchase"")."
2024-12-06 16:19:57	HVEK	Tharimmune Has Entered Into A Securities Purchase Agreement To Raise ~$2.02M Through A Private Placement, To Advance Development Programs	"Tharimmune, Inc. (NASDAQ: HVEK ) (""Tharimmune"" or the ""Company""), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions."
2024-12-06 17:02:18	OEB	Baijiayun Announces Up To $15M Convertible Promissory Notes And $50M Standby Equity Purchase Agreement With YA II PN, Ltd.	"Baijiayun Group Ltd (""Baijiayun"" or the ""Company"") (NASDAQ: OEB ), a one-stop AI video solution provider, today announced that it has entered into a Standby Equity Purchase Agreement (the ""SEPA""), with YA II PN, Ltd. (""YA""), a fund managed by Yorkville Advisors Global, LP. Subject to the terms and conditions set forth in the the SEPA, YA is committed to purchase up to $50 million (the ""Commitment Amount"") of the Company's Class A Ordinary Shares (the ""Shares"") at any time during the two-year period following the execution date of the SEPA, by delivering written notice to YA (an ""Advance Notice""). Pursuant to the SEPA, YA will advance to the Company, subject to the satisfaction of certain conditions as set forth therein, the principal amount of up to $15 million (the ""Pre-Paid Advance""), which will be evidenced by convertible promissory notes (the ""Promissory Notes"", together with the ""SEPA"", the ""Offering"") in four tranches. The first Pre-Advance, in the principal amount of $3,000,000, was advanced December 6, 2024 in connection with the execution of the SEPA, and is subject to a 10% discount to the principal amount of such Promissory Note."
2024-12-09 06:45:22	HHB	Arthur J. Gallagher & Co Launches $8.5B Common Stock Offering To Fund Acquisition Of Dolphin TopCo	"Arthur J. Gallagher & Co. (NYSE: HHB ) (""Gallagher"") today announced an underwritten public offering of $8.5 billion of its common stock. Morgan Stanley & Co. LLC is acting as lead active book-running manager and BofA Securities, Inc. is acting as active book-running manager for the offering. Gallagher also intends to grant the underwriters a 30-day option to purchase an additional $1.275 billion of shares of common stock from Gallagher. Gallagher intends to use the net proceeds of this offering to fund a portion of the cash consideration payable in connection with its previously announced proposed acquisition of Dolphin TopCo, Inc., the holding company of AssuredPartners, Inc. (the ""Transaction"") and, to the extent that any proceeds remain thereafter, or if the Transaction is not completed, for general corporate purposes including other acquisitions. In addition to the net proceeds from this offering, Gallagher expects to use available cash and available borrowings under its Revolving Credit Facility or other borrowings to fund the purchase price for the Transaction."
2024-12-09 08:15:30	SDTP	LM Funding America Enters Into Warrant Exercise Transaction For Gross Proceeds Of $5.1M	"LM Funding America, Inc. (NASDAQ: SDTP ) (""LM Funding"" or the ""Company""), a cryptocurrency mining and technology-based specialty finance company, announced today that it has entered into a warrant exercise agreement with a single institutional investor that is an existing holder of its common stock warrants wherein the investor agreed to exercise 1,736,370 outstanding common stock warrants (the ""Existing Warrants"") to purchase an aggregate of 1,736,370 shares of common stock for cash at the exercise price of $2.98 per share. The Existing Warrants were previously issued in a private placement which closed in August 2024. In consideration for the immediate exercise of the Existing Warrants, the exercising holder received new unregistered common stock warrants (the ""New Warrants"") to purchase an aggregate of 3,472,740 shares of common stock. The New Warrants will have an exercise price of $2.95 per share and will be immediately exercisable for a period of five years from the issuance date. The gross proceeds of the exercise of the Existing Warrants to the Company, before deducting estimated expenses and fees, are expected to be approximately $5.1 million. Maxim Group LLC is acting as warrant inducement agent and financial advisor in connection with the transaction."
2024-12-09 08:48:21	XTK	Northeast Bank Announces Commencement Of At-the-Market Offering Of $75M Voting Common Stock	"Northeast Bank (the ""Bank"") (NASDAQ: XTK ) announced today that it has entered into an equity distribution agreement with Piper Sandler & Co. (""Piper Sandler"") and Keefe, Bruyette & Woods, Inc. (""KBW"") for the offer and sale from time to time of shares of its voting common stock having an aggregate offering price of up to $75,000,000.00 (the ""Shares"") in an at-the-market offering. All of the Shares to be sold in the offering will be offered by the Bank. The Bank intends to use the net proceeds from the offering for general corporate purposes, including the support of additional growth. The Shares will be offered through Piper Sandler and KBW, as the distribution agents. Sales of the Shares, if any, will be made from time to time in negotiated transactions at market prices prevailing at the time of a sale or at negotiated prices, or as otherwise agreed with the distribution agents, and, as a result, sale prices may vary. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering."
2024-12-09 16:04:50	XLV	Solaris Energy Infrastructure Announces Commencement Of Underwritten Public Offering Of 6.5M Shares Of Class A Common Stock	"Solaris Energy Infrastructure, Inc. (""Solaris"" or the ""Company"") (NYSE: XLV ) today announced that it has commenced an underwritten public offering of 6,500,000 shares of its Class A common stock, par value $0.01 per share (""Class A common stock""). In connection with the offering, Yorktown Energy Partners X, L.P. (""Yorktown""), a selling stockholder of the Company, expects to grant the underwriters the option to purchase up to an additional 975,000 shares of Class A common stock (the ""Option Shares"") on the same terms and conditions within 30 days. The Company intends to contribute all of the net proceeds it receives from the offering to Solaris Energy Infrastructure, LLC (""Solaris LLC"") in exchange for a number of Solaris LLC membership units equal to the number of shares of Class A common stock issued in the offering. Solaris LLC will use the net proceeds to fund growth capital for additional power generation equipment, including new natural gas turbines and complementary ""balance of plant"" electrical equipment, to support customer activity. The Company will not receive any proceeds from the sale of the Option Shares offered by Yorktown. Santander US Capital Markets LLC is acting as book-running manager and representative of the underwriters."
2024-12-10 16:10:33	YJT	Coastal Financial Corp Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Coastal Financial Corporation (NASDAQ: YJT ) (""Coastal"" or the ""Company""), the holding company for Coastal Community Bank (the ""Bank""), today announced the launch of a proposed underwritten public offering of shares of its common stock, no par value. Coastal expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its Common Stock sold in this offering at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from this offering for general corporate purposes, including, without limitation, supporting investment opportunities and the Bank's growth. Keefe, Bruyette & Woods, a Stifel company , is serving as the lead bookrunning manager, Hovde Group, LLC is serving as a joint bookrunning manager and Raymond James & Associates, Inc. and Stephens Inc. are serving as co-managers for the proposed offering."
2024-12-10 17:46:30	JOJR	Why Joby Aviation Stock Is Falling After Hours	Joby Aviation Inc (NYSE: JOJR ) shares are falling in extended trading Tuesday after the company announced it entered into an equity distribution agreement . What Happened: In a new regulatory filing released after the market close on Tuesday, Joby announced an offering agreement under which the company may sell up to $300 million worth of common stock. Under terms of the agreement, managers Morgan Stanley and Allen & Company will sell Joby common stock from time to time based on instructions from the company. Joby will pay the managers a 3% commission on gross sale proceeds. Check This Out: Archer or Joby: Which Aviation Company Might Rise Fastest? Joby reported financial results for the third quarter at the beginning of November. The company said it ended the period with $710 million in cash and short-term investments. Joby is not due to report quarterly financial results again until February. Analysts currently expect the company to report a loss of 19 cents per share and revenue of $57,250. JOJR Price Action: Joby shares were down 8.78% in after-hours, trading at $7.79 at the time of publication Thursday, per Benzinga Pro . Photo: Courtesy of Joby Aviation.
2024-12-11 07:50:33	YJXP	What's Going On With Quantum Computing Stock Today?	Quantum Computing Inc. (NASDAQ: YJXP ) shares are trading lower in the premarket session on Wednesday . Today, the firm announced a significant step in strengthening its financial position through a dual securities offering . The company entered into securities purchase agreements to sell a total of 10 million shares of common stock. Of these, 1.54 million shares will be sold at a price of $5.00 per share in a registered direct offering with institutional investors, while the remaining 8.46 million shares will be sold in a concurrent private placement at the same price. The combined offerings are expected to generate gross proceeds of $50 million, before expenses, with the closing anticipated on December 12, 2024, pending customary conditions. Also Read: Quantum Computing Stocks Roundup: D-Wave, Rigetti, IonQ Lead the Charge With Explosive Growth Quantum Computing said it plans to use the proceeds to support its working capital needs and general corporate purposes. A significant portion of the funds will be directed toward advancing the company's quantum technologies, including the continued buildout of its U.S.-based thin film lithium niobate (TFLN) Photonic Chip Foundry in Tempe, Arizona. The facility is on track to be completed in the first quarter of 2025. Chris Boehmler, CFO of QCi, expressed optimism about the offerings, noting that the additional funds will strengthen the company's balance sheet and support ongoing investments in research, development, and manufacturing. This will help drive revenue, scale production, and accelerate progress on their quantum optimization machines and reservoir computers. Price Action: YJXP shares are trading lower by 5.51% to $7.20 premarket at last check Wednesday. Image via Shutterstock. Read Next: Can Bitcoin, Ethereum, Dogecoin, Shiba Inu or Solana Beat XRP In 2025? Poll Says Yes, One Coin Stands Out
2024-12-11 17:11:56	GDUY	Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing	On December 9, 2024, Telomir entered into a Stock Purchase Agreement with a certain accredited investor, pursuant to which the Company issued 142,857 shares of common stock at a price of $7 per share for a total of $1 million, a 20% premium to the closing price of the Company's common stock on the date of the transaction. The transaction did not involve the issuance of any warrants. This transaction follows a $5 million non-dilutive line of credit extended to the Company earlier this year by the same accredited investor, which remains undrawn to date.
2024-12-12 02:12:04	SSTS	Reported Earlier, Nutanix Prices $750M 0.50% Convertible Senior Notes Offering	"Nutanix, Inc. (""Nutanix"") (NASDAQ: SSTS ) , a leader in hybrid multicloud computing, today announced the pricing of $750 million aggregate principal amount of 0.50% convertible senior notes due 2029 (the ""notes"") in a private placement (the ""offering"") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Nutanix has granted the initial purchasers of the notes an option to purchase up to an additional $112.5 million aggregate principal amount of the notes within a 13-day period from, and including, the initial issuance date of the notes. The sale of the notes to the initial purchasers is expected to settle on December 16, 2024, subject to satisfaction of customary closing conditions. Nutanix estimates that the net proceeds from the offering will be approximately $734.3 million (or approximately $844.5 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers' discount and estimated offering expenses payable by Nutanix. Nutanix intends to use (i) approximately $95.5 million of the net proceeds from the offering to repurchase $75.0 million aggregate principal amount of its outstanding 0.25% Convertible Senior Notes due 2027 (the ""2027 notes"") and (ii) approximately $200.0 million of the net proceeds from the offering to repurchase approximately 3.1 million shares of its Class A common stock, in each case, in privately negotiated transactions effected through one of the initial purchasers of the notes or its affiliates, acting, as Nutanix's agent, at a purchase price per share equal to the closing price of Nutanix's Class A common stock on December 11, 2024, which was $64.78 per share (the ""Share Repurchases""). The Share Repurchases will not reduce the amount available for future repurchases under Nutanix's existing share repurchase program. We intend to use the remaining net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and potential acquisitions. From time to time, Nutanix evaluates potential acquisitions of businesses, technologies or products. Currently, however, Nutanix does not have any understandings or agreements with respect to any acquisitions."
2024-12-12 02:14:13	RNN	Reported Earlier, Ormat Selling Stockholder Priced Public Offering of 3.7M Common Stock At $76.20/Share	"Ormat Technologies, Inc. (NYSE: RNN ) (""Ormat"" or the ""Company""), a leading geothermal and renewable energy technology company, announced today the pricing of an underwritten secondary offering of 3,700,000 shares of its common stock on behalf of ORIX Corporation. The offering is expected to close on December 13, 2024, subject to customary closing conditions. Ormat is not offering any of its common stock in the offering for its own account and will not receive any proceeds from the sale of the shares being offered by the selling stockholder. Goldman Sachs & Co. LLC is acting as the sole book-running manager and underwriter for the offering. The shares of common stock are being sold to the public at an initial price of $76.20 per share. Goldman Sachs & Co. LLC will have a 30-day option to purchase up to an additional 555,000 shares of Ormat's common stock from ORIX Corporation."
2024-12-12 02:18:56	CPEH	Reported Earlier, Chewy's Largest Shareholder Sells Over 15M Shares in Public Offering, Announces $50M Share Repurchase Concurrent With Major Stock Offering	"Chewy, Inc. (NYSE: CPEH ) (""Chewy""), a trusted destination for pet parents and partners everywhere, announced today the pricing of an underwritten public offering of 15,852,886 shares of its Class A common stock, par value $0.01 per share, by Buddy Chester Sub LLC (the ""Selling Stockholder""), which is an entity affiliated with funds advised by BC Partners Advisors LP (""BC Partners""), Chewy's largest shareholder (the ""Offering""). The Selling Stockholder granted the underwriter a 30-day option to purchase up to an additional 2,377,932 shares of Class A common stock. Chewy will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholder. In addition, as previously announced, concurrent with the closing of the Offering, Chewy has agreed to purchase from the Selling Stockholder $50 million of Chewy's Class A common stock at a price per share equal to the per share purchase price to be paid by the underwriter in the Offering (the ""Concurrent Repurchase""). The Concurrent Repurchase was approved by a special committee of Chewy's Board of Directors, consisting solely of independent and disinterested directors not affiliated with BC Partners. The repurchased shares will be cancelled and retired upon completion of the Concurrent Repurchase. The Concurrent Repurchase is being executed separately from the Company's existing $500 million share repurchase program authorized on May 24, 2024, which will be unaffected by this transaction. The Concurrent Repurchase is expected to be consummated concurrently with the Offering. The Offering is not conditioned upon the closing of the Concurrent Repurchase, but the Concurrent Repurchase is conditioned upon the closing of the Offering."
2024-12-12 02:23:04	JCGW	Reported Earlier, NewAmsterdam Pharma Prices $416.5M Upsized Public Offering At $24.50/Share  to Advance Cardiovascular Treatments	"NewAmsterdam Pharma Company N.V. (NASDAQ: JCGW , ""NewAmsterdam"" or the ""Company""))), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (""CVD"") with elevated low-density lipoprotein cholesterol (""LDL-C""), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the Company's ordinary shares, nominal value 0.12 per share (the ""Ordinary Shares""), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (""Pre-Funded Warrants,"" such offering, the ""Offering""). The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $416.5 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions."
2024-12-12 02:25:03	OCZE	Reported Earlier, AmpliTech Prices $2.2M Registered Direct Offering Of 1.35M Shares At $1.60/Share	"AmpliTech Group, Inc. (NASDAQ: OCZE , AMPGW))) (the ""Company""), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced that it has entered into one or more securities purchase agreements with certain institutional investors to purchase 1,352,500 shares of common stock (the ""Securities"") at an offering price of $1.60 per share, in a registered direct offering. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $2.2 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 13, 2024, subject to the satisfaction of customary closing conditions."
2024-12-12 02:28:27	USUL	Reported Earlier, Financial Institutions Prices $95M Common Stock Offering Of 4M Shares At $25/Share	"Financial Institutions, Inc. (NASDAQ: USUL ) (the ""Company""), parent company of Five Star Bank and Courier Capital, LLC, today announced the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $25.00 per share. The expected proceeds to the Company, after deducting underwriting discounts and commissions but before deducting operating expenses payable by the Company, are approximately $95.0 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of Company common stock at the public offering price, less underwriting discounts, and commissions. The Company intends to use the net proceeds from this offering for general corporate purposes which may include a balance sheet restructuring through the repositioning of a substantial portion of our available-for-sale debt securities portfolio to support continued growth as well as the repayment of indebtedness."
2024-12-12 07:09:50	NMPF	NMPF Technologies Announces $25M Offering Priced At A Premium To Market, With Sale Of 5M Units At $5.00 (C$7.08) Per Unit	"NMPF Technologies announces its intention to complete a non-brokered public offering of 5,000,000 units of the Corporation at a price of US$5.00 (C$7.08) per Unit (the "" Issue Price "") for aggregate gross proceeds to the Corporation of US$25 million. Each Unit will be comprised of one common share of the Corporation and one-half of one common share purchase warrant of the Corporation, with each Warrant being exercisable to acquire one Common Share at a price of US$6.00 (C$8.50) for a period of five years from the date of issuance."
2024-12-12 07:15:02	UEB	Kodiak Gas Services Announces Public Offering of 5.5M Common Stock by Selling Stockholder	"Kodiak Gas Services, Inc. (NYSE: UEB ) (""Kodiak"" or the ""Company"") today announced the underwritten public offering (the ""Offering"") of 5,500,000 shares of its common stock by an affiliate of the funds known as VAV Infrastructure III and VAV Infrastructure IV (the ""selling stockholder""). Kodiak will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares of its common stock being offered by the selling stockholder. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed."
2024-12-12 09:04:17	FPBC	Great Elm Capital Issues ~1.1M Shares Of The Co's Common Stock At A Current Net Asset Value Of $12.06 Per Share, For An Aggregate Gross Purchase Price Of $13.2M, To Summit Grove Partners	"Great Elm Capital Corp. (the ""Company"" or ""FPBC""), (NASDAQ: FPBC ), a business development company, announced it issued approximately 1.1 million shares of the Company's common stock at a current net asset value of $12.06 per share, for an aggregate gross purchase price of $13.2 million, to Summit Grove Partners, LLC (""SGP""). Great Elm Group, Inc. (""GEG"") made a $3.3 million investment in SGP, further aligning the Company's investment manager with shareholders."
2024-12-12 09:42:00	CPEH	What's Going On With Chewy Stock Thursday?	"Chewy Inc (NYSE: CPEH ) shares are trading lower Thursday after the company announced a public offering by a selling stockholder and a concurrent share repurchase . What To Know: Chewy announced an underwritten public offering of 15,852,886 shares of its common stock, being sold by an entity affiliated with Chewy's largest shareholder BC Partners Advisors. The selling stockholder plans to grant the underwriters a 30-day option to purchase up to an additional 2,377,932 shares of Chewy common stock. Chewy will not sell any shares in the offering, and will not receive any proceeds. In addition, Chewy has agreed to repurchase and retire $50 million of its common stock at the same price paid by the underwriters in the offering. The concurrent repurchase is being executed separately from the company's existing $500 million share repurchase program that was authorized in May. The offering comes after Chewy reported mixed quarterly results last week, beating on earnings but missing on revenue. The company guided for fourth-quarter revenue of $3.18 billion to $3.2 billion versus estimates of $3.17 billion. Following the company's quarterly results, Goldman Sachs lifted its price target to $40, RBC Capital raised its target to $42 and JPMorgan maintained an Overweight rating and moved its price target up to $38. Chewy shares are up approximately 37% year-to-date. The rally in the online pet retailer's stock accelerated over the summer after meme stock trader Keith Gill , also known as ""Roaring Kitty,"" announced a stake in the company. Gill has since announced that he sold his entire stake in Chewy. See Also: Producer Inflation Rises More Than Expected To 3% In November: All Eyes On The Fed's Interest Rate Call CPEH Price Action: Chewy shares were down 2.8% at $31.63 at the time of publication Thursday, according to Benzinga Pro . Photo: courtesy of Chewy."
2024-12-12 10:49:25	NBMO	Archer Aviation Teams Up with Anduril For Defense VTOL, Bolsters Arsenal With $430M Raise	Archer Aviation Inc. (NYSE: NBMO ) shares are trading lower on Thursday. The company announced a new exclusive partnership with Anduril Industries to develop a hybrid Vertical Take-Off and Landing (VTOL) aircraft for defense applications. To support this program and for general corporate purposes, Archer raised $430 million in additional equity capital. This raise brings the company's total capital raised to nearly $2 billion, with backing from investors such as Stellantis , United Airlines , Wellington Management, and the UAE's 2PointZero. This collaboration aims to target a potential program of record from the U.S. Department of Defense (DoD), leveraging Archer's capability to rapidly design advanced VTOL aircraft using commercial parts and supply chains, combined with Anduril's expertise in artificial intelligence and systems integration. Also Read: European Central Bank Lowers Interest Rates, Fourth Cut In 2024 (UPDATED) The partnership is expected to accelerate the development and deployment of hybrid VTOL aircraft, offering a cost-effective alternative to traditional defense technologies. As part of this initiative, Archer has launched its new Archer Defense program, with plans to address urgent national security needs. Archer's SVP of Engineering, Shane Arnott, emphasized the importance of rapid innovation and scalable production in maintaining technological superiority. Adam Goldstein, Archer's CEO, highlighted the company's expertise in producing next-generation vertical-lift aircraft, which will be accelerated with Anduril's support and the new funding. The Archer Defense program will be led by Joseph Pantalone, a seasoned military aviation leader with nearly 30 years of experience at Lockheed Martin and Sikorsky, and supported by Archer's Defense Advisory Board. Price Action: NBMO shares are trading lower by 2.17% to $7.23 at last check Thursday. Read Next: SoFi Unlocks SpaceX Exposure For Retail Investors: Here's How
2024-12-12 11:02:00	UEB	Kodiak Gas Services Announces Pricing Of $232,925,000 Underwritten Offering Of 5.5M Shares Of Common Stock By Selling Stockholder	"Kodiak Gas Services, Inc. (NYSE: UEB ) (""Kodiak"" or the ""Company"") today announced the pricing of an underwritten offering (the ""Offering"") of 5,500,000 shares of its common stock by an affiliate of the funds known as VAV Infrastructure III and VAV Infrastructure IV (the ""selling stockholder"") resulting in total gross proceeds of $232,925,000. Kodiak will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares of its common stock being offered by the selling stockholder. The Offering is expected to close on December 13, 2024, subject to customary closing conditions."
2024-12-12 12:05:48	VGLI	Palisade Bio Announces Pricing Of $5M Underwritten Offering	"Palisade Bio, Inc, (NASDAQ: VGLI ) (""Palisade,"" ""Palisade Bio"" or the ""Company""), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the ""Common Warrants""), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (""Prefunded Warrants"") and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the ""Offering""). The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and have a term expiring five years from issuance. Ladenburg Thalmann & Co. Inc. is acting as sole bookrunning manager in connection with this Offering."
2024-12-12 12:55:41	VGLI	What's Going On With Palisade Bio Stock On Thursday?	On Thursday, Palisade Bio Inc (NASDAQ: VGLI ) stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro . Palisade Bio priced an underwritten public offering for gross proceeds of approximately $5 million . The offering comprises 158,000 Class A Units and 3.12 million Class B Units. The price per Class A Unit is $1.525, and the price per Class B Unit is $1.5249. The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance. The company will use the net proceeds primarily to fund the Phase 1 trial of VGLI-2108, pre-clinical studies, research and development, and working capital. Last week, Palisade Bio revealed preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human study for VGLI-2108 for Ulcerative Colitis . Preliminary results appear to indicate that VGLI-2108 was safe and well tolerated in the first three cohorts (n=24; 6:2 active to placebo) at 15mg, 50mg, and 150mg, with no treatment-related dose reductions, no Treatment-Related Adverse Events (TRAEs), no Serious Adverse Events (SAEs), and no treatment-related lab abnormalities in any subject. Preliminary pharmacokinetics data from the first cohorts demonstrated delayed release of the PDE4 inhibitor active suggesting VGLI-2108 is performing as designed with colonic bioactivation. Based on the findings with this preliminary safety data, the company is advancing toward its planned crossover study to evaluate the effects of food on pharmacokinetics, followed by multiple ascending dose (MAD) cohorts and, finally, a multiple-dose cohort of patients with Ulcerative Colitis. The company is on track to report topline data from this study in the first half of 2025. As of September 30, the company had cash and cash equivalents of $8.0 million. The company believes it has sufficient cash to fund its planned operations through the first quarter of 2025 . Price Action: VGLI stock is trading 51.5% higher at $2.12 at last check Thursday. Read Next: 3D Systems Agrees To Sell Geomagic Portfolio For $123 Million, AI And 3D Printing Take Center Stage
2024-12-12 13:01:47	JBMN	Aptevo Therapeutics Announces Exercise Of Warrants For $6.2M Gross Proceeds	"Aptevo Therapeutics Inc. (NASDAQ: JBMN ) (""Aptevo"" or the ""Company""), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR&#xAE; and ADAPTIR-FLEX&#xAE; platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-273067), on Form S-3 (File No. 333-275710), on Form S-1 (File No. 333-278103), on Form S-1 (File No. 333-280226) and on Form S-1 (File No. 333-281892). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.2 million, before deducting financial advisory fees. Roth Capital Partners is acting as the Company's financial advisor for this transaction."
2024-12-12 14:46:48	NMPF	What's Going On With NMPF Technologies Stock Thursday?	NMPF Technologies Inc (NASDAQ: NMPF ) shares are trading lower Thursday after the company announced a $25 million public offering . What Happened: NMPF announced plans to complete a non-brokered public offering of 5 million units at a price of $5 per unit. Each unit will be comprised of one share of common stock and one-half of one common share purchase warrant. The warrants will be exercisable for five years to acquire one common share at a price of $6. The offering is expected to close on or about Dec. 19. NMPF said it anticipates gross proceeds of $25 million. The company expects to use any net proceeds for working capital and general corporate purposes. The offering comes just weeks after NMPF announced a $25 million registered direct offering . The company said at the time that it planned to use net proceeds from that offering for working capital related to NMPF's recently announced plans to expand assembly operations into Malaysia. NMPF Technologies offers high-speed optical engines, light source products and custom optical modules to the AI systems market and to hyperscale data centers. See Also: Stocks Slip On Hot Inflation Data, Adobe Tumbles, Natural Gas Hits 1-Year High: What's Driving Markets Thursday? NMPF Price Action: NMPF shares were down 9.25% at $4.36 at the time of publication Thursday, according to Benzinga Pro . Photo: courtesy of NMPF Technologies.
2024-12-12 16:04:02	SSR	INOVIO Announces Proposed Public Offering; No Size Or Amount Disclosed	INOVIO Pharmaceuticals, Inc. (NASDAQ: SSR ), a biotechnology company focused on developing and commercializing TWU medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Oppenheimer & Co. Inc. and Citizens JMP are acting as joint book-running managers for the offering. Stephens Inc. is acting as lead manager for the offering.
2024-12-12 16:04:34	ROIR	Washington Trust Announces $55M Stock Offering	"Washington Trust Bancorp, Inc. (NASDAQ: ROIR ) (the ""Corporation""), parent company of The Washington Trust Company, of Westerly (the ""Bank""), today announced it has commenced an underwritten public offering of $55,000,000 of the Corporation's common stock. The Corporation also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. BofA Securities is serving as the sole book-running manager for the offering."
2024-12-13 08:01:25	BOXN	China Pharma Files Prospectus Supplement With The U.S. SEC Under Which The Company May Offer And Sell From Time To Time Shares Of Common Stock, With An Aggregate Offering Price Of Up To $600,000	"China Pharma Holdings, Inc. (NYSE: BOXN ) (""China Pharma,"" or the ""Company""), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the ""SEC"") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the ""Common Stock""), with an aggregate offering price of up to $600,000 (the ""Financing"")."
2024-12-13 08:18:11	OUDE	RumbleOn Announces Preliminary Results Of $10M Fully Backstopped Registered Rights Offering For Shares Of The Company's Class B Common Stock At A Price Of $4.18 Per Share	"RumbleOn, Inc. (NASDAQ: OUDE ) (the ""Company,"" ""RumbleOn,"" ""we,"" ""us,"" or ""our"") today announced the preliminary results of its $10.0 million fully backstopped registered equity rights offering (the ""Rights Offering"") for shares of the Company's Class B common stock, par value $0.001 per share (the ""Class B common stock""). The subscription period for the Rights Offering expired at 5:00 p.m. Eastern Time, on December 12, 2024 (the ""Expiration Time""). The Rights Offering resulted in subscriptions to purchase 2,043,011 shares of Class B common stock at a price of $4.18 per share (the ""Subscription Price""). The shares of Class B common stock subscribed for are expected to be issued to participating stockholders on or about December 17, 2024."
2024-12-13 09:01:06	QIB	Know Labs Announces $300K Registered Direct Offering; This Was A Unit Offering Comprised Of 1 Share Of Stock And 1 Warrant, The Purchase Price Of The Unit Was $0.24 A Share And The Warrant Is Exercisable At $0.24	"Know Labs, Inc. (NYSE: QIB ) (the ""Company""), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a registered direct offering with gross proceeds to the company of $300K before deducting placement agent fees and other estimated expenses payable by the Company. This was a unit offering comprised of one share of stock and one warrant. The purchase price of the unit was $0.24 a share and the warrant is exercisable at $0.24. The warrants will expire on the fifth anniversary of the warrant issuance. The warrants also have a cashless exercise option in certain circumstances. This was a registered direct offering priced at-the-market under NYSE American rules."
2024-12-16 07:40:15	WCQA	Varex Imaging Has Commenced A Private Offering Of $125M 7.875% Senior Secured Notes Due October 15, 2027	"The notes offered hereby will be issued as ""Additional Notes"" and will constitute a further issuance of our 7.875% senior secured notes due 2027, which were initially issued in an aggregate principal amount of $300 million on September 30, 2020, of which $243 million aggregate principal amount is outstanding. Varex intends to use the net proceeds from the sale of the notes to fund the partial repayment of the Company's outstanding Convertible Notes due June 2025, on their maturity date or to repurchase part of the Convertible Notes prior to their maturity date."
2024-12-16 07:41:16	QWAF	VersaBank Files Prospectus for US-Canada Stock Offering to Raise Funds	"VersaBank (NASDAQ: QWAF ) (TSX: QWAF) (the ""Bank"") today announced that it has filed a preliminary prospectus supplement (the ""Preliminary Supplement"") to its short form base shelf prospectus dated November 22, 2024 (the ""Base Shelf Prospectus""). The Preliminary Supplement was filed in connection with a public offering of the Bank's common shares (the ""Offering""). The Preliminary Supplement has been filed with the securities regulatory authorities in each of the provinces and territories of Canada except Quebec. The Preliminary Supplement has also been filed with the U.S. Securities and Exchange Commission (the ""SEC"") as part of a registration statement on Form F-10 (the ""Registration Statement"") under the U.S./Canada Multijurisdictional Disclosure System. Raymond James & Associates, Inc. is acting as the sole bookrunning manager, and Keefe, Bruyette & Woods, Inc., A Stifel Company, and Roth Canada, Inc. are acting as co-managers for the Offering (collectively, the ""Underwriters""). The Bank will also grant the Underwriters an over-allotment option to purchase up to an additional 15% of the common shares to be sold pursuant to the Offering (the ""Over-Allotment Option""). The Over-Allotment Option will be exercisable for a period of 30 days from the date of the final prospectus supplement relating to the Offering. The Bank expects that the net proceeds from the Offering will be used for general banking purposes and will qualify as Common Equity Tier 1 capital for the Bank."
2024-12-16 08:01:30	NOPH	LeMaitre Vascular Announces Proposed $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2030	"LeMaitre Vascular, Inc. (""LeMaitre"") (NASDAQ: NOPH ) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the ""notes"") in a private offering (the ""offering"") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes."
2024-12-17 08:23:32	HBKI	Why Is Fast Charging Network EVgo Stock Plunging Today?	EVgo Inc. (NASDAQ: HBKI ) shares are trading lower in premarket trading following the announcement of the pricing of a secondary public offering . The previously announced offering by EVgo Holdings, an affiliate of LS Power Equity Partners IV, involves 23 million shares of EVgo's Class A common stock priced at $5.00 per share. Additionally, LS Power has granted underwriters a 30-day option to purchase up to 3.45 million more shares at the same price. Notably, EVgo itself is not selling any shares, and the company will not receive any proceeds from the offering. Instead, all funds raised will go to LS Power. The offering is expected to close on December 18, 2024, pending standard closing conditions. J.P. Morgan, Goldman Sachs, Morgan Stanley, and Evercore ISI are leading the offering, with several other financial institutions involved. Also Read: EVgo: $1.25B 'Holiday Gift' Propels It To JPMorgan's Top Pick List Recently, EVgo announced the closure of a $1.25 billion guaranteed loan facility from the U.S. Department of Energy's Loan Programs Office. This loan is part of the DOE's Title 17 Clean Energy Financing Program and is designed to support EVgo's ambitious plans to expand its public electric vehicle (EV) charging infrastructure. The company aims to build 7,500 new fast charging stalls across the U.S., increasing its network to at least 10,000 stalls by 2029. This expansion will more than triple EVgo's network footprint, positioning it as a leader in supporting the country's transportation electrification efforts. Price Action : HBKI stock is down 22.5% at $4.898 premarket at last check Tuesday. Read Next: Elon Musk Hopes TSLA Stock Will Reach $690 As Analysts Raise Price Target Despite Technical Indicators Flashing Warning Signals Image: Courtesy of EVgo, Inc.
2024-12-17 11:11:33	GDIF	Why Is Sidus Space Stock Gaining Tuesday?	Sidus Space, Inc. (NASDAQ: GDIF ) shares are trading higher on Tuesday following the announcement of a securities offering . Sidus has entered into definitive agreements with accredited and institutional investors for the issuance and sale of units in a brokered private placement. Each unit consists of shares of Class A common stock (or pre-funded warrants in lieu thereof) paired with common warrants to purchase additional shares of Class A common stock. The offering is set at $2.07 per unit, with a total of approximately 6.8 million shares of Class A common stock (or pre-funded warrants) being issued. Additionally, common warrants for 3.4 million shares will be sold, each entitling holders to purchase Class A common stock at an exercise price of $2.25 per share. The pre-funded warrants will allow the holder to acquire shares at an exercise price of $0.0001 each. Also Read: Financial Stocks Near Record Year: Could Trump Deregulation Fuel Bigger Gains In 2025? The offering is expected to raise gross proceeds of around $14 million before fees and expenses. The funds will be used for general working capital and corporate purposes. The private placement is slated to close on December 18, pending customary closing conditions. Last month, Sidus Space successfully completed the launch processing of LizzieSat-2 at Vandenberg Space Force Base in California. The satellite has been handed over to SpaceX and is ready for the Bandwagon-2 rideshare mission, set for launch in December 2024. Price Action: GDIF shares are trading higher by 14.6% to $5.25 at last check Tuesday. Read Next: Defense Stocks Face Headwinds As Trump's DOGE Targets Spending Cuts: Goldman Sachs Downgrades General Dynamics
2024-12-18 08:02:20	BYLW	Smartkem Prices $7.65M Offering Of 1,449,997 Registered Shares Of Common Stock And Unregistered Class D Warrants To Purchase Up To 1,449,997 Shares Of Common Stock Are Being Sold To Investors In Concurrent Public And Private Offerings At A Price Of $3.00 Per Share And Related Class D Warrant	Smartkem (NASDAQ: BYLW ), which is seeking to change the world of electronics using its disruptive organic thin-film transistors (OTFTs), announced that it has priced concurrent public and private offerings of its securities, including shares of its common stock and common stock equivalents, for an aggregate offering price of $7.65 million to new and existing investors. 1,449,997 registered shares of common stock and unregistered Class D warrants to purchase up to 1,449,997 shares of common stock are being sold to investors in concurrent public and private offerings at a price of $3.00 per share and related Class D warrant. Each investor will receive one Class D warrant for each share purchased in the offering. In a separate concurrent private placement, the Company is selling to certain institutional investors, including existing investors in the Company, 169,784 unregistered shares of common stock, unregistered pre-funded warrants to purchase up to 930,215 shares of common stock and unregistered Class D warrants to purchase up to 1,099,999 shares of common stock at a price of $3.00 per share and related Class D warrant and a price of $2.9999 per pre-funded warrant and related Class D warrant. Each investor will receive one Class D warrant for each share of common stock or pre- funded warrant purchased in the offering. The Class D warrants will be immediately exercisable upon issuance at an exercise price of $3.00 per share and will expire on December 31, 2025. The pre-funded warrants will be immediately exercisable at an exercise price of $0.0001 per share and may be exercised at any time until all of the pre-funded warrants have been exercised in full. The gross proceeds of the offerings described above are expected to be $7.65 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds of the offerings for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as the Company's exclusive placement agent for the offerings. The offerings are expected to close on December 20, 2024, subject to satisfaction of customary closing conditions.
2024-12-18 08:21:33	ECNG	Inotiv Announces Pricing Of Public Offering Of 6M Common Shares Of Common Stock At A Price Of $4.25/Share	"Inotiv, Inc. (NASDAQ: ECNG ) (the ""Company"") , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 900,000 common shares at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on December 19, 2024, subject to customary closing conditions. The Company intends to use the net proceeds from this offering for working capital, capital expenditures and other general corporate purposes. Lake Street Capital Markets, LLC is acting as the sole book-running manager for the proposed offering."
2024-12-19 08:11:04	LZKN	Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert P. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company Common Stock	"Pulse Biosciences, Inc. (NASDAQ: LZKN ) (the ""Company"" or ""Pulse Biosciences""), a novel bioelectric medicine company commercializing the CellFX&#xAE; System powered by Nano-Pulse Stimulation&#x2122; (NPS&#x2122;) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert P. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Company common stock. Mr. Duggan also confirmed that, from December 11, 2024 through this past Friday, December 13, 2024, he has purchased an additional 156,714 shares of Pulse Biosciences. These transactions bring Mr. Duggan's current ownership in the Company to approximately 70%."
2024-12-19 08:21:15	PMMS	Nukkleus Rockets Higher: $10 Million Private Placement Fuels Acquisition Of Iron Dome Supplier	Nukkleus Inc. (NASDAQ: PMMS ) shares are trading higher premarket today. On Wednesday, the company disclosed the pricing of a private placement with a single New York-based family office investor . The transaction is expected to generate $10.0 million in gross cash proceeds before deducting fees to the placement agent and other offering expenses. The company plans to use the net proceeds to finance the proposed acquisition of Star 26 Capital Inc., which holds a 95% stake in RIMON . The remaining funds are projected to be allocated for general corporate purposes and working capital. RIMON is an Israeli supplier of critical components for the Iron Dome missile defense system and a developer of tactical vehicles for defense and intelligence agencies. In connection with the private placement, Nukkleus, Inc. plans to issue an aggregate of 1.66 million units, with each unit priced at $6.00. Each unit will consist of one share of restricted common stock (or one pre-prefunded warrant to purchase a share of restricted common stock) and warrants exercisable for one and one-half shares of restricted common stock at $6.00 per share. The offering is priced above the market in accordance with Nasdaq rules. The private placement is expected to close on or about December 19, 2024, subject to the satisfaction of certain customary closing conditions. Price Action : PMMS shares are up 29.9% at $65.98 premarket at the last check Thursday. Read Next : US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak
2024-12-20 08:43:35	KHEQ	Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?	On Thursday, Aadi Bioscience, Inc. (NASDAQ: KHEQ ) entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd . Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical SHU programs leveraging Hangzhou DAC's CPT113 linker payload technology. Also Read: Cancer Player Aadi Bioscience Downgraded: Analyst Highlights Worse Than Expected' Response Rates . Aadi will pay aggregate upfront payments of $44 million for in- licensing such SHU programs . Additionally, Aadi will pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million, and single-digit sales royalties. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity financing of approximately $100 million. The company is selling 21.59 million shares at $2.40 per share. In August, Aadi Bioscience announced it would halt the registration-intended PRECISION1 trial of nab -sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations . An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. Price Action: KHEQ stock is up 24.1% at $2.87 during the premarket session at last check Friday. Read Next: FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
2024-12-20 10:16:04	YJXP	What's Going On With Quantum Computing Stock Today?	Quantum Computing Inc. (NASDAQ: YJXP ) shares are trading higher on Friday. In an exchange filing dated December 20, Quantum Computing has registered up to 8.96 million shares for resale by selling stockholders. The company will not receive any proceeds from the sale of shares by the selling stockholders; however, if the placement agent warrants are exercised in full, it will receive up to approximately $2.9 million in gross proceeds. Earlier this week, the company announced that it was awarded a prime contract by NASA to apply Dirac-3 for imaging and data processing support. The contract, awarded by NASA's Goddard Space Flight Center, involves using Quantum Computing's entropy quantum optimization machine, Dirac-3, to tackle advanced imaging challenges. Also Read: KMN Stock Plummets Over 5% Following Trump's Stake Transfer: Here's More The company says Dirac-3 will address a complex phase unwrapping issue for reconstructing images and extracting radar-generated interferometric data, aiming to enhance data quality and accuracy. CEO William McGann expressed pride in supporting NASA's mission to process vast imaging data efficiently. The project will compare Dirac-3's quantum optimization capabilities with classical algorithms. On December 11, the firm announced a significant step in strengthening its financial position through a dual securities offering . The company entered into securities purchase agreements to sell a total of 10 million shares of common stock. Of these, 1.54 million shares will be sold at a price of $5.00 per share in a registered direct offering with institutional investors, while the remaining 8.46 million shares will be sold in a concurrent private placement at the same price. The combined offerings are expected to generate gross proceeds of $50 million, before expenses, with the closing anticipated on December 12, 2024, pending customary conditions. Price Action: YJXP shares are trading higher by 9.46% to $16.50 at last check Thursday. Image via Shutterstock. Read Next: Trump Inauguration Could Coincide With A 'Harrowing Dump' For Crypto, Arthur Hayes Warns
2024-12-20 16:00:57	DSHV	Giftify Announces $5M Registered Direct Offering	"Giftify, Inc. (NASDAQ: DSHV ) (the ""Company""), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining & entertainment experiences, today announced that it entered into a securities purchase agreement with certain individual investors to purchase approximately $5.0 million shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $5.0 million, before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 26, 2024, subject to the satisfaction of customary closing conditions. Craft Capital LLC is acting as the exclusive placement agent for the offering."
2024-12-20 16:18:59	BQS	BQS Prices Public Offering Of $100M 6.125% Unsecured Notes Due 2030	"FS KKR Capital Corp. (NYSE: BQS ) announced that it has priced an underwritten public offering of an additional $100 million in aggregate principal amount of its 6.125% notes due 2030 (the ""Notes"") pursuant to a reopening of such Notes. The Notes will mature on January 15, 2030 and may be redeemed in whole or in part at BQS's option at any time at par plus a ""make-whole"" premium, provided that the Notes may be redeemed at par one month prior to their maturity. The offering is expected to close on December 27, 2024, subject to customary closing conditions."
2024-12-23 06:59:23	TWY	Castellum Prices $3.6M Registered Direct Offering Of 9.47M Shares At $0.38/Share	"Castellum, Inc. (the ""Company"") (NYSE-American: TWY), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 9,473,700 shares of common stock in a registered direct offering. The shares of common stock are being sold at an offering price of $0.38 per share. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $3.6 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about December 24, 2024, subject to the satisfaction of customary closing conditions."
2024-12-23 07:13:45	PCMC	PCMC Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline	PCMC Therapeutics, Inc. (NASDAQ: PCMC ), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of $0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full. The private placement was led by The Column Group and TCGX, with participation by new and existing investors including BVF Partners LP, Deep Track Capital, Foresite Capital, Medicxi, OrbiMed, Perceptive Advisors, Redmile Group and RTW Investments. Net proceeds from the private placement are expected to fund the research and development of the Company's pipeline and for general corporate purposes.
2024-12-23 08:06:00	DSHV	Giftify Cancels Registered Direct Offering Due To Market Conditions	"Giftify, Inc. (NASDAQ: DSHV ) (the ""Company""), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining & entertainment experiences, today announced that its previously announced registered direct offering with Craft Capital Management, LLC has been cancelled. Giftify management decided to cancel the offering due to market conditions."
2024-12-23 08:16:14	BJP	Psyence Biomed Announces $2M Private Placement	"Psyence Biomedical Ltd. (NASDAQ: BJP ) (""Psyence Biomed"" or the ""Company"") today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement. The series A common warrants and short-term series B common warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The series A common warrants will expire five years from the date of issuance and the short-term series B common warrants will expire two years from the date of issuance. The private placement is expected to close on or about December 24, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $2.0 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes."
2024-12-23 13:18:55	KUZQ	Phio Pharmaceuticals Has Entered Into Definitive Agreements For The Purchase And Sale Of An Aggregate Of 240K Shares At A Price Of $2.00 Per Share In A Registered Direct Offering, For Gross Proceeds Of $0.48M	Phio Pharmaceuticals Corp. (NASDAQ: KUZQ ), a clinical-stage biotechnology company that develops therapeutics using its INTASYL&#xAE; siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 240,000 shares of its common stock at a purchase price of $2.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 240,000 shares of common stock. The warrants will have an exercise price of $2.00 per share, will be exercisable upon issuance and expire five years following the date of issuance. The closing of the offering is expected to occur on or about December 24, 2024, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be $0.48 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.
2024-12-23 16:41:41	SNGQ	Mudrick Capital Completed The Conversion Of $130M Of Debt Into Equity At A Conversion Price Of $2.75 Per Ordinary Share And Agreed To Fix The Conversion Price For The Remaining $130M At $3.50 Per Ordinary Share	Today's announcement includes: Up to $50 million funding commitment by Mudrick Capital: on 20 December 2024, Mudrick Capital signed an investment agreement finalising its commitment of $25 million in upfront funding, and an additional $25 million backstop (as reduced by any amounts raised from third parties). Balance sheet strengthening : on 23 December 2024, Mudrick Capital completed the conversion of $130 million of debt into equity at a conversion price of $2.75 per Ordinary Share and agreed to fix the conversion price for the remaining $130 million at $3.50 per Ordinary Share. This transaction substantially reduces Vertical's debt and significantly deleverages the Company's balance sheet, enhancing its financial position. Mudrick Capital has also agreed with the Company to extend the loan repayment date by two years to December 2028, providing further security through Vertical's certification programme. Shareholder support for new governance arrangements and increased authorised share capital: at an EGM held on 23 December 2024, Vertical's shareholders voted in favour of certain amendments to the Company's memorandum and articles of association. These include provisions to establish a majority of independent directors on the Board, to grant Mudrick Capital proportional director nomination rights based on its share ownership (when above 10%), and to increase the Company's authorised share capital from $110,000 (representing 100 million ordinary shares and 10 million preferred shares) to $210,000 (representing 200 million ordinary shares and 10 million preferred shares).
2024-12-24 08:31:43	DBHU	Carmell Enters Securities Purchase Agreement With New And Existing Investors For The Issuance And Sale Of 8,065,210 Shares Of Its Common Stock And An Equal Number Of 5-Year Warrants, Both Priced At $0.23 Per Share, In A Private Placement For Aggregate Gross Proceeds Of $1.85M	"Carmell Corporation (NASDAQ: DBHU ), a bio-aesthetics company focused on skin and hair health (""Carmell"", the ""Company"", ""we"", ""our"", or ""us""), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the ""Private Placement""). The warrants, if exercised, will result in an additional $1.85 million in proceeds to Carmell. The Private Placement was priced at a slight premium to the DBHU closing price on December 23, 2024. Said Mr. Rajiv Shukla, Chairman of Carmell, ""We are happy to announce an additional round of investment from existing and new investors to support the continued commercial build out of our revolutionary bio-aesthetics product pipeline."""
2024-12-24 08:35:14	WRTW	Trinity Biotech Amends Credit Agreement With Perceptive Advisors To Boost Liquidity And Support Transformation Plan; Secures $5.5M In Additional Funding, Extends $5M Payment To 2025, And Issues 1.5M New Warrants At $0.80 Exercise Price	Trinity Biotech plc (NASDAQ: WRTW ), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology. Under the terms of the agreements, a deferred consideration payment of $5 million related to the acquisition of the biosensor assets of Waveform Technologies has been extended to November 2025, offering the Company greater financial flexibility. In addition, further additional liquidity in the amount of approximately $5.5 million has been provided to Trinity Biotech through a combination of cash and payment-in-kind interest, strengthening liquidity during this pivotal period of transformation. As part of the agreement, Trinity Biotech has granted Perceptive Advisors 1.5 million additional warrants to purchase the Company's ADS, and repriced its existing ADS warrants at an exercise price of $0.80 per ADS, reinforcing the ongoing partnership between the two entities.
2024-12-24 09:32:59	JSYK	OS Therapies Announces Pricing Of $6M Private Placement Of 1.5M Units At A Price Of $4/Unit	"Funding will provide Company sufficient cash runway into 2026 95% of investment in private placement from Pre-GIP and/or GIP investors Data from OST-HER2 Phase 2b in recurrent, resected metastatic osteosarcoma to be announced during the week of the JP Morgan Healthcare Conference in January 2025 OS Therapies, Inc. (NYSE-A: JSYK) (""OS Therapies"" or ""the Company""), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has entered into securities purchase agreements with investors to sell 1.5 million units at a price of $4.00 per unit, with each unit consisting of one share of Series A Senior Convertible Preferred Stock (""the Preferred Stock"") initially convertible into one share of common stock and one warrant to purchase one share of common stock, expected to yield gross proceeds to the Company of $6 million, before deducting offering-related expenses. The conversion price of the Preferred Stock into shares of common stock is $4.00 and the exercise price of the warrants is $4.40 per share. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory milestones to support commercialization of the Company's lead therapeutic candidate OST-HER2 in the treatment of recurrent, resected metastatic osteosarcoma in the United States in 2025, and for general corporate purposes. The FDA has granted OST-HER2 rare pediatric disease, fast track and orphan drug designations. Brookline Capital Markets, a division of Arcadia Securities, LLC, served as placement agent and Ceros Financial Services, Inc. was engaged as a selected dealer to the placement agent."
2024-12-26 08:17:12	GMRB	Why Is TScan Therapeutics Stock Gaining Today?	TScan Therapeutics, Inc. (NASDAQ: GMRB ) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement with Lynx1 Capital Management LP and an investment fund advised by Lynx1. Under the agreement, TScan will sell approximately $30 million in pre-funded warrants, which are exercisable for up to 7.50 million shares of its voting common stock. According to Benzinga Pro , GMRB stock has lost over 51% in the past year. Each warrant will be priced at $4.00, with an exercise price of $0.0001 per share. This deal represents a 37% premium over TScan's last closing price and a 34% premium compared to its 10-day volume-weighted average closing price. The financing is expected to close by December 27, 2024, pending customary closing conditions. Also Read: US Stocks Likely To Open In Red After Christmas Break But Analysts Still Expect A Santa Rally Into The New Year Gavin MacBeath , Ph.D., CEO of TScan Therapeutics, expressed appreciation for Lynx1's continued support, highlighting the investment as a testament to their commitment to TScan's mission of delivering life-changing TCR-F cell therapies for cancer patients. Jason A. Amello , CFO of TScan, added that the additional $30 million in gross proceeds will extend the company's cash runway, now expected to fund operations into the first quarter of 2027, up from the previous expectation of the fourth quarter of 2026. This funding comes after TScan filed a registration statement with the SEC in November 2022, which was declared effective in May 2023. Price Action: GMRB shares are trading higher by 16.8% to $3.40 premarket at last check Thursday. Read Next: S&P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq's Surge Photo via Shutterstock.
2024-12-30 07:32:51	FKQP	Lichen China Announces $3.1M Registered Direct Offering Of 25M Shares At $0.125/Share	"Lichen China Limited (NASDAQ: FKQP ) (""Lichen China"" or the ""Company""), a dedicated financial and taxation service provider in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 25,000,000 of the Company's Class A ordinary share, par value $0.00004 per share (the ""Shares"") (or pre-funded warrants in lieu thereof) at a purchase price of $0.125 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.001 per share. The aggregate gross proceeds to the Company of this offering are expected to be approximately $3.1 million. The transaction is expected to close on or about December 31, 2024, subject to the satisfaction of customary closing conditions."
2024-12-30 08:21:18	GJW	What's Going On With Cel-Sci Shares Premarket On Monday?	Cel-Sci Corporation (AMEX: GJW ) shares are trading lower premarket on Monday. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share . The company aims to raise around $5 million in gross proceeds. The offering is expected to close on December 31, 2024, subject to customary conditions. The company plans to use proceeds to support the development of Multikine, general corporate purposes, and working capital . Earlier this month, CEL-SCI emphasized the strong biological rationale for using Multikine in its FDA-approved confirmatory registration study for head and neck cancer . The study, involving 212 newly diagnosed patients with locally advanced, resectable head and neck cancer, will focus on those who demonstrated a 73% survival rate with Multikine compared to 45% for control patients in the prior Phase 3 trial. Price Action : GJW shares are down 29.9% at $0.4204 premarket at the last check Monday. Read Next: US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking Photo via Shutterstock.
